study_arm,TrialID,url,Interventions,vaccine,conventional,traditional
im,ACTRN12616000046404,https://anzctr.org.au/ACTRN12616000046404.aspx,"All participants will have received 24-72 hours of intravenous site specific antibiotics,  followed by 3 days of oral amoxicillin-clavunate acid, prescribed by site hospitals. Participants will then receive active or placebo treatment for an additional 8 days as below.<br><br>Active arm: 8 days of oral amoxcillin-clavulanate 400/57 duo formulation (70-90mg/kg/day, twice daily dosing; max 980mg per day)<br><br>Placebo arm: 8 days of oral placebo (equivalent volume as the active arm)<br><br>Treatment dose (range) is determined by local site hospital treatment protocols. Parents will keep a medication diary and/or receive phone calls to monitor adherence to intervention medication. Where possible, we will also collect empty medication bottles at the 4 week clinical review.<br>",NA,Yes,NA
im,ACTRN12616001475437,https://anzctr.org.au/ACTRN12616001475437.aspx,"New formulation of zanamivir, AWP-09VDB-S, to be administered in a gastric resistant capsule.<br>Participants will receive two doses in total.  Each dose is 2 x capsules of 150mg (300mg total) in feed and fasted state.  4-13 days washout between period 1 and 2<br>Compliance check of the mouth and hand at administration.<br><br>FED Cohort: Participants in the fed period will be dosed following a high–fat, high-calorie breakfast. These participants will be required to fast overnight for at least 10 hours until 30 minutes prior to their scheduled dosing times, when they will be given a standard high-fat, high calorie breakfast which will be entirely consumed within 30 minutes. The breakfast will consist of two eggs fried in butter, two strips of bacon, two slices of toast with butter, four ounces of hash brown potatoes (1 serving or approximately 114 gm) and 240 mL of whole milk. Participants will fast for at least 4 hours following dosing.  IP will be administered with 240 mil of water.  No food is allowed for at least 4 hours post-dose. Water can be consumed as desired except for one hour after drug administration.<br>FASTED Cohort Participants : Following an overnight fast of at least 10 hours, participants will be administered IP with 240 mL of water. No food is allowed for at least 4 hours post-dose. Water can be consumed as desired except for one hour before and after drug administration.",NA,Yes,NA
im,ACTRN12617000322336,https://anzctr.org.au/ACTRN12617000322336.aspx,"Infants randomised to the intervention will receive budesonide 0.25 mg/kg (0.5 mL/kg). Exogenous surfactant (Curosurf [trademark], Chiesi Farmaceutici, Parma, Italy) will be used as a carrying vehicle for the budesonide. The dose of surfactant will be 200 mg/kg for the initial dose, and 100 mg/kg for subsequent doses (if required). Each enrolled infant will receive at least one, and no more than two, interventions. The intervention will be administered intra-tracheally via an endotracheal tube or catheter, by a medical officer or appropriately credentialed neonatal nurse.",NA,NA,NA
im,ACTRN12617000626369,https://anzctr.org.au/ACTRN12617000626369.aspx,"Each ICU patient will receive a single bolus dose of 13C-labeled lactate (2.7mg/kg body weight). Existing arterial and venous lines will be used. Blood samples will be drawn at t=0 and then every two minutes during the first hour and every fifth minute for the second hour (t=2,4,6...56,58,60,65,70...110,115,120)",NA,NA,NA
im,ACTRN12617001365358,https://anzctr.org.au/ACTRN12617001365358.aspx,Withholding angiotensin converting enzyme II inhibitors (ACEi) and angiotensin receptor blockers (ARBs) medication at least twenty-four hours prior to noncardiac surgery. The commencement of ACEi and ARB after surgery will be independent of the clinical trial and at the discretion of the treating clinician.,NA,NA,NA
im,ACTRN12617001392358,http://www.anzctr.org.au/ACTRN12617001392358.aspx,1.5 g intravenous Sodium Ascorbate every 6 hours for 5 days.  A review of medication charts by study investigators and sampling of Vitamin C levels levels in 5 randomly selected patients in each arm on day 3 of the study will occur to verify group separation and adherence to protocol.,NA,NA,Yes
im,ACTRN12618000112268,https://anzctr.org.au/ACTRN12618000112268.aspx,"The study is in 2 parts,with 4 parallel treatment groups in Part A and 9 parallel treatment groups in Part B. In both study parts the interventional exposure group being studied is the Micro array projections (MAPs) coated with A/Singapore/GP1908/2015 antigen (A/Sing) in various doses. The comparator products are listed in the section below.   <br><br>The A/Sing MAP comes in 2 doses; 5mcg Haemagglutinin protein (HA) or 2.5 mcg HA. They are single use. For each subject, a MAP is applied for 2 mins then removed then the next patch is applied for 2 mins then removed etc.<br>The MAP is applied by a trained medical professional.  <br><br>Study Part A: <br>Group 1 subjects will receive 3 x 5mcg A/Sing coated MAPs to the forearm,  total dose 15mcg HA.<br>Groups 2, 3 and 4 will receive comparator products (described in section below)<br><br>Study Part B: <br>Group 1 subjects receive 3 x 5mcg A/Sing coated MAPs to the forearm, total dose 15mcg HA<br>Group 2 subjects receive 3 x 5mcg A/Sing coated MAPs to the forearm, total dose 15mcg HA and they will undergo additional testing of punch biopsy of application site.  <br>Group 3 subjects receive 2 x 5mcg A/Sing coated MAPs to the forearm plus 1 uncoated (placebo MAP, total dose 10mcg HA<br>Group 4 subjects  receive 1 x 5mcg A/Sing coated MAP to the forearm plus 2 uncoated (placebo MAPs, total dose 5mcg HA<br>Group 5 subjects receive 1 x 2.5mcg A/Sing coated MAP (2.5mcg HA) plus 2 uncoated (placebo) MAPs to the forearm, total dose 2.5 mcg HA<br>Group 8 subjects receive 3 x 5mcg A/Sing coated MAPs to the deltoid muscle, total dose 15 mcg HA<br><br>The MAP delivery device is a hand-held mechanical, spring loaded, disposable applicator (Vaxxas Clinical Applicator, disposable, CAP) calibrated at a specific speed of 20 m/s. Each MAP will be delivered to the skin and left in situ for 2 minutes. It will then be removed by a gloved finger by gently tensioning the skin around the patch with one hand, whilst pulling the MAP directly up an",NA,NA,NA
im,ACTRN12618000260224,https://anzctr.org.au/ACTRN12618000260224.aspx,"Anti-Chlamydaphila antibiotic combination: Doxycycline, Azithromycin & Rifabutin<br>Dose: 50mg  Doxycycline, 250mg Azithromycin & 150mg Rifabutin (3 separate capsules) daily (days 1 to 7), 50mg  Doxycycline, 250mg Azithromycin & 150mg Rifabutin (3 separate capsules) twice daily (days 8 to 90).<br>Duration: 90 days<br>Mode: oral capsules",NA,Yes,NA
im,ACTRN12618000365268,https://anzctr.org.au/ACTRN12618000365268.aspx,"Everolimus (oral tablets) alone or together with  BEZ235 (oral capsules) and corresponding placebo oral tablets and oral capsules will be dosed on a once daily basis. Subjects will be randomized to receive placebo,  or 0.1 mg everolimus alone or in a combination of 0.1 mg everolimus and 10 mg BEZ235 once daily for either 4 weeks (Group A) or 6 weeks (Group B). <br><br>Group A (receive influenza vaccination at baseline and start dosing after vaccination at  baseline visit for a period of 4 weeks. Total treatment period is 4 weeks)<br>I.Everolimus 0.1 mg or matched placebo<br>II.Everolimus 0.1 mg plus 10 mg  BEZ235 (combination) or matched placebo<br><br>Group B (receive study drug for 2 weeks starting at the baseline visit and then receive influenza vaccination at week 2 and then continue dosing for an additional 4 weeks. Total treatment period is 6 weeks). <br>III.Everolimus 0.1 mg or matched placebo<br>IV.Everolimus 0.1 mg plus 10 mg BEZ235 (combination) or matched placebo<br><br>Subjects will then be followed for 1 week off study drug.<br><br>Compliance will be assessed by the investigator and/or study personnel at each visit by having subjects bring remaining study drug to each visit and having the site staff count the remaining number of capsules and/or tablets and having this information recorded in the eCRF.<br>",NA,NA,NA
im,ACTRN12618001675213,https://anzctr.org.au/ACTRN12618001675213.aspx,"Enteral ivabradine 5mg twice daily in addition to standard care.<br>Study treatment will be given for a total of 120 hours (5 days) or until the patient is discharged from ICU (whichever occurs first). In the event of bradycardia with a HR of <50 or in the presence of symptomatic bradycardia or in the event of AF or any visual disturbance, Ivabra-dine will be discontinued. These data will be included in the final manuscript of the study.",NA,NA,NA
im,ACTRN12618002028280,https://anzctr.org.au/ACTRN12618002028280.aspx,"Two doses of 11.4mg betamethasone by intramuscular injection into the thigh, arm or buttock, 24 hours apart given within seven days of planned caesarean section.",NA,Yes,NA
im,ACTRN12618002041235,https://anzctr.org.au/ACTRN12618002041235.aspx,"A randomized, double-blind, placebo controlled, Phase I study with 33 sero-susceptible individuals aged 18 to 45 years. <br><br>A total of 33 healthy individuals will be enrolled and randomized into 2 groups where each participant will receive a single dose of either CodaVax-H1N1, or placebo (22:11). Participants will receive one 0.1ml into both nostrils (one immediately after the other).<br><br>Twenty-two (22) participants will be administered CodaVax-H1N1 and 11 participants will be administered a placebo. All subjects will receive an intranasal (IN) dose of either CodaVax-H1N1,  or saline (placebo).<br><br>Arm 1: Intranasal dose of CodaVax-H1N1<br>Arm 2: Intranasal dose of Placebo (Saline)<br><br>CodaVax-H1N1 is a potential universal live attenuated influenza vaccine (LAIV) manufactured using a proprietary SAVE platform based on the H1N1 A/California/07/2009 (H1N1) strain. The vaccination dose will be 8 x 10^5 PFU in 200 microlitre of current Good Manufacturing Practice (cGMP) Dulbecco Modified Eagle Medium media and 7.5% sucrose, and is to be administered through an intranasal sprayer into one or both nostrils.<br><br>As the CodaVax-H1N1 dose is 8-times higher than the highest dose administered in the first clinical trial (UTN: U1111-1191-3515), the first 3 participants dosed with CodaVax-H1N1 will be sentinel participants. These participants will be monitored for 60 to 90 minutes immediately following dosing on Day 0 (visit 3), and return for testing on Day 2 (visit 3) and Day 6 (visit 4). If dosing of the sentinels proceeds without clinically significant adverse events (AEs) over 7 days, all remaining participants will be dosed.<br><br>Following vaccination all participants (CodaVax, and placebo) will be monitored at the clinic for at least 60-90 minutes following vaccination, after which they will return to the clinic (Day 2 and 6) to be monitored until Day 6 post-vaccination and on Day 30 post-vaccination for a Follow-up visit.<br><br>A soft-lock will be pla",Yes,NA,NA
im,ACTRN12619000118101,https://anzctr.org.au/ACTRN12619000118101.aspx,"A total of 40 children (aged between 6 months and 9 years of age) will be enrolled into this research study.  After written and informed parental consent, a 3ml blood sample will be collected to determine the baseline anti-haemagglutination antibody titre. The participant will then be administered the Licensed Quadrivalent Seasonal Influenza vaccine according to the Australian Immunisation Handbook (AIH) guidlines. At the last visit, a second 3ml blood sample will be collected for the determination of post-vaccination antibody titres.<br><br>All participants will receive an intramuscular injection of the seasonal licensed southern hemisphere seasonal influenza vaccine according to the Australian Immunisation Handbook recommendation. The World Health Organisation (WHO) provides a recommendation for the composition of the Southern Hemisphere influenza virus vaccines.<br> <br>For Children aged 6 months to up to 3 years of age <br>FluQuadri Junior- Sanofi-Aventis Australia Pty Ltd (quadrivalent inactivated influenza virus). Each 0.25mL pre-filled syringe contains 7.5µg haemagglutinin of each of the four recommended influenza virus strains; 50µg formaldehyde; 125µg octoxinol 9; 0.5µg ovalbumin.<br><br>For Children aged 3 years of age and older<br>FluQuadri – Sanofi-Aventis Australia Pty Ltd (quadrivalent inactivated influenza virus). Each 0.5 mL pre-filled syringe contains 15 µg haemagglutinin of each of the four recommended influenza virus strains; 100 µg formaldehyde; 250 µg octoxinol 9; 1 µg ovalbumin.<br><br>According to the Australian Immunisation Handbook, children aged 6 months to <9 years receiving influenza vaccine for the first time require two doses, at least 4 weeks apart, to maximize the immune response to vaccine strains. For children who have previously received 1 or more doses of trivalent or quadrivalent influenza vaccine, only 1 dose of influenza vaccine is required in the current season and all seasons thereafter. Therefore participants in the study wi",Yes,NA,NA
im,ACTRN12619000256178,https://anzctr.org.au/ACTRN12619000256178.aspx,"Vitamin C: Intravenous infusion of 2.5 g /8 hours will be started as soon as possible, but not later than 72 hours after hospital admission and within 24 hours of the documentation of a community acquired pneumonia CURB-65 severity score >1. <br>Intravenous vitamin C will be provided while the patient is receiving intravenous antimicrobial therapy and will continue until the patient is changed to oral antimicrobial therapy or for a maximum of 7 days. <br>Following the cessation of intravenous vitamin C therapy the patient will receive a further 7 days of oral vitamin C at a dose of 1 g (2 x 500 mg chewable tablets) three times per day. This may be administered via nasogastric tube if the patient cannot swallow.<br>The intravenous infusion of vitamin C will be made up by the attending nurse just prior to administering the agent. Five milliliters of a 500 mg/mL vitamin C IV solution (2.5 g total dose) will be drawn up and added to a 100 mL bag of normal saline and will be administered over a 20-30 minute period. A new solution will be made up and administered every 8 hours while the patient is on intravenous antimicrobial therapy or for a maximum of 7 days.<br>Participants will receive vitamin C for a minimum of 8 days and a maximum of 14 days.",NA,NA,Yes
main,ACTRN12619000305123,https://anzctr.org.au/ACTRN12619000305123.aspx,"Following enrolment (within 1-2 weeks), each subject will be randomised to 12 weeks treatment with capsules containing sitagliptin (100 mg daily) or matching placebo (table salt), in a double-blind parallel design, facilitated by the Royal Adelaide Hospital Pharmacy. During each of weeks 1 and 12, they will attend the laboratory twice for intraduodenal infusion studies, 2-5 days apart.<br>On each study day, a silicone rubber catheter will be inserted through an anaesthetised nostril into the stomach, and be positioned with the infusion port located 12 cm below to the pylorus (in the duodenum). An intravenous cannula will be placed into a vein of each forearm for hyperglycaemic clamping and infusion of the GIP antagonist GIP(3-30)NH2 and blood sampling, respectively.<br>After correct positioning of the intraduodenal catheter, a hyperglycaemic clamp will be maintained at 15 mmol/L from t = 0 to 270 min. This is achieved by intravenous administration of an initial bolus of 25% dextrose, followed by a 25% dextrose infusion at a rate adjusted according to blood glucose concentrations measured every 5 min. Concurrently, a solution of 100 units of insulin, made up to 500 ml with Gelofusine to yield a final concentration of 0.2 IU/ml, will also be infused intravenously at rates according to a sliding scale used in previous similar studies. An IV infusion of the GIP antagonist GIP(3-30)NH2 at the rate of 800 pmol/kg/min, or saline control, will run from t = 30 to 270 min. Intraduodenal glucose will be infused at 2 kcal/min from t = 90 to 190 min.  <br>During the 12 week intervention, subjects will keep a daily diary for study medication, receive a fortnightly telephone call to reinforce compliance and document any adverse effects, and visit our centre in weeks 4 and 8 to return any unused medication, receive the next 4 weeks’ supply and undergo repeated physical examinations and assessment of liver and renal function.<br>",NA,NA,NA
main,ACTRN12619000391178,https://anzctr.org.au/ACTRN12619000391178.aspx,"Test and Reference drugs, in a single oral dose (75 mg) in 2 periods under fasting conditions and 2 periods under food conditions From the signing of the informed consent to the medical discharge<br><br>Test drug: Amfepramone<br>Reference drug: Neobes Amfepramone<br><br>The study includes two designs (fasting and food) with two periods each of approximately 36 hours of internment and a post-discharge sample taking of 48 hours, in each period of both designs. Between each internment there are a period of 2 weeks of washout.<br><br>The study begins with two periods under fasting conditions (2x2x2 design under fasting conditions). After a previous fast of at least 10 hours, the sample of time 0.00 will be obtained. Next, 75 mg of amfepramone will be administered, orally with 250mL of water at room temperature.<br><br>Subsequently, the design of two periods in post-prandial conditions will be continued (2x2x2 design with food). After a previous fast of 10 hours, the sample of time 0.00 will be obtained. Likewise, 30 minutes before dosing, each research subject will receive a standard breakfast; the research subjects will have 30 minutes to finish all the breakfast and immediately afterwards the medication will be administered orally, with 250mL of water.<br><br>Breakfast is high in calories (approximately 923 kcal: 506.19 kcal fat, 241.51 kcal carbohydrate, 175.3 kcal protein) and high in fat (aprosoimadamente 54.8%).<br><br>The staff of the clinical pharmacology center is responsible for the preparation and dispensing of medicines (test or reference) must wear protective glasses, gloves, gown. the medication must always keep its identification label (container label). The study coordinator must verify that the data on the label of the medication container correspond to those of the research subject to whom the medication is delivered. The medical collaborator indicates to the research subjects when they should ingest the medication. The clinical collaborator verifies t",NA,NA,NA
main,ACTRN12619000437167,https://anzctr.org.au/ACTRN12619000437167.aspx,"This study will consist of 2 treatment periods. A popular choice among women of child-bearing potential is a monophasic oral contraceptive combination containing a fixed dose of 3 mg drospirenone (DRSP) and 0.02 mg ethinyl estradiol (EE). The study will be conducted in approximately 32 subjects. In Period 1, healthy female subjects will receive a single dose of DRSP/EE on Day 1, administered as oral tablet, followed by a washout of 5 days. In Period 2, subjects will receive AB-506 400 mg, administered as oral tablet, once daily for 13 days, with a single oral dose of DRSP/EE (same dose as Day 1) co-administered on Day 15. The duration of the study will be approximately 7 weeks, including the screening period. Subjects will take their study drug in the presence of study staff. Compliance will be confirmed by a mouth check after dosing.",NA,NA,NA
main,ACTRN12619000583145,https://anzctr.org.au/ACTRN12619000583145.aspx,"A phase 2 study, single group assignment.<br>Participants have been categorised into two cohorts upon registration into the study. Each cohort is defined as the following:<br>- Cohort 1: Participants registered to the study who have had most recent treatment with substrate-PARPi. Patients n=20 <br>- Cohort 2: Participants registered to the study who have had most recent treatment with chemotherapy. Patients n=20<br><br>Experimental drug is Pamiparib (BGB-290)<br>60 mg of Pamiparib (3 capsules of 20mg) will be administered orally twice a day, once in the morning and once in the evening continuously in 28 day cycles.<br><br>Patients will remain on treatment until progressive disease, unacceptable toxicity, patient discontinuation/withdrawal or at the discretion of the investigator. Patients who discontinue treatment due to progressive disease will be followed for survival only and patients who discontinue treatment for other reasons will be followed for progression and survival.<br><br>Patients can be on treatment continuously until 3 years after the last patient has commenced treatment. This equates to an average of 3 to 5 years for the purpose of this study<br><br>A patient diary will be used to monitor adherence to the study drug Pamiparib. <br><br>",NA,NA,NA
main,ACTRN12619000611123,https://anzctr.org.au/ACTRN12619000611123.aspx,"Orally administered encapsulated lyophilised faecal microbiota transplantation administered daily over a period of 8 weeks. Given the nature of FMT, the dose of FMT will vary.<br>-Participants will be contacted weekly to check compliance and for further reminders and arranged unused product return.",NA,NA,NA
im,ACTRN12619000617167,https://anzctr.org.au/ACTRN12619000617167.aspx,"Influenza vaccination (intramuscular injections) comparing a new two dose strategy using the trivalent high dose influenza vaccine (HD) followed by a second dose of quadrivalent standard dose (SD) influenza vaccine one month later (HD-SD, Arm 1) and the current standard two dose strategy of quadrivalent influenza vaccine one month apart (SD-SD, Arm 2). Each dose is a 0.5 mL intramuscular injection into the deltoid muscle. Annual seasonal influenza vaccination is currently recommended for patients following autoHSCT within 12 months of tranpslant. At Peter MacCallum Cancer Centre (PMCC), patients commence a program of re-vaccination at 6 months post-autoHSCT. This includes two doses of seasonal influenza vaccine (separated by 4 weeks) if they have not received this by 6 months post-transplant. Quadrivalent standard dose vaccine (FluQuadri) contains 60 micrograms (µg) haemagglutinin (HA) per 0.5 mL dose in the recommended ratio of 15 µg HA of each of the four influenza strains. Trivalent high dose vaccine (Fluzone-HD) contains 180 micrograms (µg) haemagglutinin (HA) per 0.5mL dose in the recommended ration of 60(µg) HA of each of the three influenza strains.<br>Throughout the study, patients will be sent a weekly short message service (SMS) asking whether they have experienced an ILI (fever with at least one acute respiratory symptom or sign) in the previous 7 days. Patients will also receive SMS reminders about any follow-up appointments. The use of SMS reminders has been shown to improve retention in research studies. The SMS reminder will include their appointment time and the location. Patients failing to attend their appointment will be contacted by phone to reschedule the appointment.",Yes,NA,NA
main,ACTRN12619000736145,https://anzctr.org.au/ACTRN12619000736145.aspx,Vitamin C tablets: 1g twice daily for 5 weeks<br>Commencing one week prior to HSCT<br>Adherence monitored by tablet return and plasma levels<br><br><br>,NA,Yes,Yes
main,ACTRN12619000746134,https://anzctr.org.au/ACTRN12619000746134.aspx,"All patients will  will be administered Venetoclax orally once daily (QD) Days 1 through 28, of a 28-day cycle, with a designated dose of 600 mg daily. <br>Cytarabine (20 mg/m2) will be administered by subcutaneous injection be given QD following administration of Venetoclax on Days 1-10 of every cycle.<br><br>Patients will remain on treatment for up to 24 cycles unless discontinuation criteria is met.<br>Adherence is monitored through hospital drug administration records and tablet adherence through drug packet return.",NA,NA,NA
im,ACTRN12619000792123,https://anzctr.org.au/ACTRN12619000792123.aspx,"Afluria Quad/Afluria Quad Junior<br><br>Afluria Quad/Afluria Quad Junior is an inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as either one or two intramuscular dose(s) depending on their previous history of influenza virus vaccination according to age appropriate national vaccine administration recommendations outlined in the Australian or New Zealand Immunisation Handbooks. Participants with previous history of influenza virus vaccination will receive 1 dose; and participants 6 months to <9 years receiving an influenza vaccine for the first time will receive 2 doses. <br><br>In each vaccination season, participants 6 months to less than 3 years will be randomly<br>administered one of three manufacturing batches of Afluria Quad Junior, and participants 3 years to less than 9 years will be randomly administered one of three manufacturing batches of Afluria Quad vaccine. Participants will receive the following dose depending upon their age at the time of administration of the first dose of Study Vaccine:<br> - 6 months to less than 3 years of age: 1 or 2 doses of 7.5 mcg hemagglutinin antigen<br> - 3 years to less than 9 years of age: 1 or 2 doses of 15 mcg hemagglutinin antigen<br><br><br>",Yes,NA,NA
im,ACTRN12619000829112,https://anzctr.org.au/ACTRN12619000829112.aspx,"Early Metabolic Resuscitation: After initial shock treatment including fluids and a first intravenous inotrope patients receive concomitant treatment with Hydrocortisone, Vitamin C, and Thiamine:<br>1.Ascorbic acid (Vitamin C). The dosing schedule is 30mg/kg intravenously every 6 hours for the duration of study treatment and will be infused over 1 hour. <br>2.Thiamine (Vitamin B1): The dosing schedule is 4mg/kg intravenously every 12 hours for the duration of study treatment and will be infused over 1 hour. <br>3.Hydrocortisone: The dosing schedule is 1mg/kg intravenously every 6 hours for the duration of study treatment given as a slow bolus. <br>Study drugs will be given through an existing intravenous line using. Drug delivery will occur through guardrails or similar system to ensure safe delivery of applied standardized drug concentrations.<br>Study treatments will be given for a duration of 7 days, or until resolution of shock, discharge from intensive care unit, death, or occurrence of major side effects, whichever occurs first.<br>Compliance with protocol will be assessed through the prospective institutional drug charts, and the prospective study case report form.",NA,NA,Yes
main,ACTRN12619001043123,https://anzctr.org.au/ACTRN12619001043123.aspx,"Avatrombopag will be administered by an oral tablet, 20 mg per day for 180 days. Dose will be adjusted every 2 weeks guided by reticulocyte count, platelet count/platelet transfusion and neutrophil counts.<br>Titration of avatrombopag will be based on FBE/reticulocyte counts which will be measured at every time point, day 1, 14, month 1,1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 15, 18, 21, 24.<br>A patient diary will be issued to participants which will be required at each monthly visit with their clinical trial clinician/coordinator. Any unused tablets are to be returned at each participant visit.<br>",NA,NA,NA
main,ACTRN12619001048178,https://anzctr.org.au/ACTRN12619001048178.aspx,"A five year phase III cluster randomised control trial was conducted among 18 schistosomiasis- endemic barangay comprising 18,221 residents in Northern Samar, The Philippines. We examined the impact of a combination of human mass chemotherapy, snail control through mollusciciding and SjCTPI bovine vaccination on the human incidence of infection. Following the baseline survey, the interventions were implemented in 18 intervention groups from 2013 to 2017. The investigators, including the research team, and study participants were blind to the vaccine allocation. At baseline all residents (60 mg/kg directly observed split oral dose) and bovines (30 mg/kg directly feed oral dose) were treated with a directly observed oral dose of PZQ. Villages were then pair-matched for the RCT based on historical prevalence, baseline outcomes, and transmission ecology. One of three intervention ARMs (no specific intervention (control), human mass praziquantel (PZQ) treatment, mollusciciding) were randomly assigned to each pair to achieve three pairs per intervention type. Within each pair, one village was randomly assigned the active vaccine for vaccinating bovines and the other village received a placebo vaccine. The intervention matrix is shown below:<br><br>Intervention---------Vaccinated Bovines-------Unvaccinated bovines<br><br>Mollusciciding----------3 Villages (A)----------------3 Villages (B)<br><br>Human treatment-----3 Villages (C)----------------3 Villages (C)<br><br>Neither------------------3 Villages (D)----------------3 Villages (e) Controls<br><br>Bovines received the priming SjCTPI DNA vaccine and then the protein boost or placebo control in VacSIM® six months later, in 2013 with subsequent booster vaccinations or placebo controls in VacSIM® given in 2014, 2015 and 2016. Full details of the production and formulation of the SjCTPI vaccines (plasmids encoding SjCTPI-HSP70 and UMVC3-mIL12 and recombinant SjCTPI), placebo control vaccine, the vaccination regimen, and the",Yes,NA,NA
main,ACTRN12619001079134,https://anzctr.org.au/ACTRN12619001079134.aspx,"This study will evaluate the in vivo safety and infectivity of a Plasmodium falciparum 3D7-MBE008 master cell bank (MCB) in healthy subjects using the induced blood stage malaria (IBSM) model. The study will be conducted in up to 2 subjects. The safety data review team (SDRT) will review the parasitaemia and safety data obtained from the first subject up until the end of Riamet® treatment before the second subject is inoculated with the malaria challenge agent. <br>The malaria challenge agent, containing an estimated ~2,800 viable P. falciparum 3D7 parasite-infected RBCs in a volume of 2 mL, will be administered once intravenously on Day 0. The subject will undergo intravenous cannulation with an appropriate gauge cannula. The challenge agent will be injected immediately by an infectious disease physician, and the cannula again flushed with 5-10 mL of clinical grade saline. The cannula will then be removed, and haemostasis ensured by use of an appropriate dressing. The subject will be observed for a minimum of 60 minutes after inoculation.<br>Subjects will be intravenously inoculated with P. falciparum-infected human erythrocytes on Day 0 (approximately 2,800 viable parasites). Subjects will be monitored daily via phone call or text message on Days 1 to 3 to solicit any adverse events (AEs). Subjects will then come to the clinical unit twice daily from Day 4, separated by approximately 12 hours, for safety assessments and to monitor the progression of parasitaemia by collecting blood samples and performing qPCR targeting the gene encoding P. falciparum 18S rRNA. <br>Antimalarial treatment with artemether/lumefantrine (Riamet®) will be initiated when parasitaemia reaches =10,000 parasites/mL. Subjects will be admitted to the clinical unit for earlier treatment if:<br>•t",NA,NA,NA
im,ACTRN12619001518156,https://anzctr.org.au/ACTRN12619001518156.aspx,"Patients allocated to the study gas arm will receive nitric oxide (NO), which will be blended into the fresh gas flow for the ECMO oxygenator and maintained at 20 ppm.<br>ECMO specialists and/or Perfusionists will administer the  study drug via a Nitric Oxide delivery system (such as SoKinox provided by Air Liquide Healthcare) with continuous sampling of NO and NO2 concentration from an access port just prior to the oxygenator. <br>NO will be started when the patient is cannulated for ECMO and ceased once patient is off ECMO. <br>The duration of the intervention should be equal to the duration of ECMO (i.e. several days). ECMO specialists and/or Perfusionists will record electronically the start time and stop time of the study drug.<br>Patients allocated to the intervention arm will receive standard respiratory gases (oxygen-air mix) during ECMO as per institutional practice.<br>Compliance with protocol will be assessed through the prospective institutional drug charts, and the prospective study case report form.",NA,NA,NA
main,ACTRN12619001568101,https://anzctr.org.au/ACTRN12619001568101.aspx,"Tocotrienol-Rich Vitamin E from palm oil. Details are as follows:<br>Contents:<br>1. d-Alpha-Tocotrienol 15.38 mg<br>2. d-Gamma-Tocotrienol 28.20 mg<br>3. d-Delta-Tocotrienol 6.42 mg<br>4. d-Alpha-Tocopherol 22.90 IU<br>5. Plant Squalene 12.82 mg<br>6. Phytosterol Complex 5.12 mg<br>7. Phytocarotenoid Complex 90.00 ug<br>Dose: 200mg twice daily<br>Duration: 48 weeks<br>Mode of administration: oral capsule<br><br>Adherence will be assessed by calculating the number of remaining capsules in the bottles containing investigation products given to the participants during the follow-up visits. Besides, the serum Vitamin E levels will be measured to assess adherence of the participants.",NA,NA,Yes
main,ACTRN12619001623189,https://anzctr.org.au/ACTRN12619001623189.aspx,"This is a single and multiple dose study with participants receiving oral (Z)-endoxifen 4mg tablets or placebo tablets. Participants will be assigned to the same allocated study treatment ((Z)-endoxifen or placebo) through both Part A and Part B.<br>12 healthy female volunteers will be screened 28 days prior to commencement of dosing.<br>Participants will be admitted to the clinical facility on Day -1 for up to 3 days in Part A (single dose). Participants will also be admitted for a second confinement period in Part B (multiple dose) on Day 13 for up to 3 days.<br>Part A: Single Dose<br>The first dose of study drug (one 4mg (Z)-endoxifen tablet or placebo tablet) will be administered on Day 1. Following completion of all safety assessments and sampling for PK analyses, participants will be discharged from the clinical facility on Day 3.<br>On days 4, 6, 8 and 15 participants will return to the clinical facility to attend out-patient visits including safety tests and pharmacokinetics (PK)<br>Days 2 through 25 is a study drug-free period, or daily dosing wash out period (of a minimum 25 days). The minimum period between the completion of Part A (Day 15) and commencement of Part B will be 10 days. <br>A Safety Summary, (consisting of laboratory safety data obtained though Day 6) and<br>pharmacokinetic (PK) data (through Day 6) will be analysed (in blinded manner) for review by the Principal Investigator and Sponsor’s Representative prior to the initiation (dosing) of the multiple dosing part of the study.<br><br>Part B: Multiple Dose<br>Day 1 starts the multi-dose administration period. Participants will return to the clinic for a pre-dose blood draw and commence daily oral administration of the study drug (one 4mg (Z)-endoxifen tablet or placebo tablet daily) for 14 conse",NA,NA,NA
main,ACTRN12619001694101,https://anzctr.org.au/ACTRN12619001694101.aspx,"This Randomized Controlled Trial (RCT) investigates whether the double orexin receptor antagonist suvorexant increases rapid eye movement (REM) sleep and improves fear extinction recall compared to an active control condition (temazepam) and placebo control.<br><br>Participant will be recruited and randomly assigned to the double-blinded drug condition. The intervention group receives one dose of 20mg suvorexant orally about 30 minutes before bedtime.<br>On the test day, participants will complete a standardized and well-validated fear conditioning and extinction task which examines their capacity to acquire conditioned fear (via recording skin conductance response [SCR] reflecting physiological arousal to stimuli paired with a mild electric shock) and extinguishing fear. For the fear acquisition phase, they will look at visual images of a scene containing a desktop lamp which lights up with a color. One color will be associated with a mild electrical shock (the CS+), the other colored circle is never associated with shock (the CS-). This will be followed immediately by the fear extinction phase in which they will look at both colored lights which will never be followed by shock. This paradigm is adapted from Milad, Orr, Pitman, & Rauch (2005). SCR will be recorded to reflect sympathetic arousal. SCR amplitude typically increases to the CS+ compared to the CS- in the acquisition phase, and then gradually reduces over the extinction phase. The slope of decline of SCR over the fear extinction phase reflects how well an individual can inhibit/regulate their fear and reflects their capacity for fear extinction learning. Next, participants view emotive and neutral images selected from the International Affective Picture System (IAPS). Then, participants will take the drug an",NA,NA,NA
covid,ACTRN12620000588998,https://anzctr.org.au/ACTRN12620000588998.aspx,"This is a two- stage study.<br> Stage 1:  Patients will receive STC3141 60 mg/hr as an initial infusion rate which was based on phase Ia study in health volunteer and 60mg/hr is the dosage in long term infusion in phase Ia without aPTT increase, followed by a dose increase of 10 mg/hr every 6 hours  until the max infusion rate is 100 mg/hr or the aPTT reaches 1.5 x ULN which ever comes first, then the infusion rate will be fixed in the rest of time. The infusion will continue at this rate for 72 hr. <br>Stage 2: Arm 1 will receive STC3141 with the initial infusion rate decided from Stage 1 by DSMB, the dosage will be adjusted every 6 hours according to subjects’ aPTT as same as stage 1. The target aPTT and Maximum dosage will be based on DSMB recommendation based on data from stage 1. The infusion last up to 120 hours, unless the patients is well enough to be discharged from ICU, or pass away or experienced intolerable adverse event etc.",NA,NA,NA
covid,ACTRN12620000676910,https://anzctr.org.au/ACTRN12620000676910.aspx,8 million amniotic epithelial cells (hAECs) per kg bodyweight in saline containing 2% human serum albumin will be delivered intravenously over the course of an hour by a nurse under the supervision of an ICU consultant.,NA,NA,NA
covid,ACTRN12620000816954,https://anzctr.org.au/ACTRN12620000816954.aspx,"Participants will be randomised to one of the four cohorts only.<br><br>AT-301 Nasal Spray<br>Part 1 maximum exposure - 0.4 mL total (single dose)<br>Each spray is metered to 0.1 mL, and a single dose is to be administered in Part 1. <br><br>Part 1 has Cohort 1 and Cohort 2. Participants in Cohort 1 will receive 1 spray per nostril and Participants in Cohort 2 will receive 2 sprays per nostril.<br><br>Participants will receive one or two sprays into each nostril once only.<br>Adherence will be monitored via spray returns.<br><br>Part 2 maximum exposure - 16.8 mL total (over 14 days) <br><br>Each spray is metered to 0.1 mL, and is to be taken 3 times a day. <br><br>Part 2 consists of Cohort 3 and Cohort 4. Participants in Cohort 3 will receive 1 spray per nostril and participants in Cohort 4 will receive 2 sprays per nostril<br><br>Participants will receive one or two sprays per nostril three times a day for 14 days.<br>Adherence will be monitored via spray returns.",NA,NA,NA
covid,ACTRN12620000817943,https://anzctr.org.au/ACTRN12620000817943.aspx,"RBD SARS-CoV-2 HBsAg VLP Vaccine, administered at two dose amounts, 5mcg and 25 mcg, by intramuscular injection by Investigators (or delegate) during in-clinic visit. Phase 1 will include three cohorts, to receive either 5mcg dose on Day 0 and 28; 25mcg dose on Days 0 and 28 or placebo on Day 0 and 28. <br><br>Phase 2 will evaluate both dose amounts either as single dose (given at day 0, with placebo at Day 28) or two doses (at Days 0 and 28). Participants will be randomised into one of 5 cohorts. These are 1) 5mcg dose administered on Days 0 and 28; 2) 25mcg dose administered on Days 0 and 28; 3) 5mcg dose administered on Days 0 and placebo on Day 28; 4) 25mcg dose administered on Days 0 and placebo on Day 28, or 5) placebo on day 0 and 28.<br><br>Phase 2 will commence following DSMB review of safety data from Phase 1.<br><br>Two groups of participants will be enrolled. Phase 1 will include a group of healthy adults aged 18-45. Phase 2 will include a separate group of healthy adults aged 18 - 79 years.<br><br>Participants will return to site at day 7 and 14 from vaccine administration dates to undergo safety assessments and blood sampling for immunogenicity evaluation. Further on site assessments are conducted monthly or bi-monthly for up to 180 days from date of first vaccine administration.",Yes,NA,NA
covid,ACTRN12620000841976,https://anzctr.org.au/ACTRN12620000841976.aspx,"ARM 3 - Moderate COVID-19 infection<br>Drug: Selinexor<br>Dose: 20mg 3x weekly<br>Duration: 14 days<br>Mode: oral - self administered tablet<br>adherence: supervised administration while inpatient. self reported.<br><br>Description of study design:<br>This SMART design specifies that participants entering the trial who have had no known COVID-19 exposure are initially randomised to either low-dose intranasal IFN-a or placebo as pre-exposure prophylaxis against developing COVID-19. Any participants who have a known COVID-19 exposure are randomised to high-dose IFN-a or placebo as a post-exposure prophylaxis against developing COVID-19. If, at any stage after enrolling, a participant develops ‘moderate’ COVID-19, then they are then randomised to either selinexor or placebo, and if at any stage after enrolling the participant develops ‘severe’ COVID-19 they are then randomised to either lenzilumab or placebo.<br>Importantly, participants enrolling into the trial can directly enter any of the four interventions if they meet the appropriate entry criteria.",NA,Yes,NA
covid,ACTRN12620000844943,https://anzctr.org.au/ACTRN12620000844943.aspx,"ARM 4 - Severe COVID-19 infection<br>Drug: Lenzilumab<br>Dose: 600mg 8 hourly<br>Duration: 24 hours<br>Mode: Intravenous - administered by nurse.<br>adherence: inpatient records<br><br>Description of study design:<br>This SMART design specifies that participants entering the trial who have had no known COVID-19 exposure are initially randomised to either low-dose intranasal IFN-a or placebo as pre-exposure prophylaxis against developing COVID-19. Any participants who have a known COVID-19 exposure are randomised to high-dose IFN-a or placebo as a post-exposure prophylaxis against developing COVID-19. If, at any stage after enrolling, a participant develops ‘moderate’ COVID-19, then they are then randomised to either selinexor or placebo, and if at any stage after enrolling the participant develops ‘severe’ COVID-19 they are then randomised to either lenzilumab or placebo.<br>Importantly, participants enrolling into the trial can directly enter any of the four interventions if they meet the appropriate entry criteria.",NA,Yes,NA
covid,ACTRN12620000982910,https://anzctr.org.au/ACTRN12620000982910.aspx,The investigational product ivermectin will be administered at a dose of 200µg/kg on day 1. For participants who report at day 7 follow-up that their condition has not definitely improved a second dose may be dispensed.  <br>Mode of administration is oral tablet. Drug accountability will be performed by the dispensing pharmacy.<br>Participants' will be in isolation and provide a self-report to determine if a second dose will be dispensed. The second dose will also be 200µg/kg.,NA,NA,NA
covid,ACTRN12620001048976,https://anzctr.org.au/ACTRN12620001048976.aspx,"Participants in all cohorts (impaired renal function and matched normal renal function) will receive a single dose of 100 mg Remdesivir on Day 1 in the morning, IV infusion for 30 minutes ± 5 minutes. The participants will be supervised by a health care professional during the infusion and will be confined to the clinic for up to 11 days.",NA,Yes,NA
covid,ACTRN12620001104943,https://anzctr.org.au/ACTRN12620001104943.aspx,"The study consists of 4 cohorts which will be studied sequentially. Participants in each cohort will receive a single dose of either placebo or 5 mcg, 15 mcg, 30 mcg or 50 mcg of REVTx-99 intranasally. Study drug will be administered by a registered nurse.",NA,NA,NA
im,ChiCTR-IIC-16008366,http://www.chictr.org.cn/showproj.aspx?proj=14056,OSAHS-inhaled corticosteroids(ICS):use ICS before adenotonsillectomy;,NA,NA,NA
im,ChiCTR-IIR-17011570,http://www.chictr.org.cn/showproj.aspx?proj=19604,Test Group 1:Single Dose;Test Group 2:Multiple Dose;Test Group 3:Food influence;Blank Group:Taking placebo;,NA,NA,NA
im,ChiCTR-IOR-16009102,http://www.chictr.org.cn/showproj.aspx?proj=15384,low dose vitamin D group:vitamin D 400IU;high dose vitamin D group:vitamin D 1200IU;,NA,NA,Yes
im,ChiCTR-IPD-17011387,http://www.chictr.org.cn/showproj.aspx?proj=16724,three doses:ulinastatin;,NA,NA,NA
im,ChiCTR-IPR-16008419,http://www.chictr.org.cn/showproj.aspx?proj=14187,experiment group:Conventional therapy + dexamethasone;Control group:Conventional therapy + placebo;,NA,Yes,NA
im,ChiCTR-IPR-17011522,http://www.chictr.org.cn/showproj.aspx?proj=19484,"1:Yichang HEC Changjiang Pharmaceutical Co.,Ltd. produced OSELTAMIVIR PHOSPHATE CAPSULES 7.5MG Under fasting and fed condition, respectively;2:reference product OSELTAMIVIR PHOSPHATE CAPSULES 7.5MG Under fasting and fed condition, respectively;",NA,Yes,NA
im,ChiCTR-IPR-17012450,http://www.chictr.org.cn/showproj.aspx?proj=21119,Experience group:Nebulization inhalation  Andrographolide sulfonate;Control:inhalation 0.9%NS;,NA,NA,NA
im,ChiCTR1800014691,http://www.chictr.org.cn/showproj.aspx?proj=25104,control group:none;Group 1:Methylprednisolone 1mg/kg;Group 2:Methylprednisolone 2mg/kg;,NA,NA,NA
im,ChiCTR1800014733,http://www.chictr.org.cn/showproj.aspx?proj=25020,control group:conventional therapy;Thymosin group:Thymosin 20mg intramuscular injection 1 times a day for 7 days;GM-CSF group:rhGM-CSF 250ug/m2 intravenous injection 1 times a day for 7 days;,NA,NA,NA
im,ChiCTR1800014970,http://www.chictr.org.cn/showproj.aspx?proj=25468,"Lidocaine group:Bolus 1.0-1·5 mg/kg before induction,then 1.0-1.5 mg/kg/h until 1 h after operation;Saline control group:Control group received a normal saline bolus and an infusion to simulate  the study drug;",NA,Yes,NA
im,ChiCTR1800014998,http://www.chictr.org.cn/showproj.aspx?proj=25576,"control group:normal saline 100ml, ivdrip;MSC group:hucMSCs 10^6/kg+N.S 100ml, ivdrip;",NA,NA,NA
im,ChiCTR1800015609,http://www.chictr.org.cn/showproj.aspx?proj=26398,"standard dosage group:caffeine treatment with loading dose of 20mg/kg, and maintenance dose of 5-10mg/kg;high dosage group:In case of standard regimen not works, the maintenance was increased to 20mg/kg.dose;",NA,Yes,NA
im,ChiCTR1800017571,http://www.chictr.org.cn/showproj.aspx?proj=29786,Influenza A group I:Oseltamivir granules;Influenza B group II:Oseltamivir granules;Influenza A group III:Oseltamivir capsules;Influenza B group IV:Oseltamivir capsules;,NA,Yes,NA
im,ChiCTR1800018138,http://www.chictr.org.cn/showproj.aspx?proj=30065,"Treatment Group:Hydrocortisone, Vitamin C, and Thiamine;Control Group:normal saline;",NA,NA,Yes
im,ChiCTR1800018230,http://www.chictr.org.cn/showproj.aspx?proj=30702,Group 1:Conventional therapy;Group 2:Conventional therapy + small dose methylprednisolone;Group 3:Routine treatment + blood purificatio;Normal control (for reference of neuroendocrine immune mechanism but not for treatment):Nil;,NA,NA,NA
im,ChiCTR1800018471,http://www.chictr.org.cn/showproj.aspx?proj=31202,Group 1:Probiotic intervention;Group 2:Normal treatment without probiotics;,NA,NA,NA
im,ChiCTR1800018852,http://www.chictr.org.cn/showproj.aspx?proj=31769,"EPO group:EPO 10000u, H, qd×3d;Control group:No;",NA,NA,NA
im,ChiCTR1800019173,http://www.chictr.org.cn/showproj.aspx?proj=28073,Aminophylline group: Receive a infusion of Aminophylline 3mg/kg within 30 min and followed by an infusion at 0.4mg/kg/h for 5 days;control group:Based on standard of care;,NA,NA,NA
im,ChiCTR1800019204,http://www.chictr.org.cn/showproj.aspx?proj=32446,High-dose group:10mg/kg maintenance doses of caffeine;Low-dose group:5mg/kg 10mg/kg maintenance doses of caffeine;,NA,Yes,NA
im,ChiCTR1800019454,http://www.chictr.org.cn/showproj.aspx?proj=31274,Group 1:Tan-Re-Qing capsule;Group 2:Oseltamivir;,NA,Yes,NA
im,ChiCTR1800020367,http://www.chictr.org.cn/showproj.aspx?proj=34337,Ulinastatin group:Ulinastatin treatment;Control group:Routine treatment;,NA,NA,NA
main,ChiCTR1900020551,http://www.chictr.org.cn/showproj.aspx?proj=24920,"Experimental group:Take orally, Lianhuaqingwen capsule, 1 bag per time, three times per day+ analogous oseltamivir phosphate capsule, two grains at one time, two times per day;Control group:Take orally, analogous Lianhuaqingwen capsule, 1 bag per time, three times per day+ oseltamivir phosphate capsule, two grains at one time, two times per day;",NA,Yes,NA
main,ChiCTR1900020626,http://www.chictr.org.cn/showproj.aspx?proj=34885,Group 1:0.5% ropivacaine 20ml + dexmedetomidine 0.5ug/kg;Group 2:0.5% ropivacaine 30ml + dexmedetomidine 0.5ug/kg;Group 3:0.5% ropivacaine 30ml;,NA,Yes,NA
im,ChiCTR1900020928,http://www.chictr.org.cn/showproj.aspx?proj=33420,"low-dose group:4 Baicalein Tablets and 2 placebo per time, three times a day;high-dose group:6 Baicalein Tablets per time, three times a day;placebo group:6 placebo per time, three times a day;",NA,NA,NA
main,ChiCTR1900021020,http://www.chictr.org.cn/showproj.aspx?proj=34828,low dose methylprednisolone:injevt 40mg methylprednisolone introvenous;high dose methylprednisolone:injevt 120mg methylprednisolone introvenous;control group :injevt normal saline introvenous;,NA,NA,NA
im,ChiCTR1900021135,http://www.chictr.org.cn/showproj.aspx?proj=35531,Group A:Oral oseltamivir;Group B:Intravenous drip of peramivir;,NA,Yes,NA
main,ChiCTR1900021724,http://www.chictr.org.cn/showproj.aspx?proj=35982,Experimental group:Continuous intravenous infusion of furosemide was performed at 0.2-0.5mg/kg for 24 hours after coronary interventional procedures;control group:Continuous intravenous infusion of  Normal saline was performed at 1-1.5ml/kg /h for 12 hours before operation and 24 hours after operation;,NA,NA,NA
main,ChiCTR1900021807,http://www.chictr.org.cn/showproj.aspx?proj=35109,Group 1:Standard treatment + phosphocreatine;Group 2:Standard treatment + nicodil;Group 3:Standard treatment;,NA,NA,NA
im,ChiCTR1900021886,http://www.chictr.org.cn/showproj.aspx?proj=36349,Combination treatment:oseltamivir and cefaclor sustained-release tablets;Antibiotic:cefaclor sustained-release tablets and placebo;anti-influenza:oseltamivir;control:placebo;,NA,Yes,NA
main,ChiCTR1900021970,http://www.chictr.org.cn/showproj.aspx?proj=28261,1:benaglutide plus metformin;2:biphasic insulin aspart 30 plus metformin;,NA,NA,NA
main,ChiCTR1900022030,http://www.chictr.org.cn/showproj.aspx?proj=36478,Group 1:Autologous immunotherapy+Surgical;Group 2:Surgical;Group 3:Autologous immunotherapy+MIT;Group 4:MIT;Group 5:Autologous immunotherapy+general treatment;advance group:general treatment;,NA,NA,NA
im,ChiCTR1900022050,http://www.chictr.org.cn/showproj.aspx?proj=32170,"Sevoflurane group:Induced by inhalation of 8% sevoflurane and remifentanil 1 µ g kg-1, 2 ~ 5% sevoflurane (BIS to 40 µ g) was inhaled during operation, and remifentanil (1 µ g kg- 1 ·min-1) was continuously infused to maintain anesthesia;Propofol group :Induced by remifentanil (1 µ g/ kg-1 and propofol 2 -4 mg /kg-1 , and infusion of  propofol (9 /-15 mg/ kg- 1 ·h-1)  and  remifentanil( 1 µ g/ kg-1) to maintain  anesthesia with BIS between 40 and 50  ;",NA,NA,NA
im,ChiCTR1900022125,http://www.chictr.org.cn/showproj.aspx?proj=13073,Group 1:basic treatment+Oseltamivir+recombinant human interferon a1b;Group 2:Basic treatment+oseltamivir + inhalation mimetic;,NA,Yes,NA
main,ChiCTR1900022280,http://www.chictr.org.cn/showproj.aspx?proj=37648,A:Control;B:Topical TXA 1g/100ml;C:Topical TXA 2g/100ml;D:Topical TXA 3g/100ml;,NA,NA,NA
im,ChiCTR1900022429,http://www.chictr.org.cn/showproj.aspx?proj=37757,Experimental group:Buzhong Yiqi Decoction Combined with Basic Therapy;contrast group: Basic Therapy;,NA,NA,NA
im,ChiCTR1900022862,http://www.chictr.org.cn/showproj.aspx?proj=37947,Group1:Routine treatment;Group2:Routine treatment combined with low dose esmolol;Group 3:Routine treatment combined with high dose esmolol;,NA,NA,NA
im,ChiCTR1900022903,http://www.chictr.org.cn/showproj.aspx?proj=38615,"Experimental group:Qingfei Xiaoyan Pills, 60 pills * 3 times / day * 5 days;Control group:Oseltamivir phosphate capsule, 75mg*2 times/day*5 days;",NA,Yes,NA
main,ChiCTR1900022911,http://www.chictr.org.cn/showproj.aspx?proj=38634,1:use calf blood eye drops;2:use 0.3% sodium hyaluronate;,NA,NA,NA
main,ChiCTR1900022946,http://www.chictr.org.cn/showproj.aspx?proj=38661,1:Tegafur combined with Thalidomide;2:Tegafur;,NA,NA,NA
main,ChiCTR1900022982,http://www.chictr.org.cn/showproj.aspx?proj=38613,Group A:Oral Pyridoxine 60mg/d;Group B:Oral placebo 6 pills/d;,NA,NA,NA
main,ChiCTR1900023297,http://www.chictr.org.cn/showproj.aspx?proj=35595,Experiment Group:Basic therapy + Cognitive rehabilitation training+ Modified Suanzaoren Decoction;Control group 1:Basic therapy + Cognitive rehabilitation training + Estazolam;Control group 2:Basic therapy + Cognitive rehabilitation training;,NA,NA,NA
main,ChiCTR1900023364,http://www.chictr.org.cn/showproj.aspx?proj=39349,1:Basic treatment + 5days of prednisone + 4 days of prednisone placebo + Modified Bushen Yiqi Fang granules placebo;2:Basic treatment + 5 days of prednisone + 4 days of prednisone placebo + Modified Bushen Yiqi Fang granules;3:Basic treatment + 9 days of prednisone + Modified Bushen Yiqi Fang granules placebo;4:basic treatment + 9 days of prednisone + Modified Bushen Yiqi granules;,NA,NA,NA
main,ChiCTR1900023378,http://www.chictr.org.cn/showproj.aspx?proj=39378,1:Traditional Chinese Medicinal Hantangping formula;2:Metformin Tables;3:Hantangping formula + Metformin Tables;,NA,NA,Yes
main,ChiCTR1900023385,http://www.chictr.org.cn/showproj.aspx?proj=39435,experimental group :Desflurane combined with dexmedetomidine;control group:Desflurane;,NA,NA,NA
main,ChiCTR1900023411,http://www.chictr.org.cn/showproj.aspx?proj=39443,Lidocaine Group:systemic lidocaine;TAP block Group:TAP block;Control Group:None;,NA,Yes,NA
main,ChiCTR1900023427,http://www.chictr.org.cn/showproj.aspx?proj=38906,1:Guidance of glucocoticoids in patients with AECOPD by peripheal blood eosinophils;2:Traditional treatment;,NA,NA,Yes
main,ChiCTR1900023515,http://www.chictr.org.cn/showproj.aspx?proj=38275,experimental group :statins;control group:without statins;,NA,NA,NA
main,ChiCTR1900023679,http://www.chictr.org.cn/showproj.aspx?proj=25839,herbal group:herbal LC09 and routine care;control group:placebo and routine care;,NA,NA,Yes
main,ChiCTR1900023690,http://www.chictr.org.cn/showproj.aspx?proj=39815,"Experimental group:primary immunization at 2, 3, 4 months; the booster immunization at 18 months;positive control group:primary immunization at 2, 3, 4 months; the booster immunization at 18 months;",NA,NA,NA
main,ChiCTR1900024129,http://www.chictr.org.cn/showproj.aspx?proj=40515,experimental group :Levosimendan combined with conventional therapy;control group:conventional therapy;,NA,NA,NA
im,ChiCTR1900024129,http://www.chictr.org.cn/showproj.aspx?proj=40515,experimental group :Levosimendan combined with conventional therapy;control group:conventional therapy;,NA,NA,NA
main,ChiCTR1900024261,http://www.chictr.org.cn/showproj.aspx?proj=40346,A:methotrexate (7.5~15 mg/week)+ placbo (1 mg/d);B:sirolimus (1 mg/d) + methotrexate (7.5~15 mg/week);,NA,NA,NA
main,ChiCTR1900024370,http://www.chictr.org.cn/showproj.aspx?proj=40238,expreimental group:prednisolone+MMF;control group:diuretics+methylprednisolone;,NA,NA,NA
main,ChiCTR1900024414,http://www.chictr.org.cn/showproj.aspx?proj=39680,Group A:Use premixed insulin and metformin;Group B:Use premixed insulin and shaaglitine;Group C:Use short-acting insulin + long-acting insulin;Group D:Use short-acting insulin + long-acting insulin and shaaglitine;,NA,NA,NA
main,ChiCTR1900024591,http://www.chictr.org.cn/showproj.aspx?proj=41168,TCM Group:Prednisone+New Wumeiwan Formula;Convenience medicine Group:Prednisone+Mesalazine Enteric-coated tablets (Salofalk);Combined Group:Prednisone+New Wumeiwan Formula+Mesalazine Enteric-coated tablets(Salofalk);,NA,NA,NA
main,ChiCTR1900024606,http://www.chictr.org.cn/showproj.aspx?proj=40236,Group 1:continuous subcutaneous insulin infusion;Group 2:multiple subcutaneous insulin injection;,NA,NA,NA
main,ChiCTR1900024622,http://www.chictr.org.cn/showproj.aspx?proj=41119,experimental group 1:ENDOSTAR & AP;control group 1:AP;experimental group 2:ENDOSTAR & GP;control group 2:GP;,NA,NA,NA
im,ChiCTR1900024825,http://www.chictr.org.cn/showproj.aspx?proj=41485,"Experimental group:Sulbactam in combination with Ceftazidime and doxycycline Infected patients who meet the inclusion criteria will receive 4.0g ceftazidime plus 8.0g sulbactam per day by intravenous infusion together and followed by doxycycline 0.2g per day for 7 to 14 days. Intervention: Drug: Sulbactam Drug: ceftazidime D;Control group:Cefoperazone-sulbactam (2:1) in combination with doxycycline Infected patients who meet the inclusion criteria will receive Sulperazon (cefoperazone-sulbactam, 2 vs 1) 12.0g per day by intravenous infusion and followed by doxycycline 0.2g per day for 7 to 14 days. Intervention: Drug: cefoperazone-Sulba;",NA,NA,NA
main,ChiCTR1900024830,http://www.chictr.org.cn/showproj.aspx?proj=41484,experimental group:cefuroxime;control group:cefotaxime sodium and sulbactan sodium;,NA,NA,NA
main,ChiCTR1900025151,http://www.chictr.org.cn/showproj.aspx?proj=42074,Group1:Induced by sufentanil;Group2:Induced by remifentanil;Group3:Induced by remifentanil+surface anesthesia;,NA,NA,NA
main,ChiCTR1900025244,http://www.chictr.org.cn/showproj.aspx?proj=42211,"Methylprednisolone group:common medical treatment, combined with methylprednisolone 40mg intravenously once a day, discontinued after 5 days;Zidaxian group:common medical treatment, combined with the Zidaxian 1.6mg subcutaneous injection once a day, discontinued after 5 days.;Control group:Routine medical treatment.;",NA,NA,NA
main,ChiCTR1900025438,http://www.chictr.org.cn/showproj.aspx?proj=42558,Group C:Saline ;nalbuphine group:Nalbuphine;Lidocaine group:Lidocaine;,NA,Yes,NA
main,ChiCTR1900025871,http://www.chictr.org.cn/showproj.aspx?proj=43196,Experimental group:pyrotinib combined with treatment of physicians choice (TPC);Control group:TPC;,NA,NA,NA
main,ChiCTR1900025907,http://www.chictr.org.cn/showproj.aspx?proj=42673,Group 1:Intraarticular stem cells injection with shame low intensity pulsed ultrasound;Group 2:receive Intraarticular stem cells injection with low intensity pulsed ultrasound;Group 3:Normal saline with low intensity pulsed ultrasound;,NA,Yes,NA
main,ChiCTR1900025938,http://www.chictr.org.cn/showproj.aspx?proj=42791,"Experimental Group:FTZ 4 capsules each time (2.52g), 3 times a day;Control group:FTZ simulant 4 capsules per time, 3 times a day;",NA,NA,NA
im,ChiCTR1900026086,http://www.chictr.org.cn/showproj.aspx?proj=42335,"Experimental:Under the basal therapy, experimental group will be proffered a continues infusion of SFI (40ml SFI dissolved in 10ml 5% GLI in each set, and proceeded according to the same volume) for 96 hours via a light-proof syringe and infusion set with a infusion speed of 5ml/h;Control :Under the basal therapy, control group will be proffered a continues infusion of placebo (50ml 5% GLI in each set, and proceeded according to the same volume) for 96 hours via a light-proof syringe and infusion set with a infusion speed of 5ml/h;",NA,NA,NA
main,ChiCTR1900026118,http://www.chictr.org.cn/showproj.aspx?proj=43632,Group S:single inhalation of 6% sevoflurane with a mask;Group K:intranasal ketamine 2 mg/kg;,NA,NA,NA
main,ChiCTR1900026129,http://www.chictr.org.cn/showproj.aspx?proj=43613,A:quadratus lumborum block with 0.33% ropivacaine;B:quadratus lumborum block with 0.33% ropivacaine combined with 1 ug/kg dexmedetomidine;C:quadratus lumborum block with 0.25% ropivacaine combined with 1 ug/kg dexmedetomidine;D:quadratus lumborum block with 0.25% ropivacaine combined with 0.75ug/kg dexmedetomidine;,NA,Yes,NA
im,ChiCTR1900026362,http://www.chictr.org.cn/showproj.aspx?proj=33578,A2:Vitamin E administered via gastric tube 50mg/d;A3:Vitamin E administered via gastric tube 100mg/d;B2:Vitamin E administered via gastric tube 50mg/d;B3:Vitamin E administered via gastric tube 100mg/d;C2:Vitamin E administered via gastric tube 50mg/d;C3:Vitamin E administered via gastric tube 100mg/d;normal nutrition group (A)1:placebo;nutrition risk group (B) 2:placebo;malnutrition group (C)1:placebo;,NA,NA,Yes
main,ChiCTR1900026563,http://www.chictr.org.cn/showproj.aspx?proj=44091,experimental group:Oral vitamin D3;control group:none;,NA,NA,Yes
main,ChiCTR1900026602,http://www.chictr.org.cn/showproj.aspx?proj=44333,"Experimental group:TKI / TKI + statins were added. TKI dose: Imatinib 0.3g-0.4g/day or Dashatinib 50mg-100mg/day. Atorvastatin Calcium Tablets were treated with 10-40 mg/day according to its routine dosage. The course of treatment was 12 months. The follow-up period was 36 months;Control group:Conventional anti-cGVHD drugs, such as hormones, immunosuppressants, monoclonal antibodies, etc.;",NA,NA,NA
main,ChiCTR1900026713,http://www.chictr.org.cn/showproj.aspx?proj=44492,TR group:Phase I: T; Phase II: R;RT group:Phase I: R; Phase II: T;,NA,NA,NA
main,ChiCTR1900026747,http://www.chictr.org.cn/showproj.aspx?proj=44597,Experimental group:Intravenous injection of ulinastatin;Control group:Placebo (0.9% normal saline);,NA,NA,NA
main,ChiCTR1900026751,http://www.chictr.org.cn/showproj.aspx?proj=44546,Group 1:conventional TACE;Group 2:cTACEcombined with HAIC;,NA,NA,NA
main,ChiCTR1900026772,http://www.chictr.org.cn/showproj.aspx?proj=44533,"BAT1406:BAT1406, 40mg/0.8ml/box, subcutaneous insulin;Humira:Humira, 40mg/0.8ml/box, subcutaneous insulin;",NA,NA,NA
main,ChiCTR1900026827,http://www.chictr.org.cn/showproj.aspx?proj=44444,1:Remifentanil ;2:sufentanil ;,NA,NA,NA
main,ChiCTR1900026938,http://www.chictr.org.cn/showproj.aspx?proj=44890,experimental group:Hydroxychloroquine;control group:Placebo;,NA,Yes,NA
main,ChiCTR1900027042,http://www.chictr.org.cn/showproj.aspx?proj=44237,Trial Group:fire needle;Control Group:0.1% tacrolimus ointment;,NA,NA,NA
main,ChiCTR1900027049,http://www.chictr.org.cn/showproj.aspx?proj=45086,Experimental group:Conventional treatment Plus Take Huangqi Xiaobai Granule;Control group:Conventional treatment Plus placebo of Huangqi Xiaobai Granule;,NA,NA,NA
main,ChiCTR1900027112,http://www.chictr.org.cn/showproj.aspx?proj=44713,experimental group:Nab-TPC regimen;Control group:gemcitabine plus cisplatin;,NA,NA,NA
im,ChiCTR1900027121,http://www.chictr.org.cn/showproj.aspx?proj=43921,"Group-1:Mycophenolate mofetil dispersible tablets 2 g /d; Steroid 0.75 mg/kg/d;Group-2:Tacrolimus capsule, 3mg/d, Steroid 0.75 mg/kg/d;Group-3:Cyclophosphamide 1-2mg/kg/d, Steroid 0.75 mg/kg/d;Control group:Steroid from 0.75 mg/kg/d to 15 mg/d.;",NA,NA,NA
main,ChiCTR1900027140,http://www.chictr.org.cn/showproj.aspx?proj=44104,Experimental Group1:Dental pulp stem cell complex + Bio-Oss bone meal;Experimental Group2:Dental pulp stem cell + exosome complex + Bio-Oss bone meal;Control group:Bio-Oss bone meal;,NA,Yes,NA
main,ChiCTR1900027380,http://www.chictr.org.cn/showproj.aspx?proj=45656,A:Oral carvedilol;B:PSE;,NA,NA,NA
main,ChiCTR1900027390,http://www.chictr.org.cn/showproj.aspx?proj=45544,Low dose level:infuse 0.3×10^6 CAR+ T Cells/kg;Middle dose level:infuse 0.6×10^6 CAR+ T Cells/kg;High dose level:infuse 1.0×10^6 CAR+ T Cells/kg;,NA,NA,NA
main,ChiCTR1900027477,http://www.chictr.org.cn/showproj.aspx?proj=44787,experimental group:Take fresh motherworst capsules;control group:Take motherworst capsules;,NA,NA,NA
im,ChiCTR1900027824,http://www.chictr.org.cn/showproj.aspx?proj=43897,Series 1:Lefamulin Injection to Lefamulin Tablets;Series 2:Lefamulin Tablets to Lefamulin Injection;,NA,NA,NA
im,ChiCTR1900028215,http://www.chictr.org.cn/showproj.aspx?proj=46894,Case series:Aliskiren;,NA,NA,NA
covid,ChiCTR2000029308,http://www.chictr.org.cn/showproj.aspx?proj=48684,"intervention group:Lopinavir-ritonavir tablets (each containing 200 mg of lopinavir and  50 mg of ritonavir), twice a day, 2 tablets at a time;Control group:Conventional standardized treatment;",NA,Yes,NA
covid,ChiCTR2000029387,http://www.chictr.org.cn/showproj.aspx?proj=48782,arm A:Ribavirin + Interferon alpha-1b;arm B:lopinavir / ritonavir + interferon alpha-1b;arm C:Ribavirin + LPV/r+Interferon alpha-1b;,NA,Yes,NA
covid,ChiCTR2000029638,http://www.chictr.org.cn/showproj.aspx?proj=49224,Treatment group:baseline antiviral treatment (lopinavir / ritonavir or abidol) and inhaled with rSIFN-co;Control group:baseline antiviral treatment  (lopinavir / ritonavir or abidol) and inhaled with interferon-a;,NA,Yes,NA
covid,ChiCTR2000029742,http://www.chictr.org.cn/showproj.aspx?proj=49297,General patients treated with normal treatment:Normal Treatment;General patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;Severe patients control group 1:Normal treatment plus hormonotherapy;Severe patients control group 2:Normal Treatment;Severe patients experimental group:Normal Treatment plus Sodium Aescinate for Injection;,NA,NA,NA
covid,ChiCTR2000029757,http://www.chictr.org.cn/showproj.aspx?proj=49081,Experimental group:Conventional treatment and convalescent plasma therapy;Control group:Conventional treatment;,NA,Yes,NA
covid,ChiCTR2000029760,http://www.chictr.org.cn/showproj.aspx?proj=49369,Experimental group:Hydroxychloroquin;Control group:Lopinavir /Ritonavir;,NA,Yes,NA
covid,ChiCTR2000029768,http://www.chictr.org.cn/showproj.aspx?proj=49131,"experimental group:Diammonium Glycyrrhizinate Enteric-coated Capsules (oral, 150mg, Tid), Vitamin C tablets (oral, 0.5g, QD) and clinical standard antiviral treatment;control group:clinical standard antiviral treatment;",NA,NA,Yes
covid,ChiCTR2000029817,http://www.chictr.org.cn/showproj.aspx?proj=49384,"High dose group:High-dose NK cells (>5x10^9)and mesenchymal stem cells(>5x10^9),Intravenous infusion once every two days for a total of five times;Conventional dose group:Conventional dose NK cells (>3x10^9)and mesenchymal stem cells(>3x10^9),Intravenous infusion once every two days for a total of three times;Preventive dose group:Preventive dose NK cells (>3x10^9)and mesenchymal stem cells(>3x10^9),Intravenous infusion once every week for a total of one time;",NA,Yes,NA
covid,ChiCTR2000029826,http://www.chictr.org.cn/showproj.aspx?proj=49481,"Phosphoric chloroquine:2 tablets phosphoric chloroquine BID, complicated with therapy recommended by ""New Coronavirus Infected Pneumonia Diagnosis and Treatment Scheme (revision of Trial Version 5)"";Placebo:2 tablets placebo BID;",NA,Yes,NA
covid,ChiCTR2000029899,http://www.chictr.org.cn/showproj.aspx?proj=49536,"hydroxychloroquine sulfate:Day1: first dose: 6 tablets(0.1g/table), second dose: 6 tablets (0.1g/table)after 6h ;Day2~5: 2 tablets (0.1g/table), BID;phosphate chloroquine:Day1-3:500mg,BID Day4-5:250mg,BID;",NA,Yes,NA
covid,ChiCTR2000029984,http://www.chictr.org.cn/showproj.aspx?proj=49712,Experimental group:Routine treatment +biological preparation of human placenta;Control group:conventional therapy;,NA,NA,NA
covid,ChiCTR2000029996,http://www.chictr.org.cn/showproj.aspx?proj=49510,Low-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 1600 mg per time on first day; the duration of treatment will be 10 d.;Middle-dose group:Tablets; 200mg; orally; twice a day;The adult dose is 1800 mg per time on first day; the duration of treatment will be 10 d.;High-dose group:Tablets; 200mg; oral; twice a day; The adult dose is 2400 mg per time on first day; the duration of treatment will be 10 d.;,NA,NA,NA
covid,ChiCTR2000030002,http://www.chictr.org.cn/showproj.aspx?proj=49738,control group:conventional therapy;Experience group:conventional therapy and Tranilast;,NA,NA,NA
covid,ChiCTR2000030041,http://www.chictr.org.cn/showproj.aspx?proj=49891,Case series:FNC;,NA,NA,NA
covid,ChiCTR2000030058,http://www.chictr.org.cn/showproj.aspx?proj=49831,Experimental group :Oral leflunomide;Control group:Oral placebo;,NA,NA,NA
covid,ChiCTR2000030138,http://www.chictr.org.cn/showproj.aspx?proj=50004,Experimental group:Intravenous injection of human umbilical cord mesenchymal stem cells (UC-MSC);Control group:Routine treatment + placebo;,NA,Yes,NA
covid,ChiCTR2000030218,http://www.chictr.org.cn/showproj.aspx?proj=50115,Experimental group of ordinary COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;Control group of ordinary COVID-19:Keep ritonavir/ritonavir treatment;Experimental group of severe COVID-19:Lopinavir / ritonavir tablets combined with Xiyanping injection;,NA,Yes,NA
covid,ChiCTR2000030224,http://www.chictr.org.cn/showproj.aspx?proj=49968,1 the critical group :injecting Mesenchymal stem cells;2 the severe group:injecting Mesenchymal stem cells;3 the control group of the critical group:injecting normal saline;4 the control group of the severe group:injecting normal saline;,NA,Yes,NA
covid,ChiCTR2000030259,http://www.chictr.org.cn/showproj.aspx?proj=49918,"Experimental group:Danoprevir sodium tablets,/ritonavir oral;Control group:Symptomatic treatment;",NA,Yes,NA
covid,ChiCTR2000030262,http://www.chictr.org.cn/showproj.aspx?proj=50136,Group 1:Standard therapy plus aerosol inhalation for 3 times (once for every day);Group 2:Standard therapy plus aerosol inhalation for 3 times (once for every 2 days);Third group:Standard therapy;Fourth group:Standard therapy plus aerosol inhalation for 6 times (once for every day);,NA,NA,NA
covid,ChiCTR2000030300,http://www.chictr.org.cn/showproj.aspx?proj=50022,Case series:mesenchymal stem cells therapy;,NA,Yes,NA
covid,ChiCTR2000030314,http://www.chictr.org.cn/showproj.aspx?proj=50248,Case series:Traditional Chinese medicine Ma-Xing-Shi-Gan-Tang and Sheng-Jiang-San;,NA,NA,Yes
covid,ChiCTR2000030398,http://www.chictr.org.cn/showproj.aspx?proj=50173,"Experimental group:Capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;Control group:Simulated capsules of bismuth potassium citrate, 2 capsules at a time, once every 12 hours; take warm water with breakfast and dinner; do not take high protein foods such as milk at the same time.;",NA,NA,NA
covid,ChiCTR2000030480,http://www.chictr.org.cn/showproj.aspx?proj=50470,Interferon Therapy Group:Standard treatment + cerrokin (recombinant human interferon alpha 1beta) 10UG BID is administered by nebulization for 10 days.;Control group:Standard treatment + blank;,NA,Yes,NA
covid,ChiCTR2000030545,http://www.chictr.org.cn/showproj.aspx?proj=50126,"Control group:Basic treatment refers to the treatment according to the diagnosis and treatment plan of the health care Commission (Sixth Edition). (after three days of medication, if the symptoms cannot be controlled in time and effectively, the patients can be sent out of the group immediately to receive the treatment&#;Experimental group 1:Basic treatment + honeysuckle oral liquid at a low dose of 60ml / time, three times a day;Experimental group 2:Basic treatment + honeysuckle oral liquid high dose group, honeysuckle oral liquid120ml / time, three times a day.;",NA,NA,NA
covid,ChiCTR2000030627,http://www.chictr.org.cn/showproj.aspx?proj=50727,Experimental group:Convalescent plasma therapy + routine treatment;Control group:routine treatment;,NA,Yes,NA
covid,ChiCTR2000030701,http://www.chictr.org.cn/showproj.aspx?proj=50795,"experimental group:Based on the standard treatment recommended in the guidelines, a combination of Prolongin (Enoxaparin Sodium Injection) was used.;control group:Follow the guidelines for standard treatment.;",NA,NA,NA
covid,ChiCTR2000030704,http://www.chictr.org.cn/showproj.aspx?proj=50778,Experimental group:Bufonis venenum injection;Control group:0.9% N.S.;,NA,NA,NA
covid,ChiCTR2000030810,http://www.chictr.org.cn/showproj.aspx?proj=50986,Experimental group:oral medicine(trditional medicine);control group:oral medicine( anti virious);,NA,NA,NA
covid,ChiCTR2000030835,http://www.chictr.org.cn/showproj.aspx?proj=51050,High dose group:routine treatment + MSc (2 x10^6 / kg / time);Low dose group:routine treatment + MSc (1x10^6 / kg / time);,NA,NA,NA
covid,ChiCTR2000030892,http://www.chictr.org.cn/showproj.aspx?proj=51118,Experimental group:Pirfenidone;Control group:Blank;,NA,NA,NA
covid,ChiCTR2000030920,http://www.chictr.org.cn/showproj.aspx?proj=50476,Tricholoma matsutake group:Taking tricholoma matsutake ;Cannabis sativa capsule group:Taking cannabis sativa capsule ;Dendrobium candidum group:Taking dendrobium candidum;Routine treatment group:Taking routine drugs and food;,NA,NA,NA
covid,ChiCTR2000030939,http://www.chictr.org.cn/showproj.aspx?proj=51059,Case series:oral CSA0001;,NA,NA,NA
covid,ChiCTR2000030946,http://www.chictr.org.cn/showproj.aspx?proj=51265,1:7/5000   Low molecular weight heparin therapy;2:The mechanical prevention;,NA,Yes,NA
covid,ChiCTR2000031319,http://www.chictr.org.cn/showproj.aspx?proj=51647,hDPSCs group:Routine treatment + Intravenous injection of human dental pulp stem cells;Control group:Routine treatment + Placebo;,NA,Yes,NA
covid,ChiCTR2000031430,http://www.chictr.org.cn/showproj.aspx?proj=49254,Experimental group:Conventional treatment regimen + MSC treatment;Control group:Conventional treatment regimen;,NA,NA,NA
covid,ChiCTR2000031672,http://www.chictr.org.cn/showproj.aspx?proj=51940,Experimental Group:Xiaotan Sanjiefang granule;Control Group:placebo (contain 5% test drug);,NA,NA,NA
covid,ChiCTR2000031781,http://www.chictr.org.cn/showproj.aspx?proj=52006,1:Middle dose (1E11vp);2:Low dose (5E10vp);3:placebo;,NA,NA,NA
covid,ChiCTR2000032135,http://www.chictr.org.cn/showproj.aspx?proj=52506,"Experimental group: mild cases:Ulinastatin 300,000 IU, Q12H;Experimental group: severe or critical cases:Severe cases: 1 million IU of ulinastatin, Q8H; Critical cases: ulinastatin 1.6 million IU, Q8H;Control group: mild cases:conventional therapy;Control group: severe or critical cases :conventional therapy;",NA,NA,NA
covid,ChiCTR2000032487,http://www.chictr.org.cn/showproj.aspx?proj=52394,Experimental group:Administration of hydroxychloroquine sulfate;control group:Placebo given;,NA,Yes,NA
covid,ChiCTR2000032573,http://www.chictr.org.cn/showproj.aspx?proj=53225,"Control:conventional therapy;Experimental group:Bufei Huoxue Capsule, 1.4g/day, three times a day, three months of treatment;",NA,NA,NA
covid,ChiCTR2000033133,http://www.chictr.org.cn/showproj.aspx?proj=53925,Experimental group:standard treatment + shuanghuanglian treatment;Control group:standard treatment;,NA,NA,NA
covid,ChiCTR2000033323,http://www.chictr.org.cn/showproj.aspx?proj=54346,Case series:convalescent plasma of COVID;,NA,Yes,NA
covid,ChiCTR2000033774,http://www.chictr.org.cn/showproj.aspx?proj=55097,Experimental group:Bromhexine Hydrochloride Tablets + Standard treatment;Control group:Standard treatment;,NA,NA,NA
covid,ChiCTR2000034076,http://www.chictr.org.cn/showproj.aspx?proj=55582,Case series:COVID19 s-vax loaded autologous dendritic cell injection;,NA,NA,NA
covid,ChiCTR2000034825,http://www.chictr.org.cn/showproj.aspx?proj=56834,1:Adult-Low dose;2:Adult-High dose;3:Adult-Placebo;4:Elderly-Low dose;5:Elderly-High dose;6:Elderly-Placebo;,NA,NA,NA
covid,ChiCTR2000035633,http://www.chictr.org.cn/showproj.aspx?proj=57741,"Group 1:Atomization treatment, 0.2mg IFN-k/ 0.5 mg TFF2;Group 2:Atomization treatment, 1mg IFN-k/ 2.5 mg TFF2;Group 3:Atomization treatment, 2mg IFN-?/ 5 mg TFF2;Group 4:Atomization treatment, 4mg IFN-?/ 10 mg TFF2;",NA,NA,NA
covid,ChiCTR2000037782,http://www.chictr.org.cn/showproj.aspx?proj=55421,Experimental group:vaccination;Placebo control group:vaccination;,NA,NA,NA
covid,ChiCTR2000038152,http://www.chictr.org.cn/showproj.aspx?proj=59326,experimental group:Vaccine INO-4800;control group:placebo;,Yes,NA,NA
covid,ChiCTR2000038740,http://www.chictr.org.cn/showproj.aspx?proj=62250,Jiexingjunzi granule group:Jiexingjunzi granules;Qibei Fuzheng granule formation:Qibei Fuzheng granule;,NA,NA,NA
im,CTRI/2016/12/007559,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14195,Intervention1: Short duration caffeine therapy-Stopping Caffeine for Apnea of Prematurity after 7 apnea free days.: Caffeine therapy in all premature infants for treatment of apnea will be stopped after attaining 7 apnea free days.<br>Control Intervention1: Longer duration of Caffeine therapy- Continuing caffeine for Apnea of Prematurity till infants reach 34 completed weeks.: caffeine therapy in all premature infants for treatment of apnea will be continued till infants reach 34 completed weeks.<br>,NA,Yes,NA
im,CTRI/2017/01/007726,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=14266,Intervention1: Leucoreduced Packed Red blood cell: GroupI Will receive PRBC if hemoglobin less than 7 gm/dl<br>Group II will receive PRBC if hemoglobin less than 9 gm/dl<br>Intervention2: Leukoreduced Packed red blood cell: Transfuse if hemoglobin is less than 7 gm/dl and maintain hemoglobin between 7gm/dl to 9 gm/dl<br>Control Intervention1: Leukoreduced Packed red blood cell: Transfuse if hemoglobin is less than 9 gm/dl and maintain hemoglobin between 9 gm/dl to 11 gm/dl.<br>,NA,NA,NA
im,CTRI/2017/02/007782,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=12039,Intervention1: inj. hydrocortisone: 100mg vial 5mg/kg/dose thrice daily for 3 days<br>Control Intervention1: Inj cefotaxime: 250mg vial 5mg/kg/day thrice daily for 3 days. similar looking vial withrespect to intervention drug<br>,NA,NA,NA
im,CTRI/2017/04/008326,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=17527,"Intervention1: Dexamethasone: A single course of 6mg IM dexamethasone administered every 12 hours, to a total of four (4) doses (time points 0 hours, 12 hours, 24 hours and 36 hours)<br>Control Intervention1: Identical placebo: A single course of 6mg IM Identical placebo administered every 12 hours, to a total of four (4) doses (time points 0 hours, 12 hours, 24 hours and 36 hours)<br>",NA,Yes,NA
im,CTRI/2017/05/008530,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=18443,"Intervention1: Group D- receives dexmedetomidine for sedation: Dexmedetomidine bolus of 1mcg/kg given over 10 minutes, followed by infusion at 0.5 mcg/ kg/hour -1mcg/kg/hour  to achieve the required sedation depth<br>Control Intervention1: Group p- receives propofol for sedation: Group P- (Propofol infusion  at 100 mcg/kg/min with intermittent boluses of 0.1 -0.2 mg/kg to <br>achieve the required sedation depth)<br><br>",NA,NA,NA
im,CTRI/2017/08/009273,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=17286,"Intervention1: DEXAMETHASONE: Study group (24-hour pre-treatment with 0.25mg/Kg/dose): In this group (henceforth will be called as Group 1), patients will receive 6 doses of intravenous dexamethasone (0.25mg/Kg/dose, max 4mg/dose). The first dose will be administered 24 hour before anticipated extubation and will subsequently every 6 hours for a total of 6 doses. The planned extubation will be done during daytime immediately after receiving the 5th dose of dexamethasone.<br>Control group (24-hour pre-treatment with 0.5mg/Kg/dose): In this group (henceforth will be called as Group 2),patients will receive 6 doses of intravenous dexamethasone(0.5mg/Kg/dose, max 8mg/dose). The first dose will be administered 24 hour before anticipated extubation and will subsequently every 6 hours for a total of 6 doses. The planned extubation will be done during daytime immediately after receiving the 5th dose of dexamethasone  <br><br>Control Intervention1: DEXAMETHASONE: Study group (24-hour pre-treatment with 0.25mg/Kg/dose): In this group (henceforth will be called as Group 1), patients will receive 6 doses of intravenous dexamethasone (0.25mg/Kg/dose, max 4mg/dose). The first dose will be administered 24 hour before anticipated extubation and will subsequently every 6 hours for a total of 6 doses. The planned extubation will be done during daytime immediately after receiving the 5th dose of dexamethasone. Control group (24-hour pre-treatment with 0.5mg/Kg/dose): In this group (henceforth will be called as Group 2),patients will receive 6 doses of intravenous dexamethasone(0.5mg/Kg/dose, max 8mg/dose). The first dose will be administered 24 hour before anticipated extubation and will subsequently every 6 hours for a total of 6 doses. The planned extubation will be done during daytime immediate",NA,Yes,NA
im,CTRI/2018/01/011387,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=21993,Intervention1: FluCare Capsule: Each Flu Care capsule consists of combination of seven polyherbal formulation (350 mg). Participant will be instructed to take one capsule thrice daily at a fixed time in the day for the study duration of 7 days along with 75 mg of Oseltamivir.<br>Control Intervention1: Standard of Care Group- Active Comparator: Standard of care consist of 75 mg of Oseltamivir twice daily for five days and any other required provision of care. These will be determined on case by case basis by research clinician.<br>,NA,Yes,Yes
im,CTRI/2018/04/013384,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=25680,Intervention1: Intravenous hydrocortisone <br>Intravenous ascorbic acid<br>Intravenous Thiamine<br>: Hydrocortisone 50 mg iv 6 hrly for 5 days<br>Ascorbic acid 1.5 gm iv 6 hrly for 4 days<br>Thiamine 200 mg iv 12 hrly for 4 days<br>Control Intervention1: Placebo: Intravenous saline in similar quantity and duration to the test drugs<br>,NA,NA,NA
im,CTRI/2018/04/013442,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=23771,Intervention1: IV infusions ofsingle IV dose of 3600 mg of ASN100 (comprised of separate infusions each of 1800 mg ASN-1 and 1800 mg ASN-2): IV infusions ofsingle IV dose of 3600 mg of ASN100 (comprised of separate infusions each of 1800 mg ASN-1 and 1800 mg ASN-2)<br>Control Intervention1: Placebo: administered either sequentially or simultaneously as 2 separate IV infusions: Placebo: administered either sequentially or simultaneously as 2 separate IV infusions<br>,NA,NA,NA
im,CTRI/2018/05/014329,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=25135,"Intervention1: CAFFEINE: Loading dose 20mg/kg of caffeine citrate over 30 minute intravenously, followed by maintenance dose of 5 mg/kg (2.5 mg/kg of caffeine base) in once daily dosing beginning 24 hour after the loading dose<br>Control Intervention1: Aminophylline: Intravenous aminophylline loading dose 5 mg/kg followed by maintenanace dose of 2 mg/kg 8 hourly, initiated 12 hour after loading dose<br>",NA,Yes,NA
im,CTRI/2018/06/014563,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=21991,"Intervention1: Dexmedetomidine: Intravenous dexmedetomidine 0.75 mcg/kg, single dose, given at onset of bronchoscopy over 10 minutes<br>Control Intervention1: Midazolam: Intravenous Midazolam 0.035mg/kg given at onset of bronchoscopy<br>",NA,NA,NA
im,CTRI/2018/07/014968,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=27222,"Intervention1: oral zinc: GROUP A:Patients will receive oral zinc gluconate in liquid formulation containing 20 mg elemental zinc in each 5 ml of solution,10 mg (2.5ml) in patients less than 6 months of age ,20 mg (5ml) in patients more than 6 months of age along with conventional management of pneumonia as per unit protocol.<br>Control Intervention1: placebo: GROUP B:Patients will receive placebo ( Identical in appearance, consistency and taste)<br>2.5ml in patients less than 6 months of age,5ml in patients more than 6 months of age along with conventional management of pneumonia as per unit protocol.<br>Control Intervention2: Placebo: GROUP B:Patients will receive placebo ( Identical in appearance, consistency and taste) 2.5ml in patients less than 6 months of age,5ml in patients more than 6 months of age along with conventional management of pneumonia as per unit protocol.<br>",NA,NA,NA
im,CTRI/2018/08/015193,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26506,Intervention1: Combination of Vitamin C hydrocortisone and thiamine: Inj vitamin c 1.5 gm iv 6 hourly for 4 days or upto discharge from hospital<br>Inj hydrocortisone 50 mg iv 6 hourly for 1 week followed by taper<br>Inj thiamine 200 mg iv 12 hourly for 4 days or until discharge<br>Vitamin C hydrocortisone and thiamine have been used in combination for the treatment of sepsis and septic shock by Marik PE et al. the study showed significant reduction in mortality from 40% to 8 % in control and treatment groups respectively. it was a retrospective before after study and we are going to replicate this study in our hospital.<br>Control Intervention1: nil: nil<br>,NA,NA,Yes
im,CTRI/2018/09/015762,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=27894,"Intervention1: Aztreonam-Avibactam (ATM-AVI): (Creatinine clearance  50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI<br><br>(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI<br><br>(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI<br><br>Intervention2: Metronidazole (MTZ): For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h<br>Control Intervention1: Meropenem (MER): Where pathogen initially not suspected of being MER-resistant:<br><br>(Creatinine clearance  50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h<br><br>(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h<br><br>(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h<br><br>Where pathogen initially suspected of being MER-resistant (Creatinine clearance  50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h<br><br>(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h<br><br>(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h<br><br>Control Intervention2: Colistin (COL): Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight  60 kg) followed by one of the following maintenance doses:<br><br>(Creatinine clearance  50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.<br><br>(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million",NA,NA,NA
im,CTRI/2018/09/015844,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=27477,Intervention1: Norepinephrine PLUS Dobutamine: Norepinephrine will be started at 0.1 mcg/kg/min and Dobutamine will be started at 10 mcg/kg/min through intravenous route. The dose will be increased depending on the clinical response every 15 min to a maximum of Norepinphrine of 0.3 mcg/kg/min and Dobutamine of 20 mcg/kg/min. Drugs will be gradually tapered and stopped with shock resolution<br>Control Intervention1: Epinephrine: Epinephrine will be started at 0.1 mcg/kg/min and will be gradually increased depending on clinical response every 15 min to a maximum of 0.3 mcg/kg/min through intravenous route. It will be gradually tapered and stopped with shock resolution<br>,NA,NA,NA
im,CTRI/2018/10/015914,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=26330,Intervention1: Erector Spinae Plane Block: Ultra sound guided erector spinae plane block with 0.375% ropivacaine with adrenaline 5 microgram/ml<br>Control Intervention1: Local Infiltration: 20 ml of 0.375% ropivacaine with adrenaline 5 microgram/ml injected at the surgical port site<br>,NA,Yes,NA
main,CTRI/2019/01/016879,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=29796,"Intervention1: Obinil: Obinil or Placebo are  tablets with multiple ingredients. Treatment will be allocated as per randomization code list. Eligible subjects have to consume two tablets of obinil or placebo twice daily, orally, after meals for 90 days.<br>",NA,NA,NA
main,CTRI/2019/01/016889,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=29686,"Intervention1: Group P: multimodal intra venous analgesia with<br>a) fentanyl 2mcg/kg at induction, <br>b)morphine 100 mcg/kg post induction, <br>c)diclofenac sodium 75 mg prior to incision<br>d)paracetemol 1gm at end of surgery <br><br>e)Along with Pectoral nerve block prior to surgical incision<br>Control Intervention1: Group C: multimodal intra venous analgesia with<br>a) fentanyl 2mcg/kg at induction, <br>b)morphine 100 mcg/kg post induction, <br>c)diclofenac sodium 75 mg prior to incision<br>d)paracetemol 1gm at end of surgery<br>",NA,NA,NA
main,CTRI/2019/01/016927,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=29841,"Intervention1: 1% curcumin chip in biodegradable hydroxy propyl methyl cellulose vehicle: Following routine full mouth scaling and root planing within 48 hours, a single 4x5x0.5mm chip of 1% curcumin in biodegradable hydroxy propyl methyl cellulose vehicle will be placed locally within a single isolated periodontal pocket(the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip(second placement)<br>Control Intervention1: Placebo chips in biodegradable hydroxy propyl methyl cellulose vehicle: Following routine full mouth scaling and root planing within 48 hours, a single 4x5x0.5mm placebo chip (identical to test chip except for  the active therapeutic ingredient) in biodegradable hydroxy propyl methyl cellulose vehicle will be placed locally within a single isolated periodontal pocket (the deepest pocket in a patient will be chosen) using a forceps. The patient will be recalled after two weeks for the placement of another chip (second placement)<br>",NA,NA,Yes
main,CTRI/2019/01/016960,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=28927,Intervention1: 6% Ocimum sanctum (Tulsi) extract mouth wash<br><br>: Intervention agent<br>6% Tulsi extract mouth wash 10ml twice a day for 15 days <br><br><br>Control Intervention1: 0.2% Chlorhexidine mouthwash (Hexidine): 0.2% Chlorhexidine mouthwash 10ml twice a day for 15 days<br>,NA,NA,NA
main,CTRI/2019/01/016974,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=29536,"Intervention1: Tuloplastâ?¢ (Tulobuterol transdermal<br>patches - 0.5/1/2 mg): 0.5 mg and 1mg patches for pediatric asthma patients, and 2mg patches for children above 9 years of age, adolescents and adult asthma or COPD patients.<br>The patch is to be applied once daily for 4 weeks.<br>Control Intervention1: NOT APPLICABLE: NOT APPLICABLE<br>",NA,NA,NA
main,CTRI/2019/01/017169,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30317,Intervention1: Alternate day Iron therapy: Administering 200mg Ferrous sulfate oral iron tablets on alternate days for 2 months.<br>Control Intervention1: Daily oral Iron Therapy: Administering 200mg ferrous sulfate oral iron tablets daily for 2 months<br>,NA,Yes,NA
main,CTRI/2019/01/017201,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=29246,Intervention1: Amla extract (AMX 160): 500 mg capsule of Amla extract (AMX-160) once daily at night after food for 90 days<br>Intervention2: Amla extract (AMX 500): 250 mg capsule of Amla extract(AMX-500) one in the morning and one at night after food for 90 days<br>Control Intervention1: Amla extract (AMX 160): 500 mg capsule of Amla extract (AMX 160) one in the morning and one at night after food for 90 days<br><br>,NA,NA,NA
main,CTRI/2019/02/017396,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31102,"Intervention1: Nano life (silver 100% nano particle) Mouth wash for oral and dental infectious conditions: Rajata Bhasma Liquid - 20 ppm<br>with flavors added<br>Flavors used : Clove bud extract, peppermint extract<br>Direction for use : 1 teaspoon full to be diluted upto 15 ml (1 table full spoon) with water. Then to be used.<br><br>Control Intervention1: Chlorhexidine mouthwash: Chlorhexidine 0.1% . 10 ml taken twice daily and rinse the mouth for 2 minutes.<br>",NA,NA,NA
main,CTRI/2019/02/017415,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30988,Intervention1: bupivacaine and morphine: instill bupaivacaine- morphine cccktail over epidural space after lumbar surgery (decompression and discectomy) and assess the post operative pain scores<br>Control Intervention1: no drug: drug is not instilled over epidural space after elective lumbar surgery(decompression and discectomy) and assess post operative pain scores<br>,NA,Yes,NA
main,CTRI/2019/02/017452,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30054,Intervention1: Test Drug 1:  Ivabradine Extended Release Tablets 10 mg: Each patient will be receiving four tablets in a day (two in morning and two in evening). Patient will be<br>asked to take the medication on regular basis preferably on same time.<br>Duration: 12 Weeks<br>Intervention2: Test Drug 2:  Ivabradine Extended Release Tablets 15 mg: Each patient will be receiving four tablets in a day (two in morning and two in evening). Patient will be asked to take the medication on regular basis preferably on same time.<br>Duration: 12 Weeks<br>Control Intervention1: Comparator 1: Ivabradine Tablets 5 mg: Each patient will be receiving four tablets in a day (two in morning and two in evening). Patient will be<br>asked to take the medication on regular basis preferably on same time.<br>Duration: 12 Weeks<br>Control Intervention2: Comparator 2: Ivabradine Tablets 7.5 mg: Each patient will be receiving four tablets in a day (two in morning and two in evening). Patient will be asked to take the medication on regular basis preferably on same time.<br>Duration: 12 Weeks<br>Control Intervention3: Ivabradine 5 mg (Run in period): The dose will be the same as they were receiving during<br>screening.<br>Duration: 01 Week<br>Control Intervention4: Ivabradine 7.5 mg (Run in period): The dose will be the same as they were receiving during<br>screening.<br>Duration: 01 Week<br>,NA,NA,NA
main,CTRI/2019/02/017499,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30565,"Intervention1: Gemcitabine: Gemcitabine for injection, is a nucleoside metabolic inhibitor that exhibits antitumor activity. Gemcitabine is supplied in a sterile form for intravenous use only.<br>Dose, frequency and route of administration:-Gemcitabine  is 1000 mg/m2 body weight administered intravenously for one dose on days 1, 8 and 15 once every 4 weeks until disease progression or development of intolerable side effects.<br>Control Intervention1: NA: NA<br>",NA,NA,NA
main,CTRI/2019/02/017655,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31475,Intervention1: Group D: Group D will recieve dexmedetomedine 0.4mcg/kg over 5 mins prior to induction followed by infusion at the rate of 0.4mcg/kg/hr till 10 mins prior to completion of surgery<br>Intervention2: Group F: Group F - would receive fentanyl 1 mcg/kg over 5 mins prior to induction followed by infusion at the rate of 1mcg/kg/hr till 10 mins prior to completion of surgery<br>Control Intervention1: Group N (Control): Group N (Control)- would receive normal saline over 5 mins prior to induction followed by infusion till 10 mins prior to completion of surgery<br>,NA,NA,NA
main,CTRI/2019/02/017722,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31485,Intervention1: compound formulation (in powdered form ): Khurma(Phoenix dactylifera Linn)<br>Rasuat(Berberis aristata)<br>Talmakhan (Asteracontha logifolia linn)<br>lodh pathani( Symlocos racemosa Roxb)<br>Control Intervention1: nil: nil<br>,NA,NA,NA
main,CTRI/2019/02/017815,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31537,"Intervention1: Metformin: Metformin, orally with food, administered continuously, beginning with chemotherapy. Metformin treatment will follow a dose escalation scheme, starting with a dose of 500 mg twice a day (day 0). At day 8, a metformin dose increase is planned, with the first daily dose of 1000 mg and 500 mg as the second dose. At the start of 2nd cycle metformin will be increased to 1000 mg twice a day<br>Control Intervention1: Not Applicable: Not Applicable<br>",NA,NA,NA
main,CTRI/2019/02/017859,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30672,Intervention1: KRABEVAÂ® /or AbevmyTM: Study Type:-INTERVENTION<br>Name:-KRABEVAÂ® /or AbevmyTM<br>Details:-100 mg per 4 mL single-use vial and /or 400 mg per 16 mL single-use vial administered as per the prescribing information<br>Intervention2: KRABEVAÂ® /or AbevmyÂ®: 100 mg per 4 mL single-use vial and /or 400 mg per 16 mL single-use vial administered as per the prescribing information<br>Control Intervention1: Not Applicable: Not Applicable<br>,NA,NA,NA
main,CTRI/2019/03/017893,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30681,Intervention1: Injection Enalapril 1.25mg: Enalapril<br>Dose - 1.25mg<br>Route - Intravenous<br>Time period - Over 10 minutes<br>Frequency - Single injection<br>Control Intervention1: Injection Clonidine 100microgram<br>: Clonidine<br>Dose - 100 microgram<br>Route - Intravenous<br>Time period - Over 10 minutes<br>Frequency - Single injection<br>,NA,NA,NA
main,CTRI/2019/03/017987,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31815,Intervention1: Dexmedetomidine: 0.3mcg/kg/hr infusion started 15 minutes before induction of anaesthesia till the release of pneumoperitoneum<br>Intervention2: Clonidine: 2mcg/kg/hr infusion started 15 minutes before induction of anaesthesia till the release of pneumoperitoneum<br>Control Intervention1: nil: nil<br>,NA,NA,NA
main,CTRI/2019/03/018134,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31942,Intervention1: Relamorelin: Relamorelin 10 microgram injected twice daily for 52 weeks<br>Control Intervention1: Placebo: Placebo injected twice daily for 2 weeks or 52 weeks<br>,NA,NA,NA
main,CTRI/2019/03/018337,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=28931,Intervention1: Tab Lorazepam [1mg]: Tab Lorazepam [1mg] as CNS Depressant given as a single dose and after that the psychometric performance test battery will be administered<br>Intervention2: Tab Caffeine [250mg]: Tab Caffeine [250mg] as CNS stimulant given as single dose and after that the psychometric performance test battery will be administered<br>Control Intervention1: NA: NA<br>,NA,Yes,NA
main,CTRI/2019/04/018538,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30305,Intervention1: GROUP 1<br>: 1.DEXAMETHASONE 4 mg AS AN ADJUVANT TO 0.5% BUPIVACAINE IN SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK.<br><br>Control Intervention1: GROUP 2: DEXAMETHASONE 8mg AS AN ADJUVANT TO 0.5% BUPIVACAINE IN SUPRACLAVICULAR BRACHIAL PLEXUS BLOCK<br>,NA,Yes,NA
main,CTRI/2019/04/018550,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31780,"Intervention1: Silymarin-Choline: Silymarin-Choline<br>Intervention2: Silymarin-Choline: Silymarin-Choline<br>â?¢Tablet Mariliv (Manufacturer: EMCEE Pharmaceuticals (P) Ltd.): A combination of Tablet Silymarin (140 mg) and Choline bitartrate (450 mg) 1 tablet thrice daily (TDS) for 1month (To be continued till 6 months) <br>(Oral)<br>â?¢All drugs will be procured at one time, all bearing the same batch number<br>Control Intervention1: Silymarin-Choline: Silymarin-Choline<br>Control Intervention2: Silymarin-Choline: Silymarin-Choline<br>Control Intervention3: UDCA: UDCA<br>â?¢Tablet Ursocol 300 mg (Manufacturer: Sun Pharmaceutical Industries Ltd.): UDCA (Ursodeoxycholicacid) 300 mg 1 tablet twice daily for 1 month (to be continued till 6 months)<br>(Oral)<br>All drugs will be procured at one time, all bearing the same batch number<br>",NA,NA,NA
main,CTRI/2019/04/018569,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=32288,Intervention1: Samshamana Snehapana: Samshamana Snehapana with Tikta Shatpala Ghrita 10 ml twice a day for 30 days<br>Control Intervention1: Virechana followed by samshamana snehapana: Tiktka shatpala ghrita 10 ml twice a day as Samshamana Snehapana  for 30 days after Virechana Karma with Triphala 40gm  Trivrit 20 gm  and Danti 5 gm<br>,NA,NA,NA
main,CTRI/2019/04/018732,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31618,"Intervention1: rasnasaptak kwatha: kwatha formation done by 7 plants named rasna, gokshura, eranda, devadaru, punarnava, guduchi and aragwadha<br>duration - 1 month, <br>route - orally<br>Control Intervention1: rasnasaptak kwatha ghanavati: ghanavati will be made after the prepartation of kwatha with 7 drugs rasna, gokshura, eranda, devadaru, punarnava, guduchi and aragvadha<br>duration - 1 month<br>Control Intervention2: rasnasaptak kwatha ghanasattva: rasnasaptak kwatha will be evoparated till thik consitency optain then powder form will be made from this kwath<br>duration - 1 month<br>",NA,NA,NA
im,CTRI/2019/04/018836,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=29185,Intervention1: Antibiotics: Early change of intravenous to oral antibiotics in severe pediatric pneumonia<br> Amoxyclav - 80mg/kg/day Q12H<br> Ceftriaxone-100mg/kg/day Q12H<br>  for a duration of 2 days followed by oral therapy in clinically stable children.<br>Control Intervention1: Duration of Hospital Stay: To compare the duration of hospital stay between conventional therapy and those with early streamlining of antibiotics<br>,NA,Yes,NA
im,CTRI/2019/04/018847,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33177,Intervention1: Use of 2 different modes of administration of an antibiotic and compare the efficacy.: Use of Colistin in gram negative Ventilator Associated Pneumonia as Intermittent dosing regime.<br>Control Intervention1: Use of 2 different modes of administration of an antibiotic and compare the efficacy.: Use of Colistin as Continous infusion regime in gram negative Ventilator Associated Pneumonia<br>,NA,Yes,NA
im,CTRI/2019/04/018855,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=32894,"Intervention1: Experimental Arm - Combine Murepavadin with one authorized anti-pseudomonal agent from either group, preferably with one anti-pseudomonal Î²-lactam antibiotic.: Combine murepavadin with one authorized anti-pseudomonal agent from either group, preferably with one anti-pseudomonal Î²-lactam Î²-lactam Antibiotics include Piperacillin-tazobactam, Ceftazidime, Cefepime and Meropenem. Non Î²-lactam Antibiotics include Amikacin, Ciprofloxacin, Levofloxacin, i.v./inh. CMS. Dosage form: Liquid solution/concentrate for infusion. Subjects will be randomized in a 2:1 ratio to receive either i.v. murepavadin (230 mg every 8 hours in subjects with a eGFR-MDRD-6 â?¥ 60 mL/min/1.73 m2 as 2-hour infusions) + one i.v. anti-pseudomonal antibiotic or two anti-pseudomonal antibiotics for 7 to up 14 days.<br>Control Intervention1: Reference arm:<br>Combine two anti-pseudomonal antibiotics listed below.: Î²-lactam Antibiotics include Piperacillin-tazobactam, Ceftazidime, Cefepime and Meropenem. Non Î²-lactam Antibiotics inlcude Amikacin, Ciprofloxacin, Levofloxacin, i.v./inh. CMS.   <br>Combination of two Î²-lactam-based<br>anti-pseudomonal antibiotics should be avoided. Antipseudomonal<br>antibiotics will be administered according to<br>the site practice.<br>",NA,Yes,NA
main,CTRI/2019/05/018958,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=32844,Intervention1: Opioid Free Anesthesia: Control group will be given opioid for anesthesia<br>study group will not be given Opioid.<br>Control Intervention1: Opioid based Anesthesia: this group will receive opioid for anesthesia<br>,NA,NA,NA
main,CTRI/2019/05/018962,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=29117,Intervention1: Oral Medication: From administration of drug to upto 24 hours of surgery<br>Control Intervention1: Two doses of oral Gabapentin administered as pre-emptive medication: Gabapentin 800mg and Gabapentin 1200mg per oral 2 hours before surgery and to assess total morphine requirement in first 24 hours after surgery<br>,NA,NA,NA
main,CTRI/2019/05/019009,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=20114,Intervention1: ASHWAGANDHA POWDER: Route of Drug administration: Oral<br><br>Form of drug : powder form<br><br>Dosage of the drug: 12 gram<br><br>Anupana(vehicle): milk<br>Intervention2: ASHWAGANDHA CHOORNA (POWDER): GROUP 1   :  A minimum of 50 persons will be given 2 Haritaki tablets for Kostha Shuddhi with hot water for minimum of 3 days and 200 ml Dugdha for 60 days in empty stomach early in the morning kept as a control.<br>GROUP  2 : A minimum 50 persons will be  given  2  Haritaki  tablets   for  Kostha Shuddhi with hot water for minimum of 3 days  and 12gm of  Ashwagandha Choorna with 200 ml Dugdha for 60 days  in empty stomach  early in the  morning .<br>Intervention3: Ashwagandha Choorna: A minimum 50 persons will be  given  2  Haritaki  tablets   for  Kostha Shuddhi with hot water for minimum of 3 days  and 12gm of  Ashwagandha Choorna with 200 ml Dugdha for 60 days  in empty stomach  early in the  morning<br>Intervention4: ASHWAGANDHA POWDER: Route of Drug administration: Oral<br><br>Form of drug : Choorna(powder)<br>Dosage of the drug:12gm<br> <br>Anupana: Dugdha (milk)<br><br>Duration: 60 days<br>Control Intervention1: none: none<br>,NA,NA,NA
main,CTRI/2019/05/019112,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=30090,Intervention1: silver diammine fluoride: fluoride levels in the urine samples before and after application of silver diammine fluoride and patient with severe early childhood caries will be estimaterd.this silver diammine fluoride is the FDA approved fluoride varnish which is for dentinehypersensitivity and breakthrough therapy status for arresting caries.i will start my study after ctri approval.single drop contain 9.5mg which is 400 fold safety margin.single visit topcal application on tooth.<br>Control Intervention1: No treatment: No treatment<br>Control Intervention2: urine sample before application of silver diammine fluoride: urine sample collected before application of silver diammine fluoride taken as the base.<br>,NA,NA,NA
im,CTRI/2019/05/019116,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33014,"Intervention1: Chlorhexidine mouth wash    0.12%<br>: Chlorhexidine 0.12% will be prepared by diluting 0.2% chlorhexidine (6 ml 0.2% chlorhexidine + 40ml sterile water)<br><br>Available brand -  Hexiclear Mouth Wash ( Ikon remedies Pvt. Ltd.)<br><br><br>Cleaning of Oral Cavity with chlorhexidine soaked sterile gauze 3 times a day, <br><br>A sterile gauze will be soaked in sterile water (15-20cc of sterile water) and any particulate matter from the oropharyngeal area will be rinsed off.<br><br>A sterile gauze will be soaked in 15 ml of Chlorhxidine mouth wash (0.12%) and used to swab the entire oropharyngeal mucosa, teeth and part of the endotracheal tube inside the oropharyngeal area.<br>Control Intervention1: Chlorhxidine   mouth wash    0.2% <br>: Available brand -  Hexiclear Mouth Wash ( Ikon remedies Pvt. Ltd.)<br><br>Cleaning of Oral Cavity with chlorhexidine soaked sterile gauze  3 times a day,<br><br>A sterile gauze will be soaked in sterile water (15-20cc of sterile water) and any particulate matter from the oropharyngeal area will be rinsed off<br><br>A sterile gauze will be soaked in 15 ml of Chlorhxidine mouth wash (0.2%)  and used to swab the entire oropharyngeal mucosa, teeth and part of the endotracheal tube inside the oropharyngeal area.<br><br>",NA,NA,NA
main,CTRI/2019/05/019171,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33195,Intervention1: ondansetron: Group 1: patients will receive 0.1mg/kg iv of Inj. Ondansetron.<br>Control Intervention1: dexamethasone: group 2 receives 0.1mg/kg of dexamethasone plus 0.1 mg/kg of ondansetron<br>,NA,Yes,NA
main,CTRI/2019/05/019294,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33659,"Intervention1: Adathoda rasayanam: Adathoda rasayanam, dosage 170 mg-3-4 years,500mg-5-7 years,oral route for 45 days<br>Control Intervention1: NIL: NIL<br>",NA,NA,NA
main,CTRI/2019/05/019355,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=34078,"Intervention1: Gplife-Advance diabetic support: Subjects will be advised to consume Gplife Advanced diabetic support tablet 2 tablets twice daily, orally 30-45 minutes before meal with water for 2 months.<br>Control Intervention1: NIL: NIL<br>",NA,NA,NA
main,CTRI/2019/05/019450,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=34202,Intervention1: Palasha Kshar Bhavit Pippali: Route of administration of drug â?? oral <br>Dose â??one capsule (500mg)<br>Time of administration â?? before and after meal in morning<br>Duration â?? 4 weeks<br><br>Control Intervention1: Palasha Kshar Bhavit Pippali: Route of administration of drug â?? oral <br>Dose â??one capsule (500mg)<br>Time of administration â?? before and after meal in morning<br>Duration â?? 4 weeks<br><br>Control Intervention2: NIL: NIL<br>,NA,NA,NA
main,CTRI/2019/05/019471,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33579,"Intervention1: Bispectral index and minimum alveolar concentration both<br>are non invasive methods of monitoring depth of anaesthesia without any added risk.<br>Inhalational anaesthetic agents (sevoflurane and desflurane) will be admisnistered during standard balanced general anaesthesia in Indian population in tertiary<br>care teaching public hospital.: All the elective <br>surgery patients will be assessed and investigated by attending anaesthesiologists <br>All patients who fit in the inclusion criteria will be included in study<br>after written, valid and informed consent. Standard balanced general anaesthesia with endotracheal intubation and controlled ventilation depending upon patientsâ?? and surgical requirement will be administered. One of the inhalational anaesthetic agents(Sevoflurane or Desflurane) will be used. Once the patient achieves stable depth of anaesthesia with<br>target BIS value 40-60, patient will be maintained in the same depth by titrating the end<br>tidal concentration of inhalational agent. End tidal concentration and MAC value of<br>sevoflurane or desflurane will be noted. Study period is predetermined as the 1st 60 minutes after surgical incision as some<br>time is required to achieve steady state concentration and stable depth of anaesthesia.<br>Control Intervention1: NA: NA<br>",NA,NA,NA
main,CTRI/2019/06/019598,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33748,Intervention1: vitamin C: vitamin C 1000 mg/day is added along with standard treatment for 3 months of duration<br>Control Intervention1: Paroxetine: Paroxetine upto 50 mg/day is given to both arm as standard treatment for 3 months duration<br>,NA,NA,Yes
main,CTRI/2019/06/019601,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=34057,"Intervention1: Dexamethasone as an adjuvant to ropivacaine in transversus abdominis plane block: To compare the duration of postoperative analgesic effect,quality of postoperative analgesia(VNRS) and total postoperative analgesic consumption in 24 hours between 0.25% ropivacaine alone and 0.25% ropivacaine with 8 mg dexamethasone in ultrasound guided transversus abdominis plane block<br>Control Intervention1: Ropivacaine alone in transversus abdominis plane block: Comparison with dexamethasone as an adjuvant to ropivacaine for same aims and objectives listed above<br>",NA,Yes,NA
main,CTRI/2019/06/019614,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=34372,Intervention1: Active Control group<br>Prostaglandin E2 gel: Prostaglandin E2 gel<br>0.5mg vaginally maximum 3doses 6hrs apart<br><br>Control Intervention1: Active Control group<br>Oral Misoprostol: Misoprostol 25mcg Oral <br>maximum 4 doses 2hours apart<br>Control Intervention2: Active Control group<br>Foleys bulb vaginally and Oral Misoprostol: Foleys bulb vaginally and Oral Misoprostol 25mcg maximum 4 doses 2hours apart<br>,NA,NA,NA
main,CTRI/2019/06/019863,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=27536,Intervention1: TYPBAR TCV: O.5 ml Typbar TCV administered at DAY 0<br>Control Intervention1: Not applicable: Not applicable<br>,NA,NA,NA
main,CTRI/2019/06/019878,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=31679,Control Intervention1: Phenytoin and Fosphenytoin: Phenytoin 5mg/kg/Day in 3 divided doses for seven days.<br>Fosphenytoin 5mg PE (phenytoin equivalent) /kg/Day in 3 divided doses for seven days<br>,NA,NA,NA
im,CTRI/2019/06/019884,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=29298,"Intervention1: Aztreonam-Avibactam (ATM-AVI): ATM-AVI doses (loading, extended loading and maintenance) and the dosing frequency of the<br>maintenance dose are dependent on renal function. Subjects will be given a loading dose of<br>500 mg ATM plus 167 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 30 minutes. This treatment will immediately be followed by an extended loading dose of 1500 mg ATM plus 500 mg AVI or 675 mg ATM plus 225 mg AVI over a period of 3 hours. Then there will be a 3 hour or 5 hour gap. Subjects will receive a maintenance dose of 1500 mg ATM plus 500 mg AVI<br>every 6 hours or 750 mg ATM plus 250 mg AVI every 6 hours, or 675 mg ATM plus 225 mg AVI every 8 hours.<br><br>Subjects with cIAI will also receive Metronidazole (MTZ) 500 mg IV q8h over 60 minutes. The first dose of MTZ will be started immediately after the extended loading dose of ATM-AVI has completed and treatment will be continued until the end of the treatment period.<br>Control Intervention1: Best Available Therapy (BAT): The comparator treatments in this study are to be the best available therapy (BAT) based upon site practice and local epidemiology. The choice of BAT for each subject must be recorded prior to randomization. Acceptable BAT may include but not limit to the following Aminoglycoside;<br>Colistin (or polymixin B if colistin not available /accessible); Fosfomycin; Meropenem; Tigecycline. If the chosen BAT does not provide adequate anaerobic coverage for cIAI subjects<br>MTZ is to be administered as a co therapy. BAT dose, frequency, dose adjustments with renal impairment will be based on per local package inserts.<br>",NA,Yes,NA
main,CTRI/2019/07/020058,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=34230,Intervention1: Tablet Myostaal forte: One tablet three times daily for 6 months<br>Control Intervention1: Tablet Glucosamine sulphate: One tablet of 500 mg three times daily for 6 months<br>,NA,NA,NA
main,CTRI/2019/07/020274,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=34724,"Intervention1: Apremilast: Oral apremilast 30 mg BD, starting at 10 mg/day with an increment of 10 mg/day over 5 days, for 8 weeks.<br>Intervention2: Methotrexate plus apremilast: Oral methotrexate 0.2 mg/kg/week, maximum 25 mg/week along with oral apremilast 30 mg BD, starting at 10 mg/day with an increment of 10 mg/day over 5 days, for 8 weeks.<br>Control Intervention1: Methotrexate: Oral methotrexate 0.2 mg/kg/week, maximum 25 mg/week for 8 weeks.<br>",NA,NA,NA
main,CTRI/2019/07/020388,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=35717,"Intervention1: Peptide Receptor Radionuclide Therapy plus Chemotherapy: Arm A Peptide Receptor Radionuclide Therapy plus Chemotherapy <br>Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE, 180-200 mCi administered intravenously for 4 cycles, at interval duration of 6-8 weeks<br>Plus<br>CAP-TEM Protocol:<br>Day 1: Oral Capecitabine 1500 mg/m2, per oral, twice daily within 15 min of food for 14 days, followed by 2 week rest period<br>Day 10-D14: Oral Temozolomide 20 mg/m2 per oral, daily dose for 5 days as a single dose with a glass of water at bed time. To be taken empty stomach at least 30 min before or 2 hours after meal.<br><br>Control Intervention1: Arm B Peptide Receptor Radionuclide Therapy: Peptide Receptor Radionuclide Therapy with Lu-177-DOTATATE, 180-200 mCi administered intravenously for 4 cycles, at interval duration of 8-12 weeks<br>",NA,NA,NA
main,CTRI/2019/07/020455,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33252,Intervention1: 7% SUCRALFATE CREAM: 7%V SUCRALFATE CREAM SHALL BE USED IN POST OPERATIVE FISTULECTOMY WOUND TO ASSESS THE PAIN RELIEF AND ENHANCE THE WOUND HEALING<br>Control Intervention1: VASELINE: VASELINE CREAM SHALL BE USED AS PLACEBO AS COMPARED TO 7% SUCRALFATE CREAM IN POST FISTULECTOMY WOUND FOR ASSESSMENT OF PAIN RELIEF AND ENHANCE WOUND HEALING<br>,NA,NA,NA
main,CTRI/2019/08/020653,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=35490,"Intervention1: Desmopressin: Intranasal Desmopressin to be given to intervention group two hour prior to procedure. For patients with less than 50kg, 150mcg (one puff) and for greater than 50 kg, 300mcg (two puff) will be given.<br>Control Intervention1: Normal saline: Intranasal normal saline to be given to control group two hours prior to procedure. For patients with less than 50kg, one puff and for greater than 50 kg, two puff will be given.<br>",NA,NA,NA
main,CTRI/2019/08/020666,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=36018,"Intervention1: Oryza cream(TR001): Intervention<br>1.Oryza Cream(TR001) <br><br> The product  is leave on, so placed directly in the aluminum chambers of the patch and applied on the back of the volunteer.<br><br>Control Intervention1: Sodium Lauryl Sulphate (SLS) Isotonic Saline Solution as Negative control: 1% Solution of SLS for leave on products 0.9% Isotonic Saline Solution<br>",NA,NA,NA
main,CTRI/2019/08/020845,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=35997,"Intervention1: Osimertinib<br>: Savolitinib.<br><br>Total duration of therapy will be until either objective disease progression, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criteria is met.<br>Control Intervention1: Not Applicable: Not Applicable<br>",NA,NA,NA
main,CTRI/2019/09/021027,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=35964,"Intervention1: Dr.Dalaya MD( Psychiatrist): Nityanand Rehabilitation and Residential Mental Health Care Centre, Patang Plaza, Behind Bharati Vidyapeeth, Katraj, Pune-411046<br>Intervention2: Jivaniya Ghrita: Jivaniya Ghrita 20 m.l in 2 divided dosages for 30 days through oral route will be given to Angry Patients.<br>Control Intervention1: Jivaniya Ghrita: Jivaniya Ghrita 20 ml in 2 divided dosages for 30 days through oral route will be given to Angry Patients<br>",NA,NA,NA
main,CTRI/2019/09/021164,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=35430,"Intervention1: Vitamin-D3-Cholecalciferol (60,000 I.U.): Vitamin-D3-Cholecalciferol (60,000 I.U.) or placebo will be given once weekly for 8 weeks<br><br>Intervention2: Imatinib 400 mg once daily to continue plus Vitamin D Cholecalciferol 60,000 IU: Drug- Vitamin D Cholecalciferol Dose- 60,000 IU <br>Dosage form- sachet <br>Frequency- once weekly <br>Duration- 8 weeks<br>Control Intervention1: Imatinib 400 mg once daily plus  Placebo: Matching Placebo sachet once weekly for 8 weeks<br>",NA,NA,Yes
main,CTRI/2019/09/021230,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=36712,Intervention1: Minoxidil Topical solution USP 5% w/v (Fortification): 0.04 ml will be filled in patch chambers and will be occluded for 24 hours.<br>Application will be done once<br>Control Intervention1: SLS: 0.04 ml will be filled in patch chambers and will be occluded for 24 hours.<br>Application will be done once<br>Control Intervention2: Isotonic Saline: 0.04 ml will be filled in patch chambers and will be occluded for 24 hours.<br>Application will be done once<br>,NA,NA,NA
main,CTRI/2019/09/021275,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=32178,"Intervention1: Ormeloxifene: 3rd generation SERM (Selective Estrogen Receptor Modulator). Non steroidal Non Hormonal OCP. <br>Ormeloxifene will be given in the dose of 60mg twice a week for 3 months, followed by once a week for one month.<br>Control Intervention1: Medroxyprogesterone Acetate: Synthetic Progestin. Used as a contraceptive drug as well as in abnormal uterine bleeding.<br><br>It will be given in the dose of 10mg 12 hourly for 4 months from Day 5 to Day 25 of cycle.<br>",NA,NA,NA
main,CTRI/2019/10/021561,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=37181,"Intervention1: Intraocular pressure changes following induction with sevoflurane and thiopentone: Preoxygenation done for three minutes with 100% oxygen. Induction will be done with fentanyl 2 microgram per kg , thiopentone 5 milligram per kg or sevoflurane in graded concentration. Intraocular pressure change noted after induction   and before PLMA placement. After the loss of eyelash reflex bag and mask ventilation done and vecuronium 0.12 milligram per kg will be given. After that airway secured with PLMA and intraocular pressure measured after 1 minute and 3 minutes of PLMA placement.<br>Control Intervention1: Nil: Nil<br>",NA,NA,NA
main,CTRI/2019/10/021679,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=32700,Intervention1: Guduchyadi tail(oil): Drug- guduchyadi tail<br>dose 5ml<br>duration- 2 consecutive cycle<br>follow up- will be taken 1 cycle after completion of treatment <br>Route of administration- intra vaginal<br>Control Intervention1: guduchyadi tail (oil) intravaginal uttarbasti: Drug- guduchyadi tail(oil)<br>Dose- 5ml<br>Duration- 2 consecutive cycle<br>Follow up- will be taken 1 cycles after completion of treatment<br>Route- Intra vaginal<br>,NA,NA,NA
im,CTRI/2019/10/021690,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=37279,Intervention1: Modified INSURE technique: Preterm infants with RDS will receive surfactant by             new technique   in which Surfactant will be delivered without IPPV while baby will be connected to Bubble CPAP with the help of two special connector (ET CPAP for 2-3 minutes).<br><br>Control Intervention1: INSURE technique: Preterm infants with RDS will receive surfactant by        InSuRE technique   in which Surfactant will be delivered by conventional InSuRE technique with IPPV.<br><br>,NA,NA,NA
main,CTRI/2019/11/021849,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=24439,Intervention1: 25% DEXTROSE: DEXTROSE AND INSULIN WILL BE ADMINISTERED INTRAOPERATIVELY AND ALL VALUES INTRAOPERATIVELY AND POSTOPERATIVELY WILL BE RECORDED BY PRINCIPAL INVESTIGATOR<br>STUDY DURATION 1.5YEARS<br>Control Intervention1: NORMAL SALINE AT SAME RATE OF 25% DEXTROSE: DEXTROSE AND INSULIN  WILL BE ADMINISTERED INTRAOPERATIVELY AND ALL VALUES INTRAOPERATIVELY AND POSTOPERATIVELY WILL BE RECORDED BY PRINCIPAL INVESTIGATOR DURATION OF STUDY IS 1.5 YEARS<br>,NA,NA,NA
main,CTRI/2019/11/021876,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=37267,"Intervention1: Concizumab: Participants are to inject concizumab under their skin, with a needle in the stomach or thigh.  Participants will inject concizumab once daily at same time. During main phase of the trial, Participants randomized on Concizumab Prophylaxis arm will administer Initial Loading dose of 1.0mg/kg/ body weight at Visit 2 and will continue with daily dose of 0.25mg/kg/Body weight. Participants randomized on Concizumab On-Demand arm will on routine treatment during main phase of the trial (from Visit 2 to Visit 9). <br><br>During extension phase (i.e from Visit 9) On-demand patients will administer Initial Loading dose of 1.0mg/kg/ body weight at Visit 9 and will continue with daily dose of 0.25mg/kg/Body weight. The dose can be increased more (up to 0.35mg/kg/Body weight). <br><br>Control Intervention1: NIL: NIL<br>",NA,Yes,NA
im,CTRI/2019/11/021964,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=33404,Intervention1: Nafithromycin: 800 mg (two 400-mg tablets) orally (PO) every 24 hours (q24h) for 3 days<br>Control Intervention1: Moxifloxacin 400 mg: PO q24h for 7 days<br>,NA,Yes,NA
main,CTRI/2019/11/022129,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=37902,Intervention1: Intraperitoneal instillation of local anaesthetic agent alone or with adjuvant: After the removal of the gall bladder a total of 40 ml study drug solution will be instilled intaperitoneally<br>Control Intervention1: Group R Intraperitoneal instillation of 0.2% Ropivacaine: Intraperitoneal instillation of 0.2% plain Ropivacaine in a total volume of 40 ml of instilled solution after removal of gall bladder<br>Control Intervention2: Group RD Intraperitoneal instillation of 0.7Âµg/kg Dexmedetomidine mixed with 0.2% Ropivacaine: Intraperitoneal instillation of 0.7Âµg/kg Dexmedetomidine mixed with 0.2% Ropivacaine in a total volume of 40 ml of instilled solution after removal of gall bladder<br>Control Intervention3: Group RK Intraperitoneal instillation of 0.5 mg/kg Ketamine mixed with 0.2% Ropivacaine: Intaperitoneal instillation of 0.5 mg/kg Ketamine mixed with 0.2% Ropivacaine in a total volume of 40 ml of instilled solution after removal of gall bladder<br>,NA,Yes,NA
main,CTRI/2019/11/022178,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=38367,Intervention1: Itraconazole: Per oral Dose 200mg BD for 1 day<br>Control Intervention1: Fluconazole: Per oral Dose 150mg Stat on same day<br>,NA,NA,NA
im,CTRI/2019/12/022490,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=34936,Intervention1: Baloxavir Marboxil: Single oral dose of 20mg tablet (dosed according to body weight  - 40 mg for patients 80 kg and 80mg for patients 80kg<br>Control Intervention1: placebo: A single dose of Oral tablet matching Baloxavir Marboxil 20mg tablet<br>,NA,Yes,NA
covid,CTRI/2020/04/024479,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42713,Intervention1: Hydroxychloroquine sulphate: Hydroxychloroquine sulphate tablets will be given in the dose of 400 mg twice on day 1 and then 400 mg once in a day for 04 days daily to the patients who meets the inclusion criteria<br>Control Intervention1: No drug: Hydroxychloroquine will not be given to control group. These patients will be managed as per standard protocol.<br>,NA,Yes,NA
covid,CTRI/2020/04/024729,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42933,Intervention1: Topical Nasal 0.03% chloroquine eye drops: To receive 0.03% Chloroquine drops 1ml â?? 6 times daily X 10 days. <br>		+ all treatments & observations recommended by the treatment team<br><br>Control Intervention1: Standard Treatment: Control Arm - all treatments & observations recommended by the treatment team<br>                           No nasal drops<br><br>,NA,Yes,NA
covid,CTRI/2020/04/024773,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42897,"Intervention1: Remdesivir: local standard of care plus Remdesivir (daily infusion for 10 days) <br><br>Intervention2: chloroquine or hydroxychloroquine: local standard of care plus chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days)<br>Intervention3: Lopinavir with Ritonavir (orally twice daily for 14 days): Local standard of Care plus Lopinavir with Ritonavir (orally twice daily for 14 days)<br>Intervention4: Lopinavir with Ritonavir (ditto) plus Interferon: Local standard of care plus Lopinavir with Ritonavir ((orally twice daily for 14 days) plus Interferon (daily injection for 6 days).<br>Control Intervention1: Local standard of care: Local standard of care<br>",NA,Yes,NA
covid,CTRI/2020/04/024775,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43149,"Intervention1: Convalescent plasma: Convalescent plasma, 2 doses of 200 mL each, from recovered COVID-19 patient.<br>Control Intervention1: Usual care for COVID-19 disease: Usual care for COVID-19 disease<br>",NA,Yes,NA
covid,CTRI/2020/04/024806,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=42843,Intervention1: Imatinib - Oral Drug: Imatinib- 600mg per oral once daily<br>(D1-D14)<br>Control Intervention1: supportive care: supportive care<br>,NA,NA,NA
covid,CTRI/2020/04/024846,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43004,Intervention1: Suspension of heat killed (autoclaved)Mycobacterium w: 0.3 ml (0.1 ml x 3 Inj.) of Mw intra-dermal for 3 consecutive days with Standard therapy of COVID-19<br>Control Intervention1: Placebo: 0.3 ml (0.1 ml x 3 Inj.) of Placebo intra-dermal for 3 consecutive days with Standard therapy of COVID-19<br>,NA,NA,NA
covid,CTRI/2020/04/024883,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43168,"Intervention1: ZingiVir H: It is a poly herbomineral drug.Therapeutic dose:  <br>ONE tablet (500 mg) each consumed once in 3 hours Â±1 hour between 6 AM and 9 PM in a given day (6AM, 9AM, 12Noon, 3PM, 6PM, 9PM) for a minimum duration of 10 days to Maximum 15 days as per the clinical conditions and disease outcome.<br>Control Intervention1: not applicable: not applicable<br>",NA,Yes,Yes
covid,CTRI/2020/04/024915,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43332,"Intervention1: Convalescent Plasma: 200 ml of ABO compatible plasma  transfusion will be done to the subject randomized for the therapy<br>Control Intervention1: Standard care of treatment: control group will be treated as per Standard care of treatment. The Ministry of Health and Welfare has issued detailed guidelines for the management of sCOVID-19 based on varying grades of severity. For the management of ARDS or sepsis, the respective guidelines issued by ARDSNet and Surviving Sepsis campaign will be followed. Other institutional protocols for supportive management will be implemented.<br>",NA,Yes,NA
covid,CTRI/2020/05/024962,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43237,Intervention1: Povidone Iodine: 2% Povidone Iodine gargle diluted to 1% (w/v) is used as oropharyngeal gargle and intranasal application given 4 times to 48 laboratory tested COVID-19 patients and followed up for 12 weeks<br>Control Intervention1: normal saline: 48 patients  laboratory tested COVID-19 positive  selected and tested on  7th and 21st day for comparison and followed for 12 weeks to check for any relapse<br>,NA,NA,NA
covid,CTRI/2020/05/024983,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43204,Intervention1: Topical Lignocaine: Topical lignocaine lozenges to be used before collecting nasal and throat swabs for Covid-19<br>,NA,Yes,NA
covid,CTRI/2020/05/025167,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43378,Intervention1: Thymoquinone 50 mg tablet as an add on to best supportive as per guidelines of clinical management of COVID-19 as issued by MOHFW.: Dose : 50 mg once daily for 14 days<br>Control Intervention1: best supportive care: Best supportive care will be as defined in Guidelines on Clinical Management of COVID-19 issued by MOHFW.<br>,NA,NA,NA
covid,CTRI/2020/05/025214,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43727,Intervention1: AYUSH 64: Dose:2 capsules (500 mg each) thrice  daily<br>Dosage form:Capsules/Tablets <br>Route of Administration:	Oral<br>Time of Administration:	Thrice a day after food<br>Anupana: Water 	<br>Duration of therapy: 30 days<br><br>Control Intervention1: Conventional standard therapy for COVID-19 positive patients: Conventional standard therapy as per ICMR/WHO parameters<br>,NA,NA,Yes
covid,CTRI/2020/05/025271,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43206,Intervention1: Suspension of heat killed (autoclaved)Mycobacterium w: 0.3 ml (0.1ml x 3 Injection) of intradermal Mw for 3 consecutive days with Standard therapy of COVID-19<br>Control Intervention1: Placebo: 0.3 ml (0.1 ml x 3 Inj.) of intradermal Placebo for 3 consecutive days with Standard therapy of COVID-19<br>,NA,NA,NA
covid,CTRI/2020/05/025276,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43892,"Intervention1: Ayurvedic medicines: 1. Sanshamani Vati <br>(Tinospora cordifolia)	 		1gm BD with 50ml Nagaradi kwath(Decoction of Zingiber officinale -2 part, Terminalia chebula- 4 part, Tinospora cordifolia-6 part in quantity)<br><br>2.Amalaki  Churna <br>( Powder of Phyllanthus emblica)3gm with water<br>once a day at 5pm<br>3.Golden  Milk (100ml of milk with 3gm of Curcuma longa) at 9pm. 	<br>Intervention2: Ayurveda Protocol: 1. Sanshamani Vati (Tinospora cordifolia) 1gm BD with 50ml Nagaradi kwath(Decoction of Zingiber officinale -2 part, Terminalia chebula- 4 part, Tinospora cordifolia-6 part in quantity) 2.Amalaki Churna ( Powder of Phyllanthus emblica)3gm with water once a day at 5pm 3.Golden Milk (100ml of milk with 3gm of Curcuma longa) at 9pm.<br>all to be taken orally <br>Duration 14 days<br>Control Intervention1: Not applicable: Not applicable<br>",NA,NA,Yes
covid,CTRI/2020/05/025299,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43752,Intervention1: Convalescent Plasma: SARS-CoV-2 convalescent plasma (single unit; additional unit will be given only if required based on subjectâ??s clinical status)<br>Control Intervention1: COVID Standard treatment: As per Revised Guidelines on ClinicalManagement of COVID â?? 19; Government of India<br>Ministry of Health & Family Welfare<br>Directorate General of Health Services<br>(EMR Division);31st March 2020<br>,NA,Yes,NA
covid,CTRI/2020/05/025335,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43949,"Intervention1: Ayush-64, a polyherbal formulation.<br>: The composition of AYUSH 64 includes aqueous extract of Saptaparna (Alstoniascholaris R. Br.) Katuki (Picrorhizakurroa Royle ex. Benth), Kiratatikta (SwertiaChirataPexbex. Karst) and powder of Kuberaksha (Caesalpinia crista Linn.) in the ratio of 1:1:1:2.Dose:- 2 Tablets (500 mg) thrice daily (2-2-2)<br>Dosage form:-	Tablet<br>Route of Administration:-	Oral<br><br>Time of Administration:-after food<br><br>Anupana:- Warm water<br> 	<br>Duration of therapy:- 14 days <br><br>Control Intervention1: Not applicable: Not applicable<br>",NA,NA,Yes
covid,CTRI/2020/05/025337,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43940,"Intervention1: Resveratrol-Copper tablets: Patients will receive Resveratrol-Copper tablets. Each tablet contains 5.6 mg of Resveratrol and 560 ng of Copper. Route - per oral.<br>Frequency - 1 tablet 4 times per day. Duration - From the date of randomization to the day of discharge or death, whichever is earlier. Patients in this arm can also receive all standard treatment that the treating team considers appropriate including any other antibiotic, antibacterial, antiviral or antimicrobial drugs.<br>Intervention2: Chlorophyllin tablets: Patients will receive oral Chlorophyllin tablets daily under fasting conditions at a dose of 750 mg OD from the date of randomization to the day of discharge or death, whichever is earlier. Patients in this arm can also receive all standard treatment that the treating team considers appropriate including any other antibiotic, antibacterial, antiviral or antimicrobial drugs.<br>Control Intervention1: Standard treatment: Patients in this arm can receive all standard treatment that the treating team considers appropriate including any other antibiotic, antibacterial, antiviral or antimicrobial drugs. However, patients in this arm cannot receive Resveratrol -Copper treatment. The treatment proptocol will be in sync with the emerging scientific evidence and evolving national guidelines<br>",NA,Yes,NA
covid,CTRI/2020/05/025338,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44033,Intervention1: Ayush 64: Dose:		2 capsules (500 mg each) thrice  daily (2-2-2)<br>Dosage form: 		Tablets <br>Route of Administration:	Oral<br>Time of Administration:	Thrice a day after food<br>Anupana:		Warm Water 	<br>Duration of therapy:	14 days<br><br>Control Intervention1: Not applicable: Not applicable<br>,NA,NA,Yes
covid,CTRI/2020/05/025369,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43485,"Intervention1: Tocilizumab and Current Standard of Care: Dose:  6 mg/kg (up to a maximum of 480 mg), Frequency: Once, Route of Administration: Intravenous Infusion, Total duration of administration: 1 Hour and Standard of CARE will be as per individual Hospital (Study Site) Policy<br>Control Intervention1: Current Standard of Care: Standard of CARE will be as per individual Hospital (Study Site) Policy<br>",NA,Yes,NA
covid,CTRI/2020/06/025575,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43076,"Intervention1: Standard Treatment (STns): 1.	Strict Isolation<br>2.	Standard Precautions (Hand hygiene, Cough Etiquette, Wear surgical mask)<br>3.	Hydration<br>4.	Proper Nutrition<br>5.	Supportive Pharmacotherapy (Antipyretic, Antiallergic, Cough Suppressant)<br>6.	Treatment of Comorbid Diseases<br>7.	Oseltamivir (75 mg BD) for patient who are tested positive for H1N1<br>If the patient improves clinically the same treatment will be continued. If the patient do-not improve or shows sign of severity (mentioned above) the patient will be shifted to the severity arm (S-group) of the clinical trial with randomization again.<br>Intervention2: Standard Treatment for severe patients: (STs): 1.	Strict Isolation<br>2.	Standard Precautions (Hand hygiene, Cough Etiquette, Wear surgical mask)<br>3.	Fluid Therapy <br>4.	Supportive Pharmacotherapy (Antipyretic, Antiallergic, Cough Suppressant)<br>5.	Oxygen supplementation (As required)<br>6.	Invasive ventilation (As required)<br>7.	Antibiotic agents for other associated infections (according to 2019 ATS/IDSA guidelines for non-ICU and ICU patients)<br>8.	Vasopressor support<br>9.	Renal-replacement therapy<br>10.	Treatment of Comorbid Diseases<br>11.	Oseltamivir (75 mg BD) for patient who are tested positive for H1N1<br>Patients will be assessed for clinical improvement in every 48-72 hours of treatment. In case the patient do not respond to the current treatment regimen the patient will be shifted to alternative regimen in the same treatment group. If the patient progress in the same group then patient will be shifted to biologics (Tocilizumab). In case the patient do not respond in the next 48-72 hours and continue to deteriorate on the current treatment then the all experimental treatment will be stopped and Standard Treatment (STs) will be continued. <br><br>Intervention3: Standard Treatment (",NA,Yes,NA
covid,CTRI/2020/06/025760,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44441,Intervention1: Drug sofosbuvir: sofosbuvir 400 mg twice daily for 10 days in all eligible study subjects along with standard of care including tablet hydroxy chloroquine 400 mg twice a day on day 1 followed by 200 mg twice a day upto day 5.<br>Control Intervention1: nil: nil<br>,NA,Yes,NA
covid,CTRI/2020/06/025798,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44460,"Intervention1: Intervention Arm 1: Reinitiation of intravesical BCG from the beginning of the regimen<br>120 mg of intravesical BCG dissolved in 50 ml Normal Saline instilled in bladder via a per urethral catheter, weekly for 6 weeks followed by monthly for 12 months<br>Control Intervention1: Intervention Arm 2: Resumption of Intravesical BCG from where it was interrupted<br>120 mg of intravesical BCG dissolved in 50 ml Normal Saline instilled in bladder via a per urethral catheter, weekly for 6 weeks followed by monthly for 12 months, depending upon from where in the course, the therapy was resumed<br>",NA,NA,NA
covid,CTRI/2020/06/025855,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44386,Intervention1: AYUSH 64: AYUSH 64 02 Capsules of 500mg each orally thrice daily for 14 days as add-on therapy to supportive and symptomatic allopathic treatment for COVID 19 patients<br>Control Intervention1: Control arm: Supportive or symptomatic allopathic treatment as per guideline of study site hospital for COVID 19 patients	<br>,NA,NA,Yes
covid,CTRI/2020/06/025874,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44684,"Intervention1: Kabasura kudineer: Siddha medicine<br>30 â?? 60 ml twice daily orally<br>Control Intervention1: Zinc and Vitamin C: Zinc -100 mg, Vit C â?? 60000 IU twice daily orally<br>",NA,NA,Yes
covid,CTRI/2020/06/025957,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44709,"Intervention1: Favipiravir 200mg Tablets: Dosage Form: Tablets,  <br>Dosage Frequency: 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days, <br>Mode of Administration: Oral<br>Intervention2: Umifenovir capsules: 800 mg BID: Dosage Form:  Capsule<br>Dosage Frequency: 800 mg BID, <br>Mode of Administration: Oral<br>Control Intervention1: Favipiravir 200mg Tablets: Dosage Form: Tablets <br>Dosage Frequency: 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days, <br>Mode of Administration: Oral<br><br>",NA,Yes,NA
covid,CTRI/2020/06/026119,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44218,Intervention1: ARSENIC ALBUM 30 add on to standard care: 1.	Administration Of Medicine :- Oral Route<br>2.	Form Of Dose:-  04 Globules (Medicated Globules ) <br>3.	Repetition: - according to severity of symptoms Or according to posology<br><br>Intervention2: ARSENIC ALBUM 200 add on to standard care: 1.	Administration Of Medicine :- Oral Rout<br>2.	Form Of Dose:-  04 Globules (Medicated Globules ) <br>3.	Repetition: - according to severity of symptoms Or according to posology<br><br>Control Intervention1: standard care alone: standard care to be given as per applicable guideline<br>,NA,NA,NA
covid,CTRI/2020/06/026187,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45027,Intervention1: ACT12 tablets and ACT 13 dry Syrup along with standard treatment: 2 tablets of ACT12 and 20 ml ACT 13 dry syrup TDS along with standard of care for 10 days<br>Control Intervention1: Standard treatment: Standard treatment as per<br>protocol of ICMR for 10 days<br>,NA,NA,NA
covid,CTRI/2020/06/026220,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44350,"Intervention1: Nafamostat Mesilate Injection 50 mg/ 100 mg vial: Dissolve a daily dose of Nafamostat mesilate in 1000 ml of 5 % dextrose and to be infused at dose of 0.1 mg/kg/hr for 24 hrs by continuous infusion for 10 days<br>If the patient meets clinical improvement/ discharge criteria any time prior to completing infusion on Day 10, the treatment can be stopped earlier and subject can be discharged and followed up as defined in protocol<br>Also, Standard of care as per institutional practice.<br>Patients may be given prophylactic LMWH (e.g., Enoxaparin 1mg/kg per day Subcutaneously) as per investigatorâ??s discretion. Before starting LMWH, investigator should check for bleeding tendency riskand presence of any contraindications. When Nafamostat and LMWH are given concomitantly daily PT/INR and aPTT should be monitored.<br>Control Intervention1: Standard of care as per institutional practice: Standard of care as per institutional practice<br><br>Patients may be given prophylactic LMWH (e.g., Enoxaparin 1mg/kg per day Subcutaneously) as per investigatorâ??s discretion. Before starting LMWH, investigator should check for bleeding tendency riskand presence of any contraindications. When Nafamostat and LMWH are given concomitantly daily PT/INR and aPTT should be monitored.<br>",NA,NA,NA
covid,CTRI/2020/06/026221,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44542,Intervention1: Arogya Kashayam-20: Dose : 100 ml <br>Frequency: Twice a day (morning and evening)<br>Route: Oral.<br>Duration: 10 days.<br>Control Intervention1: Hydroxychloroquine (HCQ): Dose: First day - 800 mg<br>maintenance dose for next five days - 400 mg. <br>Frequency: Twice a day in divided dose.<br>Route : Oral.<br>Duration: 6 days.<br>,NA,Yes,NA
covid,CTRI/2020/06/026227,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44584,"Intervention1: Khameera Marwareed: 5g orally once daily in the morning for 14days<br>Intervention2: Tiryaq-e-Arba: 5gm orally with lukewarm water in the Morning for 14days<br>Intervention3: Unani Joshanda/decoction (Behidana (Cydonia oblonga) 3 gm, Unnab (Zizyphus jujube)<br>5 in number, Sapistan (Cordia myxa)9 in numbers: lukewarm decoction once<br>daily in the Evening for 14days<br><br>Intervention4: Conventional treatment being given in quarantine centers in Delhi: As per Centre/State Govt policy<br>Control Intervention1: Conventional treatment being given in quarantine centers in Delhi: As per Centre/State Govt policy<br>",NA,NA,NA
covid,CTRI/2020/07/026340,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44929,Intervention1: Zinc sulphate 100mg: Micronutrient Zinc combined with standard treatment <br>Tab Zinc Sulphate 100 mg OD<br>Control Intervention1: Standard treatment: Standard medications<br>,NA,NA,NA
covid,CTRI/2020/07/026463,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43844,"Intervention1: Ganjhuvir Syrup: 10 ml Ganjhuvir syrup will be administered 3 times a day, 1 hr before meal, along with SOC for 10 days<br>Intervention2: Ganjhuvir Tablet: 1 Ganjhuvir Tablet will be administered 3 times a day, 1hr before meal, along with SCO for 10 days.<br>Control Intervention1: Standard of Care treatment: As prescribed and as recomended<br>",NA,Yes,NA
covid,CTRI/2020/07/026468,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44844,"Intervention1: Formulation 3 and SOC: Yashtimadhu, 300 mg, 2 tablets ,2 times a day for 12 weeks along with standard of care.<br>Control Intervention1: Only Standard of Care Treatment: As per Hospital protocol<br>",NA,NA,NA
covid,CTRI/2020/07/026470,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45363,"Intervention1: Siddha Medicines in fixed regimen: Kaba Sura Kudineer Chooranam â?? Decoction â?? Two times daily before 30 min of meals for 14 days, <br><br>Adathodai Manapagu â?? 10 ml â?? Three times daily after meals for 14 days,<br><br>Thaleesadhi Chooranam Mathirai 500 mg â?? 2 tablet - Four times daily after meals for 14 days,<br><br>Brammhanandha bairavam 100 mg â?? 1 pill - Two times daily after meals for 7 days when fever does not subside for 7 days after administering above three medicines. This Brammhanandha bairavam 100 mg pill will not be administered initially for first 7 days. <br><br>Control Intervention1: Not Applicable: No treatment<br>",NA,NA,Yes
covid,CTRI/2020/07/026515,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45584,"Intervention1: Resveratrol-Copper tablets: Patients will receive Resveratrol-Copper tablets (1 tablet 4 times per day) from the date of randomization to the day of discharge or death, whichever is earlier. Patients in this arm can also receive all standard treatment that the treating team considers appropriate including any other antibiotic, antibacterial, antiviral or antimicrobial drugs.<br>Intervention2: Chlorophyllin tablets: Patients will receive oral Chlorophyllin tablets daily under fasting conditions at a dose of 750 mg OD from the date of randomization to the day of discharge or death, whichever is earlier. Patients in this arm can also receive all standard treatment that the treating team considers appropriate including any other antibiotic, antibacterial, antiviral or antimicrobial drugs.<br>Control Intervention1: Standard treatment: Patients in this arm can receive all standard treatment that the treating team considers appropriate including any other antibiotic, antibacterial, antiviral or antimicrobial drugs.<br>",NA,Yes,NA
covid,CTRI/2020/07/026529,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45475,"Intervention1: Eflornithine: Treatment arm 1: Dose 2.5g, Oral solution administered every 6 hours + Standard of Care (SoC) excluding antimalarials and antivirals<br>Treatment arm 2: Dose 5.0, oral solution administered every 6 hours + Standard of Care (SoC) excluding antimalarials and antivirals.<br>Control Intervention1: Standard Of Care (SoC): SoC including antimalarials, antivirals and macrolides.<br>",NA,NA,NA
covid,CTRI/2020/07/026534,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45137,Intervention1: PICOVRID syrup along with standard care: PICOVRID syrup 10 ml once a day along with standard care for 14 days<br>Control Intervention1: Standard care: Standard care for 14 days<br>,NA,NA,NA
covid,CTRI/2020/07/026570,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45007,Intervention1: Cap. IP: Ayurvedic formulation to be taken twice daily in addition to standard of care<br>Control Intervention1: Placebo: Capsule to be taken twice daily in addition to standard of care<br>,NA,NA,Yes
covid,CTRI/2020/07/026575,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45500,Intervention1: Cap of Sahadevi Powder: Dose 2 cap[1gm powder] <br>Frequency Thrice daily with warm water after food<br>route of administration oral<br>Duration of therapy 15 days<br>Control Intervention1: Cap placebo [wheat powder 500 mg]  <br>Dose 2 capsule <br>Frequency three times a day<br>Route of administration Oral<br>Duration 15 days <br>: Standard care as per modern sciences<br><br>,NA,NA,NA
covid,CTRI/2020/07/026705,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45088,Intervention1: Group I : (Ayurveda as add-on to standard care as per: guidelines)<br>AYUSH 64<br>Dose		2 capsules (500 mg each) thrice  daily<br>Dosage form 		Capsules/Tablets <br>Route of Administration	Oral<br>Time of Administration	Thrice a day after food<br>Anupana		Water 	<br>Duration of therapy	1 month<br><br>Control Intervention1: Group-II: <br>Conventional standard therapy as per ICMR/WHO guidelines<br><br>,NA,NA,Yes
covid,CTRI/2020/07/026922,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45909,"Intervention1: Ayurveda Drug intervention for 10 days: Vyaghryadi kwatha <br>	50  ml twice a day<br><br>Samshamani Vati <br>	2 tablets 500 mg each twice daily<br>Ashwagandha (Withania somniferum)<br>	2gm in powdered form, once daily with warm water.<br>Rasona Kalka 	1gm once daily with warm water.<br><br><br><br><br>Intervention2: biochemical markers: Haemogram, Platelet count, TLC, DLC, Haemoglobin and ESR.<br>Blood Sugar level<br>C-Reactive Protein<br>Liver Function Test<br>Kidney Function Test<br>Ferritin<br>D-Dimer<br>LDH<br>Selected Cytokines: Gamma Interferon, Tumor Necrosis factor (Alpha and Beta), Interleukin-6.<br>Nasal and Throat swab for specific test for COVID 19 based on RT-PCR.<br><br>Control Intervention1: Not applicalble: Not applicable<br>",NA,Yes,Yes
covid,CTRI/2020/08/027043,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43175,Intervention1: Mesenchymal Stem Cells: Mesenchymal Stem cells derived from umbilical cord and placenta<br>Control Intervention1: Not Applicable: Not Applicable<br>,NA,Yes,NA
covid,CTRI/2020/08/027061,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45729,Intervention1: Immunocin Î± 1.6 mg: Two subcutaneous injections of 1.6 mg TÎ±1 TID per day for at least seven consecutive days.<br>Control Intervention1: Not Applicable: Not Applicable<br>,NA,Yes,NA
covid,CTRI/2020/08/027284,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46679,"Intervention1: Aceinavir (1 gram uncoated tablet): Arm A would enroll 22 moderately symptomatic COVID-19 subjects treated with Aceinavir (Investigational Product) and Standard of Care (SoC). <br>Dose is 4 tablets thrice daily till end of clinical recovery or as per the discretion of clinical investigator<br>Control Intervention1: Standard of Care (SoC): Arm B would enroll 22 moderately symptomatic COVID-19 subjects treated with SoC.<br>The Standard of Care(SoC) will be as per the local hospital protocol and as per recommendations / guidelines by the respective authorities (Ministry of Health and Family Welfare, CDC and USFDA) whichever fits best at the time of initiation of this study. This will also be followed by the best supportive care guidelines recommended by the authorities (Ministry of Health and Family Welfare, CDC and USFDA).<br>",NA,Yes,NA
covid,CTRI/2020/08/027345,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45932,Intervention1: Daclatasvir and Sofosbuvir: FDC of Daclatasvir (60mg) and Sofosbuvir (400mg) <br>To be given once a day for 14 days<br>Intervention2: Ledipasvir and Sofosbuvir: FDC of Ledipasvir (90mg) and Sofosbuvir (400mg) to be given once a day for 14 days<br>Control Intervention1: Standard of care: standard of care<br>,NA,Yes,NA
covid,CTRI/2020/08/027346,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46229,"Intervention1: Ayush-64, Agasthya Haritaki, Anu taila Nasal drops: AYUSH-64 500 mg Tablets Oral<br>Twice a day 2 hrs after food<br>Lukewarm water for 10 days<br>Agasthya Haritaki Avleha 5 gm<br><br>Oral<br>Twice a day 2 hrs before food Lukewarm water for 10 days<br>Anu taila 2 drops<br>Oil Nasal instillation<br>Twice a day for 10 days<br>Intervention2: Broncho-T Granules: 50 ml<br>Decoction Oral Thrice a day 1 hrs before food Lukewarm water<br>for 10 days<br>Control Intervention1: Standard conventional treatment as per ICMR guidelines: Symptomatic care<br>",NA,NA,Yes
covid,CTRI/2020/08/027501,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=44303,"Intervention1: Nuvastaticâ?¢ (C5OSEW5050ESA): Nuvastaticâ?¢ (C5OSEW5050ESA) in the form of powder to be reconstituted in water to be consumed thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14days.<br>Control Intervention1: Placebo: Placebo in the form of powder to be reconstituted in water to be consumed thrice daily (morning, afternoon and evening (one sachet each) to be taken for 14days.<br>",NA,NA,NA
covid,CTRI/2020/09/027622,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46908,"Intervention1: Estradiol valerate, standard care: Study group will receive Estradiol Valerate orally 2 mg once a day  for 7 days along with standard care as an adjunctive therapy.<br>Control group will receive only standard care.<br><br><br>Control Intervention1: Standard care: Control group will receive only standard care.<br>",NA,NA,NA
covid,CTRI/2020/09/027775,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47367,"Intervention1: ES16001: Elaeocarpus sylvestris var. ellipticus extract <br>Dosage Regimen: 480 mg per day orally for 10 days<br>Control Intervention1: Standard of care treatment plus placebo: Standard of care treatment as per the revised clinical management protocol for COVID-19 as issued by Govt of India, MoHFW for 10 days.<br>",NA,NA,NA
covid,CTRI/2020/09/027938,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47586,Intervention1: Particle Life Sciences Formulation Capsules: Each capsule to be consumed orally twice a day immediately after meals for 10<br>days<br>Control Intervention1: Standard Treatment protocol designed by MOHFW/ICMR: Tab. Hydroxychloroquine (400 mg) BD on 1st day followed by<br>200 mg BD for 4 days; Azithromycin 500 mg 1-0-0 for 3 days (if needed); and Vitamin support for 10 days<br>,NA,Yes,Yes
covid,CTRI/2020/09/028043,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47443,"Intervention1: Vasa Ghana (Aqueous extract of Adhatoda<br>vasica),: <br> The Asymptomatic OR/and Mild symptomatic COVID19 RT-PCR swab test<br>positive will be administered Vasa Ghana (whole water soluble extract): 500mg BD 15<br>min. before meals<br>for 14 days<br>Intervention2: Ayurvediic: Guduchi Ghana (Aqueous extract of Tinospora cordifolia)<br>Intervention3: Ayurvedic: Vasa-Guduchi<br>Ghana (Aqueous extract of Adhatoda vasica  Tinospora cordifolia combined)<br>Intervention4: Guduchi Ghana (Aqueous extract of Tinospora cordifolia): 	 <br>The Asymptomatic OR/and Mild symptomatic COVID19 RT-PCR swab test<br>positive will be administered Guduchi Ghana (whole water soluble extract): 500mg BD<br>15 min. before meals for 14 days<br>Intervention5: Vasa- Guduchi Ghana (whole water soluble extract):<br>500mg (250 mg each of Vasa and Guduchi): The Asymptomatic OR/and Mild symptomatic COVID19 RT-PCR swab test<br>positive will be administered Vasa- Guduchi Ghana (whole water soluble extract):<br>500mg (250 mg each of Vasa and Guduchi) BD 15 min. before meals for 14 days<br>",NA,NA,Yes
covid,CTRI/2020/10/028231,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47237,Intervention1: KETOJI: Ketoji is liquid containing 25 gm of Beta-hydroxybuterate (BHB) i.e. 41.6% BHB esters and 57.39% solvent (Water) with no added salts or acids.<br>Control Intervention1: NA: NA<br>,NA,NA,NA
covid,CTRI/2020/10/028253,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47986,"Intervention1: Thalidomide: Drug - Thalidomide<br>Dose - 100 mg, single tablet <br>Frequency - Once daily<br>Route of administration - Oral<br>Duration of therapy - 7 days<br>Control Intervention1: N/A: N/A<br>",NA,NA,NA
covid,CTRI/2020/10/028326,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48214,"Intervention1: Mycobacterium Indicus Pranii (MIP) Vaccine<br>: 0.3 ml intradermal on either deltoid for three days in critically ill subjects with COVID-19 disease<br>Intervention2: Mycobacterium Indicus Pranii (MIP) Vaccine: 0.1ml intradermal on both deltoids on day 1, followed by randomization to receive 0.1 ml on day 30, in 30 health care workers or close contacts of COVID-19 patients<br>Control Intervention1: Non-vaccinated health care workers: Till end of study<br>",Yes,NA,NA
covid,CTRI/2020/10/028471,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48593,"Intervention1: Immune-combination of Devadaaru, Aswagandha, Yashthimadu and Jeevanthi which are already proven drugs: 6 drops in 50 ml of water every 4 hours <br>Administered for 15 days<br><br>Control Intervention1: placebo-distilled water: 6 drops in 50 ml of water every 4 hours <br>administered for 15 days<br><br>",NA,NA,NA
covid,CTRI/2020/10/028581,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47042,"Intervention1: Budesonide, Local standard of care: Budesonide Rotacaps 200 mcg BD for 10 - 14 days depending on onset of symptoms given in addition to the local standard of care<br>Intervention2: BUDESONIDE ROTACAP DRY POWDER INHELAR: BUDESONDE ROTACAP DPI TAKEN TROUGH ROTAHELAR TWICE DAY<br>Control Intervention1: Local standard of care: Local standard of care for mild COVID-19 cases as provided by the centre<br>",NA,NA,NA
covid,CTRI/2020/10/028695,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=43749,"Intervention1: oral vitamin C tablets: oral tablet vitamin C tablet 500mg (b.d)twice a day along with other sympto9matic treatment and then asses for reduce in severity and duration of symptom<br>Intervention2: Intervention Group: Oral tablet vitamin C tablet 500mg (B.D)twice a day along with other symptomatic treatment till the symptoms relived or maximum 14 days,which ever earlier.<br>Control Intervention1: <br>control group: No vitamin C has been given to control group only symptomatic treatment will be given<br>Control Intervention2: control group: No vitamin C has been given to control group.Only symptomatic treatment will be given<br>",NA,NA,Yes
covid,CTRI/2020/10/028731,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=46442,"Intervention1: Dexamethasone 12mg: Intervention period is up to 10 days from randomisation or until hospital discharge or death, whichever comes first.<br>Route: IV; Frequency: Once Daily<br>Control Intervention1: Dexamethasone 6mg: Intervention period is up to 10 days from randomisation or until hospital discharge or death, whichever comes first<br>Route: IV; Frequency: Once Daily<br>",NA,Yes,NA
covid,CTRI/2020/11/028779,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48578,Intervention1: SARS-CoV-2 (COVID-19) Antiserum<br>Immunoglobulins (Purified F(ab)2 fragment along with standard of<br>care: Patients in this group will receive two 4mL<br>doses (at day 0 and Day 1) of BioEâ??s SARS-CoV-2 (COVID-19) Antiserum Immunoglobulins<br>(Purified F(ab)2 fragment) intravenously along with standard of care.<br>Control Intervention1: Standard care for Covid-19 patients: Patients in this group will receive only standard of care for Covid-19<br>patients.<br>,NA,NA,NA
covid,CTRI/2020/11/028959,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=48272,"Intervention1: recombinant erythropoietin (r-EPO)in addition to standard care.: In 20 moderate to severely diseased patients who require ventilatory support(NIV/IV), 4000IU of r-EPO in addition to standard care would be administered subcutaneously on day 1, 2, 4 and 7th days.<br>Control Intervention1: only standard care.: In 20 number of moderate to severely diseased patients only standard care treatment protocol will be followed.<br>",NA,NA,NA
covid,CTRI/2020/11/029328,http://www.ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=49552,"Intervention1: Study Drug: IND02 [Cinamuneâ?¢] capsules 500 mg <br><br>Placebo: Placebo capsules 500 mg (containing all excipients except active ingredient) to be provided by Indus Biotech Pvt. Ltd., India.<br>: Patients with receive either the Test or the Placebo product as per the dosing regimen below (along with SoC treatment):<br>â?¢	Loading dose: 3 g/day [2 capsules of 500 mg X 3 times] for initial 3<br>â?¢	days<br>â?¢	Maintenance dose: 1.5 g/day [ 1 capsule of 500 mg X 3 times] fornext 12 days<br><br>Intervention2: IND02 [Cinamuneâ?¢] capsules 500 mg <br><br>: Patients with receive either the Test or the Placebo product as per the dosing regimen below (along with SoC treatment): - Loading dose: 3 g/day [2 capsules of 500 mg X 3 times] for initial 3 - days - Maintenance dose: 1.5 g/day [ 1 capsule of 500 mg X 3 times] fornext 12 days<br>Control Intervention1: Placebo capsules 500 mg (containing all excipients except active ingredient) to be provided by Indus Biotech Pvt. Ltd., India.: Patients with receive either the Test or the Placebo product as per the dosing regimen below (along with SoC treatment):<br>- Loading dose: 3 g/day [2 capsules of 500 mg X 3 times] for initial 3<br>- days<br>- Maintenance dose: 1.5 g/day [ 1 capsule of 500 mg X 3 times] fornext 12 days<br><br>",NA,NA,NA
im,DRKS00007265,http://www.drks.de/DRKS00007265,"Intervention 1: Drug: Adempas, Riociguat (BAY63-2521) Intervention 2: Device: Placebo",NA,NA,NA
im,DRKS00010307,http://www.drks.de/DRKS00010307,Intervention 1: Drug: S-649266 Intervention 2: Drug: Best Available Therapy,NA,NA,NA
im,DRKS00011159,http://www.drks.de/DRKS00011159,"Intervention 1: Daily measurement of piperacillin blood concentration with individual dosing based on the minimal inhibitory concentration of the infecting organism beginning on 1st day after randomization<br><br>optional: Measurement of the blood concentration of piperacillin and individual drug dosage already on day of randomisation (day 0)<br> <br>duration of therapy with piperacillin/tazobactam is at the discretion of the treating physician, intervention (TDM + dose adjustment) for a maximum of 10 days Intervention 2: standard piperacillin/tazobactam therapy, dosing based on summary of product characteristics",NA,NA,NA
main,DRKS00016147,http://www.drks.de/DRKS00016147,"Intervention 1: Nasturtium (BITC-containing), 7 days 1.5 g and further 7 days 3 g, which are taken in the morning and evening at intervals of about 12 h. Special diet during washout (7 days before intervention) and during the intervention phase.",NA,NA,NA
main,DRKS00016757,http://www.drks.de/DRKS00016757,"Intervention 1: Investigation, if rinsing with a calcium or fluoride containing solution prior to an erosive attack reduces the softening of the eroded enamel. Intervention 2: No rinsing with a test solution before the erosive attack.",NA,NA,NA
main,DRKS00016907,http://www.drks.de/DRKS00016907,"Intervention 1: The intervention group receives a bone density measurement as a routine examination within the first 3 months after the start of aromatase inhibitor therapy. In addition, the FRAX (Fracture Risk Assessment Tool) score and the TBS (Trabecular Bone Score) are calculated. Intervention 2: The control group also receives a bone density measurement and a calculation of the FRAX score and the TBS. These are healthy women.",NA,NA,NA
im,EUCTR2006-001095-21-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2006-001095-21,"<br>Trade Name: PEDIACEL: Diphtheria, tetanus, five component acellular pertussis, inactivated poliomyelitis and H. influenzae type b conjugate vaccine (adsorbed)<br>Product Name: PEDIACEL<br>Pharmaceutical Form: Suspension for injection<br><br>Trade Name: Infanrix?-IPV+Hib: Diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and adsorbed conjugated H. influenzae type b vaccine.<br>Product Name: Infanrix?-IPV+Hib<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br><br>Trade Name: Prevenar: pneumococcal saccharide conjugated vaccine, adsorbed<br>Product Name: Prevenar<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br><br>",Yes,NA,NA
im,EUCTR2011-004451-39-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-004451-39,<br>Product Name: DTaP-IPV-Hep B-PRP~T combined vaccine<br>Pharmaceutical Form: Suspension for injection<br><br>Trade Name: Infanrix™ hexa<br>Product Name: Infanr?ix™ Hexa<br>Pharmaceutical Form: Suspension for injection<br><br>Trade Name: Prevenar<br>Product Name: Prevenar<br>Product Code: PCV7<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br><br>,Yes,NA,NA
im,EUCTR2012-002633-11-GR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-002633-11,"<br>Trade Name: Tamiflu<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: OSELTAMIVIR<br>CAS Number: 204255-11-8<br>Current Sponsor code: RO64-0796<br>Other descriptive name: Oseltamivir phosphate<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 30-<br><br>Trade Name: Tamiflu<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: OSELTAMIVIR<br>CAS Number: 204255-11-8<br>Current Sponsor code: RO64-0796<br>Other descriptive name: Oseltamivir phosphate<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 45-<br><br>Trade Name: Tamiflu<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: OSELTAMIVIR<br>CAS Number: 204255-11-8<br>Current Sponsor code: RO64-0796<br>Other descriptive name: Oseltamivir phosphate<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br><br>Trade Name: Tamiflu<br>Pharmaceutical Form: Powder for oral suspension<br>INN or Proposed INN: OSELTAMIVIR<br>CAS Number: 204255-11-8<br>Current Sponsor code: RO64-0796<br>Other descriptive name: Oseltamivir phosphate<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 6-<br><br>",NA,Yes,NA
im,EUCTR2013-000046-19-SK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-000046-19,<br>                Trade Name: Xarelto<br>                Product Name: Rivaroxaban<br>                Product Code: JNJ-39039039/BAY 59-7939<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: RIVAROXABAN<br>                CAS Number: 366789-02-8<br>                Current Sponsor code: BAY 59-7939<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 2.5-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
im,EUCTR2013-004154-22-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004154-22,<br>                Product Name: TR-701 FA Powder for Concentrate for Solution for Infusion<br>                Product Code: TR-701 FA<br>                Pharmaceutical Form: Powder for solution for infusion<br>                INN or Proposed INN: Tedizolid Phosphate<br>                CAS Number: 856867-55-5<br>                Current Sponsor code: TR-701 FA<br>                Other descriptive name: TR-701 FA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 200-<br><br>                Trade Name: ZYVOXID - 2 MG/ML SOLUZIONE PER INFUSIONE 25 SACCHE MONOUSO FREEFLEX<br>                Product Name: Linezolid<br>                Product Code: Linezolid<br>                Pharmaceutical Form: Solution for infusion<br><br>,NA,NA,NA
im,EUCTR2013-004615-45-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-004615-45,<br>Trade Name: Zevtera©<br>Pharmaceutical Form: Powder for concentrate for solution for infusion<br>INN or Proposed INN: Ceftobiprole medocaril sodium <br>Current Sponsor code: BAL5788-001 <br>Other descriptive name: CEFTOBIPROLE MEDOCARIL SODIUM<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 666.6-<br><br>Trade Name: Ceftriaxone Kabi<br>Product Name: Ceftriaxone<br>Pharmaceutical Form: Powder for solution for injection/infusion<br>INN or Proposed INN: CEFTRIAXONE<br>CAS Number: 73384-59-5<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 2-<br><br>Trade Name: Ceftazidime Kabi<br>Product Name: Ceftazidime<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: CEFTAZIDIME<br>CAS Number: 72558-82-8<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 2-<br><br>Trade Name: Vancomycin Kabi<br>Product Name: Vancomycin<br>Pharmaceutical Form: Powder for solution for injection/infusion<br>INN or Proposed INN: VANCOMYCIN<br>CAS Number: 1404-90-6<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>,NA,Yes,NA
im,EUCTR2013-005429-21-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-005429-21,"<br>Trade Name: Curosurf<br>Product Name: Curosurf<br>Pharmaceutical Form: Endotracheopulmonary instillation, solution<br><br>",NA,NA,NA
im,EUCTR2013-005577-43-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2013-005577-43,<br>Trade Name: Infanrix® -IPV/Hib<br>Product Code: Infanrix-IPV+Hib<br>Pharmaceutical Form: Powder and suspension for suspension for injection<br>INN or Proposed INN: -<br>Current Sponsor code: D<br>Other descriptive name: DIPHTHERIA TOXOID<br>Concentration unit: IU international unit(s)<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: -<br>Current Sponsor code: T<br>Other descriptive name: TETANUS TOXOID<br>Concentration unit: IU international unit(s)<br>Concentration type: not less then<br>Concentration number: 40-<br>INN or Proposed INN: -<br>Current Sponsor code: PT<br>Other descriptive name: PERTUSSIS TOXOID<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>INN or Proposed INN: -<br>Current Sponsor code: FHA<br>Other descriptive name: FILAMENTOUS HAEMAGGLUTININ<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>INN or Proposed INN: -<br>Current Sponsor code: PRN<br>Other descriptive name: PERTUSSIS PERTACTIN<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 8-<br>INN or Proposed INN: -<br>Other descriptive name: POLIOVIRUS (INACTIVATED) TYPE 1 (MAHONEY STRAIN)<br>Concentration unit: DAgU D antigen unit(s)<br>Concentration type: equal<br>Concentration number: 40-<br>INN or Proposed INN: -<br>Other descriptive name: POLIOVIRUS (INACTIVATED) TYPE 2 (MEF-1 STRAIN)<br>Concentration unit: DAgU D antigen unit(s)<br>Concentration type: equal<br>Concentration number: 8-<br>INN or Proposed INN: -<br>Other descriptive name: POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN)<br>Concentration unit: DAgU D antigen unit(s)<br>Concentration type: equal<br>Concentration number: 32-<br>INN or Proposed INN: -<br>Current Sponsor code: HIB<br>Other descriptive name: HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 10-<br><br>,Yes,NA,NA
im,EUCTR2014-001117-41-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001117-41,<br>Trade Name: INFANRIX HEXA<br>Pharmaceutical Form: Powder and suspension for suspension for injection<br>INN or Proposed INN: N/A<br>Current Sponsor code: D<br>Other descriptive name: DIPHTHERIA TOXOID<br>Concentration unit: IU international unit(s)<br>Concentration type: not less then<br>Concentration number: 30-<br>INN or Proposed INN: N/A<br>Current Sponsor code: T<br>Other descriptive name: TETANUS TOXOID<br>Concentration unit: IU international unit(s)<br>Concentration type: not less then<br>Concentration number: 40-<br>INN or Proposed INN: N/A<br>Current Sponsor code: PT<br>Other descriptive name: PERTUSSIS TOXOID<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>INN or Proposed INN: N/A<br>Current Sponsor code: FHA<br>Other descriptive name: FILAMENTOUS HAEMAGGLUTININ<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>INN or Proposed INN: N/A<br>Current Sponsor code: PRN<br>Other descriptive name: PERTUSSIS PERTACTIN<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 8-<br>INN or Proposed INN: N/A<br>Current Sponsor code: HBsAg<br>Other descriptive name: HEPATITIS B SURFACE ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 10-<br>INN or Proposed INN: N/A<br>Other descriptive name: POLIOVIRUS (INACTIVATED) TYPE 1 (MAHONEY STRAIN)<br>Concentration unit: DAgU D antigen unit(s)<br>Concentration type: equal<br>Concentration number: 40-<br>INN or Proposed INN: N/A<br>Other descriptive name: POLIOVIRUS (INACTIVATED) TYPE 2 (MEF-1 STRAIN)<br>Concentration unit: DAgU D antigen unit(s)<br>Concentration type: equal<br>Concentration number: 8-<br>INN or Proposed INN: N/A<br>Other descriptive name: POLIOVIRUS (INACTIVATED) TYPE 3 (SAUKETT STRAIN)<br>Concentration unit: DAgU D antigen unit(s)<br>Concentration type: equal<br>Concentration number: 32-<br>INN or Proposed INN: N/A<br>Current Sponsor code: Hib<br>Other descriptive name: HAEMOPHILUS TYPE B CONJUGATE VACCINE (TETANUS TOXOID CONJUGATE)<br>Concentration unit: µg microgram(s)<br>Concentration typ,Yes,NA,NA
im,EUCTR2014-001120-30-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-001120-30,<br>                Trade Name: PREVENAR 13<br>                Pharmaceutical Form: Suspension for injection<br>                INN or Proposed INN: -<br>                Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 2.2-<br>                INN or Proposed INN: -<br>                Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 2.2-<br>                INN or Proposed INN: -<br>                Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 CONJUGATED TO CRM197<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 2.2-<br>                INN or Proposed INN: -<br>                Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 CONJUGATED TO CRM197<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 2.2-<br>                INN or Proposed INN: -<br>                Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A CONJUGATED TO CRM197<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 2.2-<br>                INN or Proposed INN: -<br>                Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B CONJUGATED TO CRM197<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 4.4-<br>                INN or Proposed INN: -<br>                Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO CRM197<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>,NA,NA,NA
im,EUCTR2014-004039-37-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004039-37,"<br>Product Name: Solithromycin<br>Product Code: CEM-101<br>Pharmaceutical Form: Powder for solution for injection/infusion<br>INN or Proposed INN: SOLITHROMYCIN<br>CAS Number: 760981-83-7<br>Current Sponsor code: CEM-101<br>Other descriptive name: SOLITHROMYCIN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br><br>Product Name: Solithromycin<br>Product Code: CEM-101<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: SOLITHROMYCIN<br>CAS Number: 760981-83-7<br>Current Sponsor code: CEM-101<br>Other descriptive name: SOLITHROMYCIN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: Solithromycin<br>Product Code: CEM-101<br>Pharmaceutical Form: Powder for oral suspension<br>INN or Proposed INN: 760981-83-7<br>Current Sponsor code: CEM-101<br>Other descriptive name: SOLITHROMYCIN<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: range<br>Concentration number: 32-64<br><br>Product Name: Ceftriaxone<br>Pharmaceutical Form: Powder and solvent for solution for injection/infusion<br>INN or Proposed INN: CEFTRIAXONE<br>CAS Number: 73384-59-5<br>Other descriptive name: Ceftriaxone<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 2-<br><br>Product Name: Co-amoxiclav<br>Pharmaceutical Form: Powder for oral suspension<br>INN or Proposed INN: AMOXICILLIN<br>CAS Number: 26787-78-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 125-<br><br>Product Name: Co-amoxiclav<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: AMOXICILLIN<br>CAS Number: 26787-78-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Product Name: Amoxicillin<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: AMOXICILLIN<br>CAS Number: 26787-78-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 250-<br><br>Product Name: Amoxil<br>Pharmaceutical Form: Powder for injection<br>INN or Proposed INN: AMOXICILLIN<br>CAS Number: 26787-78-0<br>Other descriptive name: Am",NA,Yes,NA
im,EUCTR2014-004471-23-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-004471-23,<br>Trade Name: Tamiflu 75 mg hard capsules<br>Product Name: Tamiflu 75 mg hard capsules<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: Oseltamivir Phosphate<br>CAS Number: 204255-11-8<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br><br>Trade Name: Tamiflu 6 mg/ml powder for oral suspension<br>Product Name: Tamiflu 6 mg/ml powder for oral suspension<br>Pharmaceutical Form: Powder for oral suspension<br>INN or Proposed INN: Oseltamivir Phosphate<br>CAS Number: 204255-11-8<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 6-<br><br>,NA,Yes,NA
main,EUCTR2014-005521-12-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-005521-12,<br>                Trade Name: TARGIN - 10 MG/5 MG COMPRESSE A RILASCIO PROLUNGATO 100 COMPRESSE IN FLACONE HDPE<br>                Product Name: TARGIN<br>                Pharmaceutical Form: Prolonged-release tablet<br>                INN or Proposed INN: OSSICODONE CLORIDRATO<br>                CAS Number: 76-42-6<br>                Current Sponsor code: 5284603<br>                Other descriptive name: OSSICODONE CLORIDRATO<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 10-<br><br>                Trade Name: MORFINA CLORIDRATO - 5 FIALE10 MG/ML<br>                Product Name: MORFINA CLORIDRATO<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: MORFINA CLORIDRATO<br>                CAS Number: 57-27-2<br>                Current Sponsor code: 5288826<br>                Other descriptive name: MORFINA CLORIDRATO<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 10-<br><br>,NA,NA,NA
im,EUCTR2015-000066-62-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000066-62,"<br>                Product Name: Imipenem/Cilastatin + MK-7655<br>                Product Code: MK-7655A<br>                Pharmaceutical Form: Powder for solution for injection<br>                INN or Proposed INN: IMIPENEM<br>                CAS Number: 64221-86-9<br>                Current Sponsor code: .<br>                Other descriptive name: IMIPENEM<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br>                INN or Proposed INN: CILASTATINA<br>                CAS Number: 82009-34-5<br>                Current Sponsor code: .<br>                Other descriptive name: CILASTATINA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br>                INN or Proposed INN: RELEBACTAM<br>                Current Sponsor code: MK-7655<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 250-<br><br>                Trade Name: Primaxin<br>                Product Name: Imipenem/Cilastatin<br>                Product Code: MK-0787B<br>                Pharmaceutical Form: Powder for solution for injection<br>                INN or Proposed INN: IMIPENEM<br>                CAS Number: 64221-86-9<br>                Current Sponsor code: .<br>                Other descriptive name: IMIPENEM<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br>                INN or Proposed INN: CILASTATINA<br>                CAS Number: 82009-34-5<br>                Current Sponsor code: .<br>                Other descriptive name: CILASTATINA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br><br>                Trade Name: Colistimethate for Injection, USP<br>                Product Name: Colistimethate for Injection, USP<br>                P",NA,NA,NA
im,EUCTR2015-000246-34-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000246-34,<br>                Product Name: imipenem/cilastatin/relebactam<br>                Product Code: MK-7655A<br>                Pharmaceutical Form: Powder for injection<br>                INN or Proposed INN: IMIPENEM<br>                CAS Number: 64221-86-9<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br>                INN or Proposed INN: Relebactam<br>                Other descriptive name: MK-7655<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 250-<br>                INN or Proposed INN: Cilastatin<br>                CAS Number: 82009-34-5<br>                Other descriptive name: CILASTATIN<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br><br>                Trade Name: Piperacillin/Tazobactam-Teva<br>                Product Name: piperacillin/tazobactam<br>                Pharmaceutical Form: Powder for injection<br>                INN or Proposed INN: Tazobactam<br>                Other descriptive name: TAZOBACTAM<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br>                INN or Proposed INN: Piperacillin<br>                Other descriptive name: PIPERACILLIN<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 4000-<br><br>                Trade Name: Piperacillin / Tazobactam-Accord<br>                Product Name: Piperacillin/tazobactam<br>                Pharmaceutical Form: Powder for injection<br>                INN or Proposed INN: Tazobactam<br>                Other descriptive name: TAZOBACTAM<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br>                INN or Proposed INN: Piperacillin<br>,NA,NA,NA
im,EUCTR2015-000728-27-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-000728-27,"<br>                Product Name: Adjuvanted Quadrivalent Influenza Vaccine (aQIV) -surface antigen, inactivated, adjuvanted with MF59<br>                Product Code: aQIV<br>                Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>                INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>                CAS Number: -<br>                Current Sponsor code: -<br>                Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN (CALIFORNIA)<br>                Concentration unit: µg microgram(s)<br>                Concentration type: not less then<br>                Concentration number: 15-<br>                INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>                CAS Number: -<br>                Current Sponsor code: -<br>                Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN (HONG KONG)<br>                Concentration unit: µg microgram(s)<br>                Concentration type: not less then<br>                Concentration number: 15-<br>                INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>                CAS Number: -<br>                Current Sponsor code: -<br>                Other descriptive name: B/ -LIKE VIRUS ANTIGEN (PHUKET)<br>                Concentration unit: µg microgram(s)<br>                Concentration type: not less then<br>                Concentration number: 15-<br>                INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>                CAS Number: -<br>                Current Sponsor code: -<br>                Other descriptive name: B/ -LIKE VIRUS ANTIGEN (BRISBANE)<br>                Concentration unit: µg microgram(s)<br>                Concentration type: not less then<br>                Concentration number: 15-<br><br>                Trade Name: Boostrix<br>                Product Name: Boostrix<br>                Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>                INN or Proposed INN: -<br>                CAS Number: -<br>                Current Sponsor code: -<br>                Other descriptive name: DIPHTHERIA, TETANUS AN",Yes,NA,NA
im,EUCTR2015-001706-34-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-001706-34,<br>                Product Name: MEDI3902<br>                Product Code: MEDI3902<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: NA<br>                CAS Number: NA<br>                Current Sponsor code: MEDI3902<br>                Other descriptive name: MEDI3902<br>                Concentration unit: mg/g milligram(s)/gram<br>                Concentration type: equal<br>                Concentration number: 50-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2015-001763-39-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-001763-39,"<br>Trade Name: Mutaflor® Suspension<br>Pharmaceutical Form: Oral suspension<br>Other descriptive name: E. coli Nissle 1917, EcN<br>Concentration unit: CFU/ml colony forming unit(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1E08-<br>Pharmaceutical form of the placebo: Oral suspension<br>Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
im,EUCTR2015-001932-38-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-001932-38,<br>Product Name: FLU-v<br>Product Code: FLU-v<br>Pharmaceutical Form: Powder for suspension for injection<br>INN or Proposed INN: FLU-5<br>Other descriptive name: FLU-5<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 180-<br>INN or Proposed INN: FLU-7<br>Other descriptive name: FLU-7<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 113.5-<br>INN or Proposed INN: FLU-8NEW<br>Other descriptive name: FLU-8NEW<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 108.4-<br>INN or Proposed INN: FLU-10<br>Other descriptive name: FLU-10<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 151-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Subcutaneous use<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Subcutaneous use<br><br>,NA,NA,NA
im,EUCTR2015-002255-10-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002255-10,<br>                Trade Name: Eprex<br>                Product Name: Eprex (rhEPO)<br>                Product Code: NA<br>                Pharmaceutical Form: Solution for injection in pre-filled syringe<br>                INN or Proposed INN: epoetin alpha<br>                Concentration unit: IU/ml international unit(s)/millilitre<br>                Concentration type: up to<br>                Concentration number: 0-3<br>                Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>                Route of administration of the placebo: Subcutaneous use<br><br>,NA,NA,NA
main,EUCTR2015-002276-25-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002276-25,<br>                Trade Name: Repatha 140 mg Solution for Injection in Pre-filled Pen<br>                Product Name: Evolocumab<br>                Product Code: AMG 145<br>                Pharmaceutical Form: Solution for injection in pre-filled pen<br>                INN or Proposed INN: EVOLOCUMAB<br>                Current Sponsor code: AMG 145<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 140-<br>                Pharmaceutical form of the placebo: Solution for injection in pre-filled pen<br>                Route of administration of the placebo: Subcutaneous use<br><br>                Trade Name: Repatha 420 mg solution for injection in cartridge<br>                Product Name: Evolocumab<br>                Product Code: AMG 145<br>                Pharmaceutical Form: Solution for injection in cartridge<br>                INN or Proposed INN: EVOLOCUMAB<br>                Current Sponsor code: AMG 145<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 120-<br><br>,NA,Yes,NA
im,EUCTR2015-002340-14-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14,<br>Trade Name: Levofloxacin<br>Product Name: Levofloxacin 5mg/ml Solution for Infusion<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: LEVOFLOXACIN HEMIHYDRATE<br>CAS Number: CAS 138199-7<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: Solu-Cortef®(Hydrocortisone)<br>Product Name: hydrocortisone<br>Pharmaceutical Form: Powder for solution for injection/infusion<br>INN or Proposed INN: HYDROCORTISONE<br>CAS Number: 50-23-7<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Trade Name: Ceftriaxone<br>Product Name: Ceftriaxone<br>Pharmaceutical Form: Powder for solution for injection/infusion<br>INN or Proposed INN: CEFTRIAXONE<br>CAS Number: 73384-59-5<br>Concentration unit: g gram(s)<br>Concentration type: up to<br>Concentration number: 2-<br><br>Trade Name: Zedbac (azithromycin)<br>Product Name: azithromycin<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: AZITHROMYCIN<br>CAS Number: 83905-01-5<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Trade Name: Clarithromycin<br>Product Name: clarithromycin<br>Pharmaceutical Form: Powder for concentrate for solution for infusion<br>INN or Proposed INN: CLARITHROMYCIN<br>CAS Number: 81103-11-9<br>Other descriptive name: CLARITHROMYCIN LACTOBIONATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Trade Name: Erythrocin (Erythromycin)<br>Product Name: Erythrocin IV Lactobionate Injection<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: ERYTHROMYCIN LACTOBIONATE<br>CAS Number: 3847-29-8<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>Trade Name: Augmentin (Amoxicilline-clavulanate)<br>Product Name: Amoxicillin-Clavulanate<br>,NA,Yes,NA
im,EUCTR2015-002501-11-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002501-11,<br>Pharmaceutical Form: Concentrate and solvent for solution for injection/infusion<br>INN or Proposed INN: BENZYLPENICILLIN SODIUM<br>CAS Number: 69-57-8<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 600-1200<br><br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: PHENOXYMETHYLPENICILLIN POTASSIUM<br>CAS Number: 132-98-9<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 330-660<br><br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: AMOXICILLIN<br>CAS Number: 26787-78-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: AMOXICILLIN<br>CAS Number: 26787-78-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br>INN or Proposed INN: CLAVULANIC ACID<br>CAS Number: 58001-44-8<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 125-<br><br>Pharmaceutical Form: Concentrate and solvent for solution for injection/infusion<br>INN or Proposed INN: CEFUROXIME SODIUM<br>CAS Number: 56238-63-2<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 750-1500<br><br>Pharmaceutical Form: Concentrate and solvent for solution for injection/infusion<br>INN or Proposed INN: CIPROFLOXACIN LACTATE MONOHYDRATE<br>Other descriptive name: CIPROFLOXACIN<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 200-400<br><br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: CIPROFLOXACIN HYDROCHLORIDE<br>Other descriptive name: CIPROFLOXACIN HYDROCHLORIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Pharmaceutical Form: Concentrate and solvent for solution for injection/infusion<br>INN or Proposed INN: CLARITHROMYCIN<br>Othe,NA,Yes,NA
im,EUCTR2015-002994-39-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002994-39,<br>Product Code: Cx611<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: to be determined<br>Current Sponsor code: Cx611<br>Other descriptive name: EXPANDED HUMAN ALLOGENEIC MESENCHYMAL ADULT STEM CELLS EXTRACTED FROM ADIPOSE TISSUE<br>Concentration unit: Munit million units<br>Concentration type: equal<br>Concentration number: 80-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,Yes,NA
im,EUCTR2015-003095-68-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003095-68,<br>Product Name: clonidine<br>Product Code: C02AC01<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: CLONIDINE<br>CAS Number: 4205-90-7<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 0.15-<br><br>Product Name: propofol<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: propofol<br>Other descriptive name: PROPOFOL<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>,NA,NA,NA
im,EUCTR2015-003458-42-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003458-42,"<br>Product Name: Influenza A (H5N1) Virus Monovalent Vaccine 1.9 mcg, Adjuvanted with AS03B<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: -<br>Other descriptive name: Split-virion Monovalent, A/Indonesia/5/2005 (H5N1) <br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 15-<br><br>Product Name: Influenza A (H5N1) Virus Monovalent Vaccine 0.9 mcg, Adjuvanted with AS03C<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: -<br>Other descriptive name: Split-virion Monovalent, A/Indonesia/5/2005 (H5N1) <br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 15-<br><br>Product Name: Influenza A (H5N1) Virus Monovalent Vaccine 1.9 mcg, Adjuvanted with AS03C<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: -<br>Other descriptive name: Split-virion Monovalent, A/Indonesia/5/2005 (H5N1) <br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 15-<br><br>Product Name: Influenza A (H5N1) Virus Monovalent Vaccine 3.75 mcg, Adjuvanted with AS03C<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: -<br>Other descriptive name: Split-virion Monovalent, A/Indonesia/5/2005 (H5N1) <br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>Product Name: Influenza A (H5N1) Virus Monovalent Vaccine 3.75 mcg, Adjuvanted with AS03D<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: -<br>Other descriptive name: Split-virion Monovalent, A/Indonesia/5/2005 (H5N1) <br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>Product Name: Influenza A (H5N1) Virus Monovalent Vaccine 3.75 mcg, non-adjuvanted<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: -<br>Other descriptive name: Split-virion Monovalent, A/Indonesia/5/2005 (H5N1) <br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentr",Yes,NA,NA
im,EUCTR2015-003519-40-IE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003519-40,"<br>                Product Name: Lyophilized lucinactant<br>                Pharmaceutical Form: Nebuliser suspension<br>                INN or Proposed INN: dipalmitoylphosphatidylcholine<br>                CAS Number: 63-89-8<br>                Other descriptive name: 1,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHATIDYLCHOLINE (DPPC)<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 22.50-<br>                INN or Proposed INN: Palmitic acid<br>                CAS Number: 57-10-3<br>                Other descriptive name: Hexadecanoic acid (Palmitic acid)<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 4.05-<br>                INN or Proposed INN: SINAPULTIDE; INN #7636<br>                CAS Number: 138531-07-4<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 0.862-<br>                INN or Proposed INN: palmitoyloleoyl-phosphatidylglycerol<br>                CAS Number: 268550-95-4<br>                Other descriptive name: 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol, sodium salt (POPG, Na)<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 7.50-<br><br>",NA,NA,NA
im,EUCTR2015-003895-65-SE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-003895-65,<br>                Product Name: Dalcetrapib<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: Dalcetrapib<br>                CAS Number: 211513-37-0<br>                Current Sponsor code: RO4607381<br>                Other descriptive name: DALCETRAPIB<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 300-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
im,EUCTR2015-004276-29-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004276-29,<br>Product Name: MEDI8852<br>Product Code: MEDI8852<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: Not assigned<br>Current Sponsor code: MEDI8852<br>Other descriptive name: HUMAN IMMUNOGLOBULIN G<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Concentrate for solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2015-004424-65-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004424-65,<br>Product Name: Simvastatin<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Simvastatin<br>CAS Number: 79902-63-9<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 40-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Enteral use (Noncurrent)<br><br>,NA,NA,NA
im,EUCTR2015-004703-23-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004703-23,<br>                Product Code: S-649266<br>                Pharmaceutical Form: Powder for solution for infusion<br>                INN or Proposed INN: NA<br>                Other descriptive name: S-649266<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 1-<br><br>,NA,NA,NA
im,EUCTR2015-004782-92-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004782-92,<br>Product Name: lefamulin<br>Product Code: BC-3781<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Lefamulin<br>CAS Number: 1061337-51-6<br>Current Sponsor code: BC-3781<br>Other descriptive name: Lefamulin<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 600 -<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Avelox 400 mg film-coated tablets<br>Product Name: Avelox<br>Product Code: NA<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Moxifloxacin<br>CAS Number: 186826-86-8<br>Other descriptive name: Avelox<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
im,EUCTR2015-005014-30-AT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005014-30,<br>Trade Name: Alprostapint<br>Product Name: Alprostadil<br>Pharmaceutical Form: Concentrate and solvent for solution for infusion<br>INN or Proposed INN: Alprostadil<br>CAS Number: 745-65-3<br>Current Sponsor code: Alprostadil<br>Other descriptive name: ALPROSTADIL<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.5-<br>Pharmaceutical form of the placebo: Infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2015-005112-15-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005112-15,<br>Trade Name: Noradrenalin SAD<br>Pharmaceutical Form: Concentrate and solvent for solution for infusion<br>INN or Proposed INN: NOREPINEPHRINE<br>CAS Number: 51-41-2<br>Concentration unit: µg/kg microgram(s)/kilogram<br>Concentration type: not less then<br>Concentration number: 0.01 per minute-<br><br>,NA,NA,NA
im,EUCTR2015-005624-26-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005624-26,"<br>Product Name: Lyophilized lucinactant<br>Pharmaceutical Form: Nebuliser solution<br>INN or Proposed INN: SINAPULTIDE<br>CAS Number: 138531-07-4<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 0,862-<br>INN or Proposed INN: dipalmitoylphosphatidylcholine<br>CAS Number: 63-89-8<br>Other descriptive name: 1,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHATIDYLCHOLINE (DPPC)<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 22,5-<br>INN or Proposed INN: Palmitic acid<br>CAS Number: 57-10-3<br>Other descriptive name: PALMITIC ACID<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 4,05-<br>INN or Proposed INN: palmitoyloleoyl-phosphatidylglycerol<br>CAS Number: 268550-95-4<br>Other descriptive name: PALMITOYL-OLEOYL PHOSPHATIDYLGLYCEROL<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 7,5-<br><br>",NA,NA,NA
im,EUCTR2015-005742-58-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-005742-58,<br>Product Name: 60 µg PreF<br>Product Code: 60 µg PreF<br>Pharmaceutical Form: Powder and solution for solution for injection<br>INN or Proposed INN: -<br>Other descriptive name: PreF protein<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 60-<br><br>Trade Name: BOOSTRIX<br>Product Code: dTpa<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: -<br>Current Sponsor code: D<br>Other descriptive name: DIPHTHERIA TOXOID<br>Concentration unit: IU international unit(s)<br>Concentration type: not less then<br>Concentration number: 2-<br>INN or Proposed INN: -<br>Current Sponsor code: T<br>Other descriptive name: TETANUS TOXOID<br>Concentration unit: IU international unit(s)<br>Concentration type: not less then<br>Concentration number: 20-<br>INN or Proposed INN: -<br>Current Sponsor code: PT<br>Other descriptive name: PERTUSSIS TOXOID<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 8-<br>INN or Proposed INN: -<br>Current Sponsor code: FHA<br>Other descriptive name: FILAMENTOUS HAEMAGGLUTININ<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 8-<br>INN or Proposed INN: -<br>Current Sponsor code: PRN<br>Other descriptive name: PERTUSSIS PERTACTIN<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 2.5-<br><br>,NA,NA,NA
im,EUCTR2016-000117-76-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000117-76,<br>                Product Name: ChAd155-RSV (high dose)<br>                Pharmaceutical Form: Suspension for injection<br>                INN or Proposed INN: -<br>                Current Sponsor code: ChAd155-RSV<br>                Concentration unit: Other<br>                Concentration type: equal<br>                Concentration number: 50000000000-<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Intramuscular use<br><br>                Product Name: ChAd155-RSV (low dose)<br>                Pharmaceutical Form: Suspension for injection<br>                INN or Proposed INN: -<br>                Current Sponsor code: ChAd155-RSV<br>                Concentration unit: Other<br>                Concentration type: equal<br>                Concentration number: 5000000000-<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Intramuscular use<br><br>                Product Name: ChAd155-RSV (middle dose)<br>                Pharmaceutical Form: Suspension for injection<br>                INN or Proposed INN: -<br>                Current Sponsor code: ChAd155-RSV<br>                Concentration unit: Other<br>                Concentration type: equal<br>                Concentration number: 15000000000-<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Intramuscular use<br><br>,NA,NA,NA
main,EUCTR2016-000936-17-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000936-17,<br>                Product Name: Cannabidiol (CBD)<br>                Product Code: GWP42003-P<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: Cannabidiol<br>                CAS Number: 13956-29-1<br>                Current Sponsor code: GWP42003-P<br>                Other descriptive name: CANNABIDIOL<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 3-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,Yes,NA
im,EUCTR2016-001008-49-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001008-49,<br>Trade Name: Tamiflu<br>Product Name: Oseltamivir<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: OSELTAMIVIR<br>CAS Number: 196618-13-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br>Pharmaceutical form of the placebo: Powder for oral suspension<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Tamiflu<br>Product Name: Oseltamivir<br>Pharmaceutical Form: Powder for oral suspension<br>INN or Proposed INN: OSELTAMIVIR PHOSPHATE<br>CAS Number: 204255-11-8<br>Other descriptive name: OSELTAMIVIR PHOSPHATE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 12-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br>Pharmaceutical form of the placebo: Powder for oral suspension<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
im,EUCTR2016-001054-17-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001054-17,"<br>Trade Name: AMIKACIN  1 g, powder for nebulization<br>Product Name: AMIKACIN<br>Pharmaceutical Form: Powder for nebuliser solution<br>Pharmaceutical form of the placebo: Nebuliser solution<br>Route of administration of the placebo: Inhalation use<br><br>",NA,Yes,NA
im,EUCTR2016-001246-26-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001246-26,<br>Product Name: Nafithromycin <br>Product Code: WCK 4873<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Nafithromycin<br>CAS Number: 1395044-49-1<br>Current Sponsor code: WCK 4873<br>Other descriptive name: WCK 4873<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Avelox 400 mg<br>Product Name: Avelox<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Moxifloxacin<br>CAS Number: 186826-86-8<br>Other descriptive name: MOXIFLOXACIN HYDROCHLORIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400 -<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
im,EUCTR2016-001788-34-AT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001788-34,<br>Trade Name: Pentaglobin<br>Product Name: Pentaglobin<br>Pharmaceutical Form: Injection<br>INN or Proposed INN: Human Plasma Protein<br>CAS Number: 02-AAQ195<br>Other descriptive name: HUMAN NORMAL IMMUNOGLOBULIN (IV)<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 50-<br><br>,NA,Yes,NA
im,EUCTR2016-001898-32-EE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001898-32,"<br>Trade Name: Aflunov<br>Product Name: Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) (clade 2.2.1) <br>Current Sponsor code: V87<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 1.875-<br><br>Trade Name: Aflunov<br>Product Name: Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) (clade 2.2.1) <br>Current Sponsor code: V87<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 1.875-<br><br>Trade Name: Aflunov<br>Product Name: Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) (clade 2.2.1) <br>Current Sponsor code: V87<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 3.75-<br><br>Trade Name: Aflunov<br>Product Name: Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) (clade 2.2.1) <br>Current Sponsor code: V87<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 3.75-<br><br>Trade Name: Aflunov<br>Product Name: Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: A/turkey/Turkey/1/2005 (H5N1)-like strain (NIBRG-23) (cla",Yes,NA,NA
main,EUCTR2016-001928-54-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-001928-54,<br>Product Name: Ipilimumab<br>Product Code: BMS-734016<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: IPILIMUMAB<br>CAS Number: 477202-00-9<br>Current Sponsor code: BMS-734016<br>Other descriptive name: BMS734016<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: JEVTANA 60 mg concentrate and solvent for solution for infusion<br>Product Name: Cabazitaxel concentrate<br>Pharmaceutical Form: Concentrate and solvent for solution for infusion<br>INN or Proposed INN: CABAZITAXEL<br>CAS Number: 183133-96-2<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 40-<br><br>Trade Name: Opdivo (100 mg/10 ml)<br>Product Name: NIVOLUMAB - 10ml vial-commercial<br>Product Code: BMS-936558<br>Pharmaceutical Form: Solution for injection/infusion<br>INN or Proposed INN: Nivolumab<br>CAS Number: 946414-94-4<br>Current Sponsor code: BMS-936558<br>Other descriptive name: BMS936558<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: Opdivo (40 mg/4 ml)<br>Product Name: NIVOLUMAB-4 ml vial- COMMERCIAL<br>Product Code: BMS-936558<br>Pharmaceutical Form: Solution for injection/infusion<br>INN or Proposed INN: Nivolumab<br>CAS Number: 946414-94-4<br>Current Sponsor code: BMS-936558<br>Other descriptive name: BMS936558<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>,NA,Yes,NA
im,EUCTR2016-002089-29-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002089-29,<br>Trade Name: Hexaxim™<br>Product Name: DTaP-IPV-Hep B-PRP-T combined vaccine<br>Pharmaceutical Form: Suspension for injection<br><br>,Yes,NA,NA
im,EUCTR2016-002134-74-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002134-74,<br>                Product Name: Influenza virus vaccine<br>                Product Code: FLU-v<br>                Pharmaceutical Form: Powder for suspension for injection<br>                INN or Proposed INN: FLU-5<br>                Other descriptive name: FLU-5<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 180-<br>                INN or Proposed INN: FLU-7<br>                Other descriptive name: FLU-7<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 113.5-<br>                INN or Proposed INN: FLU-8N<br>                Other descriptive name: FLU-8N<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 108.4-<br>                INN or Proposed INN: FLU-10<br>                Other descriptive name: FLU-10<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 151-<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Subcutaneous use<br><br>,Yes,NA,NA
im,EUCTR2016-002146-23-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002146-23,<br>Product Name: ASN-1<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Not yet assigned<br>Other descriptive name: ASN-1<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Infusion<br>Route of administration of the placebo: Intravenous use<br><br>Product Name: ASN-2<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Not yet assigned<br>Other descriptive name: ASN-2<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2016-002148-17-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002148-17,<br>Trade Name: Ketanest-S<br>Product Name: Ketamin<br>Pharmaceutical Form: Solution for injection/infusion<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2016-002195-27-EE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002195-27,<br>Product Name: Amoksiklav<br>Pharmaceutical Form: Powder for concentrate for solution for injection/infusion<br><br>,NA,NA,NA
im,EUCTR2016-002302-39-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002302-39,<br>                Product Name: Adjuvanted RSV F Vaccine<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN<br>                Other descriptive name: RESPIRATORY SYNCYTIAL VIRUS FUSION PROTEIN<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 120-<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Intramuscular use<br><br>,Yes,NA,NA
main,EUCTR2016-002411-17-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002411-17,<br>Product Name: Rozanolixizumab<br>Product Code: UCB7665<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Rozanolixizumab<br>Current Sponsor code: UCB7665<br>Other descriptive name: ROZANOLIXIZUMAB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 140-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
im,EUCTR2016-002512-40-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002512-40,<br>Product Name: Danirixin<br>Product Code: GSK1325756<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: GSK1325756<br>CAS Number: N/A<br>Current Sponsor code: GSK1325756<br>Other descriptive name: Danirixin<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>Product Name: Danirixin<br>Product Code: GSK1325756<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: GSK1325756<br>CAS Number: N/A<br>Current Sponsor code: GSK1325756<br>Other descriptive name: Danirixin<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>Trade Name: Tamiflu 75 mg hard capsules<br>Pharmaceutical Form: <br>INN or Proposed INN: N/A<br>CAS Number: 204255-11-8<br>Current Sponsor code: N/A<br>Other descriptive name: OSELTAMIVIR PHOSPHATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br><br>,NA,Yes,NA
im,EUCTR2016-002688-32-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002688-32,"<br>                Product Name: S-033188<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: Not yet assigned<br>                CAS Number: 1830312-72-5<br>                Current Sponsor code: S-033188<br>                Other descriptive name: S-033188<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 20-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: Tamiflu® Hard Capsules 75 mg<br>                Product Name: oseltamivir<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: OSELTAMIVIR<br>                CAS Number: 196618-13-0<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 75-<br>                Pharmaceutical form of the placebo: Capsule, hard<br>                Route of administration of the placebo: Oral use<br><br>",NA,Yes,NA
im,EUCTR2016-002708-17-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002708-17,<br>Trade Name: CANCIDAS 50 mg poudre pour solution à diluer pour perfusion.<br>Pharmaceutical Form: Powder for solution for infusion<br><br>Trade Name: Mycamine 50 mg poudre pour solution pour perfusion<br>Pharmaceutical Form: Powder for solution for infusion<br><br>,NA,NA,NA
im,EUCTR2016-002796-10-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002796-10,<br>Trade Name: Meropenem Accordpharma®<br>Pharmaceutical Form: Powder and solvent for solution for injection<br>INN or Proposed INN: Meropenem<br>CAS Number: 119478-56-7<br>Other descriptive name: MEROPENEM TRIHYDRATE<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>,NA,NA,NA
main,EUCTR2016-002799-28-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002799-28,<br>Product Name: MVA-HPV-IL2<br>Product Code: TG4001<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: Tipapkinogene sovacivec<br>Current Sponsor code: MVATG8042<br>Other descriptive name: MVATG8042<br>Concentration unit: PFU plaque forming unit<br>Concentration type: equal<br>Concentration number: 50000000-<br><br>Product Name: Avelumab<br>Product Code: MSB0010718C<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: Avelumab<br>Current Sponsor code: MSB0010718C<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br><br>,NA,Yes,NA
im,EUCTR2016-002873-36-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002873-36,<br>Product Name: DTaP-IPV-Hep B-PRP-T combined vaccine<br>Pharmaceutical Form: Suspension for injection<br><br>Trade Name: Pentaxim<br>Product Name: Pentaxim<br>Pharmaceutical Form: Suspension for injection<br><br>Trade Name: Euvax B<br>Product Name: Euvax B<br>Pharmaceutical Form: Suspension for injection<br><br>,Yes,NA,NA
im,EUCTR2016-002883-15-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002883-15,"<br>Product Name: Quadrivalent Influenza Vaccine cell-based (QIVc)<br>Product Code: QIVc<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>Trade Name: Menveo<br>Pharmaceutical Form: Powder and solvent for solution for injection<br>INN or Proposed INN: -<br>CAS Number: -<br>Current Sponsor code: -<br>Other descriptive name: MENINGOCOCCAL GROUP A, C, W135 AND Y CONJUGATE VACCINE<br>Concentration unit: ml millilitre(s)<br>Concentration type: equal<br>Concentration number: 0.5-<br><br>",Yes,NA,NA
im,EUCTR2016-003004-31-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003004-31,<br>Trade Name: Tamiflu<br><br>Product Name: Oseltamivir<br>Pharmaceutical Form: Injection<br><br>Trade Name: Tamiflu<br><br>Product Name: Oseltamivir<br>Pharmaceutical Form: Oral suspension<br><br>,NA,Yes,NA
im,EUCTR2016-003020-23-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003020-23,<br>                Product Name: Cefiderocol<br>                Product Code: S-649266<br>                Pharmaceutical Form: Powder for solution for infusion<br>                INN or Proposed INN: Cefiderocol<br>                Other descriptive name: S-649266<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 1-<br><br>                Trade Name: Meropenem<br>                Product Name: Meropenem<br>                Pharmaceutical Form: Powder for solution for infusion<br>                INN or Proposed INN: Meropenem<br>                CAS Number: 96036-03-2<br>                Other descriptive name: Meropenem trihydrate<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 1-<br><br>,NA,NA,NA
im,EUCTR2016-003168-37-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003168-37,<br>                Trade Name: Ventavis<br>                Product Name: Ventavis<br>                Pharmaceutical Form: Nebulisation solution<br>                INN or Proposed INN: ILOPROST TROMETAMOL<br>                CAS Number: 73873-87-7<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 20-<br><br>,NA,NA,NA
im,EUCTR2016-003265-26-AT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003265-26,<br>Trade Name: Kengrexal<br>Product Name: Kengrexal<br>Pharmaceutical Form: Powder for concentrate for solution for injection/infusion<br>INN or Proposed INN: CANGRELOR<br>CAS Number: 163706-06-7<br>Current Sponsor code: Cangrelor<br>Other descriptive name: Cangrelor tetrasodium<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2016-003406-14-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003406-14,"<br>Trade Name: Metoclopramide<br>Product Name: Metoclopramide<br>Product Code: PL 01502/0044<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: Metocolpramide<br>CAS Number: 364-62-5<br>Current Sponsor code: N/A<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-5<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Nasogastric use (Noncurrent)<br><br>Product Name: Selective Oral Decontamination Mouth Paste<br>Product Code: N/A <br>Pharmaceutical Form: Oral paste<br>INN or Proposed INN: Amphotericin B<br>CAS Number: 1397-89-3<br>Concentration unit: IU/mg international unit(s)/milligram<br>Concentration type: equal<br>Concentration number: 939-939<br>INN or Proposed INN: Colistin sulphate<br>CAS Number: 1264-72-8<br>Concentration unit: IU/mg international unit(s)/milligram<br>Concentration type: equal<br>Concentration number: 22,400 -22,400 <br>INN or Proposed INN: Tobramycin sulphate<br>CAS Number: 32986-56-4<br>Concentration unit: mg/g milligram(s)/gram<br>Concentration type: equal<br>Concentration number: 697-697<br>Pharmaceutical form of the placebo: Oromucosal paste<br>Route of administration of the placebo: Oromucosal use<br><br>",NA,Yes,NA
main,EUCTR2016-003726-17-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003726-17,<br>Product Name: Rovalpituzumab tesirine<br>Product Code: SC16LD6.5<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: ROVALPITUZUMAB TESIRINE<br>CAS Number: 1613313-09-9<br>Current Sponsor code: SC16LD6.5<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 30-<br><br>Trade Name: NA<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: TOPOTECAN HYDROCHLORIDE<br>CAS Number: 119413-54-6<br>Current Sponsor code: NA<br>Other descriptive name: TOPOTECAN HYDROCHLORIDE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1-<br><br>,NA,Yes,NA
im,EUCTR2016-003883-38-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003883-38,<br>                Product Name: Adrecizumab<br>                Product Code: HAM8101<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: Adrecizumab<br>                Current Sponsor code: HAM8101<br>                Other descriptive name: HUMANIZED MONOCLONAL ANTIBODY (IMMUNOGLOBULIN G1 (IGG1)) DIRECTED AGAINST THE N-TERMINUS OF ADRENOMEDULLIN<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 20 mg / ml-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,Yes,NA
im,EUCTR2016-004198-41-IE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004198-41,"<br>                Trade Name: CUROSURF®<br>                Product Name: CUROSURF®<br>                Pharmaceutical Form: Endotracheopulmonary instillation, suspension<br>                INN or Proposed INN: Poractant Alfa<br>                CAS Number: 129069-19-8<br>                Other descriptive name: PORACTANT ALFA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: range<br>                Concentration number: 120-240<br><br>",NA,NA,NA
main,EUCTR2016-004198-41-NO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004198-41,"<br>                Trade Name: CUROSURF®<br>                Product Name: CUROSURF®<br>                Pharmaceutical Form: Endotracheopulmonary instillation, suspension<br>                INN or Proposed INN: Poractant Alfa<br>                CAS Number: 129069-19-8<br>                Other descriptive name: PORACTANT ALFA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: range<br>                Concentration number: 120-240<br><br>",NA,NA,NA
im,EUCTR2016-004222-42-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004222-42,<br>                Trade Name: Effortil<br>                Product Name: Etilefrine<br>                Pharmaceutical Form: Oral solution<br>                INN or Proposed INN: ETILEFRINE<br>                CAS Number: 709-55-7<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 7.5-<br>                Pharmaceutical form of the placebo: Oral liquid<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: Tildiem<br>                Product Name: Diltiazem<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: DILTIAZEM<br>                CAS Number: 42399-41-7<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 60-<br>                Pharmaceutical form of the placebo: Capsule<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: Tamiflu<br>                Product Name: Oseltamivir<br>                Pharmaceutical Form: Capsule<br>                INN or Proposed INN: OSELTAMIVIR<br>                CAS Number: 196618-13-0<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 75-<br><br>,NA,Yes,NA
im,EUCTR2016-004261-10-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004261-10,"<br>                Product Name: Aerucin®<br>                Product Code: AR-105<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: INN name not assigned yet<br>                Current Sponsor code: Aerucin®<br>                Other descriptive name: AR-105,  CM101, F429, aerubumab<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 27.5-<br>                Pharmaceutical form of the placebo: Concentrate for solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>",NA,Yes,NA
im,EUCTR2016-004303-32-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004303-32,<br>Trade Name: Acetylsalicylzuur cardio 80 PCH<br>Product Name: Acetylsalicylzuur cardio 80PCH<br>Product Code: RVG16446<br>Pharmaceutical Form: Tablet<br><br>,NA,NA,NA
im,EUCTR2016-004547-36-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004547-36,<br>Trade Name: Curosurf<br>Pharmaceutical Form: Nebuliser suspension<br>INN or Proposed INN: PORACTANT ALFA<br>CAS Number: 129069-19-8<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 80-<br><br>,NA,NA,NA
main,EUCTR2016-004672-21-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004672-21,<br>                Product Name: ATIR101 (previously referred to as ATIR)<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: -<br>                CAS Number: -<br>                Current Sponsor code: -<br>                Other descriptive name: ATIR<br>                Concentration unit: Other<br>                Concentration type: range<br>                Concentration number: 2500000-13000000<br><br>                Product Name: Cyclophosphamide (Endoxan)<br>                Pharmaceutical Form: Powder for solution for injection/infusion<br>                INN or Proposed INN: CYCLOPHOSPHAMIDE<br>                CAS Number: 50-18-0<br>                Concentration unit: mg milligram(s)<br>                Concentration type: range<br>                Concentration number: 100-1000<br><br>,NA,NA,NA
im,EUCTR2016-004753-33-Outside-EU/EEA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004753-33,<br>Trade Name: Afluria Quadrivalent<br>Product Name: Seqirus Quadrivalent Inactivated Influenza Vaccine <br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ YAMAGATA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ VICTORIA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>Trade Name: Fluzone Quadrivalent<br>Product Name: Comparator Quadrivalent Inactivated Influenza Vaccine<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/ (H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ YAMAGATA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>INN or Proposed INN: B/ VICTORIA -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>,Yes,NA,NA
im,EUCTR2016-004904-74-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004904-74,"<br>Product Name: QIV (Quadrivalent Influenza Vaccine)<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: Influenza vaccine (surface antigen, inactivated)<br>Current Sponsor code: QIV (Quadrivalent Influenza Vaccine)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br><br>Trade Name: Prevenar 13<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE (13-VALENT, ADSORBED)<br>Other descriptive name: Pneumococcal conjugated vaccine <br>Concentration unit: µg microgram(s)<br>Concentration type: range<br>Concentration number: 2.2-4.4 <br><br>Trade Name: Menjugate<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: Meningococcal group C conjugate vaccine<br>Other descriptive name: Meningococcal group C conjugate vaccine<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: TicoVac Junior, FSME-IMMUN Junior<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: Tickborne encephalitis vaccine<br>Other descriptive name: TICK-BORNE ENCEPHALITIS VIRUS (INACTIVATED), NEUDOERFL STRAIN<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 1.2-<br><br>Trade Name: Havrix Junior<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: Hepatitis A vaccine<br>Other descriptive name: HEPATITIS A VIRUS (INACTIVATED)<br>Concentration unit: ELISA unit enzyme-linked immunosorbent assay unit<br>Concentration type: equal<br>Concentration number: 720-<br><br>Trade Name: Varivax, Provarivax<br>Pharmaceutical Form: Powder and solvent for suspension for injection<br>INN or Proposed INN: •Varicella vaccine<br>Other descriptive name: VARICELLA VIRUS OKA/MERCK STRAIN, (LIVE, ATTENUATED) PRODUCED IN HUMAN DIPLOID (MRC-5) CELL",Yes,NA,NA
im,EUCTR2016-005032-14-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-005032-14,<br>Product Name: MOTREM<br>Product Code: MOTREM (LR12)<br>Pharmaceutical Form: Lyophilisate for solution for injection<br>INN or Proposed INN: Nangibotide<br>CAS Number: 2014384-91-7<br>Current Sponsor code: MOTREM (LR12)<br>Other descriptive name: MOTREM<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2017-000116-42-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000116-42,"<br>Trade Name: a-RIX-Tetra<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010<br>Other descriptive name: A/CALIFORNIA/7/2009 (H1N1) PDM09-LIKE STRAIN USED (NIB-74XP) DERIVED FROM A/CHRISTCHURCH/16/2010<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>INN or Proposed INN: A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B)<br>Other descriptive name: A/HONG KONG/4801/2014 (H3N2)-LIKE STRAIN (A/HONG KONG/4801/2014, X-263B)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>INN or Proposed INN: B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE)<br>Other descriptive name: B/BRISBANE/60/2008-LIKE STRAIN (B/BRISBANE/60/2008, WILD TYPE)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br>INN or Proposed INN: B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, WILD TYPE)<br>Other descriptive name: B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, WILD TYPE)<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 15-<br><br>",NA,NA,NA
main,EUCTR2017-000146-21-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000146-21,"<br>Trade Name: Galafold<br>Product Name: Migalastat <br>Product Code: AT1001<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: migalastat<br>CAS Number: 75172-81-5<br>Current Sponsor code: AT1001<br>Other descriptive name: MIGALASTAT HYDROCHLORIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 150-<br><br>",NA,NA,NA
main,EUCTR2017-000350-19-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000350-19,<br>Product Name: Cemiplimab<br>Product Code: REGN2810<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Cemiplimab<br>CAS Number: 1801342-60-8<br>Current Sponsor code: REGN2810<br>Other descriptive name: HUMAN IGG4 ISOTYPE MONOCLONAL (GDF8) ANTIBODY<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 50-<br><br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: PEMETREXED DISODIUM<br>CAS Number: 150399-23-8<br>Other descriptive name: PEMETREXED DISODIUM<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 25-<br><br>Pharmaceutical Form: Powder for concentrate for solution for infusion<br>INN or Proposed INN: TOPOTECAN HYDROCHLORIDE<br>CAS Number: 119413-54-6<br>Other descriptive name: TOPOTECAN HYDROCHLORIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 4-<br><br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: Irinotecan hydrochloride<br>Other descriptive name: IRINOTECAN HYDROCHLORIDE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br><br>Product Name: Gemcitabine<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: gemcitabine hydrochloride<br>Other descriptive name: GEMCITABINE HYDROCHLORIDE<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 2-<br><br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: VINORELBINE TARTRATE<br>Other descriptive name: VINORELBINE TARTRATE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: TOPOTECAN HYDROCHLORIDE<br>CAS Number: 119413-54-6<br>Other de,NA,Yes,NA
im,EUCTR2017-000427-27-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000427-27,<br>                Trade Name: OctaplasLG<br>                Pharmaceutical Form: Infusion<br>                INN or Proposed INN: Octaplas<br>                Other descriptive name: HUMAN PLASMA POOLED AND TREATED FOR VIRUS INACTIVATION<br>                Concentration unit: IU/ml international unit(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 0.8-<br><br>                Trade Name: Ringer-Acetate<br>                Pharmaceutical Form: Infusion<br>                INN or Proposed INN: Ringer-acetate<br>                CAS Number: 8026-10-6<br>                Other descriptive name: RINGER'S SOLUTION<br>                Concentration unit: mOsm/kg milliosmol(s)/kilogram<br>                Concentration type: equal<br>                Concentration number: 270-<br><br>,NA,Yes,NA
im,EUCTR2017-000952-24-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-000952-24,"<br>                Trade Name: Fluenz Tetra<br>                Product Name: Fluenz Tetra<br>                Pharmaceutical Form: Nasal spray<br>                INN or Proposed INN: A/California/7/2009 (H1N1)pdm09 - like strain (A/Bolivia/559/2013, MEDI 255962)<br>                Concentration number: 107.0±0.5-FFU per dose<br>                INN or Proposed INN: A/Hong Kong/4801/2014 (H3N2) - like strain (A/New Caledonia/71/2014, MEDI 263122)<br>                Concentration number: 107.0±0.5-FFU per dose<br>                INN or Proposed INN: B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, MEDI 228030)<br>                Concentration number: 107.0±0.5-FFU per dose<br>                INN or Proposed INN: B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013, MEDI 254977)<br>                Concentration number: 107.0±0.5-FFU per dose<br><br>",NA,NA,NA
im,EUCTR2017-001103-77-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001103-77,<br>                Product Name: MVA-NP+M1<br>                Pharmaceutical Form: Solution for injection<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Intramuscular use<br><br>                Trade Name: Vaxigrip Tetra TM<br>                Product Name: Vaxigrip Tetra TM<br>                Pharmaceutical Form: Solution for injection<br><br>,NA,NA,NA
im,EUCTR2017-001406-15-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001406-15,<br>Trade Name: Actira<br>Product Name: Moxifloxacin<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Moxifloxacin<br>CAS Number: 151096-09-2<br>Current Sponsor code: Moxifloxacin<br>Other descriptive name: MOXIFLOXACIN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
im,EUCTR2017-001584-20-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001584-20,"<br>Product Name: Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1, AS03 adjuvanted<br>Product Code: cH8/1N1 + AS03A-like<br>Pharmaceutical Form: Powder and solvent for emulsion for injection<br>INN or Proposed INN: -<br>Current Sponsor code: Purified HA antigen fractions of chimeric cH8/1N1 influenza virus, inactivated split virion<br>Concentration unit: µg microgram(s)<br>Concentration type: range<br>Concentration number: 11.6-21.5<br><br>Product Name: Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH5/1N1, AS03 adjuvanted<br>Product Code: cH5/1N1 + AS03A-like<br>Pharmaceutical Form: Powder and solvent for emulsion for injection<br>INN or Proposed INN: -<br>Current Sponsor code: Purified HA antigen fractions of chimeric cH5/1N1 influenza virus, inactivated split virion<br>Concentration unit: µg microgram(s)<br>Concentration type: range<br>Concentration number: 11.6-21.5<br><br>Product Name: Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH11/1N1, AS03 adjuvanted<br>Product Code: cH11/1N1 + AS03A-like<br>Pharmaceutical Form: Powder and solvent for emulsion for injection<br>INN or Proposed INN: -<br>Current Sponsor code: Purified HA antigen fractions of chimeric cH11/1N1 influenza virus, inactivated split virion<br>Concentration unit: µg microgram(s)<br>Concentration type: range<br>Concentration number: 11.6-21.5<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>Product Name: Supraseasonal Universal Influenza Vaccine (Flu D-SUIV), chimeric strain cH8/1N1, AS01 adjuvanted<br>Product Code: cH8/1N1 + AS01A-like<br>Pharmaceutical Form: Powder and suspension for suspension for injection<br>INN or Proposed INN: -<br>Current Sponsor code: Purified HA antigen fractions of chimeric cH8/1N1 influenza virus, inactivated sp",Yes,NA,NA
main,EUCTR2017-001730-26-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001730-26,<br>Product Name: OTL-200 Dispersion for Infusion<br>Product Code: [OTL-200]<br>Pharmaceutical Form: Powder for solution for infusion<br>Current Sponsor code: OTL-200<br>Concentration unit: Other<br>Concentration type: up to<br>Concentration number: 2000000-<br><br>,NA,NA,NA
im,EUCTR2017-001851-29-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001851-29,"<br>Product Name: BAY 2253651 nasal spray 0.5 mg/ml<br>Pharmaceutical Form: Nasal spray, solution<br>Current Sponsor code: BAY 2253651<br>Other descriptive name: BAY 2253651<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 0.5-<br>Pharmaceutical form of the placebo: Nasal spray, solution<br>Route of administration of the placebo: Nasal use<br><br>",NA,NA,NA
im,EUCTR2017-002138-22-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002138-22,<br>Trade Name: Rapibloc 300 mg Pulver zur Herstellung einer Infusionslösung<br>Product Name: RAPIBLOC (Landiolol hydrochloride lyophilized powder 300 mg/50 ml)<br>Pharmaceutical Form: Powder for infusion<br>INN or Proposed INN: LANDIOLOL HYDROCHLORIDE <br>CAS Number: 144481-98-1<br>Current Sponsor code: LDLL300 <br>Other descriptive name: LANDIOLOL HYDROCHLORIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br><br>,NA,NA,NA
im,EUCTR2017-002156-84-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002156-84,<br>Product Name: Pimodivir<br>Product Code: JNJ-63623872-ZCD<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Pimodivir<br>CAS Number: 1777721-70-6<br>Other descriptive name: JNJ-63623872-ZCD<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
im,EUCTR2017-002217-59-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002217-59,<br>Product Name: Pimodivir<br>Product Code: JNJ-63623872-ZCD<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Pimodivir<br>CAS Number: 1777721-70-6<br>Other descriptive name: JNJ-63623872-ZCD<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
main,EUCTR2017-002397-39-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002397-39,<br>                Product Name: AMG 334 vials<br>                Product Code: AMG 334<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: erenumab<br>                CAS Number: 1582205-90-0<br>                Current Sponsor code: AMG 334<br>                Other descriptive name: AMG 334<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 70-<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Subcutaneous use<br><br>                Product Name: AMG 334 PFS<br>                Product Code: AMG 334<br>                Pharmaceutical Form: Solution for injection in pre-filled syringe<br>                INN or Proposed INN: erenumab<br>                CAS Number: 1582205-90-0<br>                Current Sponsor code: AMG 334<br>                Other descriptive name: AMG 334<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 70-<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
im,EUCTR2017-002514-32-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002514-32,"<br>                Product Name: XENEX™ (Xenon gas for inhalation)<br>                Pharmaceutical Form: Medicinal gas, compressed<br>                INN or Proposed INN: Xenon<br>                Current Sponsor code: XENEX™<br>                Other descriptive name: Xenon gas by inhalation<br>                Concentration unit: % percent<br>                Concentration type: equal<br>                Concentration number: 100-<br><br>",NA,NA,NA
im,EUCTR2017-002742-68-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002742-68,"<br>Trade Name: AZACTAM® (aztreonam for injection, USP)<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: aztreonam<br>CAS Number: 827611-49-4<br>Other descriptive name: AZTREONAM LYSINE<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 2-<br><br>Product Name: AVIBACTAM<br>Product Code: AVI<br>Pharmaceutical Form: Powder for concentrate for solution for infusion<br>INN or Proposed INN: Avibactam sodium<br>CAS Number: 1192491-61-4<br>Other descriptive name: AVIBACTAM SODIUM<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 663-<br><br>Trade Name: Metronidazole 500 mg / 100 mL solution for infusion<br>Product Name: Metronidazole<br>Product Code: SUB08922MIG<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: METRONIDAZOLE<br>CAS Number: 442-48-1<br>Current Sponsor code: Metronidazole<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: Meronem ®<br>Product Name: Meronem IV<br>Pharmaceutical Form: Powder for solution for injection/infusion<br>INN or Proposed INN: Meropenem<br>Other descriptive name: MEROPENEM TRIHYDRATE<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>Trade Name: COLOMYCIN INJECTION<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: COLISTIMETHATE SODIUM<br>CAS Number: 8068-28-8<br>Concentration unit: million IU million international units<br>Concentration type: equal<br>Concentration number: 2-<br><br>Trade Name: Aztreonam for injection, USP<br>Pharmaceutical Form: Powder for solution for infusion<br>CAS Number: 827611-49-4<br>Other descriptive name: AZTREONAM LYSINE<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 2-<br><br>Trade Name: Metronidazole 500 mg / 100 mL solution for infusion, USP<br><br>Product",NA,Yes,NA
main,EUCTR2017-002755-29-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-002755-29,"<br>Trade Name: Opdivo (100 mg/10 ml)<br>Product Name: NIVOLUMAB - 10ml vial-CLINICAL<br>Product Code: BMS-936558<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: NIVOLUMAB<br>CAS Number: 946414-94-4<br>Current Sponsor code: BMS-936558-01<br>Other descriptive name: BMS-936558, MDX1106, ONO-4538<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>Trade Name: Opdivo (100 mg/10 ml)<br>Product Name: NIVOLUMAB - 10ml vial - COMMERCIAL<br>Product Code: BMS-936558<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: NIVOLUMAB <br>CAS Number: 946414-94-4<br>Current Sponsor code: BMS-936558-01<br>Other descriptive name: BMS-936558, MDX1106, ONO-4538<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>",NA,Yes,NA
im,EUCTR2017-003055-30-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003055-30,"<br>                Trade Name: Zydelig 100 mg film-coated tablets<br>                Product Name: Idelalisib<br>                Product Code: IDELA, GS-1101<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: IDELALISIB<br>                CAS Number: 870281-82-6<br>                Current Sponsor code: GS-1101<br>                Other descriptive name: IDELA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 100-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: Zydelig 150 mg film-coated tablets<br>                Product Name: Idelalisib<br>                Product Code: IDELA, GS-1101<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: IDELALISIB<br>                CAS Number: 870281-82-6<br>                Current Sponsor code: GS-1101<br>                Other descriptive name: IDELA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 150-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
main,EUCTR2017-003092-55-SE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003092-55,<br>                Product Name: Inclisiran for Injection<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: INCLISIRAN<br>                CAS Number: 1639324-58-5<br>                Current Sponsor code: inclisiran sodium<br>                Other descriptive name: ALN-60212<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 200-<br>                Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>                Route of administration of the placebo: Subcutaneous use<br><br>,NA,NA,NA
im,EUCTR2017-003270-14-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003270-14,<br>Trade Name: Noxafil<br>Product Name: NOXAFIL<br>Pharmaceutical Form: Concentrate for solution for infusion<br>CAS Number: 171228-49-2<br>Other descriptive name: POSACONAZOLE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 18-<br><br>,NA,NA,NA
main,EUCTR2017-003334-82-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003334-82,<br>                Trade Name: Opdivo<br>                Product Name: Nivolumab<br>                Pharmaceutical Form: Lyophilisate for solution for infusion<br><br>,NA,Yes,NA
im,EUCTR2017-003467-34-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003467-34,<br>Trade Name: Kaudella 2017/2018: Influvac.<br>Sisäänottokriteerin mukaan tutkittava on päättänyt ottaa  influenssarokotteen HUS:n työterveyshuollon järjestämän normaalikäytännön mukaisesti. Ei ole tiedossa mitä rokotteita tulee seurannan aikana olemaan käytössä.  <br>Pharmaceutical Form: <br>INN or Proposed INN: Influenza antigens (influenza vaccine)<br>Other descriptive name: INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1)<br>Concentration unit: µl microlitre(s)<br>Concentration type: equal<br>Concentration number: 15-<br>INN or Proposed INN: Influenza antigens (influenza vaccine)<br>Other descriptive name: INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2)<br>Concentration unit: µl microlitre(s)<br>Concentration type: equal<br>Concentration number: 15-<br>INN or Proposed INN: Influenza antigens (influenza vaccine)<br>Other descriptive name: INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B<br>Concentration unit: µl microlitre(s)<br>Concentration type: equal<br>Concentration number: 15-<br>INN or Proposed INN: Influenza antigens (influenza vaccine)<br>Other descriptive name: INFLUENZA VACCINE<br><br>,Yes,NA,NA
im,EUCTR2017-003679-75-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003679-75,<br>                Product Name: Interferon beta-1a (IFN-ß1a)<br>                Product Code: SNG001<br>                Pharmaceutical Form: Nebuliser solution<br>                INN or Proposed INN: Interferon beta-1a<br>                CAS Number: 145258-61-3<br>                Current Sponsor code: SNG001<br>                Concentration unit: million IU million international units<br>                Concentration type: equal<br>                Concentration number: 12-<br>                Pharmaceutical form of the placebo: Nebuliser solution<br>                Route of administration of the placebo: Inhalation use<br><br>,NA,Yes,NA
main,EUCTR2017-003702-41-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003702-41,"<br>                Product Name: Dusquetide<br>                Product Code: SGX942<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: Dusquetide<br>                CAS Number: Not assigned<br>                Current Sponsor code: SGX942<br>                Other descriptive name: SGX94, IMX-001, IMX-942<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 60-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>",NA,NA,NA
im,EUCTR2017-003855-47-AT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003855-47,<br>Product Name: Solnatide<br>Pharmaceutical Form: Powder for nebuliser solution<br>CAS Number: 259206-53-06<br>Current Sponsor code: AP301<br>Other descriptive name: human tumour necrosis factor alpha-derived peptide Cys-Gly-Gln-Arg-Glu-Thr-Pro-Glu-Gly-Ala-Glu-Ala-Lys-Pro-Trp-Tyr-Cys<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 25-<br>Pharmaceutical form of the placebo: Solvent for...<br>Route of administration of the placebo: Inhalation use<br><br>,NA,NA,NA
im,EUCTR2017-003933-27-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-003933-27,<br>                Product Name: Murepavadin<br>                Product Code: POL7080<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: MUREPAVADIN<br>                CAS Number: 944252-63-5<br>                Current Sponsor code: POL7080 Acetate<br>                Other descriptive name: POL7080; formerly RO7033877<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 8-<br><br>                Product Name: Piperacillin Tazobactam<br>                Pharmaceutical Form:<br>                INN or Proposed INN: PIPERACILLIN<br>                Other descriptive name: PIPERACILLIN SODIUM<br>                INN or Proposed INN: TAZOBACTAM<br>                Other descriptive name: TAZOBACTAM SODIUM<br><br>                Product Name: Ceftazidime<br>                Pharmaceutical Form:<br>                INN or Proposed INN: CEFTAZIDIME<br>                CAS Number: 72558-82-8<br><br>                Product Name: Cefepime<br>                Pharmaceutical Form:<br>                INN or Proposed INN: CEFEPIME<br>                CAS Number: 88040-23-7<br><br>                Product Name: Meropenem<br>                Pharmaceutical Form:<br>                INN or Proposed INN: MEROPENEM<br>                CAS Number: 96036-03-2<br>                Other descriptive name: MEROPENEM<br><br>                Product Name: Amikacin<br>                Pharmaceutical Form:<br>                INN or Proposed INN: AMIKACIN<br>                CAS Number: 37517-28-5<br><br>                Product Name: Ciprofloxacin<br>                Pharmaceutical Form:<br>                INN or Proposed INN: CIPROFLOXACIN<br>                Other descriptive name: CIPROFLOXACIN<br><br>                Product Name: Levofloxacin<br>                Pharmaceutical Form:<br>                INN or Proposed INN: LEVOFLOXACIN<br>                CAS Number: 100986-85-4<br><br>                Product Name: i.v./inh. CMS<br>                Pharmaceutical Form:<br>                INN or Propose,NA,Yes,NA
im,EUCTR2017-004054-41-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004054-41,<br>                Product Name: etanercept<br>                Pharmaceutical Form: Solution for injection in pre-filled pen<br>                INN or Proposed INN: ETANERCEPT<br>                CAS Number: 185243-69-0<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 50-<br><br>                Pharmaceutical Form: Coated tablet<br>                INN or Proposed INN: LEFLUNOMIDE<br>                CAS Number: 75706-12-6<br>                Concentration unit: mg milligram(s)<br>                Concentration type: range<br>                Concentration number: 10-20<br><br>,NA,NA,NA
im,EUCTR2017-004318-25-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004318-25,<br>                Product Name: Ascorbic acid 1.5 gr/50 ml and 5 gr/50 ml<br>                Product Code: 1.5 gr and 5 gr<br>                Pharmaceutical Form: Solution for injection/infusion<br>                INN or Proposed INN: Ascorbic acid<br>                Other descriptive name: ASCORBIC ACID PH EUR<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: range<br>                Concentration number: 30-100<br>                Pharmaceutical form of the placebo: Infusion<br>                Route of administration of the placebo: Intravenous use<br>                Pharmaceutical form of the placebo: Injection<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2017-004339-35-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004339-35,"<br>                Product Name: tosatoxumab<br>                Product Code: AR-301, KBSA301<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: tosatoxumab<br>                Current Sponsor code: AR-301<br>                Other descriptive name: KBSA301<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 25-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>",NA,Yes,NA
im,EUCTR2017-004376-64-SE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004376-64,"<br>                Product Name: Immunose™ FLU 1%; quadrivalent inactivated split influenza antigen 30 µg HA/strain, 1% Endocine<br>                Pharmaceutical Form: Nasal drops<br>                Pharmaceutical form of the placebo: Nasal drops<br>                Route of administration of the placebo: Nasal use<br><br>                Product Name: Immunose™ FLU 2%; quadrivalent inactivated split influenza antigen 30 µg HA/strain, 2% Endocine<br>                Pharmaceutical Form: Nasal drops<br>                Pharmaceutical form of the placebo: Nasal drops<br>                Route of administration of the placebo: Nasal use<br><br>                Product Name: Immunose™ FLU 2%, 300 µl; quadrivalent inactivated split influenza antigen 30 µg HA/strain, 2% Endoc<br>                Pharmaceutical Form: Nasal drops<br>                Pharmaceutical form of the placebo: Nasal drops<br>                Route of administration of the placebo: Nasal use<br><br>                Product Name: Influenza antigen; quadrivalent inactivated split, 30 µg HA/strain<br>                Pharmaceutical Form: Nasal drops<br>                Pharmaceutical form of the placebo: Nasal drops<br>                Route of administration of the placebo: Nasal use<br><br>                Product Name: Influsplit Tetra and ImmunoseTM FLU 2%<br>                Pharmaceutical Form: Injection<br><br>                Trade Name: Influsplit Tetra<br>                Product Name: Influsplit Tetra; quadrivalent inactivated split influenza antigen 15 µg HA/strain<br>                Pharmaceutical Form: Injection<br><br>",NA,NA,NA
main,EUCTR2017-004471-31-AT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004471-31,<br>                Trade Name: Olumiant<br>                Product Name: Olumiant<br>                Product Code: LY3009104<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: BARICITINIB<br>                Other descriptive name: BARICITINIB<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 4-<br><br>                Trade Name: Olumiant<br>                Product Name: Olumiant<br>                Product Code: LY3009104<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: BARICITINIB<br>                Other descriptive name: BARICITINIB<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 2-<br><br>                Product Name: Olumiant<br>                Product Code: LY3009104<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: BARICITINIB<br>                Other descriptive name: BARICITINIB<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 1-<br><br>                Product Name: Olumiant<br>                Product Code: LY3009104<br>                Pharmaceutical Form: Suspension for oral suspension<br>                INN or Proposed INN: BARICITINIB<br>                Other descriptive name: BARICITINIB<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 2-<br><br>,NA,NA,NA
im,EUCTR2017-004767-13-SE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004767-13,<br>Trade Name: Ospolot 50 mg film-coated tablet<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: SULTIAME<br>CAS Number: 61-56-3<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Ospolot 200 mg film-coated tablet<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: SULTIAME<br>CAS Number: 61-56-3<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
main,EUCTR2017-004823-66-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004823-66,<br>                Product Name: Namisol<br>                Product Code: ECP002A<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: Namisol<br>                CAS Number: 1972-08-03<br>                Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 7.5-<br>                Pharmaceutical form of the placebo: Tablet<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: Hydrocortison CF<br>                Product Name: Hydrocortison CF<br>                Product Code: RVG 50730<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: Hydrocortison CF<br>                Other descriptive name: HYDROCORTISONE<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 20-<br>                Pharmaceutical form of the placebo: Tablet<br>                Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
im,EUCTR2017-004971-30-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004971-30,"<br>                Product Name: Bris10 M2SR Vaccine<br>                Pharmaceutical Form: Nasal spray, solution<br>                INN or Proposed INN: na<br>                CAS Number: na<br>                Current Sponsor code: Bris10 M2SR Vaccine<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Intranasal use (Noncurrent)<br><br>",Yes,NA,NA
main,EUCTR2018-000040-26-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000040-26,<br>Trade Name: Opdivo (100 mg/10 ml)<br>Product Name: NIVOLUMAB - 10mL vial- COMMERCIAL<br>Product Code: BMS-936558<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: NIVOLUMAB<br>CAS Number: 946414-94-4<br>Current Sponsor code: BMS-936558<br>Other descriptive name: BMS936558<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: Yervoy (200mg/40ml)<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: IPILIMUMAB<br>CAS Number: 477202-00-9<br>Current Sponsor code: BMS-734016<br>Other descriptive name: BMS734016<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: Opdivo (100 mg/10 ml)<br>Product Name: NIVOLUMAB - 4mL vial- COMMERCIAL<br>Product Code: BMS-936558<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: NIVOLUMAB<br>CAS Number: 946414-94-4<br>Current Sponsor code: BMS-936558<br>Other descriptive name: BMS936558<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: Oxaliplatin Bendalis 5mg/ml (100mg vial)<br>Product Name: Oxaliplatin<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: OXALIPLATIN<br>CAS Number: 61825-94-3<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: Oncofolic 50mg/ml (400mg vial)<br>Product Name: Folinic acid<br>Pharmaceutical Form: Solution for injection/infusion<br>INN or Proposed INN: Folinic Acid<br>Other descriptive name: FOLINIC ACID<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 50-<br><br>Trade Name: Erbitux 5 mg/mL (500mg vial)<br>Product Code: L01XC06<br>Pharmaceutical Form: Solution for infusion<br>INN,NA,Yes,NA
im,EUCTR2018-000059-42-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000059-42,<br>Trade Name: ZERBAXA<br>Pharmaceutical Form: Concentrate for solution for infusion<br><br>,NA,NA,NA
im,EUCTR2018-000106-32-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000106-32,"<br>Product Name: Lyophilized lucinactant<br>Product Code: R07AA-30<br>Pharmaceutical Form: Nebuliser suspension<br>INN or Proposed INN: dipalmitoylphosphatidylcholine<br>CAS Number: 63-89-8<br>Current Sponsor code: 401-000<br>Other descriptive name: 1,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHATIDYLCHOLINE (DPPC)<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 22,5-<br>INN or Proposed INN: Palmitic acid<br>CAS Number: 57-10-3<br>Current Sponsor code: 401-002<br>Other descriptive name: PALMITIC ACID (hexadecanoic acid)<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 4,05-<br>INN or Proposed INN: palmitoyloleoyl-phosphatidylglycerol, sodium salt<br>CAS Number: 268550-95-4<br>Current Sponsor code: 401-001<br>Other descriptive name: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol, sodium salt<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 7,5-<br>INN or Proposed INN: SINAPULTIDE<br>CAS Number: 138531-07-4<br>Current Sponsor code: 401-003<br>Other descriptive name: KL4 acetate<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 0.862-<br><br>",NA,NA,NA
im,EUCTR2018-000191-15-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000191-15,<br>Trade Name: Ivabradine. CAS number: 155974-00-8<br>Product Name: Ivabradine<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: IVABRADINE<br>CAS Number: 155974-00-8<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 5-7.5<br><br>,NA,NA,NA
im,EUCTR2018-000196-32-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000196-32,<br>Trade Name: Hidrocortisone<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: HYDROCORTISONE SODIUM PHOSPHATE<br>CAS Number: 6000-74-4<br>Current Sponsor code: ACTOCORTINA<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br><br>Trade Name:  Ascorbic acid<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: ASCORBIC ACID<br>Current Sponsor code: ASCORBIC ACID<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 36-<br><br>Trade Name: Benerva<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: THIAMINE<br>CAS Number: 59-43-8<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 1600-<br><br>,NA,NA,NA
main,EUCTR2018-000334-35-NO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000334-35,<br>Product Code: BI 655130<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Spesolimab<br>Current Sponsor code: BI 655130<br>Other descriptive name: MONOCLONAL ANTIBODY ANTI-IGG1<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br><br>Product Code: BI 655130<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: spesolimab<br>Current Sponsor code: BI 655130<br>Other descriptive name: MONOCLONAL ANTIBODY ANTI-IGG1<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 150-<br><br>Product Code: BI 655130<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Spesolimab<br>Current Sponsor code: BI 655130<br>Other descriptive name: MONOCLONAL ANTIBODY ANTI-IGG1<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br><br>Product Code: BI 655130<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: spesolimab<br>Current Sponsor code: BI 655130<br>Other descriptive name: MONOCLONAL ANTIBODY ANTI-IGG1<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 150-<br><br>,NA,Yes,NA
main,EUCTR2018-000349-38-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000349-38,<br>Trade Name: Olumiant<br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: baricitinib<br>Current Sponsor code: LY3009104<br>Other descriptive name: BARICITINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 4-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Olumiant<br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: baricitinib<br>Current Sponsor code: LY3009104<br>Other descriptive name: BARICITINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 2-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: baricitinib<br>Current Sponsor code: LY3009104<br>Other descriptive name: BARICITINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 1-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Olumiant<br>Product Code: LY3009104<br>Pharmaceutical Form: Suspension for oral suspension<br>INN or Proposed INN: baricitinib<br>Current Sponsor code: LY3009104<br>Other descriptive name: BARICITINIB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 2-<br>Pharmaceutical form of the placebo: Suspension for oral suspension<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
im,EUCTR2018-000431-27-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000431-27,<br>Product Name: ChAd155-RSV (high dose)<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: NA<br>Current Sponsor code: ChAd155-RSV<br>Concentration unit: Other<br>Concentration type: equal<br>Concentration number: 50000000000-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>Product Name: ChAd155-RSV (low dose)<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: NA<br>Current Sponsor code: ChAd155-RSV<br>Concentration unit: Other<br>Concentration type: equal<br>Concentration number: 15000000000-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>Trade Name: Bexsero<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: NA<br>Current Sponsor code: NHBA<br>Other descriptive name: RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NHBA FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>INN or Proposed INN: NA<br>Current Sponsor code: NadA<br>Other descriptive name: RECOMBINANT NEISSERIA MENINGITIDIS GROUP B NADA PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>INN or Proposed INN: NA<br>Current Sponsor code: fHbp<br>Other descriptive name: RECOMBINANT NEISSERIA MENINGITIDIS GROUP B FHBP FUSION PROTEIN PRODUCED IN E. COLI CELLS BY RECOMBINANT DNA TECHNOLOGY ADSORBED ON ALUMINIUM HYDROXIDE<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>INN or Proposed INN: NA<br>Current Sponsor code: OMV<br>Other descriptive name: OUTER MEMBRANE VESICLES (OMV) FROM NEISSERIA MENINGITIDIS GROUP B STRAIN NZ98/254 MEASURED AS AMOUNT OF TOTAL PROTEIN CONTAINING THE PORA P1.4 ADSORBED ON ALUMINIUM HYDROXIDE<br>Concentration unit: µg microgram(s)<br>Concentration type:,NA,NA,NA
im,EUCTR2018-000450-21-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000450-21,<br>                Trade Name: Meropenem Accordpharma 1 g POLVO PARA SOLUCION INYECTABLE Y PARA PERFUSION EFG<br>                Pharmaceutical Form: Solution for injection/infusion<br>                INN or Proposed INN: MEROPENEM<br>                CAS Number: 96036-03-2<br>                Current Sponsor code: Pfizer GEP S.L.<br>                Other descriptive name: MEROPENEM<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: range<br>                Concentration number: 500-6000<br><br>,NA,NA,NA
main,EUCTR2018-000451-41-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000451-41,<br>                Product Name: Ivosidenib<br>                Product Code: AG-120<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: Ivosidenib<br>                CAS Number: 1448347-49-6<br>                Current Sponsor code: AG-120<br>                Other descriptive name: AG-120<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 250-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>                Product Name: Enasidenib<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: ENASIDENIB<br>                Other descriptive name: AG-221<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 100-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
im,EUCTR2018-000468-27-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000468-27,<br>Product Name: Multimeric-001 <br>Product Code: M-001<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: N/A<br>Current Sponsor code: M-001<br>Other descriptive name: MULTIMERIC-001<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 2.5-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>,NA,NA,NA
main,EUCTR2018-000518-39-IS,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000518-39,<br>                Product Name: Secukinumab<br>                Product Code: AIN457<br>                Pharmaceutical Form: Solution for injection in pre-filled pen<br>                INN or Proposed INN: SECUKINUMAB<br>                CAS Number: 1229022-83-6<br>                Current Sponsor code: AIN457<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 150-<br>                Pharmaceutical form of the placebo: Solution for injection in pre-filled pen<br>                Route of administration of the placebo: Subcutaneous use<br><br>                Trade Name: COSENTYX<br>                Product Name: COSENTYX<br>                Product Code: AIN457<br>                Pharmaceutical Form: Solution for injection in pre-filled syringe<br>                INN or Proposed INN: SECUKINUMAB<br>                CAS Number: 1229022-83-6<br>                Current Sponsor code: AIN457<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 150-<br>                Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>                Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
main,EUCTR2018-000572-15-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000572-15,<br>Product Name: Eryaspase <br>Pharmaceutical Form: Dispersion for infusion<br>INN or Proposed INN: L-asparaginase encapsulated in red blood cells<br>Other descriptive name: L-ASPARAGINASE ENCAPSULATED IN RED BLOOD CELLS<br>Concentration unit: IU/kg international unit(s)/kilogram<br>Concentration type: equal<br>Concentration number: 100 -<br><br>,NA,NA,NA
main,EUCTR2018-000754-22-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000754-22,<br>                Product Name: IBP-9414<br>                Product Code: IBP-9414<br>                Pharmaceutical Form: Powder for oral suspension<br>                INN or Proposed INN: not available<br>                CAS Number: not availabl<br>                Current Sponsor code: IBP-9414<br>                Other descriptive name: LACTOBACILLUS REUTERI<br>                Concentration unit: CFU/ml colony forming unit(s)/millilitre<br>                Concentration type: range<br>                Concentration number: 1400000000-70000000000<br>                Pharmaceutical form of the placebo: Solvent for...<br>                Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
main,EUCTR2018-000993-31-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000993-31,"<br>                Product Code: LOU064<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: Not yet established<br>                Current Sponsor code: LOU064<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 10-<br>                Pharmaceutical form of the placebo: Capsule, hard<br>                Route of administration of the placebo: Oral use<br><br>                Product Code: LOU064<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: Not yet established<br>                Current Sponsor code: LOU064<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 25-<br>                Pharmaceutical form of the placebo: Capsule, hard<br>                Route of administration of the placebo: Oral use<br><br>                Product Code: LOU064<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: Not yet established<br>                Current Sponsor code: LOU064<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 50-<br>                Pharmaceutical form of the placebo: Capsule, hard<br>                Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
main,EUCTR2018-001023-38-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001023-38,"<br>                Product Name: Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector<br>                Product Code: bb2121<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: Autologous CD3+ T Cells Expressing BCMA Chimeric Antigen Receptor<br>                Other descriptive name: bb2121<br>                Concentration unit: Other<br>                Concentration type: equal<br>                Concentration number: 1-<br><br>                Trade Name: DARZALEX 20 mg/mL concentrate for solution for infusion<br>                Product Name: Daratumumab<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: DARATUMUMAB<br>                CAS Number: 945721-28-8<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 5-<br><br>                Trade Name: Revlimid 5 mg hard capsules<br>                Product Name: Lenalidomide<br>                Product Code: CC-5013<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: LENALIDOMIDE<br>                CAS Number: 191732-72-6<br>                Current Sponsor code: CC-5013<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 5-<br><br>                Trade Name: NINLARO 2.3 mg hard capsules<br>                Product Name: Ixazomib<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: Ixazomib Citrate<br>                Other descriptive name: IXAZOMIB CITRATE<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 2.3-<br><br>                Trade Name: VELCADE 3.5 mg powder for solution for injection<br>                Product Name: Bortezomib<br>                Pharmaceutical Form: Powder for solution for injection<br>                INN or",NA,Yes,NA
main,EUCTR2018-001082-17-EE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001082-17,<br>Trade Name: BAXDELA<br>Product Name: Delafloxacin<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: DELAFLOXACIN<br>CAS Number: 352458-37-8<br>Other descriptive name: DELAFLOXACIN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br><br>Trade Name: BAXDELA<br>Product Name: Delafloxacin<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: DELAFLOXACIN<br>CAS Number: 352458-37-8<br>Other descriptive name: DELAFLOXACIN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 450-<br><br>Product Name: Vancomycin<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: VANCOMYCIN HYDROCHLORIDE<br>CAS Number: 1404-93-9<br>Other descriptive name: VANCOMYCIN HYDROCHLORIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 1000-<br><br>Product Name: Linezolid<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: LINEZOLID<br>CAS Number: 165800-03-3<br>Other descriptive name: LINEZOLID<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 2-<br><br>Product Name: Linezolid<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: LINEZOLID<br>CAS Number: 165800-03-3<br>Other descriptive name: LINEZOLID<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 600-<br><br>Product Name: Piperacillin/Tazobactam <br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: PIPERACILLIN<br>CAS Number: 61477-96-1<br>Other descriptive name: PIPERACILLIN<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 4-<br>INN or Proposed INN: TAZOBACTAM<br>CAS Number: 89786-04-9<br>Other descriptive name: TAZOBACTAM<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 0.5-<br><br>Product Name: Tigecycli,NA,Yes,NA
main,EUCTR2018-001148-67-SI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001148-67,<br>Product Name: Pegunigalsidase alfa<br>Product Code: PRX-102<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: PEGUNIGALSIDASE ALFA<br>CAS Number: 1644392-61-9<br>Current Sponsor code: PRX-102<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 2-<br><br>,NA,NA,NA
im,EUCTR2018-001159-11-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001159-11,<br>                Product Name: Murepavadin<br>                Product Code: POL7080<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: MUREPAVADIN<br>                CAS Number: 944252-63-5<br>                Current Sponsor code: POL7080 Acetate<br>                Other descriptive name: POL7080; formerly RO7033877<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 8-<br><br>                Trade Name: Invanz®<br>                Product Name: Ertapenem<br>                Pharmaceutical Form: Powder for concentrate for solution for infusion<br>                INN or Proposed INN: ERTAPENEM<br>                CAS Number: 153773-82-1<br>                Other descriptive name: ERTAPENEM SODIUM<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 1-<br><br>                Trade Name: Merrem®<br>                Product Name: Meropenem<br>                Pharmaceutical Form: Powder for solution for injection/infusion<br>                INN or Proposed INN: MEROPENEM<br>                CAS Number: 96036-03-2<br>                Other descriptive name: MEROPENEM<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 1-<br><br>                Trade Name: Zosyn®<br>                Product Name: Piperacillin Tazobactam<br>                Pharmaceutical Form: Powder for solution for infusion<br>                INN or Proposed INN: PIPERACILLIN<br>                Other descriptive name: PIPERACILLIN SODIUM<br>                Concentration unit: g gram(s)<br>                Concentration type: range<br>                Concentration number: 2-4<br>                INN or Proposed INN: TAZOBACTAM<br>                Other descriptive name: TAZOBACTAM SODIUM<br>                Concentration unit: g gram(s)<br>                Concentration type: range<br>                Concentration nu,NA,NA,NA
main,EUCTR2018-001159-11-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001159-11,<br>                Product Name: Murepavadin<br>                Product Code: POL7080<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: MUREPAVADIN<br>                CAS Number: 944252-63-5<br>                Current Sponsor code: POL7080 Acetate<br>                Other descriptive name: POL7080; formerly RO7033877<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 8-<br><br>                Trade Name: Invanz®<br>                Product Name: Ertapenem<br>                Pharmaceutical Form: Powder for concentrate for solution for infusion<br>                INN or Proposed INN: ERTAPENEM<br>                CAS Number: 153773-82-1<br>                Other descriptive name: ERTAPENEM SODIUM<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 1-<br><br>                Trade Name: Merrem®<br>                Product Name: Meropenem<br>                Pharmaceutical Form: Powder for solution for injection/infusion<br>                INN or Proposed INN: MEROPENEM<br>                CAS Number: 96036-03-2<br>                Other descriptive name: MEROPENEM<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 1-<br><br>                Trade Name: Zosyn®<br>                Product Name: Piperacillin Tazobactam<br>                Pharmaceutical Form: Powder for solution for infusion<br>                INN or Proposed INN: PIPERACILLIN<br>                Other descriptive name: PIPERACILLIN SODIUM<br>                Concentration unit: g gram(s)<br>                Concentration type: range<br>                Concentration number: 2-4<br>                INN or Proposed INN: TAZOBACTAM<br>                Other descriptive name: TAZOBACTAM SODIUM<br>                Concentration unit: g gram(s)<br>                Concentration type: range<br>                Concentration nu,NA,NA,NA
main,EUCTR2018-001189-40-PT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001189-40,<br>Product Name: Ralinepag<br>Product Code: APD811<br>Pharmaceutical Form: Prolonged-release tablet<br>INN or Proposed INN: ralinepag<br>CAS Number: 1187856-49-0<br>Current Sponsor code: APD811<br>Other descriptive name: AR392830<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>Product Name: Ralinepag<br>Product Code: APD811<br>Pharmaceutical Form: Prolonged-release tablet<br>INN or Proposed INN: ralinepag<br>CAS Number: 1187856-49-0<br>Current Sponsor code: APD811<br>Other descriptive name: AR392830<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 250-<br><br>Product Name: Ralinepag<br>Product Code: APD811<br>Pharmaceutical Form: Prolonged-release tablet<br>INN or Proposed INN: ralinepag<br>CAS Number: 1187856-49-0<br>Current Sponsor code: APD811<br>Other descriptive name: AR392830<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 400-<br><br>,NA,NA,NA
im,EUCTR2018-001340-62-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001340-62,<br>Product Name: 30µg RSVPreF3<br>Pharmaceutical Form: Powder and solvent for solution for injection<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>Product Name: 60µg RSVPreF3<br>Pharmaceutical Form: Powder and solvent for solution for injection<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>Product Name: 120µg RSVPreF3<br>Pharmaceutical Form: Powder and solvent for solution for injection<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>,NA,NA,NA
im,EUCTR2018-001416-30-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001416-30,<br>                Product Name: Baloxavir marboxil<br>                Product Code: RO7191686/F04<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: BALOXAVIR MARBOXIL<br>                Current Sponsor code: RO7191686<br>                Other descriptive name: S-033188<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 20-<br>                Pharmaceutical form of the placebo: Tablet<br>                Route of administration of the placebo: Oral use<br><br>                Product Name: Baloxavir marboxil<br>                Product Code: RO7191686/F08<br>                Pharmaceutical Form: Granules<br>                INN or Proposed INN: BALOXAVIR MARBOXIL<br>                Current Sponsor code: RO7191686<br>                Other descriptive name: S-033188<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 2-<br>                Pharmaceutical form of the placebo: Granules<br>                Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
main,EUCTR2018-001451-13-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001451-13,"<br>                Product Name: VNRX-5133<br>                Product Code: VNRX-5133<br>                Pharmaceutical Form: Powder for solution for injection/infusion<br>                INN or Proposed INN:  Taniborbactam<br>                Current Sponsor code: VNRX-5133<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 0.5-<br>                Pharmaceutical form of the placebo: Solution for injection/infusion<br>                Route of administration of the placebo: Intravenous use<br><br>                Trade Name: CEFEPIME- cefepime hydrochloride injection, powder, for solution<br>                Product Name: Cefepime<br>                Pharmaceutical Form: Powder for solution for injection/infusion<br>                INN or Proposed INN: CEFEPIME HYDROCHLORIDE<br>                CAS Number: 123171-59-5<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 2-<br>                Pharmaceutical form of the placebo: Solution for injection/infusion<br>                Route of administration of the placebo: Intravenous use<br><br>                Trade Name: MEROPENEM- meropenem injection, powder, for solution<br>                Product Name: Meropenem<br>                Pharmaceutical Form: Powder for solution for injection/infusion<br>                INN or Proposed INN: MEROPENEM<br>                CAS Number: 96036-03-2<br>                Other descriptive name: MEROPENEM<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 1-<br>                Pharmaceutical form of the placebo: Solution for injection/infusion<br>                Route of administration of the placebo: Intravenous use<br><br>",NA,NA,NA
main,EUCTR2018-001547-32-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001547-32,<br>                Product Name: canakinumab<br>                Product Code: ACZ885<br>                Pharmaceutical Form: Solution for injection in pre-filled syringe<br>                INN or Proposed INN: CANAKINUMAB<br>                CAS Number: 914613-48-2<br>                Current Sponsor code: ACZ885<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 150-<br>                Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>                Route of administration of the placebo: Subcutaneous use<br><br>                Product Name: canakinumab<br>                Product Code: ACZ885<br>                Pharmaceutical Form: Solution for injection in pre-filled syringe<br>                INN or Proposed INN: CANAKINUMAB<br>                CAS Number: 914613-48-2<br>                Current Sponsor code: ACZ885<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 100-<br>                Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>                Route of administration of the placebo: Subcutaneous use<br><br>                Trade Name: Carboplatin Accord<br>                Product Name: carboplatin<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: carboplatin<br>                CAS Number: 41575-94-4<br>                Other descriptive name: CARBOPLATIN<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 10-<br><br>                Trade Name: Paclitaxel Kabi<br>                Product Name: paclitaxel<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: PACLITAXEL<br>                CAS Number: 33069-62-4<br>                Other descriptive name: paclitaxel<br>,NA,Yes,NA
im,EUCTR2018-001582-16-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001582-16,<br>                Trade Name: ALBUMINA GRIFOLS - 20 G/100 ML SOLUZIONE PER INFUSIONE FLACONE DA 100 ML<br>                Pharmaceutical Form: Solution for injection<br><br>                Trade Name: RINGER LATTATO S.A.L.F. - SOLUZIONE PER INFUSIONE 1 FLACONCINO 500 ML<br>                Pharmaceutical Form: Solution for infusion<br><br>                Trade Name: RINGER ACETATO LDB - SOLUZIONE PER INFUSIONE FLACONCINO 500 ML<br>                Pharmaceutical Form: Solution for injection<br><br>                Trade Name: CRYSTALSOL - SOLUZIONE PER INFUSIONE 20 SACCHE IN PO/PA DA 500 ML<br>                Pharmaceutical Form: Solution for injection<br><br>,NA,NA,NA
main,EUCTR2018-001588-22-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001588-22,"<br>                Product Name: CPI-613<br>                Product Code: CPI-613<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: devimistat (Rafael Pharmaceuticals)<br>                CAS Number: 95809-78-2<br>                Current Sponsor code: CPI-613<br>                Other descriptive name: 6,8-BIS(BENZYLTHIO)OCTANOIC ACID<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 50-<br><br>                Product Name: CPI-613<br>                Product Code: CPI-613<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: devimistat (Rafael Pharmaceuticals)<br>                CAS Number: 95809-78-2<br>                Current Sponsor code: CPI-613<br>                Other descriptive name: 6,8-BIS(BENZYLTHIO)OCTANOIC ACID<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 50-<br><br>",NA,NA,NA
im,EUCTR2018-001683-37-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001683-37,<br>Trade Name: Propranolol retard<br>Product Name: Propranolol R<br>Product Code: C07AA05<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: PROPRANOLOL HYDROCHLORIDE<br>CAS Number: 318-98-9<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 80-<br><br>,NA,NA,NA
im,EUCTR2018-001709-10-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001709-10,<br>                Trade Name: Ilomédine<br>                Product Name: Ilomédine<br>                Product Code: B01AC11<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
main,EUCTR2018-001801-98-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001801-98,<br>Product Name: Gepotidacin<br>Product Code: GSK2140944<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Gepotidacin<br>CAS Number: 1075236-89-3<br>Other descriptive name: GSK2140944<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 750-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Macrobid<br>Product Name: Over-encapsulated Nitrofurantoin capsules<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: Nitrofurantoin monohydrate<br>CAS Number: 17140-81-7<br>Other descriptive name: NITROFURANTOIN MONOHYDRATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
main,EUCTR2018-001803-35-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001803-35,"<br>                Product Name: DCC-2618<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: DCC-2618<br>                CAS Number: 1442472-39-0<br>                Current Sponsor code: DCC-2618<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 50-<br><br>                Trade Name: Sutent<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: NA<br>                CAS Number: 341031-54-7<br>                Current Sponsor code: NA<br>                Other descriptive name: SUNITINIB MALATE<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 50-<br><br>",NA,NA,NA
im,EUCTR2018-001857-29-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001857-29,<br>Trade Name: Flucelvax Tetra<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: A/(H1N1)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/(H1N1)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: A/(H3N2)-LIKE VIRUS ANTIGEN<br>Other descriptive name: A/(H3N2)-LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: B/ -LIKE VIRUS ANTIGEN<br>Other descriptive name: B/ -LIKE VIRUS ANTIGEN<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>Trade Name: NeisVac-C<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: Neisseria meningitidis group C (strain 11) polysaccharide (de-O-acetylated)<br>Other descriptive name: N. MENINGITIDIS GROUP C POLYSACCHARIDE<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>,NA,NA,NA
im,EUCTR2018-001894-26-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001894-26,<br>                Product Name: Quadrivalent VLP Influenza Vaccine<br>                Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>                INN or Proposed INN: Quadrivalent VLP Influenza Vaccine<br>                Other descriptive name: INFLUENZA VACCINE<br>                Concentration unit: µg/ml microgram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 60-<br><br>                Trade Name: Fluarix tetra<br>                Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>                INN or Proposed INN: Quadrivalent Influenza Vaccine<br>                Other descriptive name: INFLUENZA VACCINE<br>                Concentration unit: µg/ml microgram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 30-<br><br>,Yes,NA,NA
main,EUCTR2018-001953-28-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001953-28,<br>Product Name: Dupilumab<br>Product Code: SAR231893<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: Dupilumab<br>Current Sponsor code: SAR231893<br>Other descriptive name: REGN668<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 150-<br>Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
main,EUCTR2018-001997-52-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-001997-52,<br>Product Name: tezepelumab<br>Product Code: AMG 157<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: TEZEPELUMAB<br>Current Sponsor code: AMG 157<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 110-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
main,EUCTR2018-002063-26-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002063-26,<br>                Product Name: Secukinumab<br>                Product Code: AIN457<br>                Pharmaceutical Form: Solution for injection in pre-filled syringe<br>                INN or Proposed INN: Secukinumab<br>                CAS Number: 1229022-83-6<br>                Current Sponsor code: AIN457<br>                Other descriptive name: SECUKINUMAB<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 150-<br>                Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>                Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
main,EUCTR2018-002136-24-GR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002136-24,<br>Product Name: TD-1473<br>Product Code: TD-1473<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: Not assigned<br>Current Sponsor code: TD-1473<br>Other descriptive name: THRX-139060<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: TD-1473<br>Product Code: TD-1473<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: Not assigned<br>Current Sponsor code: TD-1473<br>Other descriptive name: THRX-139060<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 40-<br>Pharmaceutical form of the placebo: Coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: TD-1473<br>Product Code: TD-1473<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: Not assigned<br>Current Sponsor code: TD-1473<br>Other descriptive name: THRX-139060<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
im,EUCTR2018-002154-70-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002154-70,<br>                Product Name: Baloxavir marboxil<br>                Product Code: RO7191686/F08<br>                Pharmaceutical Form: Granules for oral suspension<br>                INN or Proposed INN: BALOXAVIR MARBOXIL<br>                Current Sponsor code: RO7191686<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 2-<br><br>,NA,Yes,NA
main,EUCTR2018-002155-15-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002155-15,<br>                Product Name: TSR-042<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: TSR-042<br>                Current Sponsor code: TSR-042<br>                Other descriptive name: TSR-042<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br><br>,NA,NA,NA
im,EUCTR2018-002169-21-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002169-21,<br>                Product Name: Baloxavir marboxil<br>                Product Code: RO7191686/F08<br>                Pharmaceutical Form: Granules for oral suspension<br>                INN or Proposed INN: BALOXAVIR MARBOXIL<br>                Current Sponsor code: RO7191686<br>                Other descriptive name: S-033188<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 2-<br>                Pharmaceutical form of the placebo: Granules for oral suspension<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: Tamiflu<br>                Product Code: Ro 64-0796/V36<br>                Pharmaceutical Form: Powder for oral suspension<br>                INN or Proposed INN: OSELTAMIVIR<br>                CAS Number: 196618-13-0<br>                Current Sponsor code: RO0640796<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 6-<br>                Pharmaceutical form of the placebo: Powder for oral suspension<br>                Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
main,EUCTR2018-002176-41-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002176-41,"<br>Trade Name: Eliquis 2,5mg Filmtabletten<br>Product Name: Eliquis<br>Product Code: B01AF02<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: APIXABAN<br>CAS Number: 503612-47-3<br>Current Sponsor code: Bristol-Myers Squibb / Pfizer<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: Eliquis 5mg Filmtabletten<br>Product Name: Eliquis<br>Product Code: B01AF02<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: APIXABAN<br>CAS Number: 503612-47-3<br>Current Sponsor code: Bristol-Myers Squibb / Pfizer<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: Dabigatran 110mg Hartkapseln<br>Product Name: Pradaxa<br>Product Code: B01AE07<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: DABIGATRAN ETEXILATE<br>CAS Number: 211915-06-9<br>Current Sponsor code: Boehringer Ingelheim International GmbH<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 220-<br><br>Trade Name: Dabigatran 150mg Hartkapseln<br>Product Name: Pradaxa<br>Product Code: B01AE07<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: DABIGATRAN ETEXILATE<br>CAS Number: 211915-06-9<br>Current Sponsor code: Boehringer Ingelheim International GmbH<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br><br>Trade Name: Lixiana 30mg Filmtabletten<br>Product Name: Lixiana<br>Product Code: B01AF03<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: EDOXABAN<br>CAS Number: 480449-71-6<br>Current Sponsor code: Daiichi Sankyo , Inc<br>Other descriptive name: EDOXABAN TOSYLATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 30-<br><br>Trade Name: Lixiana 60mg  Filmtabletten<br>Product Name: Lixiana<br>Product Code: B01AF03<br>Pharmaceutical Form: Film-coated tablet<br>INN or Propos",NA,NA,NA
main,EUCTR2018-002234-21-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002234-21,"<br>                Product Name: IPX203<br>                Product Code: IPX203<br>                Pharmaceutical Form: Modified-release capsule, hard<br>                INN or Proposed INN: Levodopa<br>                CAS Number: 59-92-7<br>                Current Sponsor code: LD<br>                Other descriptive name: LEVODOPA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 140-<br>                INN or Proposed INN: Carbidopa<br>                Current Sponsor code: CD<br>                Other descriptive name: ANHYDROUS CARBIDOPA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 35-<br><br>                Product Name: IPX203<br>                Product Code: IPX203<br>                Pharmaceutical Form: Modified-release capsule, hard<br>                INN or Proposed INN: Levodopa<br>                CAS Number: 59-92-7<br>                Current Sponsor code: LD<br>                Other descriptive name: LEVODOPA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 210-<br>                INN or Proposed INN: Carbidopa<br>                Current Sponsor code: CD<br>                Other descriptive name: ANHYDROUS CARBIDOPA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 52.5-<br><br>                Product Name: IPX203<br>                Product Code: IPX203<br>                Pharmaceutical Form: Modified-release capsule, hard<br>                INN or Proposed INN: Levodopa<br>                CAS Number: 59-92-7<br>                Current Sponsor code: LD<br>                Other descriptive name: LEVODOPA<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 280-<br>                INN or Proposed INN: Carbidopa<br>                Current Spo",NA,NA,NA
main,EUCTR2018-002247-28-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002247-28,<br>                Product Name: M281 Injection<br>                Product Code: M281<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: M281<br>                CAS Number: 2211985-36-1<br>                Other descriptive name: M281<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 30-<br>                Pharmaceutical form of the placebo: Injection<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
main,EUCTR2018-002264-57-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002264-57,<br>Product Name: Upadacitinib<br>Product Code: ABT-494<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: UPADACITINIB<br>CAS Number: 1310726-60-3<br>Current Sponsor code: ABT-494<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 30-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Dupixent (Dupilumab)<br>Product Name: Dupixent<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: Dupilumab<br>Other descriptive name: DUPILUMAB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 150-<br>Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
main,EUCTR2018-002339-23-AT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002339-23,"<br>Trade Name: Mydrane, 0,2mg/ml + 3,1 mg/ml + 10 mg/ml Injektionslösung<br>Product Name: Mydrane, 0,2 mg/ml +3,1 mg/ml + 10 mg/ml Injektionslösung<br>Pharmaceutical Form: Injection<br>INN or Proposed INN: Lidocaine Hydrochlorid<br>CAS Number: 6108-05-0<br>Other descriptive name: LIDOCAINE HYDROCHLORIDE MONOHYDRATE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br>INN or Proposed INN: Tropicamide<br>Other descriptive name: TROPICAMIDE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 0,2-<br>INN or Proposed INN: Phenylephrine Hydrochloride<br>Other descriptive name: PHENYLEPHRINE HYDROCHLORIDE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 3,1-<br><br>Trade Name: Minims® Phenylephrine Hydrochloride 10% w/v<br>Product Name: Minims<br>Pharmaceutical Form: Eye drops<br>INN or Proposed INN: PHENYLEPHRINE HYDROCHLORIDE<br>Other descriptive name: PHENYLEPHRINE HYDROCHLORIDE<br>Concentration unit: % (W/V) percent weight/volume<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: Agepha<br>Product Name: Mydriaticum „Agepha 0,5%<br>Pharmaceutical Form: Eye drops, solution<br>INN or Proposed INN: Tropicamide<br>Other descriptive name: TROPICAMIDE<br>Concentration unit: % (W/V) percent weight/volume<br>Concentration type: equal<br>Concentration number: 0,5-<br><br>",NA,Yes,NA
main,EUCTR2018-002371-18-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002371-18,<br>                Product Name: ultra-rapid formulation of insulin lispro<br>                Product Code: LY900014<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: INSULIN LISPRO<br>                CAS Number: 133107-64-9<br>                Concentration unit: U/ml unit(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 100-<br><br>                Trade Name: Humalog®<br>                Product Name: Humalog®<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: INSULIN LISPRO<br>                CAS Number: 133107-64-9<br>                Concentration unit: U/ml unit(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 100-<br><br>,NA,NA,NA
main,EUCTR2018-002430-21-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002430-21,<br>                Trade Name: Vyxeos<br>                Product Name: Vyxeos<br>                Product Code: CPX351<br>                Pharmaceutical Form: Powder for solution for infusion<br>                INN or Proposed INN: DAUNORUBICIN<br>                CAS Number: 20830-81-3<br>                Concentration unit: mg/m2 milligram(s)/square meter<br>                Concentration type: up to<br>                Concentration number: 44-<br>                INN or Proposed INN: Cytarabine<br>                CAS Number:  147-94-4<br>                Concentration unit: mg/m2 milligram(s)/square meter<br>                Concentration type: up to<br>                Concentration number: 100-<br><br>                Trade Name: Daunorubicine<br>                Pharmaceutical Form:<br>                INN or Proposed INN: DAUNORUBICIN<br>                CAS Number: 20830-81-3<br>                Concentration unit: mg/m2 milligram(s)/square meter<br>                Concentration type: up to<br>                Concentration number: 60-<br><br>                Trade Name: Cytarabine<br>                Pharmaceutical Form: Lyophilisate for solution for infusion<br>                INN or Proposed INN: Cytarabine<br>                CAS Number: 147-94-4<br>                Concentration unit: mg/m2 milligram(s)/square meter<br>                Concentration type: up to<br>                Concentration number: 100-<br><br>                Trade Name: Vidaza<br>                Pharmaceutical Form: Lyophilisate for solution for infusion<br>                INN or Proposed INN: AZACITIDINE<br>                CAS Number: 320-67-2<br>                Concentration unit: mg/m2 milligram(s)/square meter<br>                Concentration type: up to<br>                Concentration number: 75-<br><br>,NA,Yes,NA
main,EUCTR2018-002431-18-IE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002431-18,<br>                Product Name: Semaglutide B 1.0 mg/mL PDS290<br>                Pharmaceutical Form: Solution for injection in pre-filled pen<br>                INN or Proposed INN: semaglutide<br>                CAS Number: 910463-68-2<br>                Other descriptive name: SEMAGLUTIDE<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 1.0-<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Subcutaneous use<br><br>                Product Name: Semaglutide B 3.0 mg/mL PDS290<br>                Pharmaceutical Form: Solution for injection in pre-filled pen<br>                INN or Proposed INN: semaglutide<br>                CAS Number: 910463-68-2<br>                Other descriptive name: SEMAGLUTIDE<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 3.0-<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Subcutaneous use<br><br>,NA,NA,NA
im,EUCTR2018-002526-23-LT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002526-23,"<br>Product Name: durlobactam<br>Product Code: durlobactam, ETX2514 Sodium, NaETX2514<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: durlobactam<br>CAS Number: 1467157-21-6<br>Current Sponsor code: durlobactam<br>Other descriptive name: ETX2514, ETX2514 Sodium, NaETX2514, durlobactam sodium, durlobactam Na, Na durlobactam<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Product Name: Sulbactam<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: Sulbactam Sodium<br>CAS Number: 69388-84-7<br>Current Sponsor code: Sulbactam<br>Other descriptive name: SULBACTAM SODIUM<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 1.0-<br><br>Trade Name: Imipenem/Cilastatin Kabi 500 mg/500 mg Fresenius Kabi<br>Product Name: Imipenem/Cilastatin<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: Imipenem<br>CAS Number: 74431-23-5<br>Current Sponsor code: Imipenem<br>Other descriptive name: IMIPENEM<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 500-<br>INN or Proposed INN: Cilastatin<br>CAS Number: 82009-34-5<br>Current Sponsor code: Cilastatin<br>Other descriptive name: CILASTATIN SODIUM<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Trade Name: COLOMYCIN INJECTION 2 million IU/vial<br>Product Name: Colistin<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: COLISTIMETHATE SODIUM<br>CAS Number: 2680-63-9<br>Current Sponsor code: Colistin<br>Concentration unit: million IU million international units<br>Concentration type: equal<br>Concentration number: 2-<br><br>Trade Name: COLOMYCIN INJECTION 2 million IU/vial<br>Product Name: Colistin<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: COLISTIMETHATE SODIUM",NA,Yes,NA
main,EUCTR2018-002543-28-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002543-28,"<br>Product Name: Myramistin 0.005%<br>Pharmaceutical Form: Oromucosal spray<br>CAS Number: 15809-19-5<br>Other descriptive name: MIRAMISTIN<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 0,05-<br>Pharmaceutical form of the placebo: Oromucosal spray<br>Route of administration of the placebo: Oropharyngeal use<br><br>Product Name: Myramistin 0.01%<br>Pharmaceutical Form: Oromucosal spray<br>CAS Number: 15809-19-5<br>Other descriptive name: MIRAMISTIN<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 0,1-<br>Pharmaceutical form of the placebo: Oromucosal spray<br>Route of administration of the placebo: Oropharyngeal use<br><br>Product Name: Myramistin 0.02%<br>Pharmaceutical Form: Oromucosal spray<br>CAS Number: 15809-19-5<br>Other descriptive name: MIRAMISTIN<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 0,2-<br>Pharmaceutical form of the placebo: Oromucosal spray<br>Route of administration of the placebo: Oropharyngeal use<br><br>",NA,NA,NA
main,EUCTR2018-002573-21-LV,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002573-21,<br>Product Name: PF-04965842<br>Product Code: PF-04965842<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: PF-04965842<br>Current Sponsor code: PF-04965842<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Dupixent®<br>Product Name: Dupixent<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: DUPILUMAB<br>Other descriptive name: DUPILUMAB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 150-<br>Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>Route of administration of the placebo: Subcutaneous use<br><br>Trade Name: Dupixent®<br>Product Name: Dupixent<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: DUPILUMAB<br>Other descriptive name: DUPILUMAB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 150-<br>Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
main,EUCTR2018-002574-52-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002574-52,"<br>Product Name: Bimatoprost Sustained Release (SR), Implant<br>Product Code: AGN-192024<br>Pharmaceutical Form: Implant<br>INN or Proposed INN: BIMATOPROST<br>CAS Number: 155206-00-1<br>Current Sponsor code: AGN-192024<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 10-<br><br>",NA,NA,NA
main,EUCTR2018-002575-17-SK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002575-17,"<br>                Trade Name: Ocaliva 10mg<br>                Product Name: Obeticholic Acid<br>                Product Code: INT-747, OCA<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: obeticholic acid<br>                CAS Number: 459789-99-2<br>                Current Sponsor code: 6-ECDCA<br>                Other descriptive name: 6 alpha-ethylchenodeoxycholic acid (6-EDCA), OCA, INT-747<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 10-<br><br>                Trade Name: Ocaliva 5mg<br>                Product Name: Obeticholic Acid<br>                Product Code: INT-747, OCA<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: obeticholic acid<br>                CAS Number: 459789-99-2<br>                Current Sponsor code: 6-ECDCA<br>                Other descriptive name: 6 alpha-ethylchenodeoxycholic acid (6-EDCA), OCA, INT-747<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 5-<br><br>                Trade Name: Bezalip<br>                Product Name: Bezafibrate IR<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: BEZAFIBRATE<br>                CAS Number: 41859-67-0<br>                Other descriptive name: Bezafibrate, Beza, BZF, Bezalip<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 200-<br>                Pharmaceutical form of the placebo: Tablet<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: Bezalip mono<br>                Product Name: Bezafibrate SR<br>                Pharmaceutical F",NA,NA,NA
main,EUCTR2018-002623-42-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002623-42,<br>                Trade Name: Opsumit (macitentan)<br>                Pharmaceutical Form: Film-coated tablet<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
im,EUCTR2018-002686-19-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002686-19,"<br>Trade Name: RoActemra<br>Product Name: RoActemra<br>Product Code: EU/1/08/492/006<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Tocilizumab, RoActemra<br>CAS Number: 375823-41-9<br>Other descriptive name: TOCILIZUMAB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Infusion<br>Route of administration of the placebo: Intravenous drip use (Noncurrent)<br><br>",NA,Yes,NA
main,EUCTR2018-002747-29-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002747-29,<br>                Product Name: Eslicarbazepine Acetate<br>                Product Code: BIA 2-093<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: ESLICARBAZEPINE ACETATE<br>                CAS Number: 236395-14-5<br>                Current Sponsor code: BIA 2-093<br>                Other descriptive name: ESLICARBAZEPINE ACETATE<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 800-<br>                Pharmaceutical form of the placebo: Tablet<br>                Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
main,EUCTR2018-002757-30-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002757-30,"<br>Product Name: iscalimab<br>Product Code: CFZ533<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: iscalimab<br>Current Sponsor code: CFZ533<br>Other descriptive name: CFZ533<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 150-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Subcutaneous use<br><br>Product Name: LYS006<br>Product Code: LYS006<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: Not yet established<br>Current Sponsor code: LYS006<br>Other descriptive name: LYS006<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 5-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>",NA,Yes,NA
main,EUCTR2018-002800-16-SK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002800-16,<br>Trade Name: Zavicefta<br>Pharmaceutical Form: Powder for concentrate for solution for infusion<br>INN or Proposed INN: Ceftazidime pentahydrate<br>CAS Number: 78439-06-2<br>Current Sponsor code: CAZ<br>Other descriptive name: ceftazidime pentahydrate<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 2000-<br>INN or Proposed INN: Avibactam sodium<br>CAS Number: 1192491-61-4<br>Current Sponsor code: AVI<br>Other descriptive name: Avibactam sodium<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>,NA,NA,NA
im,EUCTR2018-002841-12-EE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002841-12,"<br>                Trade Name: Zavicefta<br>                Pharmaceutical Form: Powder for concentrate for solution for infusion<br>                INN or Proposed INN: Ceftazidime pentahydrate<br>                CAS Number: 78439-06-2<br>                Current Sponsor code: CAZ<br>                Other descriptive name: CCI 20263BQ, 113/4 pentahydrate<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 2000-<br>                INN or Proposed INN: Avibactam sodium<br>                CAS Number: 1192491-61-4<br>                Current Sponsor code: AVI<br>                Other descriptive name: AVE1330, NXL104<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br><br>",NA,NA,NA
main,EUCTR2018-002880-25-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002880-25,<br>Product Name: Fitusiran<br>Product Code: SAR439774<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: fitusiran <br>CAS Number: 1609016-97-8<br>Current Sponsor code: SAR439774<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Fitusiran<br>Product Code: SAR439774<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: fitusiran <br>CAS Number: 1609016-97-8<br>Current Sponsor code: SAR439774<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 100-<br><br>,NA,NA,NA
main,EUCTR2018-002894-23-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002894-23,<br>                Product Name: Not yet available<br>                Product Code: INCB054828<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: pemigatinib<br>                CAS Number: 1513857-77-6<br>                Current Sponsor code: INCB054828<br>                Other descriptive name: INCB054828<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 4.5-<br>                INN or Proposed INN: pemigatinib<br>                CAS Number: 1513857-77-6<br>                Current Sponsor code: INCB054828<br>                Other descriptive name: INCB054828<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 9-<br>                INN or Proposed INN: pemigatinib<br>                CAS Number: 1513857-77-6<br>                Current Sponsor code: INCB054828<br>                Other descriptive name: INCB054828<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 13.5-<br><br>                Product Name: Gemcitabine<br>                Pharmaceutical Form: Powder for solution for infusion<br>                INN or Proposed INN: GEMCITABINE<br>                CAS Number: 122111-03-9<br>                Other descriptive name: GEMCITABINE HYDROCHLORIDE<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 200-<br>                INN or Proposed INN: GEMCITABINE<br>                CAS Number: 122111-03-9<br>                Other descriptive name: GEMCITABINE HYDROCHLORIDE<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 1-<br><br>                Product Name: Cisplatin<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: CISPLATIN<br>                CAS Number: 15663-,NA,NA,NA
main,EUCTR2018-002930-19-LT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002930-19,<br>Product Name: Xlucane (proposed Ranibizumab biosimilar)<br>Product Code: Xlucane<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: Ranibizumab<br>CAS Number: 347396-82-1<br>Current Sponsor code: Xlucane<br>Other descriptive name: RANIBIZUMAB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.5-<br><br>Trade Name: Lucentis®<br>Product Name: Lucentis®<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: Lucentis®<br>CAS Number: 347396-82-1<br>Other descriptive name: RANIBIZUMAB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.5-<br><br>,NA,Yes,NA
main,EUCTR2018-002941-12-AT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002941-12,"<br>Product Name: retifanlimab<br>Product Code: INCMGA00012<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Not Available<br>CAS Number: 2079108-44-2<br>Current Sponsor code: INCMGA00012<br>Other descriptive name: MGA012, retifanlimab<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 25-<br><br>Product Name: retifanlimab<br>Product Code: INCMGA00012<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Not Available<br>CAS Number: 2079108-44-2<br>Current Sponsor code: INCMGA00012<br>Other descriptive name: MGA012, retifanlimab<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 25-<br><br>",NA,Yes,NA
main,EUCTR2018-002982-20-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-002982-20,<br>Trade Name: Ferrous Fumarate Syrup<br>Product Name: Ferrous Fumarate Syrup<br>Product Code: Ferrous fumarate syrup<br>Pharmaceutical Form: Syrup<br>INN or Proposed INN: Ferrous fumarate<br>CAS Number: 141-01-5<br>Current Sponsor code: NA<br>Other descriptive name: NA<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 140mg-5ml<br><br>,NA,NA,NA
main,EUCTR2018-003146-17-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003146-17,"<br>                Product Name: Firibastat<br>                Product Code: QGC001<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: Firibastat<br>                CAS Number: 648927-86-0<br>                Current Sponsor code: QGC001<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 50-<br><br>                Product Name: Firibastat<br>                Product Code: QGC001<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: Firibastat<br>                CAS Number: 648927-86-0<br>                Current Sponsor code: QGC001<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 250-<br><br>                Trade Name: Triatec®<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: RAMIPRIL<br>                CAS Number: 87333-19-5<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 2.5-<br><br>",NA,NA,NA
main,EUCTR2018-003148-21-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003148-21,<br>                Trade Name: Botox<br>                Product Name: Botox<br>                Pharmaceutical Form: Powder for solution for injection<br>                INN or Proposed INN: Clostridium botulinum toxin type A<br>                CAS Number: 93384-43-1<br>                Other descriptive name: BOTULINUM TOXIN TYPE A<br>                Concentration unit: U unit(s)<br>                Concentration type: equal<br>                Concentration number: 50-<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Infiltration<br><br>,NA,NA,NA
im,EUCTR2018-003202-82-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003202-82,<br>                Product Name: imipenem/cilastatin/relebactam (IMI/REL)<br>                Product Code: MK-7655A<br>                Pharmaceutical Form: Powder for injection<br>                INN or Proposed INN: RELEBACTAM<br>                Current Sponsor code: MK-7655<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 250-<br>                INN or Proposed INN: CILASTATIN<br>                CAS Number: 82009-34-5<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br>                INN or Proposed INN: IMIPENEM<br>                CAS Number: 64221-86-9<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br><br>                Trade Name: Piperacillin/Tazobactam 4 /0.5 g<br>                Pharmaceutical Form: Powder for solution for infusion<br>                INN or Proposed INN: PIPERACILLIN<br>                Other descriptive name: PIPERACILLIN<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 4000-<br>                INN or Proposed INN: TAZOBACTAM<br>                Other descriptive name: TAZOBACTAM<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 500-<br><br>,NA,NA,NA
main,EUCTR2018-003265-34-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003265-34,<br>                Product Name: M7824<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: bintrafusp alfa (proposed INN)<br>                Current Sponsor code: MSB0011359C<br>                Other descriptive name: M7824<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 10-<br>                Pharmaceutical form of the placebo: Concentrate for solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>                Trade Name: IMFINZI 50 mg/mL concentrate for solution for infusion<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: DURVALUMAB<br>                Other descriptive name: IMFINZI<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 50-<br><br>,NA,Yes,NA
main,EUCTR2018-003291-12-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003291-12,<br>Product Code: SHP611<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: N/A<br>CAS Number: N/A<br>Current Sponsor code: SHP611<br>Other descriptive name: RECOMBINANT HUMAN ARYLSULFATASE A<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br><br>,NA,NA,NA
main,EUCTR2018-003346-17-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003346-17,<br>                Trade Name: Cisplatin<br>                Product Name: cisplatin<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: CISPLATIN<br>                CAS Number: 15663-27-1<br>                Concentration unit: mg/m2 milligram(s)/square meter<br>                Concentration type: equal<br>                Concentration number: 100-<br><br>,NA,NA,NA
main,EUCTR2018-003352-20-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003352-20,"<br>Trade Name: TECENTRIQ (1200 mg concentrate for solution for infusion)<br>Product Name: TECENTRIQ<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: ATEZOLIZUMAB<br>CAS Number: 1380723-44<br>Current Sponsor code: RO554-1267, MPDL3280A<br>Other descriptive name: TECENTRIQ<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 60-<br><br>Trade Name: Cotellic<br>Product Name: Cotellic<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Cobimetinib<br>Current Sponsor code: RO5514041<br>Other descriptive name: Cotellic<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br><br>Trade Name: Venetoclax/Venclyxto<br>Product Name: Venetoclax<br>Product Code: RO5537382<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: VENETOCLAX<br>CAS Number: 934660-93-2<br>Current Sponsor code: RO5537382<br>Other descriptive name: ABT-199, GDC-0199<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>",NA,Yes,NA
main,EUCTR2018-003459-39-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003459-39,"<br>                Product Name: AG-348 sulfate hydrate<br>                Product Code: AG-348<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: Mitapivat<br>                CAS Number: 2151847-10-6<br>                Current Sponsor code: AG-348 sulfate hydrate<br>                Other descriptive name: AGI-1480, AGX-0841, AG-348, AG-348 hemisulfate<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 5-<br><br>                Product Name: AG-348 sulfate hydrate<br>                Product Code: AG-348<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: Mitapivat<br>                CAS Number: 2151847-10-6<br>                Current Sponsor code: AG-348 sulfate hydrate<br>                Other descriptive name: AGI-1480, AGX-0841, AG-348, AG-348 hemisulfate<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 20-<br><br>                Product Name: AG-348 sulfate hydrate<br>                Product Code: AG-348<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: Mitapivat<br>                CAS Number: 2151847-10-6<br>                Current Sponsor code: AG-348 sulfate hydrate<br>                Other descriptive name: AGI-1480, AGX-0841, AG-348, AG-348 hemisulfate<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 50-<br><br>",NA,NA,NA
main,EUCTR2018-003653-16-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003653-16,<br>                Trade Name: Orencia<br>                Product Name: Orencia<br>                Product Code: NDC 0003-2187<br>                Pharmaceutical Form: Solution for injection in pre-filled syringe<br>                INN or Proposed INN: ABATACEPT<br>                CAS Number: 332348-12-6<br>                Current Sponsor code: L04AA24<br>                Other descriptive name: Orencia<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 125-<br><br>,NA,NA,NA
main,EUCTR2018-003706-88-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003706-88,<br>Product Name: 15-Valent Pneumococcal Conjugate Vaccine<br>Product Code: V114<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197<br>Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 1 CONJUGATED TO CRM197<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 2-<br>INN or Proposed INN: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197<br>Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3 CONJUGATED TO CRM197<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 2-<br>INN or Proposed INN: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 CONJUGATED TO CRM197<br>Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 4 CONJUGATED TO CRM197<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 2-<br>INN or Proposed INN: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 CONJUGATED TO CRM197<br>Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 5 CONJUGATED TO CRM197<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 2-<br>INN or Proposed INN: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A CONJUGATED TO CRM197<br>Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A CONJUGATED TO CRM197<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 2-<br>INN or Proposed INN: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B CONJUGATED TO CRM197<br>Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6B CONJUGATED TO CRM197<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 4-<br>INN or Proposed INN: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO CRM197<br>Other descriptive name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F CONJUGATED TO CRM197<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 2-<br>INN or Proposed INN: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9V CONJUGATED TO CRM197<br>Other,Yes,NA,NA
main,EUCTR2018-003707-19-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003707-19,<br>                Product Name: M7824<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: bintrafusp alfa<br>                Current Sponsor code: M7824<br>                Other descriptive name: MSB0011359C<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 10-<br><br>,NA,NA,NA
main,EUCTR2018-003712-45-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003712-45,<br>Product Code: INCB018424 PHOSPHATE CREAM 0.75%<br>Pharmaceutical Form: Cream<br>INN or Proposed INN: ruxolitinib (phosphate)<br>CAS Number: 1092939-17-7<br>Current Sponsor code: INCB018424 phosphate<br>Other descriptive name: RUXOLITINIB PHOSPHATE<br>Concentration unit: % (W/W) percent weight/weight<br>Concentration type: equal<br>Concentration number: 0.75-<br>Pharmaceutical form of the placebo: Cream<br>Route of administration of the placebo: Cutaneous use<br><br>Product Code: INCB018424 PHOSPHATE CREAM 1.5%<br>Pharmaceutical Form: Cream<br>INN or Proposed INN: ruxolitinib (phosphate)<br>CAS Number: 1092939-17-7<br>Current Sponsor code: INCB018424 phosphate<br>Other descriptive name: RUXOLITINIB PHOSPHATE<br>Concentration unit: % (W/W) percent weight/weight<br>Concentration type: equal<br>Concentration number: 1.5-<br>Pharmaceutical form of the placebo: Cream<br>Route of administration of the placebo: Cutaneous use<br><br>,NA,NA,NA
main,EUCTR2018-003804-37-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003804-37,"<br>                Product Name: PF-04965842<br>                Product Code: PF-04965842<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: PF-04965842<br>                Current Sponsor code: PF-04965842<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 100-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>                Trade Name: Boostrix<br>                Product Name: Boostrix<br>                Pharmaceutical Form: Suspension for injection<br>                INN or Proposed INN: Bordetella pertussis-Antigene<br>                Other descriptive name: PERTUSSIS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 8-<br>                INN or Proposed INN: Bordetella pertussis-Antigene<br>                Other descriptive name: PERTUSSIS FILAMENTOUS HAEMAGGLUTININ ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 8-<br>                INN or Proposed INN: Bordetella pertussis-Antigene<br>                Other descriptive name: PERTUSSIS PERTACTIN ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 2.5-<br>                INN or Proposed INN: Diphtheria toxoid<br>                Other descriptive name: DIPHTHERIA TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE<br>                Concentration unit: IU international unit(s)<br>                Concentration type: not less then<br>                Concentration number: 2-<br>                INN or Pro",NA,NA,NA
main,EUCTR2018-003824-35-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003824-35,"<br>Trade Name: KEYTRUDA (pembrolizumab, MK-3475)<br>Product Name: Pembrolizumab<br>Product Code: MK-3475<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: PEMBROLIZUMAB<br>CAS Number: 1374853-91-4<br>Current Sponsor code: MK-3475<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 25-<br><br>Product Name: Lenvatinib <br>Product Code: E7080<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: LENVATINIB MESILATE<br>CAS Number: 857890-39-2<br>Current Sponsor code: MK-7902<br>Other descriptive name: LENVATINIB MESILATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 4-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>Product Name: Pembrolizumab<br>Product Code: MK-3475<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: PEMBROLIZUMAB<br>CAS Number: 1374853-91-4<br>Current Sponsor code: MK-3475<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 25-<br><br>Product Name: Lenvatinib <br>Product Code: E7080<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: LENVATINIB MESILATE<br>CAS Number: 857890-39-2<br>Current Sponsor code: MK-7902<br>Other descriptive name: LENVATINIB MESILATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 1-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>",NA,Yes,NA
im,EUCTR2018-003865-32-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003865-32,<br>Trade Name: Cayston<br>Pharmaceutical Form: Inhalation solution<br>INN or Proposed INN: AZTREONAM LYSINE<br>CAS Number: 827611-49-4<br>Current Sponsor code: Cayston<br>Other descriptive name: AZTREONAM LYSINE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br><br>,NA,NA,NA
main,EUCTR2018-003891-11-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003891-11,"<br>                Product Name: [18F]PI-2620<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: [18F]PI-2620<br>                CAS Number: 2173353-61-0<br>                Other descriptive name: 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine<br>                Concentration unit: µg microgram(s)<br>                Concentration type: up to<br>                Concentration number: 50-<br><br>",NA,NA,NA
main,EUCTR2018-003956-19-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003956-19,<br>Product Name: Zilucoplan<br>Product Code: RA101495<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: ZILUCOPLAN<br>CAS Number: 1841136-73-9<br>Current Sponsor code: RA101495<br>Other descriptive name: Synthetic 15-amino-acid macrocyclic peptide acylated with a polyethyleneglycol palmitoylated linker<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 40-<br><br>,NA,NA,NA
main,EUCTR2018-003974-29-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003974-29,<br>                Trade Name: TAGRISSO<br>                Product Name: Osimertinib<br>                Product Code: AZD9291<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: Osimertinib<br>                CAS Number: 1421373-66-1<br>                Current Sponsor code: AZD9291 mesylate<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 40-<br><br>                Trade Name: TAGRISSO<br>                Product Name: Osimertinib<br>                Product Code: AZD9291<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: Osimertinib<br>                CAS Number: 1421373-66-1<br>                Current Sponsor code: AZD9291 mesylate<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 80-<br><br>                Product Name: Savolitinib<br>                Product Code: AZD6094<br>                Pharmaceutical Form: Coated tablet<br>                INN or Proposed INN: Savolitinib<br>                CAS Number: 1313725-88-0<br>                Current Sponsor code: AZD6094<br>                Other descriptive name: Savolitinib<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 100-<br><br>                Product Name: Savolitinib<br>                Product Code: AZD6094<br>                Pharmaceutical Form: Coated tablet<br>                INN or Proposed INN: Savolitinib<br>                CAS Number: 1313725-88-0<br>                Current Sponsor code: AZD6094<br>                Other descriptive name: SAVOLITINIB<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 200-<br><br>                Trade Name: Carboplatin<br>                Product Name: carboplatin 10 mg/mL intravenous infusion<br>                Pharmaceutical Form: Solution for infusion<br>,NA,NA,NA
main,EUCTR2018-003988-54-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003988-54,"<br>                Product Name: gadopiclenol<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: GADOPICLENOL<br>                CAS Number: 933983-75-6<br>                Current Sponsor code: P03277, G03277<br>                Concentration unit: mol/l mole(s)/litre<br>                Concentration type: equal<br>                Concentration number: 0.5-<br><br>                Trade Name: Gadovist 1.0mmol/ml<br>                Product Name: gadobutrol<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: gadobutrol<br>                CAS Number: 138071-82-6<br>                Other descriptive name: GADOBUTROL<br>                Concentration unit: mol/l mole(s)/litre<br>                Concentration type: equal<br>                Concentration number: 1-<br><br>",NA,NA,NA
main,EUCTR2018-004059-18-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004059-18,<br>Product Name: BAY 1753011 30mg<br>Product Code: BAY 1753011<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: N/A<br>CAS Number: N/A<br>Current Sponsor code: BAY 1753011<br>Other descriptive name: BAY1753011<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 30-<br>Pharmaceutical form of the placebo: Coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: BAY 1753011 5mg<br>Product Code: BAY 1753011<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: N/A<br>CAS Number: N/A<br>Current Sponsor code: BAY 1753011<br>Other descriptive name: BAY1753011<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 5-<br>Pharmaceutical form of the placebo: Coated tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Furorese® 40 mg Tabletten<br>Product Name: Furorese® 40 mg Tabletten<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: FUROSEMIDE<br>CAS Number: 54-31-9<br>Current Sponsor code: N/A<br>Other descriptive name: FUROSEMIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 40-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
main,EUCTR2018-004064-62-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004064-62,<br>Product Name: Olaptesed pegol<br>Product Code: NOX-A12<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: OLAPTESED PEGOL<br>CAS Number: 1390628-22-4<br>Current Sponsor code: NOX-A12<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 14.66-<br><br>,NA,NA,NA
main,EUCTR2018-004076-35-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004076-35,<br>                Product Name: Not yet available<br>                Product Code: INCB001158 25 mg<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: not yet available<br>                Current Sponsor code: INCB001158<br>                Other descriptive name: INCB001158<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 25-<br><br>                Product Name: Not available yet<br>                Product Code: INCB001158 100 mg<br>                Pharmaceutical Form: Tablet<br>                INN or Proposed INN: not yet available<br>                Current Sponsor code: INCB001158<br>                Other descriptive name: INCB001158<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 100-<br><br>                Product Name: Daratumumab SC<br>                Product Code: JNJ-54767414<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: DARATUMUMAB<br>                CAS Number: 945721-28-8<br>                Current Sponsor code: JNJ-54767414<br>                Other descriptive name: daratumumab SC<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 120-<br><br>,NA,Yes,NA
main,EUCTR2018-004114-17-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004114-17,<br>Product Name: VGX-3100<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: pGX3001<br>CAS Number: 1977487-95-8<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 3-<br>INN or Proposed INN: pGX3002<br>CAS Number: 1977488-08-6<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 3-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>,NA,NA,NA
main,EUCTR2018-004154-25-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004154-25,<br>Product Name: LCZ696 12.5 mg film-coated granules in capsule (4 x 3.125 mg film-coated granules)<br>Product Code: LCZ696<br>Pharmaceutical Form: Granules<br>INN or Proposed INN: sacubitril/valsartan<br>Other descriptive name: SACUBITRIL VALSARTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 12.5-<br><br>Trade Name: Entresto<br>Product Name: LCZ696 50 mg<br>Product Code: LCZ696<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: sacubitril/valsartan<br>Other descriptive name: SACUBITRIL VALSARTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>Trade Name: Entresto<br>Product Name: LCZ696 100 mg<br>Product Code: LCZ696<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: sacubitril/valsartan<br>Other descriptive name: SACUBITRIL VALSARTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Trade Name: Entresto<br>Product Name: LCZ696 200 mg<br>Product Code: LCZ696<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: sacubitril/valsartan<br>Other descriptive name: SACUBITRIL VALSARTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: LCZ696 31.25 mg film-coated granules in capsule (10 x 3.125 mg film-coated granules)<br>Product Code: LCZ696<br>Pharmaceutical Form: Granules<br>INN or Proposed INN: sacubitril/valsartan<br>Other descriptive name: SACUBITRIL VALSARTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 31.25-<br><br>,NA,NA,NA
main,EUCTR2018-004201-33-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004201-33,"<br>Product Name: Sacituzumab govitecan<br>Product Code: IMMU-132, hRS7-SN38<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: SACITUZUMAB GOVITECAN<br>CAS Number: 1491917-83-9<br>Current Sponsor code: Sacituzumab Govitecan<br>Other descriptive name: IMMU-132, hRS7-SN38<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 180-<br><br>Trade Name: Halaven<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: Eribulin<br>CAS Number: 441045-17-6<br>Other descriptive name: ERIBULIN MESYLATE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 0.44-<br><br>Trade Name: Xeloda<br>Product Name: Capecitabine<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Capecitabine<br>CAS Number: 154361-50-9<br>Other descriptive name: CAPECITABINE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Trade Name: Xeloda<br>Product Name: Capecitabine<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Capecitabine<br>CAS Number: 154361-50-9<br>Other descriptive name: CAPECITABINE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 150-<br><br>Trade Name: Gemzar<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: Gemcitabine hydrochloride<br>CAS Number: 122111-03-9<br>Other descriptive name: GEMCITABINE HYDROCHLORIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Trade Name: Gemzar<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: Gemcitabine hydrochloride<br>CAS Number: 122111-03-9<br>Other descriptive name: GEMCITABINE HYDROCHLORIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 1000-<br><br>Trade Name: Gemzar<br>Pharmaceutical Form: Powder for so",NA,Yes,NA
main,EUCTR2018-004223-36-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004223-36,<br>                Product Name: Dr. Reddy’s rituximab<br>                Product Code: DRL_RI<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: RITUXIMAB<br>                CAS Number: 174722-31-7<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 10-<br><br>                Trade Name: MabThera<br>                Product Name: MabThera<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: RITUXIMAB<br>                CAS Number: 174722-31-7<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 10-<br><br>,NA,Yes,NA
main,EUCTR2018-004237-32-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004237-32,<br>Product Name: JNJ-70033093<br>Product Code: JNJ-70033093<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: Not applicable<br>CAS Number: 1802425-99-5<br>Current Sponsor code: JNJ-70033093<br>Other descriptive name: BMS986177<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>Product Name: JNJ-70033093<br>Product Code: JNJ-70033093<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: Not applicable<br>CAS Number: 1802425-99-5<br>Current Sponsor code: JNJ-70033093<br>Other descriptive name: BMS986177<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Clexane<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: ENOXAPARIN SODIUM<br>CAS Number: 9041-08-1<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 40-<br><br>,NA,NA,NA
main,EUCTR2018-004241-16-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004241-16,<br>Product Name: PF-06700841<br>Product Code: PF-06700841 5mg<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: PF-06700841<br>Current Sponsor code: PF-06700841<br>Other descriptive name: PF-06700841-15<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 5-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: PF-06700841<br>Product Code: PF-06700841 25mg<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: PF-06700841<br>Current Sponsor code: PF-06700841<br>Other descriptive name: PF-06700841-15<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
main,EUCTR2018-004253-24-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004253-24,"<br>                Product Code: LNP023<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: Not yet established<br>                Current Sponsor code: LNP023<br>                Other descriptive name:  LNP023 HYDROCHLORIDE SALT<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 5-<br><br>                Product Code: LNP023<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: Not yet established<br>                Current Sponsor code: LNP023<br>                Other descriptive name:  LNP023 HYDROCHLORIDE SALT<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 25-<br><br>                Product Code: LNP023<br>                Pharmaceutical Form: Capsule, hard<br>                INN or Proposed INN: Not yet established<br>                Current Sponsor code: LNP023<br>                Other descriptive name:  LNP023 HYDROCHLORIDE SALT<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 100-<br><br>",NA,NA,NA
main,EUCTR2018-004280-32-IE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004280-32,"<br>Product Name: AG10<br>Product Code: AG10 HCl<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Acoramidis<br>CAS Number: 2242751-53-5<br>Other descriptive name: 3-(3-(3,5-DIMETHYL-1H-PYRAZOL-4-YL)PROPOXY)-4-FLUOROBENZOIC ACID<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
main,EUCTR2018-004305-11-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004305-11,<br>                Trade Name: Ventolin Injection 500 micrograms in 1ml<br>                Product Name: Ventolin Injection 500 micrograms in 1ml<br>                Pharmaceutical Form: Injection<br>                INN or Proposed INN: Salbutamol<br>                CAS Number: 18559-94-9<br>                Current Sponsor code: n/a<br>                Other descriptive name: n/a<br>                Concentration unit: µg/ml microgram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 500-<br>                Pharmaceutical form of the placebo: Injection<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2018-004318-16-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004318-16,<br>Product Code: DAS181<br>Pharmaceutical Form: Inhalation solution<br>INN or Proposed INN: Farbefusp<br>Current Sponsor code: DAS181<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 4.5-<br>Pharmaceutical form of the placebo: Inhalation solution<br>Route of administration of the placebo: Inhalation use<br><br>,NA,NA,NA
main,EUCTR2018-004320-11-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004320-11,<br>                Trade Name: KEYTRUDA®<br>                Product Name: Pembrolizumab<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: PEMBROLIZUMAB<br>                CAS Number: 1374853-91-4<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 25-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>                Product Name: Pembrolizumab<br>                Product Code: MK-3475<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: PEMBROLIZUMAB<br>                CAS Number: 1374853-91-4<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 25-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,Yes,NA
main,EUCTR2018-004331-71-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004331-71,<br>Product Name: N-Acetyl-L-Leucine<br>Product Code: IB1001<br>Pharmaceutical Form: Powder for oral suspension<br>INN or Proposed INN: N-Acetyl-L-leucine<br>Other descriptive name: 2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>Product Name: N-Acetyl-L-Leucine<br>Product Code: IB1001<br>Pharmaceutical Form: Granules for oral suspension in sachet<br>INN or Proposed INN: N-Acetyl-L-leucine<br>Other descriptive name: 2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>,NA,NA,NA
main,EUCTR2018-004378-92-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004378-92,<br>                Trade Name: Sativex<br>                Product Name: Sativex<br>                Pharmaceutical Form: Oromucosal spray<br>                INN or Proposed INN: dronabinol<br>                CAS Number: 1972-08-3<br>                Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 2.7-<br>                INN or Proposed INN: Cannabidiol<br>                CAS Number: 13956-29-1<br>                Other descriptive name: CANNABIDIOL<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 2.5-<br><br>,NA,Yes,NA
main,EUCTR2018-004393-10-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004393-10,<br>Product Name: Zibotentan<br>Product Code: ZD4054<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Zibotentan<br>CAS Number: 186497-07-4<br>Current Sponsor code: Not applicable<br>Other descriptive name: Not applicable<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
main,EUCTR2018-004539-54-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004539-54,"<br>Trade Name: Xeljanz<br>Pharmaceutical Form: Film-coated tablet<br><br>Trade Name: Enbrel<br>Pharmaceutical Form: Injection<br><br>Trade Name: Celebrex<br>Pharmaceutical Form: Capsule, hard<br><br>",NA,NA,NA
main,EUCTR2018-004553-25-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004553-25,<br>Product Name: Iscalimab<br>Product Code: CFZ533<br>Pharmaceutical Form: Concentrate for solution for injection/infusion<br>INN or Proposed INN: iscalimab<br>Current Sponsor code: CFZ533<br>Other descriptive name: CFZ533<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 150-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,Yes,NA
main,EUCTR2018-004565-14-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004565-14,<br>Trade Name: Repatha 140 mg solution for injection in pre-filled pen<br>Product Name: Evolocumab<br>Product Code: AMG145<br>Pharmaceutical Form: Solution for injection in pre-filled pen<br>INN or Proposed INN: EVOLOCUMAB<br>Current Sponsor code: AMG 145<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 140-<br>Pharmaceutical form of the placebo: Solution for injection in pre-filled pen<br>Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
main,EUCTR2018-004575-12-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004575-12,<br>                Trade Name: Olaparib<br>                Product Name: Olaparib<br>                Product Code: AZD2281<br>                Pharmaceutical Form: Film-coated tablet<br><br>                Trade Name: IMFINZI<br>                Product Name: Durvalumab<br>                Pharmaceutical Form: Solution for infusion<br><br>,NA,Yes,NA
main,EUCTR2018-004581-34-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004581-34,"<br>                Trade Name: Hexyon®<br>                Product Name: Hexyon<br>                Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>                INN or Proposed INN: Hexyon<br>                Other descriptive name: DIPHTHERIA, TETANUS, PERTUSSIS (ACELLULAR, COMPONENT), HEPATITIS B (RDNA), POLIOMYELITIS (INACT.) AND HAEMOPHILUS TYPE B CONJUGATE VACCINE (ADSORBED)<br>                Concentration unit: U unit(s)<br>                Concentration type: range<br>                Concentration number: 20-40<br><br>",Yes,NA,NA
main,EUCTR2018-004654-17-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004654-17,<br>                Trade Name: Tecentriq<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: ATEZOLIZUMAB<br>                Current Sponsor code: RO5541267<br>                Other descriptive name: Tecentriq<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 60-<br><br>                Trade Name: Avastin<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: BEVACIZUMAB<br>                CAS Number: 216974-75-3<br>                Other descriptive name: Avastin<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 25-<br><br>,NA,Yes,NA
main,EUCTR2018-004662-33-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004662-33,<br>                Trade Name: Gardasil 9™<br>                Product Name: Gardasil 9™<br>                Product Code: V503<br>                Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>                INN or Proposed INN: Human Papillomavirus Type 6 L1 protein<br>                Other descriptive name: Vaccine<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 30-<br>                INN or Proposed INN: Human Papillomavirus Type 11 L1 protein<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 40-<br>                INN or Proposed INN: Human Papillomavirus Type 16 L1 protein<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 60-<br>                INN or Proposed INN: Human Papillomavirus Type 18 L1 protein<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 40-<br>                INN or Proposed INN: Human Papillomavirus Type 31 L1 protein<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 20-<br>                INN or Proposed INN: Human Papillomavirus Type 33 L1 protein<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 20-<br>                INN or Proposed INN: Human Papillomavirus Type 45 L1 protein<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 20-<br>                INN or Proposed INN: Human Papillomavirus Type 52 L1 protein<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 20-<br>                INN or Proposed INN: Human Papi,Yes,NA,NA
im,EUCTR2018-004704-19-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004704-19,<br>                Trade Name: Zerbaxa<br>                Pharmaceutical Form: Powder for solution for infusion<br>                INN or Proposed INN: Ceftolozane<br>                CAS Number: 936111-69-2<br>                Current Sponsor code: MK7625A<br>                Other descriptive name: CEFTOLOZANE SULFATE<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 1-<br>                INN or Proposed INN: Tazobactam<br>                CAS Number: 89785-84-2<br>                Current Sponsor code: MK7625A<br>                Other descriptive name: TAZOBACTAM SODIUM<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 0.5-<br><br>,NA,NA,NA
main,EUCTR2018-004767-31-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004767-31,"<br>Product Name: CC-92480 0.1 mg<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: Cereblon-modifying (CM) agent<br>CAS Number: 2259648-80-9<br>Current Sponsor code: CC-92480<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.1-<br><br>Product Name: CC-92480 0.5 mg<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: Cereblon-modifying (CM) agent<br>CAS Number: 2259648-80-9<br>Current Sponsor code: CC-92480<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.5-<br><br>Product Name: CC-92480 2 mg<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: Cereblon-modifying (CM) agent<br>CAS Number: 2259648-80-9<br>Current Sponsor code: CC-92480<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 2-<br><br>Trade Name: VELCADE 3.5 mg powder for solution for injection<br><br>Pharmaceutical Form: Powder for solution for injection<br>INN or Proposed INN: BORTEZOMIB<br>CAS Number: 179324-69-7<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 3.5-<br><br>Trade Name: DARZALEX 20 mg/mL concentrate for solution for infusion.<br>Product Name: DARZALEX 20 mg/mL concentrate for solution for infusion.<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: DARATUMUMAB<br>CAS Number: 945721-28-8<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br><br>Trade Name: Kyprolis 60 mg powder for solution for infusion<br>Product Name: carfilzomib<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: Carfilzomib<br>CAS Number: 868540-17-4<br>Other descriptive name: CARFILZOMIB<br>Concentration unit: millilitre(s)/gram<br>Concentration type: equal<br>Concentration number: 60-<br><br>Trade Name: Dexamethasone 2mg Tablets<br><br>Product Name: Dexamethasone<br>",NA,Yes,NA
im,EUCTR2018-004827-36-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004827-36,<br>Product Name: Nangibotide<br>Pharmaceutical Form: Lyophilisate for solution for infusion<br>INN or Proposed INN: Nangibotide<br>CAS Number: 2014384-91-7<br>Other descriptive name: LR12<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br>Pharmaceutical form of the placebo: Lyophilisate and solvent for solution for injection<br>Route of administration of the placebo: Intravenous use<br><br>Product Name: Nangibotide<br>Pharmaceutical Form: Lyophilisate for solution for infusion<br>INN or Proposed INN: Nangibotide<br>CAS Number: 2014384-91-7<br>Other descriptive name: LR12<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 1200-<br>Pharmaceutical form of the placebo: Lyophilisate and solvent for solution for injection<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
main,EUCTR2018-004837-34-AT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004837-34,<br>Product Name: Pegzilarginase<br>Product Code: AEB1102<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: PEGZILARGINASE<br>CAS Number: 1659310-95-8<br>Current Sponsor code: AEB1102<br>Other descriptive name: Co-Arg1-PEG<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>Product Name: Pegzilarginase<br>Product Code: AEB1102<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: Pegzilarginase<br>CAS Number: 1659310-95-8<br>Current Sponsor code: AEB1102<br>Other descriptive name: Co-Arg1-PEG<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>,NA,NA,NA
main,EUCTR2018-004889-34-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004889-34,<br>Product Name: Concizumab C 100 mg/mL PDS290<br>Pharmaceutical Form: Solution for injection in pre-filled pen<br>INN or Proposed INN: concizumab<br>Other descriptive name: CONCIZUMAB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: Concizumab C 40 mg/mL PDS290<br>Pharmaceutical Form: Solution for injection in pre-filled pen<br>INN or Proposed INN: concizumab<br>Other descriptive name: CONCIZUMAB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 40-<br><br>,NA,Yes,NA
main,EUCTR2018-004926-26-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004926-26,<br>                Product Name: Teplizumab<br>                Product Code: PRV-031<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: Teplizumab<br>                CAS Number: 876387-05-2<br>                Current Sponsor code: PRV-031<br>                Other descriptive name: TEPLIZUMAB<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: range<br>                Concentration number: 1.0-<br>                Pharmaceutical form of the placebo: Concentrate for solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,Yes,NA
main,EUCTR2018-005030-38-BG,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-005030-38,<br>                Trade Name: Veltassa®<br>                Product Name: Patiromer<br>                Product Code:  RLY5016<br>                Pharmaceutical Form: Oral suspension<br>                INN or Proposed INN: Patiromer for oral suspension<br>                Current Sponsor code: RLY5016<br>                Other descriptive name: PATIROMER<br>                Concentration unit: g gram(s)<br>                Concentration type: equal<br>                Concentration number: 8.4-<br>                Pharmaceutical form of the placebo: Oral suspension<br>                Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
main,EUCTR2019-000064-21-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000064-21,<br>Trade Name: Fabrazyme<br>Pharmaceutical Form: Powder for concentrate for solution for infusion<br>INN or Proposed INN: AGALSIDASE BETA<br>Current Sponsor code: GZ419828<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Trade Name: Replagal<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: AGALSIDASE ALFA<br>CAS Number: 104138-64-9<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1-<br><br>,NA,NA,NA
main,EUCTR2019-000114-11-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000114-11,<br>Product Code: MEDI8897<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: nirsevimab<br>CAS Number: 1989556-22-0<br>Current Sponsor code: MEDI8897<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>,NA,Yes,NA
main,EUCTR2019-000262-38-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000262-38,"<br>Trade Name: OPDIVO 10 mg/mL concentrate for solution for infusion.<br>Product Name: NIVOLUMAB - 10ml vial - COMMERCIAL<br>Product Code: BMS-936558<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: NIVOLUMAB<br>CAS Number: 946414-94-4<br>Current Sponsor code: BMS-936558<br>Other descriptive name: BMS936558<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intravenous use<br><br>Trade Name: PARAPLATIN 450 mg/45 ml solution for infusion<br>Product Name: Carboplatin<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: Carboplatin<br>Other descriptive name: CARBOPLATIN<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: CARBO-cell® 10 mg/ml solution for infusion, concentrate for solution for infusion<br>Product Name: Carboplatin<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: Carboplatin<br>Other descriptive name: CARBOPLATIN<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: Carboplatin Aurobindo 10 mg/ml concentrate for solution for infusion<br>Product Name: Carboplatin<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: Carboplatin<br>Other descriptive name: CARBOPLATIN<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Trade Name: Cisplatin NeoCorp® 1 mg/ml – Concentrate for solution for infusion<br>Product Name: Cisplatin<br>Pharmaceutical Form: Concentrate for s",NA,Yes,NA
main,EUCTR2019-000337-39-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000337-39,<br>Product Name: Eteplirsen<br>Product Code: AVI-4658<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: ETEPLIRSEN<br>CAS Number: 1173755-55-9<br>Current Sponsor code: AVI-4658<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 50-<br><br>,NA,NA,NA
im,EUCTR2019-000404-15-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000404-15,"<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Amoxicillin<br>Other descriptive name: AMOXICILLIN TRIHYDRATE<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Ampicillin<br>Other descriptive name: AMPICILLIN TRIHYDRATE<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>Pharmaceutical Form: Infusion<br>INN or Proposed INN: Ampicillin<br>Other descriptive name: AMPICILLIN SODIUM<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Phenoxymethylpenicillin<br>CAS Number: 132-98-9<br>Other descriptive name: PHENOXYMETHYLPENICILLIN POTASSIUM<br>Concentration unit: g gram(s)<br>Concentration type: range<br>Concentration number: 0,6-1,2<br><br>Pharmaceutical Form: Infusion<br>INN or Proposed INN: Benzylpenicillin<br>CAS Number: 69-57-8<br>Other descriptive name: BENZYLPENICILLIN SODIUM<br>Concentration unit: g gram(s)<br>Concentration type: range<br>Concentration number: 0,6-1,2<br><br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Amoxicillin<br>Other descriptive name: AMOXICILLIN TRIHYDRATE<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 0,5-<br>INN or Proposed INN: Clavulanic acid<br>CAS Number: 58001-44-8<br>Other descriptive name: CLAVULANIC ACID<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 0,125-<br><br>Pharmaceutical Form: Infusion<br>INN or Proposed INN: Piperacillin<br>Other descriptive name: PIPERACILLIN SODIUM<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 4-<br>INN or Proposed INN: Tazobactam<br>Other descriptive name: TAZOBACTAM SODIUM<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 0,5-<br><br>Pharmaceutical Form: Tablet<br>INN or Proposed INN:",NA,NA,NA
main,EUCTR2019-000586-20-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000586-20,<br>Product Name: Doravirine/Islatravir<br>Product Code: MK-8591A<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: DORAVIRINE<br>Current Sponsor code: MK-1439<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>INN or Proposed INN: MK-8591<br>Current Sponsor code: MK-8591<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.75-<br><br>Trade Name: NEVIRAPINA<br>Product Name: NEVIRAPINA<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: NEVIRAPINE<br>CAS Number: 129618-40-2<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Trade Name: Abacavir/Lamivudina<br>Product Name: ABACAVIR/LAMIVUDINA<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: ABACAVIR<br>CAS Number: 136470-78-5<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 600-<br>INN or Proposed INN: LAMIVUDINE<br>CAS Number: 134678-17-4<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br><br>Trade Name: TENOFOVIR DISOPROXILO FUMARATO/EFAVIRENZ/EMTRICITABINA<br>Product Name: TENOFOVIR DISOPROXILO FUMARATO/EFAVIRENZ/EMTRICITABINA<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: EFAVIRENZ<br>Other descriptive name: EFAVIRENZ<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 600-<br>INN or Proposed INN: EMTRICITABINE<br>CAS Number: 143491-57-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>INN or Proposed INN: TENOFOVIR DISOPROXIL FUMARATE<br>CAS Number: 202138-50-9<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 245-<br><br>Trade Name: BICTEGRAVIR SODIO/EMTRICITABINA/TENOFOVIR ALAFENAMIDA FUMARATO<br>Product Name: BICTEGRAVIR SODIO/EMTRICITABINA/TENOFO,NA,Yes,NA
main,EUCTR2019-000587-23-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000587-23,<br>Product Name: Doravirine/Islatravir<br>Product Code: MK-8591A<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: DORAVIRINE<br>Current Sponsor code: MK-1439<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>INN or Proposed INN: MK-8591<br>Current Sponsor code: MK-8591<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.75-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide)<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: BICTEGRAVIR<br>CAS Number: 1611493-60-7<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>INN or Proposed INN: EMTRICITABINE<br>CAS Number: 143491-57-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>INN or Proposed INN: TENOFOVIR ALAFENAMIDE<br>CAS Number: 379270-37-8<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide)<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: BICTEGRAVIR<br>CAS Number: 1611493-60-7<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>INN or Proposed INN: EMTRICITABINE<br>CAS Number: 143491-57-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>INN or Proposed INN: TENOFOVIR ALAFENAMIDE<br>CAS Number: 379270-37-8<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br>,NA,Yes,NA
main,EUCTR2019-000591-42-LT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000591-42,<br>Product Name: ISIS 766720<br>Product Code: ISIS 766720<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: not available yet<br>CAS Number: 2131025-83-5<br>Current Sponsor code: ISIS 766720<br>Other descriptive name: ISIS 766720<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 100-<br><br>,NA,NA,NA
main,EUCTR2019-000599-40-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000599-40,<br>Product Name: KH176 <br>Product Code: KH176 <br>Pharmaceutical Form: Powder for oral solution<br>INN or Proposed INN: KH176<br>Other descriptive name: KH176<br>Concentration unit: Bq/mg becquerel(s)/milligram<br>Concentration type: range<br>Concentration number: 50-100<br>Pharmaceutical form of the placebo: Oral solution<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
main,EUCTR2019-000612-29-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000612-29,<br>                Product Name: BMS-986165<br>                Product Code: BMS-986165<br>                Pharmaceutical Form: Film-coated tablet<br>                CAS Number: 1609392-28-0<br>                Current Sponsor code: BMS986165<br>                Other descriptive name: BMS986165<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 6-<br><br>,NA,NA,NA
main,EUCTR2019-000648-86-CZ,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000648-86,"<br>Product Name: OptiNose Fluticasone<br>Product Code: OPN-375<br>Pharmaceutical Form: Nasal spray, suspension<br>INN or Proposed INN: Fluticasone propionate<br>CAS Number: 80474-14-2<br>Current Sponsor code: OPN-375<br>Other descriptive name: FLUTICASONE PROPIONATE<br>Concentration unit: % (W/W) percent weight/weight<br>Concentration type: equal<br>Concentration number: 0.09-<br>Pharmaceutical form of the placebo: Nasal spray, suspension<br>Route of administration of the placebo: Intranasal use (Noncurrent)<br><br>",NA,NA,NA
im,EUCTR2019-000655-14-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000655-14,"<br>Product Name: quadrivalent influenza vaccine <br>Product Code: 522<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Other descriptive name: A/H1N1-like strain<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 60-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Other descriptive name: A/H3N2 -like strain<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 60-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Other descriptive name: B/Victoria Lineage <br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 60-<br>INN or Proposed INN: INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED)<br>Other descriptive name: B/Yamagata Lineage <br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 60-<br><br>Trade Name: Influvac Tetra <br>Product Name: Influvac Tetra <br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: INFLUENZA VACCINE (SURFACE ANTIGEN, INACTIVATED)<br>Other descriptive name: A/H1N1-like strain<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: INFLUENZA VACCINE (SURFACE ANTIGEN, INACTIVATED)<br>Other descriptive name: A/H3N2-like strain<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: INFLUENZA VACCINE (SURFACE ANTIGEN, INACTIVATED)<br>Other descriptive name: B/Victoria Lineage <br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 15-<br>INN or Proposed INN: INFLUENZA VACCINE (SURFACE ANTIGEN, INACTIVATED)<br>Other descripti",Yes,NA,NA
main,EUCTR2019-000716-28-SE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000716-28,<br>Trade Name: BEOVU<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: BROLUCIZUMAB<br>CAS Number: 1531589-13-5<br>Current Sponsor code: RTH258 / ESBA1008<br>Other descriptive name: Anti-VEGF monoclonal antibody<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 120-<br><br>Trade Name: Eylea<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: aflibercept<br>CAS Number: 862111-32-8<br>Other descriptive name: AFLIBERCEPT<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 40-<br><br>,NA,Yes,NA
main,EUCTR2019-000720-17-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000720-17,<br>Product Name: M281<br>Product Code: M281<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: N/A<br>CAS Number: 2211985-36-1<br>Current Sponsor code: M281<br>Other descriptive name: M281<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 30-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
main,EUCTR2019-000756-34-SE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000756-34,<br>                Trade Name: phenoxymethylpenicillin/Kåvepenin/Avopenin/Ticacillin<br>                Product Name: phenoxymethylpenicillin<br>                Product Code: J01 CE 02<br>                Pharmaceutical Form: Film-coated tablet<br><br>,NA,NA,NA
main,EUCTR2019-000794-23-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000794-23,<br>                Trade Name: XARELTO® 20 mg<br>                Product Name: Xarelto® 20mg (Rivaroxaban)<br>                Pharmaceutical Form: Coated tablet<br><br>                Trade Name: COUMADINE®<br>                Product Name: COUMADINE® (warfarine)<br>                Pharmaceutical Form: Tablet<br><br>,NA,NA,NA
main,EUCTR2019-000810-12-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000810-12,<br>Product Name: ipatasertib 100 mg<br>Product Code: RO5532961<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: IPATASERTIB<br>Current Sponsor code: RO5532961<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: ipatasertib 200 mg<br>Product Code: RO5532961<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: IPATASERTIB<br>Current Sponsor code: RO5532961<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: atezolizumab<br>Product Code: RO5541267<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: ATEZOLIZUMAB<br>Other descriptive name: atezolizumab<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 60-<br>Pharmaceutical form of the placebo: Concentrate for solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>Trade Name: Paclitaxin<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: PACLITAXEL<br>CAS Number: 33069-62-4<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 6-<br><br>Trade Name: Paclitaxel<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: PACLITAXEL<br>CAS Number: 33069-62-4<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 6-<br><br>Trade Name: Sindaxel<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: PACLITAXEL<br>CAS Number: 33069-62-4<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentrat,NA,Yes,NA
main,EUCTR2019-000904-14-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000904-14,<br>Product Name: Risankizumab<br>Product Code: ABBV-066<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: RISANKIZUMAB<br>CAS Number: 1612838-76-2<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br><br>,NA,Yes,NA
main,EUCTR2019-000942-36-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000942-36,"<br>Trade Name: Vimpat 100 mg film coated tablets<br>Product Name: lacosamide <br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: LACOSAMIDE<br>CAS Number: 175481-36-4 <br>Other descriptive name: Lacosamide<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Lyrica 75 mg hard capsules<br>Product Name: Pregabalin<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: pregabalin<br>CAS Number: 148553-50-8<br>Other descriptive name: PREGABALIN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Palexia 50 mg film-coated tablets<br>Product Name: Tapentadol<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Tapentadol hydrocloride<br>CAS Number: 175591-09-0<br>Other descriptive name: TAPENTADOL HYDROCHLORIDE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
main,EUCTR2019-001003-20-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001003-20,<br>                Product Name: AFM13<br>                Product Code: AFM13<br>                Pharmaceutical Form: Powder for solution for infusion<br>                INN or Proposed INN: Not applicable<br>                Current Sponsor code: AFM13<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 10-<br><br>,NA,NA,NA
main,EUCTR2019-001147-51-SE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001147-51,"<br>Trade Name: Ventoline tablet 2mg<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: SALBUTAMOL SULFATE<br>CAS Number: 51022-70-9<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 6-12<br><br>Trade Name: Ventoline oral solution 0,4mg/ml<br>Pharmaceutical Form: Oral solution<br>INN or Proposed INN: SALBUTAMOL SULFATE<br>CAS Number: 51022-70-9<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 6-12<br><br>",NA,NA,NA
im,EUCTR2019-001186-33-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001186-33,"<br>                Trade Name: Fluarix tetra<br>                Product Name: Fluarix Tetra<br>                Pharmaceutical Form: Injection<br>                INN or Proposed INN: A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180)<br>                Other descriptive name: A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE STRAIN (A/SINGAPORE/GP1908/2015, IVR-180)<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 15-<br>                INN or Proposed INN: A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104)<br>                Other descriptive name: A/SINGAPORE/INFIMH-16-0019/2016 (H3N2)-LIKE STRAIN (A/SINGAPORE/INFIMH-16-0019/2016, NIB-104)<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 15-<br>                INN or Proposed INN: B/COLORADO/06/2017-LIKE STRAIN (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)<br>                Other descriptive name: B/COLORADO/06/2017-LIKE STRAIN (B/VICTORIA/2/87 LINEAGE) (B/MARYLAND/15/2016, NYMC BX-69A)<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 15-<br>                INN or Proposed INN: B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, WILD TYPE)<br>                Other descriptive name: B/PHUKET/3073/2013-LIKE STRAIN (B/PHUKET/3073/2013, WILD TYPE)<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 15-<br><br>                Trade Name: Havrix 720<br>                Pharmaceutical Form: Injection<br>                INN or Proposed INN: HEPATITIS A VIRUS ANTIGEN (INACTIVATED)<br>                Other descriptive name: HEPATITIS A VIRUS ANTIGEN (INACTIVATED)<br>                Concentration unit: ELISA unit enzyme-linked immunosorbent assay unit<br>                Concentration ty",Yes,NA,NA
main,EUCTR2019-001219-22-IE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001219-22,<br>                Product Name: Tisotumab vedotin<br>                Product Code: HuMax-TF-ADC<br>                Pharmaceutical Form: Powder for concentrate for solution for infusion<br>                INN or Proposed INN: TISOTUMAB VEDOTIN<br>                CAS Number: 1418628-81-5<br>                Other descriptive name: HuMax-TF-ADC<br>                Concentration unit: mg/kg milligram(s)/kilogram<br>                Concentration type: equal<br>                Concentration number: 90-<br><br>                Product Name: Tisotumab vedotin<br>                Product Code: HuMax-TF-ADC<br>                Pharmaceutical Form: Powder for concentrate for solution for infusion<br>                INN or Proposed INN: TISOTUMAB VEDOTIN<br>                CAS Number: 1418628-81-5<br>                Other descriptive name: HuMax-TF-ADC<br>                Concentration unit: mg/kg milligram(s)/kilogram<br>                Concentration type: equal<br>                Concentration number: 200-<br><br>,NA,Yes,NA
main,EUCTR2019-001230-34-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001230-34,"<br>Trade Name: Opdivo (100 mg/10 ml)<br>Product Name: NIVOLUMAB - 10ml vial-COMMERCIAL<br>Product Code: BMS-936558<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: NIVOLUMAB<br>CAS Number: 946414-94-4<br>Current Sponsor code: BMS-936558<br>Other descriptive name: MDX1106, ONO-4538<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intravenous use<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intravenous use<br><br>Trade Name: Opdivo (40 mg/4 ml)<br>Product Name: Nivolumab-4 ml vial-COMMERCIAL<br>Product Code: BMS-936558<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: NIVOLUMAB<br>CAS Number: 946414-94-4<br>Current Sponsor code: BMS-936558<br>Other descriptive name: MDX1106, ONO-4538<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intravenous use<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intravenous use<br><br>",NA,Yes,NA
main,EUCTR2019-001285-15-SI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001285-15,<br>Trade Name: kangrelor 50 mg (Kangrexal)<br>Product Name: Kangrexal<br>Product Code: 1045926<br>Pharmaceutical Form: Powder for concentrate for solution for injection/infusion<br><br>,NA,NA,NA
main,EUCTR2019-001399-13-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001399-13,<br>                Trade Name: Mekinist<br>                Product Name: Trametinib<br>                Pharmaceutical Form: Tablet<br><br>                Trade Name: Plaquenil<br>                Product Name: Sulfate d'hydroxychloroquine<br>                Pharmaceutical Form: Tablet<br><br>,NA,Yes,NA
main,EUCTR2019-001562-15-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001562-15,"<br>                Trade Name: Lutathera 370 MBq/mL solution for infusion<br>                Product Name: Lutathera 370 MBq/mL solution for infusion<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: LUTETIUM (177LU) OXODOTREOTIDE<br>                CAS Number: 437608-50-9<br>                Other descriptive name: 177Lu-DOTA0-Tyr3-Octreotate, lutetium Lu 177 dotatate<br>                Concentration unit: MBq/ml megabecquerel(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 370-<br><br>                Trade Name: Sandostatin® LAR® 10 mg powder and solvent for suspension for injection<br><br>                Sandostatin® LAR® 20 mg powder and solvent for suspension for injection<br><br>                Sandostatin® LAR® 30 mg powder and solvent for suspension for injection<br>                Product Name: Sandostatin® LAR® powder and solvent for suspension for injection<br>                Pharmaceutical Form: Powder and solvent for suspension for injection<br>                INN or Proposed INN: Octreotide<br>                CAS Number: 79517-01-4<br>                Other descriptive name: OCTREOTIDE ACETATE<br>                Concentration unit: mg milligram(s)<br>                Concentration type: range<br>                Concentration number: 10-30<br><br>",NA,NA,NA
main,EUCTR2019-001711-23-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001711-23,<br>                Trade Name: Cicaderma®<br>                Pharmaceutical Form: Ointment<br><br>,NA,NA,NA
main,EUCTR2019-001800-39-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001800-39,<br>Product Name: Benralizumab<br>Product Code: Medi-563<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: Benralizumab<br>CAS Number: 1044511-01-4<br>Current Sponsor code: MEDI-563<br>Other descriptive name: Benralizumab<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
main,EUCTR2019-001829-26-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001829-26,<br>                Trade Name: Soliris<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: ECULIZUMAB<br>                CAS Number: 219685-50-4<br>                Other descriptive name: h5G1.1-mAb<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 10-<br><br>,NA,Yes,NA
im,EUCTR2019-001837-15-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001837-15,"<br>                Trade Name: AMIKACINE MYLAN 500 mg, poudre pour solution injectable<br>                Product Name: AMIKACINE<br>                Pharmaceutical Form: Powder for solution for injection/infusion<br><br>",NA,NA,NA
main,EUCTR2019-001861-33-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001861-33,<br>                Product Name: Bediol Cannabis Flos<br>                Pharmaceutical Form: Granules in single-dose container<br>                INN or Proposed INN: DELTA-9-TETRAHYDROCANNABINOL<br>                CAS Number: 1972-08-3<br>                Other descriptive name: DELTA-9-TETRAHYDROCANNABINOL<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 9.45-<br>                INN or Proposed INN: CANNABIDIOL<br>                CAS Number: 13956-29-1<br>                Other descriptive name: CANNABIDIOL<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 12-<br><br>                Trade Name: Oxycodone<br>                Pharmaceutical Form: Tablet<br><br>,NA,Yes,NA
main,EUCTR2019-001876-12-LT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001876-12,<br>Product Name: Dienogest 2.00 mg / Ethinyl Estradiol 0.02 mg<br>Product Code: LPRI-424<br>Pharmaceutical Form: Prolonged-release tablet<br>INN or Proposed INN: DIENOGEST<br>CAS Number: 65928-58-7<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 2-<br>INN or Proposed INN: ETHINYLESTRADIOL<br>CAS Number: 57-63-6<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.02-<br><br>,NA,NA,NA
im,EUCTR2019-001974-27-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001974-27,"<br>                Trade Name: VaxigripTetra®<br>                Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>                INN or Proposed INN: A/Michigan/45/2015 (H1N1)pdm09: (NYMC X-275)<br>                Other descriptive name: INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1)<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 15-<br>                INN or Proposed INN: A/Singapore/INFIMH-16-0019/2016 (H3N2): (IVR – 186)<br>                Other descriptive name: INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2)<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 15-<br>                INN or Proposed INN: B/Colorado/06/2017<br>                Other descriptive name: INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 15-<br>                INN or Proposed INN: B/Phuket/3073/2013<br>                Other descriptive name: INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN B<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 15-<br><br>                Trade Name: Fluad®<br>                Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>                INN or Proposed INN: A/Singapore/GP1908/2015, IVR-180<br>                Other descriptive name: INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H1N1)<br>                Concentration unit: µg microgram(s)<br>                Concentration type: equal<br>                Concentration number: 15-<br>                INN or Proposed INN: A/Singapore/INFIMH-16-0019/2016, IVR-186<br>                Other descriptive name: INFLUENZA VIRUS INACTIVATED SURFACE ANTIGEN STRAIN A (H3N2)<br>                Concentration unit: µg microgram(s)<br>",NA,NA,NA
main,EUCTR2019-001986-34-FI,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001986-34,<br>                Trade Name: Boostrix<br>                Product Name: Boostrix<br>                Pharmaceutical Form: Suspension for injection in pre-filled syringe<br><br>                Trade Name: Infanrix hexa<br>                Product Name: Infanrix hexa<br>                Pharmaceutical Form: Powder and suspension for suspension for injection<br><br>                Trade Name: RotaTeq<br>                Product Name: RotaTeq<br>                Pharmaceutical Form: Oral solution<br><br>                Trade Name: Synflorix<br>                Product Name: Synflorix<br>                Pharmaceutical Form: Suspension for injection in pre-filled syringe<br><br>,NA,NA,NA
main,EUCTR2019-001989-15-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001989-15,<br>Trade Name: AJOVY<br>Product Name: fremanezumab<br>Product Code: TEV-48125<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: fremanezumab<br>CAS Number: 1655501-53-3<br>Current Sponsor code: TEV-48125<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 150-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
main,EUCTR2019-002006-51-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002006-51,"<br>                Product Name: PEMBROLIZUMAB<br>                Product Code: MK-3475<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: PEMBROLIZUMAB<br>                CAS Number: 1374853-91-4<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 25-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>                Trade Name: KEYTRUDA (pembrolizumab, MK-3475)<br>                Pharmaceutical Form: Solution for infusion<br>                INN or Proposed INN: PEMBROLIZUMAB<br>                CAS Number: 1374853-91-4<br>                Current Sponsor code: MK-3475<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 25-<br>                Pharmaceutical form of the placebo: Solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>",NA,Yes,NA
main,EUCTR2019-002039-27-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002039-27,<br>                Product Name: benralizumab<br>                Product Code: MEDI-563<br>                Pharmaceutical Form: Solution for injection in pre-filled syringe<br>                INN or Proposed INN: benralizumab<br>                CAS Number: 1044511-01-4<br>                Current Sponsor code: MEDI-563<br>                Other descriptive name: benralizumab<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 30-<br>                Pharmaceutical form of the placebo: Solution for injection in pre-filled syringe<br>                Route of administration of the placebo: Subcutaneous use<br><br>,NA,Yes,NA
main,EUCTR2019-002085-13-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002085-13,"<br>Product Name: Oraxol<br>Product Code: HM30181AK-US<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Encequidar<br>CAS Number: 2097125-58-9<br>Current Sponsor code: HM30181A<br>Other descriptive name: -<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 15-<br><br>Product Name: Oraxol<br>Product Code: paclitaxel capsules<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: PACLITAXEL<br>CAS Number: 33069-62-4<br>Current Sponsor code: Oraxol<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 30-<br><br>",NA,NA,NA
main,EUCTR2019-002100-41-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002100-41,<br>                Product Name: Efgartigimod<br>                Product Code: ARGX-113<br>                Pharmaceutical Form: Concentrate for solution for infusion<br>                INN or Proposed INN: Efgartigimod alfa<br>                CAS Number: 1821402-21-4<br>                Current Sponsor code: ARGX-113<br>                Other descriptive name: ARGX-113<br>                Concentration unit: mg/ml milligram(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 20-<br>                Pharmaceutical form of the placebo: Concentrate for solution for infusion<br>                Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
im,EUCTR2019-002120-32-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002120-32,<br>Product Code: S-649266<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: NA<br>Other descriptive name: S-649266<br>Concentration unit: g gram(s)<br>Concentration type: equal<br>Concentration number: 1-<br><br>,NA,NA,NA
main,EUCTR2019-002285-12-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002285-12,<br>                Product Name: KERAMOD<br>                Product Code: NA<br>                Pharmaceutical Form: Gel<br>                INN or Proposed INN: IMIQUIMOD<br>                CAS Number: 99011-02-6<br>                Current Sponsor code: IMIQUIMOD<br>                Other descriptive name: NA<br>                Concentration unit: mg/g milligram(s)/gram<br>                Concentration type: equal<br>                Concentration number: 50-<br><br>                Trade Name: ALDARA<br>                Pharmaceutical Form: Cream<br>                INN or Proposed INN: IMIQUIMOD<br>                CAS Number: 99011-02-6<br>                Current Sponsor code: IMIQUIMOD<br>                Other descriptive name: NA<br>                Concentration unit: mg/g milligram(s)/gram<br>                Concentration type: equal<br>                Concentration number: 50-<br><br>,NA,NA,NA
main,EUCTR2019-002308-42-PL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002308-42,"<br>                Product Code: MK-7264<br>                Pharmaceutical Form: Film-coated tablet<br>                INN or Proposed INN: GEFAPIXANT<br>                CAS Number: 1015787-98-0<br>                Current Sponsor code: MK-7264<br>                Other descriptive name: MK-7264, AF-219 and RO4926219<br>                Concentration unit: mg milligram(s)<br>                Concentration type: equal<br>                Concentration number: 45-<br>                Pharmaceutical form of the placebo: Film-coated tablet<br>                Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
im,EUCTR2019-002310-39-SE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002310-39,<br>                Trade Name: Empressin<br>                Product Name: Empressin<br>                Pharmaceutical Form: Injection<br>                Pharmaceutical form of the placebo: Injection<br>                Route of administration of the placebo: Intravenous use<br>                Pharmaceutical form of the placebo: Injection<br>                Route of administration of the placebo: Intravenous use<br><br>                Trade Name: Solu-medrol<br>                Pharmaceutical Form: Powder and solvent for emulsion for injection<br>                Pharmaceutical form of the placebo: Injection<br>                Route of administration of the placebo: Intravenous use<br>                Pharmaceutical form of the placebo: Injection<br>                Route of administration of the placebo: Intravenous use<br><br>                Trade Name: Solu-Cortef<br>                Pharmaceutical Form: Powder and solvent for emulsion for injection<br>                Pharmaceutical form of the placebo: Injection<br>                Route of administration of the placebo: Intravenous use<br>                Pharmaceutical form of the placebo: Injection<br>                Route of administration of the placebo: Intravenous use<br><br>                Trade Name: Adrenalin<br>                Product Name: Adrenaline<br>                Pharmaceutical Form: Injection<br><br>,NA,NA,NA
main,EUCTR2019-002324-32-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002324-32,"<br>Product Name: Tropifexor<br>Product Code: LJN452<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: TROPIFEXOR<br>Current Sponsor code: LJN452<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.01-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>Product Name: Licogliflozin<br>Product Code: LIK066<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: LICOGLIFLOZIN<br>Other descriptive name: LIK066 di-proline<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Tropifexor<br>Product Code: LJN452<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: TROPIFEXOR<br>Current Sponsor code: LJN452<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.1-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>Product Name: Tropifexor<br>Product Code: LJN452<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: TROPIFEXOR<br>Current Sponsor code: LJN452<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.03-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
main,EUCTR2019-002541-37-SE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002541-37,<br>                Trade Name: FSME-IMMUN Vuxen<br>                Product Name: FSME-immun vuxen<br>                Pharmaceutical Form: Suspension for injection in pre-filled syringe<br><br>,NA,NA,NA
main,EUCTR2019-002545-38-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002545-38,"<br>                Trade Name: Erivedge capsules formulated in a cutaneous emulsion to contain  2.7 mg/ml  or 6,4 mmol/l vismodegib.<br>                Product Name: Vismodegib<br>                Product Code: GDC-0449<br>                Pharmaceutical Form: Cutaneous emulsion<br><br>",NA,NA,NA
main,EUCTR2019-002660-27-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002660-27,<br>Product Name: INC280<br>Product Code: INC280<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: capmatinib<br>Current Sponsor code: INC280<br>Other descriptive name: INC280<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 150-<br><br>Trade Name: Keytruda<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: PEMBROLIZUMAB<br>Other descriptive name: KEYTRUDA<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 25-<br><br>Product Name: INC280<br>Product Code: INC280<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: capmatinib<br>Current Sponsor code: INC280<br>Other descriptive name: INC280<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Trade Name: Keytruda<br>Pharmaceutical Form: Powder for concentrate for solution for infusion<br>INN or Proposed INN: PEMBROLIZUMAB<br>Other descriptive name: KEYTRUDA<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>,NA,Yes,NA
main,EUCTR2019-002688-89-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002688-89,<br>Product Name: HCR040<br>Product Code: HCR040<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: HCR040<br>Current Sponsor code: HCR040<br>Other descriptive name: ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED<br>Concentration unit: million organisms million organisms<br>Concentration type: range<br>Concentration number: 1-2<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,Yes,NA
main,EUCTR2019-002706-46-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002706-46,"<br>Product Name: SIIPL Tdap<br>Product Code: Tdap<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: Adsorbed Tetanus Toxoid<br>Other descriptive name: Tetanus vaccine (adsorbed)<br>Concentration unit: IU international unit(s)<br>Concentration type: not less then<br>Concentration number: 20-<br>INN or Proposed INN: Adsorbed Diphtheria Toxoid<br>Other descriptive name: Diphtheria Vaccine (adsorbed)<br>Concentration unit: IU international unit(s)<br>Concentration type: not less then<br>Concentration number: 2-<br>INN or Proposed INN: Acellular Pertussis Adsorbed PT Antigen<br>Other descriptive name: Acellular pertussis vaccine<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 8-<br>INN or Proposed INN: Acellular Pertussis Adsorbed FHA Antigen<br>Other descriptive name: Acellular pertussis vaccine<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 8-<br>INN or Proposed INN: Acellular Pertussis Adsorbed PRN Antigen<br>Other descriptive name: Acellular pertussis vaccine<br>Concentration unit: µg microgram(s)<br>Concentration type: not less then<br>Concentration number: 2.5-<br><br>Trade Name: Boostrix<br>Pharmaceutical Form: Suspension for injection in pre-filled syringe<br>INN or Proposed INN: Tetanus toxoid<br>Other descriptive name: TETANUS TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE<br>Concentration unit: IU international unit(s)<br>Concentration type: not less then<br>Concentration number: 20-<br>INN or Proposed INN: Diphtheria toxoid<br>Other descriptive name: DIPHTHERIA TOXOID ADSORBED ON ALUMINIUM HYDROXIDE, HYDRATED AND ALUMINIUM PHOSPHATE<br>Concentration unit: IU international unit(s)<br>Concentration type: not less then<br>Concentration number: 2-<br>INN or Proposed INN: Bordetella pertussis-Antigene <br>Other descrip",Yes,NA,NA
main,EUCTR2019-002847-62-AT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002847-62,"<br>Product Name: Tacrosolv 50 micrograms, eye drops<br>Product Code: Tacrosolv<br>Pharmaceutical Form: Ear/eye drops, solution<br>INN or Proposed INN: Tacrolimus <br>CAS Number: 109581-93-3<br>Current Sponsor code: n.a.<br>Other descriptive name: TACROLIMUS MONOHYDRATE<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Ear/eye drops, solution<br>Route of administration of the placebo: Ophthalmic use (Noncurrent)<br><br>",NA,NA,NA
main,EUCTR2019-003047-30-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003047-30,<br>Product Name: belantamab mafodotin <br>Product Code: GSK2857916<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: belantamab mafodotin<br>Current Sponsor code: GSK2857916<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>Product Name: bortezomib<br>Pharmaceutical Form: Powder for solution for injection<br>INN or Proposed INN: BORTEZOMIB<br>CAS Number: 179324-69-7<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 3.5-<br><br>Product Name: Lenalidomide<br>Product Code: Lenalidomide<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: LENALIDOMIDE<br>CAS Number: 191732-72-6<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 25-<br>INN or Proposed INN: LENALIDOMIDE<br>CAS Number: 191732-72-6<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 10-<br>INN or Proposed INN: LENALIDOMIDE<br>CAS Number: 191732-72-6<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 5-<br><br>Product Name: Dexamethasone<br>Product Code: Dexamethasone<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: DEXAMETHASONE<br>CAS Number: N/A<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 2-<br><br>,NA,Yes,NA
im,EUCTR2019-003387-46-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003387-46,<br>                Trade Name: Calcium Chloride<br>                Product Name: Calcium Chloride<br>                Pharmaceutical Form: Solution for injection<br>                INN or Proposed INN: Calcium Chloride<br>                Other descriptive name: CALCIUM CHLORIDE<br>                Concentration unit: mmol/ml millimole(s)/millilitre<br>                Concentration type: equal<br>                Concentration number: 0.5-<br>                Pharmaceutical form of the placebo: Solution for injection<br>                Route of administration of the placebo: Intravenous bolus use (Noncurrent)<br><br>,NA,NA,NA
main,EUCTR2019-003611-62-NO,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-003611-62,<br>Product Code: LIB003<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: not available<br>CAS Number: 2250073-78-8<br>Current Sponsor code: LIB003<br>Other descriptive name: LIB003<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 250-<br><br>Trade Name: Repatha (evolocumab) <br>Pharmaceutical Form: Solution for injection in cartridge<br>INN or Proposed INN: EVOLOCUMAB<br>CAS Number: 1256937-27-5<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 420-<br><br>,NA,Yes,NA
main,EUCTR2019-004207-13-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004207-13,<br>Product Name: Fluorouracil<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: FLUOROURACIL<br>Other descriptive name: FLUOROURACIL<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 50-<br><br>Product Name: Calciumfolinate<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: CALCIUM FOLINATE<br>Other descriptive name: CALCIUM FOLINATE<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>Product Name: Oxaliplatin<br>Pharmaceutical Form: Concentrate and solvent for cutaneous solution<br>INN or Proposed INN: OXALIPLATIN<br>CAS Number: 61825-94-3<br>Other descriptive name: OXALIPLATIN<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br><br>Product Name: Bevacizumab<br>Pharmaceutical Form: Concentrate and solvent for solution for infusion<br>INN or Proposed INN: BEVACIZUMAB<br>CAS Number: 216974-75-3<br>Other descriptive name: BEVACIZUMAB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 25-<br><br>Product Name: capecitabine<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: CAPECITABINE<br>Other descriptive name: CAPECITABINE<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 150-500<br><br>Product Name: Tocotrienol<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: TOCOTRIENOL<br>CAS Number: 6829-55-6<br>Other descriptive name: TOCOTRIENOL<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
im,EUCTR2019-004282-41-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-004282-41,<br>Product Name: RUC-4<br>Product Code: 140962<br>Pharmaceutical Form: Concentrate and solvent for solution for injection<br>INN or Proposed INN: RUC-4<br>Current Sponsor code: RUC-4<br>Other descriptive name: GLYCOPROTEIN IIB/IIIA<br>Concentration unit: mg/kg milligram(s)/kilogram<br>Concentration type: equal<br>Concentration number: 0.075-<br><br>,NA,NA,NA
covid,EUCTR2020-000982-18-SE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000982-18,<br>Trade Name: Plaquenil<br>Product Name: Plaquenil<br>Product Code: P01BA02<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: hydroxychloroquine sulphate<br>CAS Number: 747-36-4<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Product Name: Remdesivir<br>Pharmaceutical Form: Lyophilisate for solution for infusion<br>INN or Proposed INN: REMDESIVIR<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>,NA,Yes,NA
covid,EUCTR2020-001072-15-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001072-15,<br>Product Name: ChAdOx1 nCoV-19<br>Pharmaceutical Form: Solution for injection<br>Pharmaceutical form of the placebo: Powder and solvent for solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>Trade Name: Nimenrix<br>Product Name: Nimenrix<br>Pharmaceutical Form: Powder and solvent for solution for injection<br><br>Trade Name: Menveo<br>Product Name: Menveo<br>Pharmaceutical Form: Powder and solvent for solution for injection<br><br>,Yes,NA,NA
covid,EUCTR2020-001156-18-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001156-18,<br>Trade Name: Dolquine 200 mg comprimidos recubiertos.<br>Pharmaceutical Form: Coated tablet<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Buccal use<br><br>Trade Name: azitromicina cinfa 500 mg comprimidos<br>Pharmaceutical Form: Capsule<br><br>Trade Name: Kaletra<br>Pharmaceutical Form: Capsule<br><br>,NA,Yes,NA
covid,EUCTR2020-001172-15-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001172-15,<br>Product Name: Recombinant human angiotensin-converting enzyme 2<br>Product Code: APN01<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: APN01 / GSK2586881<br>Other descriptive name: GSK2586881<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 5-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
covid,EUCTR2020-001228-32-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001228-32,<br>Product Name: ChAdOx1 nCoV-19<br>Pharmaceutical Form: Solution for injection<br><br>Trade Name: Nimenrix<br>Product Name: Nimenrix<br>Pharmaceutical Form: Powder and solvent for solution for injection<br><br>Trade Name: Menveo<br>Product Name: Menveo<br>Pharmaceutical Form: Powder and solvent for solution for injection<br><br>,Yes,NA,NA
covid,EUCTR2020-001254-22-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001254-22,<br>Trade Name: Leukine<br>Product Name: Leukine<br>Pharmaceutical Form: Powder for nebuliser solution<br>INN or Proposed INN: SARGRAMOSTIM<br>CAS Number: 123774-72-1<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 250-<br><br>Trade Name: Leukine<br>Product Name: Leukine<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: SARGRAMOSTIM<br>CAS Number: 123774-72-1<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 250-<br><br>,NA,NA,NA
covid,EUCTR2020-001258-23-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001258-23,<br>Trade Name: COLCHICINA<br>Product Name: COLCHICINA<br>Pharmaceutical Form: Tablet<br><br>,NA,NA,NA
covid,EUCTR2020-001262-11-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001262-11,"<br>Pharmaceutical Form: Capsule, soft<br>INN or Proposed INN: CICLOSPORIN<br>CAS Number: 59865-13-3<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: LOPINAVIR<br>CAS Number: 192725-17-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: RITONAVIR<br>CAS Number: 155213-67-5<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: DARUNAVIR<br>CAS Number: 206361-99-1<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 800-<br><br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Chloroquine<br>CAS Number: 54-05-7<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 250-<br><br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: SPIRONOLACTONE<br>Other descriptive name: SPIRONOLACTONE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 25-<br><br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: INTERFERON BETA-1B<br>CAS Number: 145155-23-3<br>Other descriptive name: INTERFERON BETA-1B<br>Concentration unit: µg/ml microgram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 250-<br><br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: TOCILIZUMAB<br>CAS Number: 375823-41-9<br>Other descriptive name: TOCILIZUMAB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br><br>",NA,Yes,NA
covid,EUCTR2020-001264-28-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001264-28,<br>Product Name: VIDOFLUDIMUS CALCIUM<br>Product Code: IMU-838<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Vidofludimus calcium<br>CAS Number: 1354012-90-0<br>Current Sponsor code: IMU-838<br>Other descriptive name: VIDOFLUDIMUS CALCIUM<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 22.5-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
covid,EUCTR2020-001266-11-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001266-11,<br>Product Name: Allogeneic mesenchymal stromal cells isolated from adipose tissue<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: Allogeneic adipose-derived mesenchymal stromal cells in vitro expanded<br>Other descriptive name: Allogeneic adipose-derived mesenchymal stem cells in vitro expanded<br>Concentration unit: million organisms/ml million organisms/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>,NA,Yes,NA
covid,EUCTR2020-001290-74-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001290-74,<br>Trade Name: Kevzara<br>Product Name: Kevzara<br>Product Code: 1171196003<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: SARILUMAB<br>Other descriptive name: EU/1/17/1196/012<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Trade Name: Azitromicina<br>Product Name: Azitromicina<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: AZITHROMYCIN DIHYDRATE<br>CAS Number: 83905-01-5<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>Trade Name: hidroxicloroquina<br>Product Name: Hidroxicloroquina<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Hydroxychloroquine<br>CAS Number: 118-42-3<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>,NA,Yes,NA
covid,EUCTR2020-001319-26-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001319-26,<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: ROSUVASTATIN<br>CAS Number: 287714-41-4<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 5-<br><br>,NA,NA,NA
covid,EUCTR2020-001320-34-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001320-34,<br>Product Name: Valsartan or matched placebo<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: VALSARTAN<br>CAS Number: 137862-53-4<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 80-160<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
covid,EUCTR2020-001335-28-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001335-28,<br>Product Name: IFX-1<br>Product Code: vilobelimab<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: IFX-1<br>CAS Number: 2250440-41-4<br>Current Sponsor code: IFX-1<br>Other descriptive name: vilobelimab<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Concentrate for solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,Yes,NA
covid,EUCTR2020-001357-52-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001357-52,<br>Trade Name: hydroxychloroquine<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Hydroxychloroquine<br>CAS Number: 118-42-3<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-001385-11-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001385-11,<br>Trade Name: Truvada<br>Product Name: Truvada<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: TENOFOVIR DISOPROXIL FUMARATE<br>CAS Number: 202138-50-9<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>INN or Proposed INN: EMTRICITABINE<br>CAS Number: 143491-57-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 245-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Hydroxychloroquine<br>Product Name: Hydroxychloroquine<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Hydroxychloroquine<br>CAS Number: 118-42-3<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-001391-15-IE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001391-15,<br>Trade Name: Prolastin<br>Pharmaceutical Form: Powder and solvent for solution for infusion<br>INN or Proposed INN: HUMAN ALPHA1-PROTEINASE INHIBITOR<br>CAS Number: 9041-92-3<br>Other descriptive name: HUMAN ALPHA1-PROTEINASE INHIBITOR<br>Concentration unit: mg milligram(s)<br>Concentration type: not less then<br>Concentration number: 120-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
covid,EUCTR2020-001395-15-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001395-15,<br>Trade Name: Solu-Cortef<br>Product Name: Solu-Cortef<br>Pharmaceutical Form: Powder and solvent for solution for injection/infusion<br>INN or Proposed INN: hydrocortisone<br>Other descriptive name: HYDROCORTISONE SODIUM SUCCINATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Infusion<br>Route of administration of the placebo: Intravenous use<br><br>Trade Name: Isotonic Sodium Chloride (0.9%)<br>Product Name: Sodium Chloride<br>Pharmaceutical Form: Infusion<br>INN or Proposed INN: Sodium Chloride<br>Other descriptive name: SODIUM CHLORIDE SOLUTION 0.9%<br>Concentration unit: % (W/V) percent weight/volume<br>Concentration type: equal<br>Concentration number: 0.9-<br><br>,NA,NA,NA
covid,EUCTR2020-001408-41-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001408-41,<br>Trade Name: RoActemra®<br>Product Name: Roactemra®<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Roactemra®<br>CAS Number: 375823-41-9<br>Other descriptive name: TOCILIZUMAB<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,Yes,NA
covid,EUCTR2020-001411-25-AT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001411-25,"<br>Product Name: Selinexor<br>Product Code: KPT-330, XPOVIO<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: Selinexor<br>CAS Number: 1393477-72-9<br>Current Sponsor code: KPT-330<br>Other descriptive name: SELINEXOR<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
covid,EUCTR2020-001413-20-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001413-20,<br>Trade Name: Sylvant<br>Pharmaceutical Form: Powder for concentrate for solution for infusion<br>INN or Proposed INN: Siltuximab<br>CAS Number: 541502-14-1<br>Concentration unit: mg/kg milligram(s)/kilogram<br>Concentration type: equal<br>Concentration number: 11-<br><br>Trade Name: Urbason<br>Pharmaceutical Form: Powder and solvent for solution for infusion<br>INN or Proposed INN: METHYLPREDNISOLONE<br>Other descriptive name: METHYLPREDNISOLONE<br>Concentration unit: mg/kg milligram(s)/kilogram<br>Concentration type: equal<br>Concentration number: 250-<br><br>,NA,Yes,NA
covid,EUCTR2020-001417-21-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001417-21,<br>Trade Name: PLAQUENIL<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: HYDROXYCHLOROQUINE<br>CAS Number: 747-36-4<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>,NA,Yes,NA
covid,EUCTR2020-001420-34-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001420-34,<br>Product Name: Senicapoc<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: senicapoc<br>CAS Number: 289656-45-7<br>Other descriptive name: SENICAPOC<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 10-<br><br>,NA,NA,NA
covid,EUCTR2020-001431-27-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001431-27,<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: VALSARTAN<br>CAS Number: 137862-53-4<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 80-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Pharmaceutical Form: Tablet<br><br>Trade Name: P- Tabletten Weiß 10mm Lichtenstein Tabletten <br>Pharmaceutical Form: <br><br>,NA,NA,NA
covid,EUCTR2020-001435-27-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001435-27,<br>Trade Name: Imatinib Teva 400 mg<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: IMATINIB<br>CAS Number: 152459-95-5<br>Other descriptive name: IMATINIB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br><br>Trade Name: AVIGAN 200mg<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: FAVIPIRAVIR<br>Other descriptive name: FAVIPIRAVIR<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Trade Name: MICARDIS 20mg<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: TELMISARTAN<br>CAS Number: 144701-48-4<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br><br>,NA,Yes,NA
covid,EUCTR2020-001440-26-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001440-26,<br>Trade Name: Dolquine<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: Hydroxychloroquine<br>CAS Number: 118-42-3<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-001442-19-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001442-19,<br>Trade Name: RoActemra<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: TOCILIZUMAB<br>CAS Number: 375823-41-9<br>Other descriptive name: TOCILIZUMAB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 648-<br><br>,NA,Yes,NA
covid,EUCTR2020-001466-11-GR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001466-11,<br>Trade Name: Kineret<br>Product Name: Anakinra<br>Pharmaceutical Form: Injection<br><br>Trade Name: Bactrimel<br>Product Name: Sulfamethoxazole and Trimethoprim<br>Pharmaceutical Form: Tablet<br><br>,NA,NA,NA
covid,EUCTR2020-001467-82-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001467-82,"<br>Product Name: Voclosporin or Lupkynis<br>Pharmaceutical Form: Capsule, soft<br>INN or Proposed INN: Voclosporin<br>CAS Number: 515814-01-4<br>Current Sponsor code: ISA247<br>Other descriptive name: VOCLOSPORIN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 7.9-<br><br>",NA,NA,NA
covid,EUCTR2020-001492-33-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001492-33,"<br>Trade Name: Pulmozyme 2500 U/2,5ml, solution pour inhalation par nébuliseur<br>Pharmaceutical Form: Inhalation solution<br><br>",NA,NA,NA
covid,EUCTR2020-001497-30-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001497-30,<br>Trade Name: Ultomiris<br>Product Name: ravulizumab<br>Product Code: ALXN1210<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: ravulizumab<br>Current Sponsor code: ALXN1210<br>Other descriptive name: Fc- and CDR-modified humanised monoclonal antibody against C5<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br><br>,NA,Yes,NA
covid,EUCTR2020-001501-24-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001501-24,<br>Product Name: IDROSSICLOROCHINA_IRSTIRCCS<br>Product Code: [IDROSSICLOROCHINA_IRSTIRCCS]<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: IDROSSICLOROCHINA SOLFATO<br>CAS Number: 118-42-3<br>Current Sponsor code: IDROSSICLOROCHINA_IRSTIRCCS<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>,NA,NA,NA
covid,EUCTR2020-001512-26-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001512-26,<br>Trade Name: Quensyl<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: Hyroxychloroquine sulfate<br>CAS Number: 747-36-4<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-001536-98-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001536-98,<br>Trade Name: hidroxicloroquine<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: Hydroxychloroquine<br>CAS Number: 747-42-3<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 5-200<br><br>,NA,Yes,NA
covid,EUCTR2020-001541-39-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001541-39,<br>Trade Name: Avastin<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: BEVACIZUMAB<br>CAS Number: 216974-75-3<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 25-<br><br>,NA,Yes,NA
covid,EUCTR2020-001565-37-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001565-37,<br>Trade Name: Dolquine<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Hydroxychloroquine Sulfate<br>CAS Number: 747-36-4<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-001571-32-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001571-32,<br>Product Name: Aldesleukin<br>Product Code: ILT101<br>Pharmaceutical Form: Concentrate for cutaneous solution<br>CAS Number: 110942-02-4<br>Current Sponsor code: ILT101<br>Other descriptive name: ALDESLEUKIN<br>Concentration unit: IU/ml international unit(s)/millilitre<br>Concentration type: equal<br>Concentration number: 1-<br>Pharmaceutical form of the placebo: Concentrate for cutaneous solution<br>Route of administration of the placebo: Subcutaneous use<br><br>,NA,NA,NA
covid,EUCTR2020-001587-29-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001587-29,<br>Trade Name: Dolquine<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE<br>CAS Number: 747-36-4<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-001602-34-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001602-34,<br>Trade Name: ZYMAD 200 000 UI<br>Product Name: ZYMAD 200 000 UI<br>Pharmaceutical Form: Oral solution<br><br>Trade Name: ZYMAD 50 000 UI<br>Product Name: ZYMAD 50 000 UI<br>Pharmaceutical Form: Oral solution<br><br>,NA,NA,NA
covid,EUCTR2020-001605-23-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001605-23,<br>Trade Name: Lopinavir/Ritonavir Accord<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: LOPINAVIR<br>CAS Number: 192725-17-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>INN or Proposed INN: RITONAVIR<br>CAS Number: 155213-67-5<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>Trade Name: Dolquine<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: HYDROXYCHLOROQUINE<br>CAS Number: 747-36-4<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Trade Name: Zitromax<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: AZITHROMYCIN DIHYDRATE<br>Other descriptive name: AZITHROMYCIN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 500-<br><br>,NA,Yes,NA
covid,EUCTR2020-001608-40-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001608-40,<br>Product Name: Favipiravir<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Favipiravir<br>CAS Number: 259793-96-9<br>Current Sponsor code: na<br>Other descriptive name: FAVIPIRAVIR<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-001610-38-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001610-38,<br>Trade Name: Aprovel<br>Pharmaceutical Form: Tablet<br>Other descriptive name: IRBESARTAN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 300-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Tamiflu<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: OSELTAMIVIR<br>CAS Number: 196618-13-0<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 75-<br>Pharmaceutical form of the placebo: Capsule<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-001614-38-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001614-38,<br>Trade Name: azithromycine<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: AZITHROMYCIN DIHYDRATE<br>CAS Number: 117772-70-0<br><br>Trade Name: azithromycine<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: AZITHROMYCIN DIHYDRATE<br>CAS Number: 117772-70-0<br><br>Trade Name: azithromycine<br>Pharmaceutical Form: Syrup<br>INN or Proposed INN: AZITHROMYCIN DIHYDRATE<br>CAS Number: 117772-70-0<br><br>,NA,Yes,NA
covid,EUCTR2020-001634-36-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001634-36,<br>Trade Name: Kevzara<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: SARILUMAB<br>CAS Number: 1189541-98-7<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 150-200<br><br>,NA,Yes,NA
covid,EUCTR2020-001636-95-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001636-95,<br>Trade Name: Anakinra<br>Product Name: Anakinra<br>Product Code: L04AA14<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: Anakinra<br>CAS Number: 143090920<br>Current Sponsor code: 282110<br>Other descriptive name: Kineret<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>,NA,NA,NA
covid,EUCTR2020-001640-26-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001640-26,<br>Trade Name: Actilyse <br>Product Name: Actilyse <br>Pharmaceutical Form: Powder and solvent for solution for injection/infusion<br>INN or Proposed INN: Alteplase<br>CAS Number: 0105857-23-6<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 10-<br><br>,NA,NA,NA
covid,EUCTR2020-001645-40-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001645-40,<br>Product Name: Reparixin<br>Product Code: [DF1681Y]<br>Pharmaceutical Form: Concentrate for solution for injection/infusion<br>INN or Proposed INN: REPARIXIN<br>CAS Number: 266359-83-5<br>Current Sponsor code: DF1681Y<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 33-<br><br>Product Name: Reparixin<br>Product Code: [DF1681Y]<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: REPARIXIN<br>CAS Number: 266359-83-5<br>Current Sponsor code: DF1681Y<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 1200-<br><br>,NA,NA,NA
covid,EUCTR2020-001659-42-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001659-42,<br>Trade Name: Anbinex<br>Product Name: HUMAN ANTITHROMBIN<br>Pharmaceutical Form: Powder and solvent for solution for injection<br>INN or Proposed INN: Antithrombin III<br>Other descriptive name: HUMAN ANTITHROMBIN<br>Concentration unit: IU international unit(s)<br>Concentration type: equal<br>Concentration number: 1000-<br><br>,NA,NA,NA
covid,EUCTR2020-001673-75-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001673-75,"<br>Product Code: ABX464<br>Pharmaceutical Form: Capsule, hard<br>INN or Proposed INN: ABX464<br>Current Sponsor code: ABX464<br>Other descriptive name: ABX464<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
covid,EUCTR2020-001689-12-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001689-12,"<br>Trade Name: COLCHICINA SEID 0,5 mg comprimidos<br>Pharmaceutical Form: <br>INN or Proposed INN: COLCHICINE<br>CAS Number: 64-86-8<br>Other descriptive name: COLCHICINE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 0.5-<br>Pharmaceutical form of the placebo: Coated tablet<br>Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
covid,EUCTR2020-001704-42-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001704-42,<br>Trade Name: Hidroxicloroquina<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Hydroxychloroquine<br>CAS Number: 118-42-3<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-001722-66-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001722-66,<br>Trade Name: Albutein 5% solutión for infusion<br>Product Name: Human Albumin<br>Product Code: B05AA01<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: HUMAN SERUM ALBUMIN<br>Other descriptive name: ALBUMIN NORMAL HUMAN SERUM<br>Concentration unit: g/ml gram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 40-<br><br>Trade Name: Flebogamma DIF/100 Human Inmunoglobulin normal<br>Product Name: Human Immunoglobuline normal<br>Product Code: Flebogamma DIF 50 mg/ml solución para perfusión<br>Pharmaceutical Form: Solution for infusion<br>INN or Proposed INN: Human normal immunoglobulin<br>Other descriptive name: HUMAN NORMAL IMMUNOGLOBULIN<br>Concentration unit: mg/kg milligram(s)/kilogram<br>Concentration type: equal<br>Concentration number: 100-<br><br>,NA,NA,NA
covid,EUCTR2020-001747-21-PT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001747-21,<br>Trade Name: Montelucaste Generis<br>Pharmaceutical Form: Film-coated tablet<br><br>,NA,NA,NA
covid,EUCTR2020-001759-42-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001759-42,<br>Product Name: otilimab<br>Product Code: GSK3196165<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: OTILIMAB<br>CAS Number: 1638332-55-4<br>Current Sponsor code: GSK3196165<br>Other descriptive name: Anti human granulocyte-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 150-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intravenous use<br><br>,NA,Yes,NA
covid,EUCTR2020-001765-37-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001765-37,<br>Product Name: hydroxychloroquine<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Hydroxychloroquine<br>CAS Number: 118-42-3<br>Concentration unit: mg milligram(s)<br>Concentration type: range<br>Concentration number: 400-800<br><br>,NA,Yes,NA
covid,EUCTR2020-001768-27-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001768-27,<br>Trade Name: Immunoglobulines Humaines Normales<br>Pharmaceutical Form: Solution for injection/infusion<br><br>,NA,NA,NA
covid,EUCTR2020-001770-30-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001770-30,<br>Trade Name: ROACTEMRA<br>Product Name: tocilizumab<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: TOCILIZUMAB<br>CAS Number: 375823-41-9<br>Current Sponsor code: TOCILIZUMAB<br>Other descriptive name: TOCILIZUMAB<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br><br>,NA,Yes,NA
covid,EUCTR2020-001794-77-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001794-77,<br>Trade Name: LEGALON<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: Silibinin<br>CAS Number: 22888-70-6<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 150-<br><br>,NA,NA,NA
covid,EUCTR2020-001803-17-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001803-17,<br>Product Name: Remdesivir<br>Product Code: GS-5734<br>Pharmaceutical Form: Lyophilisate for solution for infusion<br>INN or Proposed INN: REMDESIVIR<br>Current Sponsor code: GS-5734<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 100-<br><br>,NA,Yes,NA
covid,EUCTR2020-001807-18-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001807-18,<br>Product Name: TD-0903<br>Pharmaceutical Form: Inhalation solution<br>INN or Proposed INN: TD-0903<br>Current Sponsor code: TD-0903<br>Other descriptive name: TD-0903<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: range<br>Concentration number: 0.5-10<br>Pharmaceutical form of the placebo: Inhalation solution<br>Route of administration of the placebo: Inhalation use<br><br>,NA,NA,NA
covid,EUCTR2020-001808-42-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001808-42,<br>Product Name: melatonina 6mg/ml<br>Product Code: melatonina 6mg/ml<br>Pharmaceutical Form: Solution for injection/infusion<br>INN or Proposed INN: Melatonin<br>CAS Number: 73-31-4<br>Current Sponsor code: Melatonin<br>Other descriptive name: MELATONIN<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 6-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
covid,EUCTR2020-001854-23-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001854-23,<br>Trade Name: Plaquenil<br>Product Name: Idrossiclorochina<br>Product Code: [Idrossiclorichina]<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: IDROSSICLOROCHINA SOLFATO<br>Current Sponsor code: idrossiclorochina<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br><br>Trade Name: roactemra<br>Product Name: RoActemra<br>Product Code: [Tocilizumab]<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: TOCILIZUMAB<br>Current Sponsor code: tocilizumab<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 162-<br><br>Trade Name: Kevzara<br>Product Name: sarilumab<br>Product Code: [sarilumab]<br>Pharmaceutical Form: Solution for injection<br>Current Sponsor code: sarilumab<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 150-<br><br>Trade Name: SYLVANT<br>Product Name: siltuximab<br>Product Code: [siltuximab]<br>Pharmaceutical Form: Powder and solvent for solution for injection<br>Current Sponsor code: siltuximab<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 20-<br><br>Trade Name: Ilaris<br>Product Name: canakinumab<br>Product Code: [canakinumab]<br>Pharmaceutical Form: Powder for solution for injection<br>INN or Proposed INN: CANAKINUMAB<br>Current Sponsor code: canakinumab<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 150-<br><br>Trade Name: Olumiant<br>Product Name: Olumiant<br>Product Code: [Olumiant]<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: BARICITINIB<br>Current Sponsor code: baricitinib<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 2-<br>INN or Proposed INN: BARICITINIB<br>Current Sponsor code: baricitinib<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 4-<br><br>Trade Name: Urbas,NA,Yes,NA
covid,EUCTR2020-001886-35-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001886-35,<br>Trade Name: Alveofact®<br>Product Name: Alveofact®<br>Pharmaceutical Form: Powder for nebuliser suspension<br>INN or Proposed INN: SF-RI 1<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 45-<br><br>,NA,NA,NA
covid,EUCTR2020-001889-10-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001889-10,<br>Trade Name: Budesonide<br>Product Name: Budesonide<br>Pharmaceutical Form: Inhalation powder<br>INN or Proposed INN: Budesonide<br>Concentration unit: µg microgram(s)<br>Concentration type: equal<br>Concentration number: 400-<br><br>,NA,NA,NA
covid,EUCTR2020-001890-56-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001890-56,"<br>Trade Name: Flebogamma (Human normal immunoglobulin (IVIg))<br><br>One ml contains: Human normal immunoglobulin,100mg ((purity of at least 97% IgG)<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: Gammaglobuline<br>CAS Number: 8000010-96-0<br>Other descriptive name: GAMMA GLOBULIN<br>Concentration unit: mg/l milligram(s)/litre<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>",NA,NA,NA
covid,EUCTR2020-001971-33-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001971-33,<br>Trade Name: Ivermectin<br>Product Name: Ivermectin<br>Product Code: Ivermectin<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Ivermectin<br>Other descriptive name: IVERMECTIN<br>Concentration unit: µg/kg microgram(s)/kilogram<br>Concentration type: range<br>Concentration number: 200-400<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Dolquine<br>Product Name: dolquine<br>Product Code: Hydroxychloroquine<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Hydroxychloroquine<br>CAS Number: 118-42-3<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Trade Name: Azitromicina Vir 500 mg<br>Product Name: azithromycin<br>Product Code: azithromycin<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: AZITHROMYCIN<br>Other descriptive name: AZITHROMYCIN<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-002027-10-SE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002027-10,<br>Trade Name: Xtandi <br>Product Name: Xtandi<br>Pharmaceutical Form: Tablet<br><br>,NA,NA,NA
covid,EUCTR2020-002130-33-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002130-33,<br>Product Name: Zilucoplan<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: ZILUCOPLAN<br>CAS Number: 1841136-73-9<br>Current Sponsor code: RA101495<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 40-<br><br>,NA,NA,NA
covid,EUCTR2020-002166-13-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002166-13,<br>Trade Name: Firazyr®<br>Product Name: Icatibant (Firazyr®)<br>Pharmaceutical Form: Solution for injection in pre-filled syringe<br>INN or Proposed INN: ICATIBANT<br>CAS Number: 130308-48-4<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 90-<br><br>,NA,NA,NA
covid,EUCTR2020-002211-21-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002211-21,<br>Product Name: AZD1656<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: AZD1656<br>Current Sponsor code: AZD1656<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
covid,EUCTR2020-002230-32-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002230-32,"<br>Product Name: TD139<br>Pharmaceutical Form: Inhalation powder, hard capsule<br>INN or Proposed INN: TD139<br>Current Sponsor code: TD139<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 10mg-<br><br>Trade Name: Futhan®50 <br>Product Name: Futhan®50 <br>Pharmaceutical Form: Injection<br>INN or Proposed INN:  Nafamostat mesilate <br>Current Sponsor code: FUTHAN?50 INJ.<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br><br>",NA,NA,NA
covid,EUCTR2020-002234-32-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002234-32,<br>Trade Name: Lixiana 60mg and 30mg<br>Product Name: edoxaban<br>Product Code: B01AF02<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Non applicable<br>CAS Number: 912273-65-5<br>Current Sponsor code: EDOXABAN<br>Concentration unit: mg milligram(s)<br>Concentration type: up to<br>Concentration number: 60-<br><br>Trade Name: Colchicine<br>Product Name: Colchicine<br>Product Code: M04AC01<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Non applicable<br>CAS Number: 64-86-8<br>Current Sponsor code: COLCHICINE<br>Concentration unit: mg milligram(s)<br>Concentration type: up to<br>Concentration number: 1-<br><br>,NA,NA,NA
covid,EUCTR2020-002283-32-IT,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002283-32,<br>Product Name: Ivermectina<br>Product Code: [-]<br>Pharmaceutical Form: Tablet<br>CAS Number: 70288-86-7<br>Current Sponsor code: -<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 9-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: Ivermectina<br>Product Code: [-]<br>Pharmaceutical Form: Tablet<br>CAS Number: 70288-86-7<br>Current Sponsor code: -<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 9-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
covid,EUCTR2020-002287-31-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002287-31,<br>Trade Name: DOLQUINE<br>Product Name: Hydroxychloroquine<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: Hydroxychloroquine<br>CAS Number: 118-42-3<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 400-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-002299-11-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002299-11,<br>Trade Name: Fevarin 50mg filmtabletta<br>Product Name: Fevarin 50mg filmtabletta<br>Pharmaceutical Form: Film-coated tablet<br>INN or Proposed INN: FLUVOXAMINE MALEATE<br>CAS Number: 61718-82-9<br>Concentration unit: mg milligram(s)<br>Concentration type: not less then<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
covid,EUCTR2020-002449-41-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002449-41,<br>Product Name: HYDROXICHLOROQUINE<br>Pharmaceutical Form: Coated tablet<br>INN or Proposed INN: HYDROXYCHLOROQUINE SULFATE<br>CAS Number: 747-36-4<br>Other descriptive name: HYDROXYCHLOROQUINE SULFATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 200-<br>Pharmaceutical form of the placebo: Coated tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,Yes,NA
covid,EUCTR2020-002503-19-NL,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002503-19,<br>Trade Name: BCG Vaccin SSI (Netherlands Vaccin Statens Serum Institute) Danish strain 1331<br>Pharmaceutical Form: Concentrate and solvent for solution for injection<br>Pharmaceutical form of the placebo: Concentrate and solvent for solution for injection<br>Route of administration of the placebo: Intradermal use<br><br>,NA,Yes,NA
covid,EUCTR2020-002567-57-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002567-57,"<br>Product Name: Almitrine Bimesylate<br>Pharmaceutical Form: Capsule<br>INN or Proposed INN: Almitrine Bismesylate<br>CAS Number: 29608-49-9<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Capsule, hard<br>Route of administration of the placebo: Oral use<br><br>",NA,NA,NA
covid,EUCTR2020-002574-27-FR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002574-27,<br>Product Name: XAV-19<br>Product Code: XAV-19<br>Pharmaceutical Form: Solution for infusion<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>,NA,NA,NA
covid,EUCTR2020-002713-17-ES,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002713-17,"<br>Product Name: n/a<br>Product Code: RO7021610/F01 (Active)<br>Pharmaceutical Form: Concentrate for solution for infusion<br>INN or Proposed INN: n/a<br>Current Sponsor code: RO7021610<br>Other descriptive name: UTTR1147A, IL22-Fc, IL-22Fc<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 10-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous use<br><br>Product Name: Astegolimab<br>Product Code: RO7187807/F01<br>Pharmaceutical Form: Solution for injection/infusion<br>INN or Proposed INN: Astegolimab<br>Current Sponsor code: RO7187807<br>Other descriptive name: MSTT1041A, anti- ST2 (IgG2) human monoclonal antibody<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 70-<br>Pharmaceutical form of the placebo: Solution for injection/infusion<br>Route of administration of the placebo: Intravenous use<br><br>",NA,Yes,NA
covid,EUCTR2020-002869-34-BE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002869-34,<br>Product Name: AT-527<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: not available<br>CAS Number: n/a<br>Current Sponsor code: AT-527<br>Other descriptive name: AT-11-hemi-sulfate salt<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 550-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>,NA,NA,NA
covid,EUCTR2020-003643-29-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003643-29,<br>Product Name: Ad26.COV2.S<br>Product Code: VAC31518<br>Pharmaceutical Form: Suspension for injection<br>INN or Proposed INN: Not available<br>Current Sponsor code: VAC31518<br>Other descriptive name: Ad26.COV2.S (also known as Ad26COVS1)<br>Concentration unit: billion organisms/ml billion organisms/millilitre<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>,NA,NA,NA
covid,EUCTR2020-003904-15-DK,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003904-15,<br>Trade Name: BCG Vaccine 'AJ Vaccines'<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: Bacillus Calmette-Guerin<br>Other descriptive name: BACILLUS CALMETTE-GUERIN VACCINE<br>Concentration unit: CFU/ml colony forming unit(s)/millilitre<br>Concentration type: range<br>Concentration number: 2 x 10_5 -8 x 10_5<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intradermal use<br><br>,Yes,NA,NA
covid,EUCTR2020-004408-32-GR,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004408-32,"<br>Product Name: AMY-101 acetate (also known as Cp40 and Cp-14 in the scientific literature/ documentation)<br>Pharmaceutical Form: Powder for solution for infusion<br>INN or Proposed INN: Not available yet<br>CAS Number: 1427001-89-5<br>Current Sponsor code: AMY-101 acetate<br>Other descriptive name: S3,S13-CYCLO(D-TYROLSYL-L-ISOLEUCYL-L-CYSTEINYL-L-VALYL-1-METHYL-L-TRYPTOPHYL-L-GLUTAMINYL-L-ASPARTYL-L-TRYPTOPHYL-N-METHYL-L-GLYCYL-L-ALANYL-L-HISTIDYL-L-ARGINYL-L-CYSTEINYL-N-METHYL-L-ISOLEUCINAMIDE) ACETATE<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 50-<br>Pharmaceutical form of the placebo: Solution for infusion<br>Route of administration of the placebo: Intravenous drip use (Noncurrent)<br><br>",NA,NA,NA
covid,EUCTR2020-004695-18-DE,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004695-18,<br>Trade Name: Foipan<br>Product Name: Foipan<br>Product Code: ONO 305<br>Pharmaceutical Form: Film-coated tablet<br>Pharmaceutical form of the placebo: Film-coated tablet<br>Route of administration of the placebo: Oral use<br><br>Product Name: convalescent plasma<br>Pharmaceutical Form: Infusion<br><br>,NA,Yes,NA
covid,EUCTR2020-004719-28-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004719-28,<br>Product Code: AZD1061<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: AZD1061<br>CAS Number: 2420563-99-9<br>Current Sponsor code: AZD1061<br>Other descriptive name: monoclonal antibody (mAb)<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>Product Code: AZD8895<br>Pharmaceutical Form: Solution for injection<br>INN or Proposed INN: AZD8895<br>CAS Number: 2420564-02-7<br>Current Sponsor code: AZD8895<br>Other descriptive name: monoclonal antibody (mAb)<br>Concentration unit: mg/ml milligram(s)/millilitre<br>Concentration type: equal<br>Concentration number: 100-<br>Pharmaceutical form of the placebo: Solution for injection<br>Route of administration of the placebo: Intramuscular use<br><br>,NA,Yes,NA
covid,EUCTR2020-004743-83-GB,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004743-83,<br>Product Name: Interferon beta-1a (IFN-ß1a) <br>Product Code: SNG001<br>Pharmaceutical Form: Inhalation solution<br>INN or Proposed INN: Interferon beta-1a<br>Current Sponsor code: SNG001<br>Concentration unit: million IU million international units<br>Concentration type: equal<br>Concentration number: 12 -<br>Pharmaceutical form of the placebo: Nebuliser solution<br>Route of administration of the placebo: Inhalation use<br><br>,NA,Yes,NA
covid,EUCTR2020-004928-42-HU,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004928-42,<br>Product Name: Remdesivir-HU 100 mg concentrate for solution for infusion                        <br>Pharmaceutical Form: Infusion<br><br>,NA,Yes,NA
covid,IRCT20080901001165N50,http://en.irct.ir/trial/47576,"Intervention 1: Intervention group: Azithromycin inhaled spray (500µg/ml) 1 puff every 12 hours, for 7 days (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2: Control group: Routine treatment according to the latest national guideline for the treatment of new corona-virus.",NA,Yes,NA
covid,IRCT20080901001165N53,http://en.irct.ir/trial/48066,"Intervention 1: Intervention group: Interferon Beta 1a  nasal spray  1 puff in each nostril every 6 hours, for 14 days (In addition to routine treatment according to the latest national guideline for the treatment of new corona-virus). Intervention 2: Control group: Routine treatment according to the latest national guideline for the treatment of new corona-virus.",NA,Yes,NA
covid,IRCT20080901001165N58,http://en.irct.ir/trial/48394,"Intervention 1: Intervention group: Plasmapheresis 3-5 session (based on clinical improvement), In addition to  Amp. Methylprednisolone (500 mg day1, 250 mg day 2 and day3, IV) and routine treatment according to the latest national guideline for the treatment of new corona-virus. Intervention 2: Control group: Amp. Methylprednisolone (500 mg day1, 250 mg day 2 and day3, IV) and routine treatment according to the latest national guideline for the treatment of new corona-virusfor the treatment of new corona-virus.",NA,Yes,NA
main,IRCT20080907001222N2,http://en.irct.ir/trial/37981,Intervention 1: In intervention group patients will use nigella sativa  orabase (5%) 3 times a day for one month. Intervention 2: Control group: In this group patients will receive routine treatment  which is orabase containing corticosteroid (Triamcinolone 0-1%) 3 time a day topically  for one month.,NA,NA,NA
main,IRCT20081011001323N23,http://en.irct.ir/trial/35993,Intervention 1: Intervention group:  Nigella sativa in form of capsule(produced by Salamat Zagros company) will prepare and prescribed in divided  dosage of 15mg/kg (milligram/kilogram) per day after meal with one glass of water for two weeks. Intervention 2: Control group: Tamsulosin capsule 0.4 mg (produced by Abidi Company) will prescribe every night with one glass of water for two weeks.,NA,NA,NA
covid,IRCT20081019001369N5,http://en.irct.ir/trial/47141,"Intervention 1: Intervention group: In addition to the standard treatment regimen for COVID-19, the lithium carbonate  tablets (300 mg/day to  900 mg/day)  will be given for 2 weeks. Intervention 2: Control group: Patients on the standard treatment regimen for COVID-19 will receive placebo tablets once a day for 2 weeks. The placebo is formulated in tablets of the same shape and size as the drug tablets and contains inert agents.",NA,NA,NA
covid,IRCT20081019001369N6,http://en.irct.ir/trial/47188,"Intervention 1: Intervention group: In addition to the standard treatment regimen for COVID-19, the trans sodium crocetinate 1 mg/kg/day will be given i.v.  for 1 weeks. Intervention 2: Control group: Patients will received the standard treatment regimen for COVID-19 for 7 days.",NA,NA,NA
main,IRCT20090117001556N122,http://en.irct.ir/trial/43102,Intervention 1: Intervention group: tablet citalopram 40 mg/day plus Capsule tipipedine 30 mg BID as intervention group for 6 weeks. Intervention 2: Intervention group: tablet citalopram 40 mg/day plus placebo as control group for 6 weeks.,NA,NA,NA
covid,IRCT20090609002017N35,http://en.irct.ir/trial/48058,Intervention 1: Group 1 consume  2 capsules containing 5 mg boron containing compound per day for two weeks. Intervention 2: Group 2 consume  2 capsules containing 200 mg oleoylethanolamide per day for two weeks. Intervention 3: Group 3 consume  2 capsules containing  5 mg boron containing compound and 200 mg oleoylethanolamide per day for two weeks. Intervention 4: Group 4 as a control group consume  2 placebo capsules containing  starch powder per day for two weeks.,NA,NA,NA
covid,IRCT20090701002113N2,http://en.irct.ir/trial/50275,"Intervention 1: Intervention group: In order to minimize any bias between groups as a general policy, all patients will only receive lopinavir/retonavir (Kaletra®) and corticosteroids as their treatment regimen for COVID-19. Antibiotic medications use will be limited as much as possible and will only be used in each specific case based on the diagnosis of the infectious specialist or intensivist when necessary. On the second day of hospital admission, the intervention group will initially receive a single intravenous bolus of 1 mg/kg (1% solution) of methylene blue administered over 20-60 minutes. The patients will then be given 0.25 mg/kg per hour dose of methylene bluefor 24 hours. Methylene blue has a commercial name of METIBLO and generic name of Methylthioninium chloride . Each 1ml ampule contains 10 mg methylthionium chloride. It is made in Belgium by Oterop company. Intervention 2: Control group:  These patients will only receive lopinavir/retonavir (Kaletra®) and corticosteroids as their treatment regimen for COVID-19. Antibiotic medications use will be limited as much as possible and will only be used in each specific case based on the diagnosis of the infectious disease specialist or emergency medicine specialist when necessary.",NA,Yes,NA
main,IRCT20091111002695N9,http://en.irct.ir/trial/39445,"Intervention 1: Intervention group 1: Itraconazole 100 mg in form of soft gelatin capsule, one each 12 hours, for 8 months. This drug is provided by Alborz Darou Company. Intervention 2: Intervention group2: Prednisoline 5mg  in form of soft gelatin capsule, one each 12 hours, for 8 months. The Active Pharmaceutical Ingredient is provided by Alborz Bulk Company. Intervention 3: Control group: Placebo in form of soft gelatin capsule containing Lactose, one each 12 hours, for 8 months.",NA,NA,NA
main,IRCT20100101002950N5,http://en.irct.ir/trial/36704,Intervention 1: Intervention group: Consumption of 80 mg oral Curcumin capsule once a day for 1 month. Intervention 2: Control group: Consumption of 2 capsules of Prednizolone 5mg once a day for 1 month and after that for 10 days 5mg Prednizolone per day for tapering.,NA,NA,Yes
im,IRCT20100107003014N19,http://en.irct.ir/trial/28183,"Intervention 1: Intervention group: Meropenem 3 gram every 8 hours, 3 hours extended infusion for 7 days. Intervention 2: Control group:  Meropenem 2 gram every 8 hours, 3 hours extended infusion for 7 days.",NA,NA,NA
im,IRCT20100107003014N22,http://en.irct.ir/trial/34554,Intervention 1: Intervention group: Dexmedetomidine 0.8 micro/kg/h for 12 hours. Intervention 2: Control group: Serum Normal saline 6 cc/kg/hr up to 12 hr.,NA,NA,NA
main,IRCT20100130003227N14,http://en.irct.ir/trial/38706,"Intervention 1: capsule of fennel (30 mg of essential oils of sweet fennel). Baryj Company is a product of the country of Iran and the soft brand of phenoline four days a day, two days before the beginning of the menstruation, up to three days after the onset of pain, for 5 days. Intervention 2: Valerian Valerian capsules (350 mg of roots of the plant) made by Herb Drug Company in Iran for 3 days at the start of menstruation for three days. Intervention 3: Control group: Control group: Control group: One of the commonly used treatments for the treatment of primary dysmenorrhea, ie, mefenamic acid (250 mg) (15) with the ponstan brand name of Razak Company, 4 times every 6 hours for 2 months (monthly cycle).",NA,NA,Yes
im,IRCT20100228003449N25,http://en.irct.ir/trial/40921,"Intervention 1: Intervention group: Patients in this group will receive midodrine tablet 10 mg three times a day (Takeda Pharmaceutical Company., Austria) concomitant with the standard care of septic shock up to when the lactate serum level reach below 18mg/dL. Intervention 2: Control group: Patients in this group will receive the standard care of septic shock.",NA,NA,NA
covid,IRCT20100228003449N27,http://en.irct.ir/trial/46545,"Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir), patients will receive interferon ß, sub-type 1b (Zist Daru Daneh Company) with dose of 250 mcg subcutaneously every other day for 14 days. Intervention 2: Control group: Patients will receive the national corona treatment recommendation (hydroxychloroquine + lopinavir/ritonavir) for at least 5 days.",NA,Yes,NA
covid,IRCT20100228003449N31,http://en.irct.ir/trial/51163,"Intervention 1: Intervention group: Concomitant with the standard of care, patients in group 1 will receive dexamethasone 4 mg IV BD for 7-10-days. Patients will be daily followed for response to the therapy and adverse reactions. Intervention 2: Intervention group: Intervention group: Concomitant with the standard of care, patients in group 2 will receive dexamethasone 8 mg IV BD for 7-10-days. Patients will be daily followed for response to the therapy and adverse reactions. Intervention 3: Intervention group: Concomitant with the standard of care, patients in group 3 will receive dexamethasone 8 mg IV TDS or more for 7-10-days. Patients will be daily followed for response to the therapy and adverse reactions.",NA,Yes,NA
main,IRCT20100513003922N4,http://en.irct.ir/trial/35370,Intervention 1: Intervention group: Olive leaf extract (capsule) is given orally three times a day for three consecutive months. Intervention 2: Control group: Pregabalin is prescribed orally twice a day for three consecutive months.,NA,NA,Yes
im,IRCT20101211005363N14,http://en.irct.ir/trial/42777,Intervention 1: Intervention group: The first group will receive 5 ml chlorhexidine 0.2% (product of Behsa pharmaceutical company) as mouthwash three times per day in a mucoadhesive form from Carbomer and HydroxyPropylCellulose containing chlorhexidine 0.2% solution prepared at the School of Pharmacy of Zanjan University of Medical Sciences . Intervention 2: Control group: The control group will receive 5 ml chlorhexidine 0.2% product of Behsa pharmaceutical company three times per day.,NA,NA,NA
main,IRCT20120215009014N267,http://en.irct.ir/trial/38082,Intervention 1: Intervention group: One tablet of Inderal 10 mg every 12 hours plus one tablet of Rosuvastatin 10 mg at evening for one month. Intervention 2: Control group: One tablet of Inderal 10 mg every 12 hours plus one tablet of placebo 10 mg at evening for one month.,NA,NA,NA
main,IRCT20120215009014N301,http://en.irct.ir/trial/42237,Intervention 1: Intervention group: Routine treatment as well as Naltrexone tablet 4.5 mg before sleep for 12 weeks. Intervention 2: Control group: Routine treatment as well as placebo tablet before sleep for 12 weeks.,NA,NA,NA
im,IRCT20120703010178N15,http://en.irct.ir/trial/10635,Intervention 1: Intervention group: Amp Ampicillin-sulbactam 6g 4 times a day with Amp Levofloxacin 750mg Daily. Intervention 2: Control group: Amp Colistin 9000000 unit stat and then Amp Colistin 4500000 unit two times a day with Amp Levofloxacin 750mg daily.,NA,Yes,NA
im,IRCT20120703010178N18,http://en.irct.ir/trial/31904,Intervention 1: Intervention group: intravenous ampicillin sulbactam 6 g every 6 hours plus nebulized colistin 2 mIU every 8 hours. Intervention 2: Control group: intravenous colistin 9 mIU stat then 4.5 mIU every 12 hours plus nebulized colistin 2 mIU every 8 hours.,NA,NA,NA
main,IRCT20120915010841N19,http://en.irct.ir/trial/40089,"Intervention 1: First Intervention group : The amount of 0.2 mg/kg Propofol 1%(10mg/ml and made by B.BRAUN company in Germany), is injected intravenously after spinal anesthesia by anesthesiologist. Intervention 2: Second Intervention group: The amount of 0.02 mg/kg Midazolam(1mg/ml and  made by Caspian pharmaceutical company in Iran),  is injected  intravenously after spinal anesthesia by anesthesiologist.",NA,NA,NA
im,IRCT20120918010876N3,http://en.irct.ir/trial/11296,Intervention 1: Treatment group: intramuscular injection of 12 mg betamethasone in two doses between 24 hours. Intervention 2: Control group: No Treatment.;Treatment - Drugs;Treatment group: intramuscular injection of 12 mg betamethasone in two doses between 24 hours;Control group: No Treatment,NA,Yes,NA
im,IRCT20120918010876N4,http://en.irct.ir/trial/11295,"Intervention 1: Intervention group: intramuscular injection of 12 mg betamethasone in two doses between 24 hours, 48 hours before cesarean section. Intervention 2: Control group: No Treatment.;Treatment - Drugs;Intervention group: intramuscular injection of 12 mg betamethasone in two doses between 24 hours, 48 hours before cesarean section;Control group: No Treatment",NA,Yes,NA
covid,IRCT20121216011763N46,http://en.irct.ir/trial/47529,Intervention 1: Intervention group: Two curcumin-piperine capsules (500 mg of curcumin + 5 mg of piperine) will be given daily for 2 weeks after lunch and dinner. Intervention 2: Control group: 2 placebo capsules ( containing 505 mg of maltodextrin) will be given daily after lunch and dinner for 2 weeks.,NA,NA,Yes
main,IRCT20130521013406N5,http://en.irct.ir/trial/40243,"Intervention 1: Intervention group: phenytoin mucoadhesive tablet                    Mucoadhesive tablets are prepared by direct compression method. The ingredients (10 mg sodium phenytoin and the remaining ingredient was HPMC: Chitosan; NaCMC, 25:25:50 w/w %) are weighed accurately and mixed by trituration in a mortar by pestle for 15 minutes. Then all of the ingredients are passed through sieve no. 100. Finally the mixture is compressed to tablet using Korsch single punch compression machine (ERWEKA, German).Each day, two tablets should be attached inside the cheek until they are dissolved and the treatment should be continued until the complete healing of oral lesions or for a maximum of two weeks. Intervention 2: Intervention group: Phenytoin mouthwash                                   Appropriate amount of sodium phenytoin is dissolved in 1 L of distilled water which contain 0.1% Tween 80 and Disodium hydrogen phosphate (2.38 g/L), with adjusted pH on 7.0±0.02 using phosphoric acid. The final concentration of phenytoin mouthwash is 0.333 mg/mL. patients are instructed to rinse (gargle) 10 ml of the solution for one minute, three times a day (to distribute evenly to all parts of the oral tissues), and then spit (to minimize the systemic absorption). They are told to avoid eating during the first hour after treatment.",NA,NA,NA
main,IRCT20130610013612N10,http://en.irct.ir/trial/41424,Treatment with levothyroxine tablet (Iran hormone) 1.7 micrograms per kg body weight daily for three months.,NA,NA,NA
main,IRCT20130616013678N29,http://en.irct.ir/trial/37653,Intervention 1: Intervention group: The Intervention group will receive a Vitamin D3 2000 IU supplement daily for the period of 6 weeks. Intervention 2: Control group: The control group will receive a placebo that is similar to Vitamin D supplements but contains Paraffin oil daily for the period of 6 weeks.,NA,NA,Yes
main,IRCT20130626013776N13,http://en.irct.ir/trial/41285,Intervention 1: Intervention group: Oral administration of a single 600 mcg dose of levothyroxine tablet manufactured by Aburaihan Pharmaceuticals to healthy volunteers. Intervention 2: Intervention group: Oral administration of a single 600 mcg dose of Euthyrox tablet manufactured by MerckSerono to healthy volunteers.,NA,NA,NA
covid,IRCT20131125015536N13,http://en.irct.ir/trial/51310,"Intervention 1: Intervention group: People in the intervention group will receive  nanocurcumin supplement at a dose of 160 mg per day for 6 days. Curcumin is a natural polyphenolic antioxidant responsible for the turmeric yellow color. Nanocurcumin supplements are produced in the form of 40 mg capsules by Exir Nano Sina Company, and patients will receive 4 supplements orally (every 12 hours 2 capsules) for 6 days in addition to the routine treatment,. Intervention 2: Control group: People in the control group are given placebo capsules that are completely similar to nanocurcumin supplements in terms of shape and color and are asked to take 4 placebo capsules daily (every 12 hours 2 capsules) for 6 days.",NA,NA,Yes
main,IRCT20140212016557N5,http://en.irct.ir/trial/43792,"Intervention 1: Intervention group: Cysteamine 5% cream (Scentispharma, Switzerland) is applied once every night for 15 minutes for 4 months on the face skin. Intervention 2: Control group: Hydroquinone 4% cream which is made by dissolution of 2 grams powder of hydroquinone (Merck, Germany) and 1.5 grams ascorbic acid powder (Merck, Germany) in 50 grams of vanishing cream (Minoo, Iran) is applied once every night overnight for 4 months on the face skin.",NA,NA,NA
im,IRCT20140310016917N8,http://en.irct.ir/trial/40133,"Intervention 1: Intervention group:  after appropriate  randomization drug (nebulized heparin in this group) in dose of 2 cc (10,000 heparin units) every 4 hours is given through a jet nebulizer  located 30 cm in the tracheal tube at the inspiratory  arm of ventilator.Other measures will be exactly the same as the recipients of standard pneumonia treatment (control group).The Heparin ampoule is supplied by the Caspian Company and is at 5000 units per cc. Intervention 2: Control group: after appropriate  randomization drug (distilled water in this group) in dose of 2 cc  every 4 hours is given through a jet nebulizer  located 30 cm in the tracheal tube at the inspiratory  arm of ventilator and standard treatment consistent of  antibiotics in  appropriate for the local prevalency in the ICU initially  was started and then continued  on the basis of culture of pulmonary secretions until the pro calcitonin serum level is in the non  infected stage or at most 14 days.",NA,Yes,NA
covid,IRCT20140428017469N1,http://en.irct.ir/trial/47989,"Intervention group: All people receiving health care services from PIHO residing in Fars, Hormozgan, and Ahwaz centers. The intervention group individuals will receive 4 drops of OPV vaccine (provided by Razi Institute). We will follow the age-adjusted incidence rate of COVID-19 in the study group for at least 2 months after the vaccination..",Yes,NA,NA
main,IRCT20140525017827N5,http://en.irct.ir/trial/28614,"Intervention 1: Intervention group: Group A will receive herbal formulation based on Myrrh, Hydro alcoholic extract of  Myrrh  resin prepared by 1: 5 ratio (90% ethanol was used). Each patient will use 15 cc in 5 liter of water for 10 minutes, twice a day for a week. Intervention 2: Intervention group: Group B will receive herbal formulation based on Boswellia, Hydro alcoholic extract of  Boswellia resin prepared by 1: 5 ratio (90% ethanol was used). Each patient will use 15 cc in 5 liter of water for 10 minutes, twice daily for a week. Intervention 3: Control group:  Patients in group C will use Betadine solution, 15 cc in 5 liter of water for 10 minutes, twice daily for a week.",NA,NA,Yes
main,IRCT20140820018866N7,http://en.irct.ir/trial/36763,"Intervention 1: Intervention group 1: Will receive one Letrozole 2.5 mg oral tablet plus one LD oral tablet per day, for a period of three months. Intervention 2: Intervention group 2: Will receive one decapeptyl 3.75 mg (made in France) IM injection every month, for three months.",NA,NA,NA
im,IRCT20141209020258N112,http://en.irct.ir/trial/39792,Intervention 1: Intervention group: We treat patients with 280 milligram Silymarin orally(mouth or gavage) every 8 hours for 3 days. Intervention 2: Control group: We treat patients with placebo every 8 hours for 3 days.,NA,NA,NA
main,IRCT20141220020377N3,http://en.irct.ir/trial/40960,Intervention 1: Intervention group: In intervention group patients will use Melatonin Tab 3 Mg (Iran Construction of A-lHavi Company) 4 times a day for 5 month. Intervention 2: Control group: In Control group patients will use PlaceboTab 4 times a day for 5 month.,NA,NA,NA
covid,IRCT20150107020592N30,http://en.irct.ir/trial/48992,"Intervention group: Thirty people in the intensive care unit who are in direct contact with COVID-positive patients have been studied and given Favipiravir 200 twice a day for three days a week for two weeks,.",NA,Yes,NA
covid,IRCT20150303021315N17,http://en.irct.ir/trial/46550,"Intervention group: Subcutaneous (two PFS injections of 162 mg Tocilizumab for ?patients <100 kg and three PFS injections of 162 mg Tocilizumab for patients >100 kg) in addition to the standard treatment. In case of inadequate response, Tocilizumab would be re-administered with a 12-hour interval between injections..",NA,Yes,NA
im,IRCT20150706023084N3,http://en.irct.ir/trial/40807,Intervention 1: Intervention group: This group received one vitamin C 1000 mg EFF tab daily and other medications for treating pneumonia for 10 days. Serum procalcitonin was measured and checked at the beginning of patient's entrance and at the end of the study(after 10 days). Intervention 2: Control group: This group received one vitamin C placebo 1000 mg EFF tab daily and other medications for treating pneumonia for 10 days. Serum procalcitonin was measured and checked at the beginning  of patient's entrance and at the end of the study(after 10 days).,NA,NA,Yes
covid,IRCT20150808023559N20,http://en.irct.ir/trial/47022,"Intervention 1: Intervention group: Group receiving Favipiravir (Nafas farmed Co, Iran) plus Hydroxychloroquine (Iran daroo Co, Iran). This group will receive stat dose of eight 200 mg Favipiravir tablets (total 1600 mg) followed by Favipiravir 600 mg three times a day for 7 days plus Hydroxychloroquine 200mg two times per day for 7 days.This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups. Intervention 2: Control group: Group receiving Kaletra (Bakhtar bioshimi Co, Iran) plus Hydroxychloroquine (Iran daroo Co, Iran) regimen. This group will receive Stat dose of two 200 mg Hydroxychloroquine tablets (total 400 mg) followed by Kaletra(Lopinavir/Ritonavir) 50/200 mg two times a day for 7 days,This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups.",NA,Yes,NA
im,IRCT20150824023743N2,http://en.irct.ir/trial/41023,"Intervention 1: Intervention group: In this group patients  that received  Meropenem (Dana company)   2g every 8 hour  , injectable Colistin ( Exir company) 4.5 million IU every 12 hour,  plus nebulized G-CSF(Sinagen company) with the dose of 150 microgram every 48h for 14 days. Intervention 2: Control group: In this group patients that received Meropenem (Dana copmany) 2 gr every 8 hours, injectable Colistin  (Exir company ) pluse nebulized Colistin 4.5 million units every 12 hours for 14 days.",NA,NA,NA
im,IRCT20150825023760N7,http://en.irct.ir/trial/31599,"Intervention 1: Intervention  group: This group has received the assessed combination therapy, including hydrocortisone (50mg/each 6h, intravenously), vitamin C (1.5g/6h in 100ml  DW5%, intravenously), and thiamine (200mg/12h in 50ml  DW5%, intravenously)in addition to standard septic shock treatment protocols for seventy two hours. Intervention 2: Control group: This group has treated by standard  septic shock  treatment protocols including  antibiotic therapy, prophylaxis of deep venous thrombosis, sedative medications, mechanical ventilation and prescription of vasopressor without additional intervention .",NA,Yes,Yes
covid,IRCT20150914024017N1,http://en.irct.ir/trial/46665,"Intervention 1: Intervention group: subcutaneous injection of Recigen (44mcg) daily until 5 days or the discharge day (which ever come sooner) in addition to standard treatment (based on the Ministry of Health protocol: chloroquine, etc .. ). Intervention 2: Control group: subcutaneous injection of placebo daily until 5 days or the discharge day (which ever come sooner) in addition to standard treatment (based on the Ministry of Health protocol: chloroquine, etc .. ).",NA,Yes,NA
im,IRCT201510172342N4,http://en.irct.ir/trial/1994,Intervention 1: control group: dose of 5 mg/ kg once daily group 1. Intervention 2: intervention group: dose of 2.5 mg/ kg twice daily in Group 2.;Treatment - Drugs;Treatment - Drugs;control group: dose of 5 mg/ kg once daily group 1;intervention group: dose of 2.5 mg/ kg twice daily in Group 2,NA,NA,NA
im,IRCT2015101724575N1,http://en.irct.ir/trial/20710,"Intervention 1: The first group (Intervention): 250mg Imiquimod 5% cream (Aldara)<br>was rubbed on deltoid region of right arm, and after 15 minutes, 0.25cc of trivalent influenza vaccine was injected intradermal.<br>      The applied inactivated trivalent influenza vaccines in this study, complied with the WHO recommendations for northern hemisphere and European Union decision for the 2015/2016 season, and contained seasonal split-virus of theses strains: -A/California/07/2009 (H1N1)pdm09–like strain, -Influenza A/Switzerland/9715293/2013 (H3N2)–like strain and -Influenza B/Phuket/3073/2013. They contained 15 µg hemagglutinin of each strain per 0.5 cc of the vaccine. Intervention 2: The second group (Intervention/Control): received 0.25cc trivalent influenza vaccine via intradermal route after rubbing 250 mg aqueous cream in the same region with the<br>same prior interval.  <br>The applied inactivated trivalent influenza vaccines in this study, complied with the WHO recommendations for northern hemisphere and European Union decision for the 2015/2016 season, and contained seasonal split-virus of theses strains: -A/California/07/2009 (H1N1)pdm09–like strain, -Influenza A/Switzerland/9715293/2013 (H3N2)–like strain and -Influenza B/Phuket/3073/2013.  They contained 15 µg hemagglutinin of each strain per 0.5 cc of the vaccine. Intervention 3: The third group (control): 0.5 cc trivalent influenza vaccine was injected intramuscular after using 250 mg aqueous topical cream on the same area. <br>      The applied inactivated trivalent influenza vaccines in this study, complied with the WHO recommendations for northern hemisphere and European Union decision for the 2015/2016 season, and contained seasonal split-virus of theses strains: -A/California/07/2009 (H1N1)pdm09–like strain, -Influenza A/Switzerland/9715293/2013 (H3N2)–like strain and -Influenza B/Phuket/3073/2013. They contained 15 µg hemagglutinin of each strain per 0.5 cc of the vaccine.;Treatment - Drugs;Placebo;Prevention;The first group (Intervention): 250mg Imiquimod 5% cream (Aldara)<br>was rubbed on deltoid region of right arm, and after 15 minutes, 0.25cc of trivalent influenza vaccine was injected intradermal.<br>      The applied inactivated trivalent influenza vaccines in this study, complied with the WHO recommendations for northern hemisphere and European Union decision for the 2015/2016 season, and contained seasonal split-virus of theses strains: -A/California/07/2009 (H1N1)pdm09–like strain, -Influenza A/Switzerland/9715293/2013 (H3N2)–like strain and -Influenza B/Phuket/3073/2013. They contained 15 µg hemagglutinin of each strain per 0.5 cc of the vaccine.;The second group (Intervention/Control): received 0.25cc trivalent influenza vaccine via intradermal route after rubbing 250 mg aqueous cream in the same region with the<br>same prior interval.  <br>The applied inactivated trivalent influenza vaccines in this study, complied with the WHO recommendations for northern hemisphere and European Union decision for the 2015/2016 season, and contained seasonal split-virus of theses strains: -A/California/07/2009 (H1N1)pdm09–like strain, -Influenza A/Switzerland/9715293/2013 (H3N2)–like strain and -Influenza B/Phuket/3073/2013.  They contained 15 µg hemagglutinin of each strain per 0.5 cc of the vaccine.;The third group (control): 0.5 cc trivalent influenza vaccine was injected intramuscular after using 250 mg aqueous topical cream on the same area. <br>      The applied inactivated trivalent influenza vaccines in this study, complied with the WHO recommendations for northern hemisphere and European Union decision for the 2015/2016 season, and contained seasonal split-virus of theses strains: -A/California/07/2009 (H1N1)pdm09–like strain, -Influenza A/Switzerland/9715293/2013 (H3N2)–like strain and -Influenza B/Phuket/3073/2013. They contained 15 µg hemagglutinin of each strain per 0.5 cc of the vaccine.",Yes,NA,NA
im,IRCT2015101924606N1,http://en.irct.ir/trial/20733,"Intervention 1: Amp Neurepinephrine, 0.5 micro gram/kilogram/minutes, For 2 hours. Intervention 2: Amp Dopamine, 5microgram/kilogram/minutes, For 2 hours.",NA,NA,NA
im,IRCT201511023576N3,http://en.irct.ir/trial/3679,Intervention 1: The intervention group: start the standard antibiotic treatment for pneumonia and  received 1000 units of vitamin D daily for 7 days from the second day after the entry into the study. Intervention 2: Control group: Starting the standard antibiotic treatment for pneumonia and received placebo tablets with the same shape and size from the second day after entry into the study.;Treatment - Drugs;Treatment - Drugs;The intervention group: start the standard antibiotic treatment for pneumonia and  received 1000 units of vitamin D daily for 7 days from the second day after the entry into the study;Control group: Starting the standard antibiotic treatment for pneumonia and received placebo tablets with the same shape and size from the second day after entry into the study,NA,Yes,Yes
covid,IRCT20151113025025N3,http://en.irct.ir/trial/46531,Intervention 1: Intervention group: Discontinuation of agents inhibiting renin-angiotensin-aldosterone system substituting by calcium channel blocker with or without beta-blocker. Intervention 2: Control group: Continuation of renin-angiotensin-aldosterone inhibiting agents.,NA,NA,NA
im,IRCT201512115363N8,http://en.irct.ir/trial/5758,Intervention 1: Intervention group 1: 10 ml Rose extract at a 0.5 percent concentration and 10 ml oral solution of chlorhexidine at a 0.12 percent will be given as a mouthwash three times a day. Intervention 2: Intervention group 2: 10 ml oral solution of chlorhexidine at a 0.12 percent will be given as a mouthwash three times a day.,NA,NA,NA
im,IRCT20151220025619N5,http://en.irct.ir/trial/37663,"Intervention 1: Intervention group: In the intervention group, neonates will receive an inhaled venolyme dose of 0.2 mg / kg by nebulizer for 20 minutes in addition to the surfactant. Intervention 2: Control group: Control group: In the control group, newborns, in addition to surfactants, will receive a normal dose of saline 0.5 mg / kg by nebulizer for 20 minutes.",NA,NA,NA
covid,IRCT20151222025660N2,http://en.irct.ir/trial/47319,"Intervention 1: Intervention group: They will receive 400 mg of hydroxychloroquine (Tehran Darou, Iran) a week for eight weeks and also this group will receive routine care for Corona's new disease. Intervention 2: Control group: They will receive routine care for Corona's new disease.",NA,Yes,NA
covid,IRCT20151227025726N12,http://en.irct.ir/trial/46561,Intervention group: Tab Hydroxychloroquine 400 mg P.O. BID for five days plusTab Oseltamivir 75 mg P.O. BID for five days plus Tab Lopinavir-Ritonavir 200/50 mg P.O. two tablets BID for five days plus Interferon beta-1a 44 mg every other day S.C for 10 days.,NA,Yes,NA
covid,IRCT20151227025726N14,http://en.irct.ir/trial/46942,"Intervention 1: Intervention group: Favipiravir (Toliddaru-Sobhan Oncology company, Iran) at dose of 1600 mg BID for one day and then 600 mg BID for totally 7 days with the standard and supportive care. Intervention 2: Control group: Lopinavir-ritonavir (Heterd company, India) at dose of 200/50 mg two tablets BID for 7 days with the standard and supportive care.",NA,Yes,NA
im,IRCT20151227025726N9,http://en.irct.ir/trial/21471,"Intervention 1: Intervention group: Received IV colistin (Colistimethate Sodium Injection, powder for solution parenteral 1000000 [IU] that belongs to Forest Laboratories Uk) based on Glomerular Filtration Rate (GFR) plus two million units of AS colistin , three times per day. Dose adjustments of IV Colistin were implemented based on table that belongs to Systematic review of the evidence for rational dosing of colistin. Prescribtion of IV colistin was countinued until the infection was completely resolved; AS colistin was prescribed only for a period of seven days (OMRON Mesh Nebulizer Model NE-U22). To prevent bronchospasm caused by nebulized colistin, patients were premedicated with salbutamol prior to administration of nebulized colistin. Intervention 2: Control group: Intravenous Colistin based on Glomerular Filtration Rate.",NA,NA,NA
im,IRCT2016011225986N1,http://en.irct.ir/trial/21665,Intervention 1: Zataria Multiflora Boiss%0.5  oral solution three times a day up to the end of extubation. Intervention 2: Chlorhexidine  0.12% oral solution three times a day up to the end of extubation. Intervention 3: Placebo( normal saline) oral solution three times a day up to the end of extubation.;Prevention;Prevention;Prevention;Zataria Multiflora Boiss%0.5  oral solution three times a day up to the end of extubation;Chlorhexidine  0.12% oral solution three times a day up to the end of extubation;Placebo( normal saline) oral solution three times a day up to the end of extubation,NA,NA,NA
im,IRCT2016012412257N4,http://en.irct.ir/trial/12356,Intervention 1: Oral rinse with 12.5% honey solution will be done twice a day (8AM-8PM) with a sterile technique and during complete 4 days by two trained nurses. Intervention 2: Oral rinse with 0.2% chlorhexidine solution will be done twice a day (8AM-8PM) with a sterile technique and during complete 4 days by two trained nurses.;Prevention;Prevention;Oral rinse with 12.5% honey solution will be done twice a day (8AM-8PM) with a sterile technique and during complete 4 days by two trained nurses.;Oral rinse with 0.2% chlorhexidine solution will be done twice a day (8AM-8PM) with a sterile technique and during complete 4 days by two trained nurses.,NA,NA,NA
covid,IRCT20160131026298N3,http://en.irct.ir/trial/47019,"Intervention 1: Intervention group: The medicinal product includes a capsule composed of two herbs(salix ,lambs quarter). The amount of each of these substances in the capsule is 250 mg. The dosage of the product is three capsules a day, which is half an hour before each meal. This product is prepared by Armaghan Sabz Araz Teb Pharmaceutical Company.In this group, common medical drug is also consumed according to the latest protocol of the Ministry of Health. Intervention 2: Control group: Patient in control group use  common medicine based on the latest protocol of the Ministry of Health and placebo.",NA,NA,Yes
covid,IRCT20160131026298N6,http://en.irct.ir/trial/50246,Intervention 1: Intervention group: Intervention groups will be two ones. Patients in the intervention group will receive the intervention drug (three capsules a day and ten grams of black seed mixture daily) that is made by Talaye sabze tooba company; in addition to the routine treatment (Azithromycin 250 mg daily for  10 days and Naproxen 250 mg twice a day for 10 days) . Intervention 2: Control group: The control group will receive the routine treatment (Azithromycin 250 mg daily for  10 days and Naproxen 250 mg twice a day for 10 days) .,NA,Yes,NA
main,IRCT20160215026563N2,http://en.irct.ir/trial/35911,Intervention group: Patients who have had a complete treatment period with intralesional glucantime injections and have resistance to treatment (no clinical improvement of lesions after 12 sessions of injection) enter the study through convenience sampling. These patients receive weekly intramuscular injection of Nimodipine for 10 weeks as treatment. The amount of medication required for intralesional injection is 30 µg / ml..,NA,NA,NA
im,IRCT2016042027498N1,http://en.irct.ir/trial/22510,"Two blood sample will be taken from enrolled infants for measurement of antibody serum titer against Diphtheria, Pertussis, Tetanus, Hepatitis B and Hib separately, the first sample will be taken immediately before first dose injection of vaccine and the second sample will be taken 4-6 weeks after third dose injection..;Prevention;Two blood sample will be taken from enrolled infants for measurement of antibody serum titer against Diphtheria, Pertussis, Tetanus, Hepatitis B and Hib separately, the first sample will be taken immediately before first dose injection of vaccine and the second sample will be taken 4-6 weeks after third dose injection.",Yes,NA,NA
main,IRCT20160422027520N13,http://en.irct.ir/trial/41180,"Intervention 1: Intervention group: Fifteen patients with knee osteoarthritis receive Autologous Conditioned Serum as the intervention group. Initially, receive informed consent from the patients and the following will be recorded for these patients who meet the inclusion criteria: 1) Pain by VAS 2) Knee function by WOMAC 3) Knee function by KOOS 4) Flexion range of motion (ROM). In this group of patients, 10 ml of blood was taken by ACS-specific syringe manufactured by Pishtaz teb zaman CO. and after incubation of this syringe according to protocol kit, we separate the ACS. The ACS is then injected by a physician into one of the two knees of the patient with knee osteoarthritis. The injection volume of  ACS is 2 cc.Repeat injections twice again 21 days apart.Then, in order to evaluate the effect of ACS on patients in the intervals and Compare it with another patient's knees who received normal saline, 1, 3 and 6 months after the first injection, 1) Pain by VAS 2) Knee function by WOMAC 3) Knee function by KOOS 4) Flexion range of motion (ROM) will be recorded. Intervention 2: Control group: Fifteen patients with knee osteoarthritis receive normal saline (NS) as the intervention group. Initially,  receive informed consent from the patients and the following will be recorded for these patients who meet the inclusion criteria: 1) Pain by VAS 2) Knee function by WOMAC 3) Knee function by KOOS 4) Flexion range of motion (ROM). Then NS by the physician is injected into another patient's knee. Repeat injections twice again 21 days apart. Then, in order to evaluate the effect of NS on patients in the intervals and Compare it with another patient's knees who received ACS, at 1, 3 and 6 months after the first injection, 1) Pain by VAS 2) Knee function by WOMAC 3) Knee function by KOOS 4) Flexion range of motion (ROM) will be recorded.",NA,NA,NA
im,IRCT201604241165N13,http://en.irct.ir/trial/312,Intervention 1: Intervention group 1: 35 healthy individuals between the ages 18 to 65; injection of one dose of Flupak seasonal Influenza vaccine. Intervention 2: Intervention group2: 35 healthy persons  between the ages 18 to 65; injection of  one dose of Vaxigrip Influenza vaccine. Intervention 3: Control group: 30 healthy persons  between the ages 18 to 65; injection of 0.5 mili liter of sterile and injectable Phosphate buffered saline (1x).;Prevention;Prevention;Placebo;Intervention group 1: 35 healthy individuals between the ages 18 to 65; injection of one dose of Flupak seasonal Influenza vaccine.;Intervention group2: 35 healthy persons  between the ages 18 to 65; injection of  one dose of Vaxigrip Influenza vaccine.;Control group: 30 healthy persons  between the ages 18 to 65; injection of 0.5 mili liter of sterile and injectable Phosphate buffered saline (1x),Yes,NA,NA
main,IRCT20160516027925N4,http://en.irct.ir/trial/39589,"Intervention 1: Intervention group: At the last 30 minutes of the surgery,1000 mg acetaminophen infusion and 4 mg of ondansetron will be injected. Intervention 2: Intervention group: At the last 30 minutes of the surgery, 1000 mg acetaminophen infusion and 8 mg of ondansetron will be injected. Intervention 3: Control group: at the last 30 minutes of the surgery, 1000 mg acetaminophen infusion and 10 mg of metoclopramide will be injected.",NA,NA,NA
im,IRCT2016051927969N1,http://en.irct.ir/trial/22798,"Intervention 1: In the intervention group, mouthwash (disinfection cheeks, gums, palate, tongue and teeth) every 8 hours  with 10 ml of ready solution of 0.2% chlorhexidine is performed by the applicator for 30 second. Also every 8 hours after oral antiseptic, anti-infectious of nasal anterior openings is performed  with 0.2% chlorhexidine solution by cotton swab. This continues until the end of the fifth day of mechanical ventilation. Intervention 2: In the control group, mouthwash (disinfection cheeks, gums, palate, tongue and teeth) every 8 hours  with 10 ml of ready solution of 0.2% chlorhexidine is performed by the applicator for 30 second. This continues until the end of the fifth day of mechanical ventilation. In this group  is not done disinfection of nose.;Prevention;Prevention;In the control group, mouthwash (disinfection cheeks, gums, palate, tongue and teeth) every 8 hours  with 10 ml of ready solution of 0.2% chlorhexidine is performed by the applicator for 30 second. This continues until the end of the fifth day of mechanical ventilation. In this group  is not done disinfection of nose.;In the intervention group, mouthwash (disinfection cheeks, gums, palate, tongue and teeth) every 8 hours  with 10 ml of ready solution of 0.2% chlorhexidine is performed by the applicator for 30 second. Also every 8 hours after oral antiseptic, anti-infectious of nasal anterior openings is performed  with 0.2% chlorhexidine solution by cotton swab. This continues until the end of the fifth day of mechanical ventilation.",NA,NA,NA
im,IRCT2016072420592N7,http://en.irct.ir/trial/18242,Intervention 1: Intervention:<br>The patients in intervention group received 2 gr daily of Borage seed extract for 5 days. Intervention 2: Control:<br>The patients in control group received 2 gr daily of placebo for 5 days.;Treatment - Drugs;Treatment - Drugs;Intervention:<br>The patients in intervention group received 2 gr daily of Borage seed extract for 5 days.;Control:<br>The patients in control group received 2 gr daily of placebo for 5 days.,NA,NA,Yes
covid,IRCT20160809029275N1,http://en.irct.ir/trial/48187,"Intervention 1: Intervention group: Group receiving mesenchymal stem cells. In this group, patients in 3 times (1, 3 and 6 days) are received 1 million Umbilical core-derived MSCc/BW by intravenous injection ( Through the catheter and the Central vein and from the superior vena cava vein ). Also, in addition to cell therapy,Other common treatments will be given to patients according to the physician's supervision.Mesenchymal  Stem cells had an ISCT standard and were given from  a healthy donor. Blood samples were given from patients on days 0, 2, and 7, as well as 14 days after the second injection and patients will follow for 20 days (in terms of clinical and immunological parameters).It should be noted that of all patients at the beginning of the study conscious consent form will be received. Intervention 2: Control group: Receiving common therapies (without stem cell). In this group, patients are received other common treatments including antiviral drugs and etc In accordance with the physician's opinion and do not receive stem cells.",NA,Yes,NA
im,IRCT20160813029327N18,http://en.irct.ir/trial/30725,Intervention 1: Intervention group: patient receives metoclopramide 10 milligram -three times a day for 5 days.first dose prescribe in form of ampul and should be used from intravenous route.the other doses prescribe in form of tablet and should be used in route of gavage. Intervention 2: Control group: patients in this group dont receive any drug or interventio n and we just monitor them .,NA,NA,NA
main,IRCT20160815029374N4,http://en.irct.ir/trial/34098,"Intervention 1: Intervention group: Use of GnRH Agonist ampule (Variopeptil, 0.1 mg, SC, varian farmed, Iran) 0.2mg plus HCG (Choriomon ,5000 IU , IM, IBSA company , Switzerland) on HCG injection day. Intervention 2: Control group: Use of HCG injection alone (Choriomon ,5000 IU , IM, IBSA company , Switzerland) on HCG injection day.",NA,NA,NA
main,IRCT20160901029640N2,http://en.irct.ir/trial/42615,"Intervention 1: Intervention group: Receiving three drugs hydrocortisone (50 mg, every 6 hours, 7 days or until ICU discharge), thiamine (200 mg, every 12 hours, 4 days or until ICU discharge), Ascorbic acid (1,500 mg, every 6 hours, 4 days or until ICU discharge) + Standard treatment of intensive care unit. Intervention 2: Control group: Receiving standard treatment of intensive care unit.",NA,NA,NA
im,IRCT2016092529327N2,http://en.irct.ir/trial/23604,"Intervention 1: Intervention group  will receive standardized extract containing 130 milligrams of poly phenol three times a day at 8 AM, 2 PM and 8 PM for one week. Intervention 2: Control group  will receive placebo three times a day at 8 AM, 2 PM and 8 PM for one week.;Treatment - Drugs;Placebo;Intervention group  will receive standardized extract containing 130 milligrams of poly phenol three times a day at 8 AM, 2 PM and 8 PM for one week;Control group  will receive placebo three times a day at 8 AM, 2 PM and 8 PM for one week",NA,NA,NA
im,IRCT2016101917413N21,http://en.irct.ir/trial/16031,Intervention 1: ?First group will undergo treatment with Intravenous Dexamethasone 0.15 mg/kg every 12 hours for 3 to 5 days. Intervention 2: The second group will undergo treatment with inhaler N-Acetyl Cysteine through jet nebulizer (400 mg every 8 hours) for 3 to 5 days.;Treatment - Drugs;Treatment - Drugs;?First group will undergo treatment with Intravenous Dexamethasone 0.15 mg/kg every 12 hours for 3 to 5 days;The second group will undergo treatment with inhaler N-Acetyl Cysteine through jet nebulizer (400 mg every 8 hours) for 3 to 5 days.,NA,Yes,NA
im,IRCT2016111617413N22,http://en.irct.ir/trial/16032,Intervention 1: The second group will undergo treatment with inhaler Albuterol plus Budesonide through jet nebulizer (400 mcg every 12 hours) for 3 to 5 days. Intervention 2: First group will undergo treatment with Albuterol Nebulizer 0.5 mg/kg every 8 hours for 3 to 5 days.;Treatment - Drugs;Treatment - Drugs;The second group will undergo treatment with inhaler Albuterol plus Budesonide through jet nebulizer (400 mcg every 12 hours) for 3 to 5 days.;First group will undergo treatment with Albuterol Nebulizer 0.5 mg/kg every 8 hours for 3 to 5 days,NA,NA,NA
im,IRCT2017010531786N1,http://en.irct.ir/trial/24926,Intervention 1: In the first group of intervention; the intervention is the injection of 1 million stromal cells of embryonic membranes intravenously in 30 minutes. Intervention 2: In the second group of intervention; the intervention is the injection of 2 million stromal cells of embryonic membranes intravenously in 30 minutes. Intervention 3: In the third group of intervention; the intervention is the injection of 5 million stromal cells of embryonic membranes intravenously in 30 minutes.;Treatment - Drugs;Treatment - Drugs;Treatment - Drugs;In the first group of intervention; the intervention is the injection of 1 million stromal cells of embryonic membranes intravenously in 30 minutes.;In the second group of intervention; the intervention is the injection of 2 million stromal cells of embryonic membranes intravenously in 30 minutes.;In the third group of intervention; the intervention is the injection of 5 million stromal cells of embryonic membranes intravenously in 30 minutes.,NA,NA,NA
im,IRCT2017012232101N1,http://en.irct.ir/trial/25092,"Intervention 1: The intervention group (mouthwash ortodentoll) ortodentol mouthwash solution containing 10% carvacrol extracts pharmaceutical company Khorramabad, Lorestan building twice a day (morning and evening) each time mouthwash is 15 mm Lytrba used syringes and Ghshh to brush and suction the patient's mouth in 30 seconds. Intervention 2: The control group (chlorhexidine)Control (chlorhexidine) solution of chlorhexidine / 12% Manufacturing Co. World Health Tehran twice a day (morning and evening) patients intubated mouth rinse with a solution of 15 ml is washed with brushes and suction is then washed and the amount and Read mouth rinse is similar to the intervention group.;Prevention;Prevention;The intervention group (mouthwash ortodentoll) ortodentol mouthwash solution containing 10% carvacrol extracts pharmaceutical company Khorramabad, Lorestan building twice a day (morning and evening) each time mouthwash is 15 mm Lytrba used syringes and Ghshh to brush and suction the patient's mouth in 30 seconds.;The control group (chlorhexidine)Control (chlorhexidine) solution of chlorhexidine / 12% Manufacturing Co. World Health Tehran twice a day (morning and evening) patients intubated mouth rinse with a solution of 15 ml is washed with brushes and suction is then washed and the amount and Read mouth rinse is similar to the intervention group.",NA,NA,NA
main,IRCT20170123032145N4,http://en.irct.ir/trial/42381,Intervention 1: Intervention group: : Sertraline(Tab) up to 200 mg/day plus Memantine (Tab) 10mg twice per day for 12 weeks. Intervention 2: Control group: Sertraline(Tab) up to 200 mg/day plus placebo(Tab) twice per day for 12 weeks.,NA,NA,NA
im,IRCT2017022032676N1,http://en.irct.ir/trial/25392,Intervention 1: chlorhexidin mouth wash. Intervention 2: Persica mouth wash.;Treatment - Drugs;Treatment - Drugs;chlorhexidin mouth wash;Persica mouth wash,NA,NA,NA
covid,IRCT20170315033086N7,http://en.irct.ir/trial/52223,"Intervention 1: Intervention group: Patients who receive natural product Faramir containing Salvia officinalis extract (750 mg oral caplet, 6 times a day, every 4 hours and for 8 days) along with standard treatments.The active ingredient of the medicinal species of ?Salvia officinali is prepared from the leaves of the medicinal species of the plant by Meem Pharmaceutical Factory and will be stored in closed containers in conditions away from light and moisture. Intervention 2: Control group: Patients who receive only standard treatments.",NA,NA,Yes
main,IRCT20170408033280N2,http://en.irct.ir/trial/34766,Intervention 1: Intervention group:Administration of 8 mg oral Beta-histein 90 minutes before surgery. Intervention 2: Control group: Oral administration of the placebo 90 minutes before surgery.,NA,NA,NA
im,IRCT2017041733480N1,http://en.irct.ir/trial/25808,Intervention 1: First group: administration of amiodarone 300 mg in 30 mL of normal saline rapidly and if previous rhythm continued after 5 minutes then administration of other 150 mg of amiodarone. Intervention 2: Second group: administration of lidocaine 1.5 mg per kg per hour if previous rhythm continued after 10 minutes then administration 75 mg per kg per hour of lidocaine.;Treatment - Drugs;Treatment - Drugs;First group: administration of amiodarone 300 mg in 30 mL of normal saline rapidly and if previous rhythm continued after 5 minutes then administration of other 150 mg of amiodarone;Second group: administration of lidocaine 1.5 mg per kg per hour if previous rhythm continued after 10 minutes then administration 75 mg per kg per hour of lidocaine,NA,Yes,NA
im,IRCT2017050727819N4,http://en.irct.ir/trial/22712,"Intervention 1: Intervention group: mouthwash will be performed by 10 mL orthodentol, three times a day for two weeks. Intervention 2: Control group: mouthwash will be performed by 10 mL chlorhexidine, three times a day for two weeks.;Prevention;Prevention;Intervention group: mouthwash will be performed by 10 mL orthodentol, three times a day for two weeks.;Control group: mouthwash will be performed by 10 mL chlorhexidine, three times a day for two weeks.",NA,NA,NA
im,IRCT20170513033941N54,http://en.irct.ir/trial/34514,"Intervention 1: Intervention group 1: 200 mg/kg intratracheal Curosurf surfactant (Chiesi Farmaceutici, Parma, Italy). Intervention 2: Intervention group 2: 135 mg/kg intratracheal BLES surfactant (BLES Biochemicals Inc., Ontario, Canada).",NA,NA,NA
main,IRCT20170513033941N58,http://en.irct.ir/trial/39531,"Intervention 1: Intervention group: 100 mg thiamine (Shafa Pharmaceutical Company, Karaj, Iran) daily for 6 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran), daily for 6 weeks orally.",NA,NA,NA
im,IRCT2017053034219N1,http://en.irct.ir/trial/26201,"Intervention 1: In the intervention group: budesonide (Pulmicort vials, product of Astrazenca Co., Canada) 0.25 mg / kg as endotracheal nebulizer immediately after standard treatment. Intervention 2: The standard treatment control group: Curosurf surfactant Manufactured by Cheisi Co., Italy, at a rate of 2.5 ml/kg initially, and an extra dose of 1.5 ml/kg, if necessary.;Treatment - Drugs;Treatment - Drugs;In the intervention group: budesonide (Pulmicort vials, product of Astrazenca Co., Canada) 0.25 mg / kg as endotracheal nebulizer immediately after standard treatment;The standard treatment control group: Curosurf surfactant Manufactured by Cheisi Co., Italy, at a rate of 2.5 ml/kg initially, and an extra dose of 1.5 ml/kg, if necessary",NA,NA,NA
im,IRCT20170614034532N2,http://en.irct.ir/trial/26366,"Intervention 1: Intervention group: Patients receive a loading dose of 150,000 IU/Kg.The loading dose is followed by 50,000 IU every 8 hours. Clinical, microbiological and laboratory findings are collected for each patient on 1th and 4th day after treatment.The Nephrotoxicity is assessed based on PRIFLE recommendation on day 4 after treatment. Intervention 2: Control group:Patients receive Colistin at the dose of 50,000 IU every 8 hours. Clinical, microbiological and laboratory findings are collected for each patient on 1th and 4th day after treatment.The Nephrotoxicity is assessed based on PRIFLE recommendation on day 4 after treatment.",NA,NA,NA
im,IRCT201706172582N17,http://en.irct.ir/trial/2360,"Intervention 1: intervention group 1: these patients will be administered with 4 mg of intravenous selenase (produced by Biosyn company, Germany). Then, for 3 days the will receive 1mg/12h then for the last 10 days they will be injected by 1mg/day of it. Intervention 2: Control group 1: they will receive placebo with the exact same doses.;Treatment - Drugs;Placebo;intervention group 1: these patients will be administered with 4 mg of intravenous selenase (produced by Biosyn company, Germany). Then, for 3 days the will receive 1mg/12h then for the last 10 days they will be injected by 1mg/day of it.;Control group 1: they will receive placebo with the exact same doses.",NA,NA,NA
im,IRCT20170627034782N2,http://en.irct.ir/trial/42913,"Intervention 1: Intervention group: In the caffeine given group (C), the premature neonate with a weight between 1250-2000 germ and spontaneous breathing with clinical signs and symptoms of RDS and requiring nasal CPAP, 20 mg/kg caffeine as loading dose will be begun (parenteral) and then each day, 10 mg/kg as maintenance dose will be used until  discontinuation of CPAP and oxygen administration . Intervention 2: Control group:In control group (P), the premature neonate with a weight between 1250-2000 germ and spontaneous breathing with clinical signs and symptoms of RDS and requiring nasal CPAP no caffeine or placebo was used.",NA,Yes,NA
im,IRCT2017082517413N27,http://en.irct.ir/trial/16037,Intervention 1: First group: Fentanyl 0.5 mcg/kg as single dose. Intervention 2: Second group: Fentanyl 1 mcg/kg as single dose.;Treatment - Drugs;Treatment - Drugs;First group: Fentanyl 0.5 mcg/kg as single dose;Second group: Fentanyl 1 mcg/kg as single dose,NA,NA,NA
im,IRCT2017091636194N1,http://en.irct.ir/trial/27125,"Intervention 1: Intervention group: During a five day period, using ten milliliters of Nanosil mouthwash(made in Iran, Kimiafam pharmaceutical company), oral care and decontamination will be performed for the experimental group every eight hours in the form of a twelve-stage program. These stages include: washing the hands of the caregiver, preparing the required equipment, wearing gloves, evaluating and recording oral and dental conditions, ensuring the at least 30 degrees head-up position, protocol-based oral and throat suctioning, rewashing the hands of the caregiver, exchanging gloves, using soft toothbrushes for washing the mouth, teeth and tongue, washing the mouth with physiological serum, rubbing 10 milliliters of Nanosil mouthwash in oral space and oropharynx by means of swab, and moisturizing the lips with Hydroderm cream. Intervention 2: Control group: During a five day period, using ten milliliters of Chlorhexidine mouthwash%0.12(made in Iran, Behsa company), oral care and decontamination will be performed for the experimental group every eight hours in the form of a twelve-stage program. These stages include: washing the hands of the caregiver, preparing the required equipment, wearing gloves, evaluating and recording oral and dental conditions, ensuring the at least 30 degrees head-up position, protocol-based oral and throat suctioning, rewashing the hands of the caregiver, exchanging gloves, using soft toothbrushes for washing the mouth, teeth and tongue, washing the mouth with physiological serum, rubbing 10 milliliters of Chlorhexidine mouthwash in oral space and oropharynx by means of swab, and moisturizing the lips with Hydroderm cream.;Prevention;Prevention;Intervention group: During a five day period, using ten milliliters of Nanosil mouthwash(made in Iran, Kimiafam pharmaceutical company), oral care and decontamination will be performed for the experimental group every eight hours in the form of a twelve-stage program. These stages include: washing the hands of the caregiver, preparing the required equipment, wearing gloves, evaluating and recording oral and dental conditions, ensuring the at least 30 degrees head-up position, protocol-based oral and throat suctioning, rewashing the hands of the caregiver, exchanging gloves, using soft toothbrushes for washing the mouth, teeth and tongue, washing the mouth with physiological serum, rubbing 10 milliliters of Nanosil mouthwash in oral space and oropharynx by means of swab, and moisturizing the lips with Hydroderm cream.;Control group: During a five day period, using ten milliliters of Chlorhexidine mouthwash%0.12(made in Iran, Behsa company), oral care and decontamination will be performed for the experimental group every eight hours in the form of a twelve-stage program. These stages include: washing the hands of the caregiver, preparing the required equipment, wearing gloves, evaluating and recording oral and dental conditions, ensuring the at least 30 degrees head-up position, protocol-based oral and throat suctioning, rewashing the hands of the caregiver, exchanging gloves, using soft toothbrushes for washing the mouth, teeth and tongue, washing the mouth with physiological serum, rubbing 10 milliliters of Chlorhexidine mouthwash in oral space and oropharynx by means of swab, and moisturizing the lips with Hydroderm cream.",NA,NA,NA
main,IRCT20171014036771N1,http://en.irct.ir/trial/36280,Intervention 1: Intervention group: intrathecal Dexmedetomidine group                                        spinal anesthesia with 3ml (15mg) hyperbaric bupivacaine 0.5% (Marcaine spinal 0.5% AstraZeneca) + 0.5ml Dexmedetomidine (Precedex 100µg/ml) from its diluted solution as 10µg/ml (5µg) and infused intravenous NaCl 0.9% first 1ml/kg/10min and then 0.5ml/kg/hour. Intervention 2: Intervention group: intravenous Dexmedetomidine group                     spinal anesthesia with 3ml (15mg) hyperbaric bupivacaine 0.5% (Marcaine spinal 0.5% AstraZeneca) + 0.5ml NaCl 0.9% and infused intravenous Dexmedetomidine (Precedex 100µg/ml) from its diluted solution as 1µg/ml first 1ml/kg/10min and then 0.5ml/kg/hour. Intervention 3: Control group: spinal anesthesia with 3ml (15mg) hyperbaric bupivacaine 0.5% (Marcaine spinal 0.5% AstraZeneca) + 0.5ml NaCl 0.9% and infused intravenous NaCl 0.9% first 1ml/kg/10min and then 0.5ml/kg/hour.,NA,Yes,NA
im,IRCT2017101631200N2,http://en.irct.ir/trial/24590,"Intervention 1: Adjusting the pressure of the cuff of the endotracheal tube  20 using a special manometer.Brushing all internal and external surfaces of the teeth, gums and tongue for 2 min using a baby toothbrush and antimicrobial chlorhexidine0.12% every 12 hours.Moisturizing all surfaces of the oral mucosa, gums, and tongue of the patient using swabs and moisturizing gel every 4 hours.<br>Thin layer of petroleum jelly was applied to the lip. Intervention 2: In the control group, oral care will be performed by staff based on the daily routine.;Prevention;Prevention;Adjusting the pressure of the cuff of the endotracheal tube  20 using a special manometer.Brushing all internal and external surfaces of the teeth, gums and tongue for 2 min using a baby toothbrush and antimicrobial chlorhexidine0.12% every 12 hours.Moisturizing all surfaces of the oral mucosa, gums, and tongue of the patient using swabs and moisturizing gel every 4 hours.<br>Thin layer of petroleum jelly was applied to the lip;In the control group, oral care will be performed by staff based on the daily routine.",NA,NA,NA
main,IRCT20171030037093N15,http://en.irct.ir/trial/40400,"Intervention 1: Intervention group: Patients received the usual drug treatment, including inhaled glucocorticoids (Fluticasone) and antihistamines once a day for one month. Intervention 2: Intervention group: Patients who had a positive prick test underwent immunotherapy with allergen extract with three vials diluted 1: 10,000 pg per week for 10 sessions, 1: 1000 pg every other week for 10 sessions and then dilution of 1: 100 pg every month for 2 years.",NA,NA,NA
im,IRCT20171224038046N1,http://en.irct.ir/trial/28507,"Intervention 1: Intervention group: 25 patients received 13 valent anti pneumococcal vaccine, after 8 weeks received 23 valent vaccine. Intervention 2: Control group: 25 patients receive 23 valent vaccine.",Yes,NA,NA
im,IRCT20171225038053N1,http://en.irct.ir/trial/33562,"Intervention 1: Intervention group: Mouthwash was performed in group A with oral chlorhexidine 0.2% by the researcher and his trained assistant. Intervention 2: Intervention group: In Group B, in addition to doing the above, 10 min after completing the work, 10 mL of hydrogen peroxide solution was poured into the Steel kidney tray, and the cotton swab was immersed in a 1.5% oxygenate solution and oral cavity, tongue, and teeth were washed for 2 minutes, and at the end of mouthwash, a deep throat mouth suction was taken.",NA,NA,NA
im,IRCT20180110038298N1,http://en.irct.ir/trial/28891,"Intervention 1: Intervention group: On the first day of intubation, oral washing perform four times a day, with normal saline solution. On the second day of intubation, collect the initial sample of the pharyngeal and tracheal secretions and sent to the laboratory for culture, then with a 2% concentration of poly-myxin, nystatin and neomycin, prepared and combined by investigator administer with a syringe on the oral cavity and the lips are used in such a way that the mucus is impregnated with it. This action is repeated four times after normal oral saline mouthwash. The duration of the study is at least three days, and if the terms of exclusion are not established, it lasts for a maximum of five days. At the end of the fifth day, the throat and tracheal secretions are again sampled and the intervention is completed. Intervention 2: Control group: On the first day of intubation, mouth washing is perform four times in day, with normal saline solution. On the second day, first sampled the tracheal and pharyngeal discharge, then, daily after each oral wash with normal saline, a solution with the appearance and volume of the same basic solution used by the researcher with a syringe in the mouth and lips, is applied in such a way that the mucosa is impregnated. This action is repeated four times. The duration of the study is at least three days, and if the terms of exclusion are not established, it lasts for a maximum of five days. At the end of the fifth day, the throat and tracheal secretions are again sampled and the intervention is completed.",NA,Yes,NA
covid,IRCT20180114038350N3,http://en.irct.ir/trial/47475,Intervention 1: Intervention group: Oral Deferiprone  is added to drugs used to treat Covid 19 (approved by the National Committee). Intervention 2: Control group: Patients receive only the drugs used to treat Quaid 19 (approved by the National Committee).,NA,NA,NA
covid,IRCT20180520039738N2,http://en.irct.ir/trial/46974,"Intervention 1: Intervention group:25000 IU vitamin A per day for ten days, the plus, the standard national treatment for COVID 19. Intervention 2: Control group: the standard national treatment for COVID19 ,and placebo.",NA,NA,Yes
im,IRCT20180520039739N2,http://en.irct.ir/trial/34921,Intervention 1: Intervention group: treatment with 10 cc of 0.2% chlorhexidine gluconate mouthwash (Emad darou company) 3 times per day for 5 days. Intervention 2: Intervention group: treatment with 20 drop of dine mouthwash (Dineh Iran) 3 times per day for 5 days.,NA,NA,NA
im,IRCT20180729040633N1,http://en.irct.ir/trial/32942,"Intervention 1: Intervention group: In intervention group, first we sedate the neonates with 2 micro gram of fentanyl per kilogram and then the mouth, nose and trachea are suctioned and surfactant is administrated via INSURE method (Intubation, Surfactant and Extubation) and mechanical ventilation is underwent. If decrease of received FIO2 to under 40% with NCPAP is impossible or worsening radiographic signs or clinical conditions after 6-12 hours of monitoring are seen, after re sedation with same dose of fentanyle , we start administrating 100 mg/kg as the second dose of surfactant and if decrease of FIO2 to less than 40% and normal clinical and radiologic signs are seen, the treatment is considered successful. Intervention 2: Control group: In control group, first, the mouth, nose and trachea are suctioned and surfactant is administrated via INSURE method (Intubation, Surfactant and Extubation) and mechanical ventilation is underwent. If decrease of received FIO2 to under 40% with NCPAP is impossible or worsening radiographic signs or clinical conditions after 6-12 hours of monitoring are seen, we start re administrating 100 mg/kg as the second dose of surfactant and if decrease of FIO2 to less than 40% and normal clinical and radiologic signs are seen, the treatment is considered successful.",NA,NA,NA
covid,IRCT20180802040678N4,http://en.irct.ir/trial/46824,"Intervention 1: Intervention group: In the case group, patients will receive 25 mg losartan tablets two times daily. Intervention 2: Intervention group: Patients will receive 5 mg amlodipine daily.",NA,NA,NA
main,IRCT20180901040915N1,http://en.irct.ir/trial/33595,"Intervention group: Receiving 1 mg (0.5 m.g in the morning, 0.5 m.g in the evening) Bumetanide (Purchased from Niche Generics Limited Ireland) twice a day for three months.",NA,NA,NA
main,IRCT20180905040955N1,http://en.irct.ir/trial/33710,"Intervention 1: Intervention group: In this group,  local dexamethasone  injection will perform then local anesthesia will perform. after surgical incision and bone removal third molar will extract. Then the tissue will suture with Silk suture 3 O and the patient will discharge. Measurements will taken in the later follow ups. Intervention 2: Intervention group: In this group,  intramuscular dexamethasone  injection will perform then local anesthesia will perform. after surgical incision and bone removal third molar will extract. Then the tissue will suture with Silk suture 3 O and the patient will discharge. Measurements will taken in the later follow ups.",NA,Yes,NA
main,IRCT20180921041079N1,http://en.irct.ir/trial/34050,"Intervention 1: Intervention group: From the 24 hours before the coronary artery bypass graft surgery, 3000 milligrams of L-carnitine solution (1 g per 10 ml) will be given at intervals of 8 hours. After the procedure, within 24 hours, the dietary intake of L-carnitine will be 3000 mg (1000 mg three times a day).  Since oral intake of carnitine is saturated in 2 grams, the doses are given in divided doses, also routine care (hydration with N.S. serum)is done. Intervention 2: Control group: The control group does not receive L-carnitine and only routine care is provided.",NA,NA,NA
main,IRCT20180923041092N1,http://en.irct.ir/trial/34180,Intervention 1: Intervention group: Participants in intervention group obtained a solution containing thymus vulgaris 2%. They were asked to spray solutions on to an orthodontic removable appliance.Swab from three specific of removable orthodontic appliance were taken three times: 1.At the beginning of study. 2. After two days. 3. After 5 five days. Intervention 2: Control group: Participants in control group obtained a solution containing Chlorhexidine 0/2%. They were asked to spray solutions on to an orthodontic removable appliance. Swab from three specific of removable orthodontic appliance were taken three times:1. At the beginning of study2. After two days3. After 5 five days.,NA,NA,NA
main,IRCT20181006041252N18,http://en.irct.ir/trial/42873,"Intervention 1: Intervention group: Patients in this group are treated with a quadruple regimen for 2 weeks: 1. Levofloxacin 500 mg twice daily 2. Bismuth subcitrate 120 mg four times daily 3. Amoxicillin 1 g twice daily 4. Pantoprazole 40 mg twice daily. Levofloxacin is provided by the Tavanx brand from Dr. Abidi company. After 4 weeks of treatment, the eradication of germs is assessed by a urea breath test. Intervention 2: Control group: Patients in this group are treated with a quadruple regimen for 2 weeks: 1. clarithromycin 500 mg twice daily 2. bismuth subcitrate 120 mg four times daily 3. amoxicillin 1 g twice daily 4. pantoprazole 40 mg. Clarithromycin is provided by the Fromilid brand from the Actoverco company. After 4 weeks of treatment, the eradication of germs is assessed by a urea breath test.",NA,Yes,NA
main,IRCT20181012041315N1,http://en.irct.ir/trial/37687,"Intervention 1: Intervention group: 1: Sterile water group, 0.5 ml intradermal Sterile water in 49 patients in Sterile water group was injected, then 5 ml intravenous normal saline was injected, patients were observed one hour after injection. Intervention 2: Intervention group: 2: Morphine group,1 ml/kg intravenous morphine in 49 patients in morphine group was injected, then 0.5 ml intradermal normal saline was injected, patients were observed one hour after injection.",NA,NA,NA
main,IRCT20181022041413N1,http://en.irct.ir/trial/34670,Intervention 1: Intervention group: The first intervention group: 61 patients receiving 20 ml of rupivacaine 0.2% once for epidural anesthesia. Intervention 2: Control group: Second intervention group: 61 patients receiving 20 ml of bupivacaine 0.5 once once for epidural anesthesia.,NA,Yes,NA
covid,IRCT20181030041504N1,http://en.irct.ir/trial/51482,Intervention 1: Intervention group: non-hospitalization patients with symptomatic COVID-19 received 1. Artemisia annua - Artemisinin ( Manufactured by Longlifenutri)150 mg every 24 hours 2. Dose of 1 g of vitamin C (Manufactured by Daroupakhsh) intravenous vitamin (2 ampoules of 500 mg in 250 cc of sodium chloride serum for 30 minutes) every 24 hours 3. Dose of 5 cc of noscapine ( Manufactured by Faran Shimi) each Eight hours 4. 500 mg dose of hesperidin (Manufactured by Swanson) every 24 hours 5. Resveratrol 500 mg (Manufactured by A Squard)  every 24 hours 6. NAC 600 mg ( Manufactured by Osvah ) every 12 hours . The duration of treatment is estimated at ten days. Supplements are taken orally and vitamin C is given to patients as an injection. Intervention 2: Control group: non-hospitalization patients with symptomatic COVID-19 Protocol of the Ministry of Health. Intervention 3: Intervention group: hospitalization patients with symptomatic COVID-19  received 1. Artemisia annua - Artemisinin ( Manufactured by Longlifenutri)150 mg every 12hours 2. Dose of 1 g of vitamin C (Manufactured by Daroupakhsh) intravenous vitamin (2 ampoules of 500 mg in 250 cc of sodium chloride serum for 30 minutes) every 12 hours 3. Dose of 5 cc of noscapine ( Manufactured by Faran Shimi) each Eight hours 4. 500 mg dose of hesperidin (Manufactured by Swanson) every 24 hours 5. Resveratrol 500 mg (Manufactured by A Squard)  every 24 hours 6. NAC 600 mg ( Manufactured by Osvah ) every 12 hours .  The duration of treatment is estimated at ten days.Supplements are taken orally and vitamin C is given to patients as an injection. Intervention 4: Control group:  hospitalization patients with symptomatic COVID-19 Protocol of the Ministry of Health.,NA,NA,Yes
main,IRCT20181113041635N2,http://en.irct.ir/trial/39245,"Intervention 1: Intervention group: Injection of 8 million stem cells derived from human adipose tissue injection, suspended in 3 ml buffer phosphate solution, by endoscopy in the lower esophageal sphincter of patients with gastroesophageal reflux. Intervention 2: Control group: Injection of 3 ml of liquid in which the cell is suspended, by endoscopy in the lower esophageal sphincter of patients with gastroesophageal reflux.",NA,Yes,NA
main,IRCT20181206041866N1,http://en.irct.ir/trial/35780,"Intervention 1: Intervention group: It is an intravaginal anesthetic drug for induction of anesthesia or sedation that can be used for a short therapeutic course, such as insertion of shoulder joint or tracheal intubation. Its metabolism is essentially carried out with steroid hydrolysis to inactive metabolites, which are then excreted in urine and bile. The duration of the effect period is linearly dependent on the dose, which results in anesthesia with about 0.1 mg / kg per 100 seconds. Intervention 2: Control group: Propofol is a drug from the family of alkaline phenols, which was discovered in the 1970s. Propofol is used in general anesthesia for induction of anesthesia and maintenance of anesthesia in the intensive care unit, and an outpatient outpatient treatment is used in adults with a dose of 1.5-5.5mg / kg / 1 intravenously. Also, side effects of the medicine include the treatment of cholestasis and stroke epilepsy.",NA,NA,NA
covid,IRCT20181208041886N1,http://en.irct.ir/trial/51501,Intervention 1: Intervention group: the patients with diagnosis of COVID19 with be treated by tablet Levamisole 50 mg daily for 14 days in addition to standard therapies for these patients. the sign and symptoms of the patients will be evaluated daily. Intervention 2: Control group: the patient with diagnosis of COVID19 will give the standard therapies and without Levamisole.,NA,NA,NA
main,IRCT20181226042132N1,http://en.irct.ir/trial/36341,"Intervention 1: Intervention group1:triple  antibiotic paste containig minocycline ,ciprofloxacin and metronidazole,once between sessions for 7 days in the root canal system. Intervention 2: Intervention group 2: Calcium Hydroxide,once between sessions for 7 days in the root canal system. Intervention 3: Control group: No medicament; rinsing with normal saline and using a piece of cotton pellet in pulp chamber between treatment sessions.",NA,Yes,NA
main,IRCT20190112042333N1,http://en.irct.ir/trial/36782,"Intervention 1: Intervention group (1): Chicory and Fumitory Syrup contains hydro alcoholic extracts of Chicory and Fumitory with dosage of 7 mil/ daily divided to 2 doses. Intervention 2: Intervention group (2): Megestrol tablet, 20 milligram 2 times daily.",NA,NA,NA
covid,IRCT20190121042444N3,http://en.irct.ir/trial/49132,"Intervention 1: In this study, randomly placed in a group of patients with desferal supplementation at a dose of 20 to 60 mg by weight over 8 to 12 hours, along with 100 mg of vitamin C ampoules at the time of hospitalization in the corona section, followed by ferritin and CRP by The patient's blood test is checked to compare their differences with before the intervention. Intervention 2: In the control group, desferal supplementation is not given at a dose of 20 to 60 mg per kg body weight with 100 mg of vitamin C ampoules, and ferritin and CRP tests are sent to the patient. They are also compared.",NA,NA,Yes
main,IRCT20190217042727N1,http://en.irct.ir/trial/38532,"Intervention 1: Intervention group:the first intervention group will receive 5 mg of solifenacin(producted by Abidi pharmaceutical company)per day for 2 months. Intervention 2: Intervention group: In the second intervention group , oxybutynin(a product of Exsir pharmaceutical company) will be started with 2.5 mg every 8 hours for 2 months.",NA,Yes,NA
covid,IRCT20190226042851N1,http://en.irct.ir/trial/48462,"Intervention 1: Intervention group: In addition to receiving the drug according to the national protocol, this group uses the drug under study by inhalation. The national protocol uses interferon beta-1a, interferon beta-1b, dexamethasone, prednisolone, corticosteroids, and heparin.This drug consists of deionized water and nano-sized silver particles with the chemical formula Ag. The equipment used in this study is only a nebulizer mask. Drug prescription: 1cc will be prescribed to investigate possible side effects of the drug. The next dose will be administered to the patient 4 hours after the first dose in the amount of 2 cc and then for 72 hours and every 8 hours 3cc. The drug is placed in a nebulizer and given to the patient for 10-15 minutes. Intervention 2: Control group: This study does not have a placebo, so patients in this group do not receive any medication from the study and receive medication according to the national protocol. The national protocol uses the drugs interferon beta-1a, interferon beta-1b, dexamethasone, prednisolone, corticosteroids and heparin. In addition to the patient's SPO2, history and clinical examination are taken from the patient.",NA,Yes,NA
main,IRCT20190407043185N1,http://en.irct.ir/trial/38673,"Intervention 1: Intervention group: dialectical behavioral therapy which includes emotion regulation , distress tolerance , mindfulness and effective communication  in  twelve sixty to ninety minute sessions , twice a week , done in groups with Methadone maintenance treatment (MMT). Intervention 2: Control group: methadone maintenance therapy.",NA,NA,NA
main,IRCT20190413043259N1,http://en.irct.ir/trial/38823,"Intervention 1: 1-Intervention group: 30 member volunteer for a 2 month period, apply twice, daily, eye cream (made in the Faculty Of Traditional Medicine) , In small quantities, which has Absinthium extract. Intervention 2: Control group: 2- Control group: 30 member volunteer for a 2 month period, apply twice, daily, eye cream(made in the Faculty Of Traditional Medicine), In small quantities, without Absinthium extract. No more act needed.",NA,NA,Yes
main,IRCT20190427043389N1,http://en.irct.ir/trial/39116,Intervention 1: Intervention group: received pioglitazone tablet (30 mg per day). Intervention 2: Control group: received placebo tablet.,NA,NA,NA
main,IRCT20190427043390N1,http://en.irct.ir/trial/39112,"Intervention 1: Intervention group: Intravenous injection of one gram of single dose tranexamic acid, during ten minutes before surgery. Intervention 2: Intervention group: Intervention group: intra-articular injection of one gram of single dose tranexamic acid, 10 minutes before surgery.",NA,NA,NA
main,IRCT20190525043704N1,http://en.irct.ir/trial/40762,"Intervention 1: Intervention group: Receiving F. assa-foetida capsule called Asafin at dose of 250 mg twice daily for 3 mounts. It is necessary to mention that standard treatment is glucose lowering drugs such as glibenclamide and metformin and all subjects should receive standard treatment.                                      Drug formulation: Studies on animal and human species used the plant's resin to determine the effects of the drug. Due to the unpleasantness of this part of the plant for the patient and the likelihood of decreasing the adaptation, according to the drug formulation used in the similar study, 250 mg of the root and seed of the plant in powder form will be used to make Asafin capsule. The drug will be formulated by the Pharmacology Laboratory of the Faculty of Pharmacy, Ahwaz University of Medical Sciences, Ahwaz, Iran. Intervention 2: Control group: Receiving placebo capsule (starch) at a dose of 250 mg twice daily for 3 mounts. It is necessary to mention that standard treatment is glucose lowering drugs such as glibenclamide and metformin and all subjects should receive standard treatment. The placebo will be formulated by the Pharmacology Laboratory of the Faculty of Pharmacy, Ahwaz University of Medical Sciences, Ahwaz, Iran.",NA,NA,NA
covid,IRCT20190602043787N3,http://en.irct.ir/trial/49180,"Intervention 1: Intervention group:in addition to similar treatments of control group,patients uses the following dose of Ivermectin 3 miligram manufactured by Erophartech/France : 200 microgram per kilogram that in a normal weight about 50-65 kilogram is about 12 miligram is equivalent to 4 tablets in one dose, in 65-80 kilogram is about 15  miligram is equivalent to 5 tablets in one dose and in weighing more than 80 kilogram with 200 microgram per kilogram in one dose daily up to two days. Intervention 2: Control group: Patients will be treated with antiviral drugs according to existing standards with the same dose and frequency of administration as the standard treatment regimen ( for example hydroxychlorquin 200 mg , 2 tablets every 12 hours for first day and 1 tablet every 12 hours for 7 days).",NA,NA,NA
im,IRCT20190602043791N1,http://en.irct.ir/trial/43103,Intervention group: Patients who candidates for CPAP titration due to obstructive sleep apnea.,NA,NA,NA
main,IRCT20190606043828N1,http://en.irct.ir/trial/39987,"Intervention 1: Intervention group 1 : M : magnesium sulfate    . Initially , personal consent in obtained from the patient . Then the patient is placed on the operating bed and standard monitoring devices are attached and vital sign is recorded .Patient undergoes general anesthesia , at the end of the surgury, while suturing the incision , 30 mg/kg magnesium sulfate is injected IV . Intervention 2: Intervention group: D : dexmedetomidine  .     Initially , personal consent in obtained from the patient . Then the patient is placed on the operating bed and standard monitoring devices are attached and vital sign is recorded .Patient undergoes general anesthesia , at the end of the surgury, while suturing the incision ,0/5 mcg/kg dexmedetomidine   is injected IV . Intervention 3: Intervention group:P: Pethidine  .  Initially , personal consent in obtained from the patient . Then the patient is placed on the operating bed and standard monitoring devices are attached and vital sign is recorded .Patient undergoes general anesthesia , at the end of the surgury, while suturing the incision , 0/5 mg/kg Pethidine is injected IV . Intervention 4: Control group: C   ; normal saline .  Initially , personal consent in obtained from the patient . Then the patient is placed on the operating bed and standard monitoring devices are attached and vital sign is recorded .Patient undergoes general anesthesia , at the end of the surgury, while suturing the incision , normal saline is injected IV .",NA,Yes,NA
main,IRCT20190614043892N1,http://en.irct.ir/trial/40139,Intervention 1: Intervention group: Platelt rich fibrin with tunnel flap. Intervention 2: Control group: Connective tissue graft with tunnel flap.,NA,NA,NA
main,IRCT20190702044076N1,http://en.irct.ir/trial/40547,"Intervention 1: Intervention group 1: The group receiving Cinaaclate (AMGEN pharmaceutical company of Netherland ) receives 30 mg daily. The ultimate target of this group is the PTH level between 150 Pg / ml and 300 Pg / ml. The dose can be increased to 90 mg daily or three 30 mg tablets daily if elevated. This treatment is continued for up to 8 weeks after starting the study and then the levels of phosphate, calcium and parathyroid hormone are measured. Intervention 2: Intervention group 2: The group receiving Calcitriol (Zahravi Pharmaceutical Company of Iran) receives 0.5-1.5 mg daily. The ultimate target of this group is the PTH level between 300 Pg / ml and 600 Pg / ml. The dose may be increased to 1.5–3 mg daily if elevated. This treatment is continued for up to 8 weeks after starting the study and then the levels of phosphate, calcium and parathyroid hormone are measured.",NA,NA,NA
im,IRCT20190719044270N1,http://en.irct.ir/trial/40947,"Intervention 1: Intervention group: Airokast® (Montelukast -as sodium- Abidi company) 10 mg Orally, Once daily for 7 days. Intervention 2: Control group: Placebo pills (Produced in the Faculty of Pharmacy, Shiraz University of Medical Sciences) like real drug, Orally, Once daily for 7 days.",NA,NA,NA
covid,IRCT20190727044343N2,http://en.irct.ir/trial/46639,Intervention 1: Intervention group: Oral Atorvastatin 40 mg for 5 days. Intervention 2: Control group: Routine Care.,NA,NA,NA
main,IRCT20190730044382N1,http://en.irct.ir/trial/41212,Intervention 1: Intervention group will be given 100 mg iron tablets daily (ferrous sulfate) and 80 mg vitamin B6 tablets (pyridoxine hydrochloride manufactured by Iran Hormone Company) for one month. Intervention 2: Control group: 100 mg iron tablets (ferrous sulfate) daily will be given for one month.,NA,Yes,Yes
covid,IRCT20190804044429N4,http://en.irct.ir/trial/52284,Intervention 1: Intervention group: therapeutic regime including hydroxychloroquine 400 mg stat and lopinavir/ritonavir and250 mcg interferon beta 1 b subcutaneous injection every other day for at least 3 doses with pentoxyfylline  tablet of Arya company at dose of 400 mg every 8 hours for 5 days. Intervention 2: Control group: Patients with inclusion criteria who received therapeutic regimen of hydroxychloroquine 400 mg stat and lopinavir/ritonavir and250 mcg interferon beta 1 b subcutaneous injection every other day for at least 3 doses for 5 days.,NA,Yes,NA
covid,IRCT20190831044653N5,http://en.irct.ir/trial/49893,"Intervention 1: Intervention group: Hydroxychloroquine and Kaletra treatment according to the national guideline for the treatment of COVID-19 and Atorvastatin, 1 tablet, 20 mg, daily, during hospitalization. Intervention 2: Control group: Hydroxychloroquine and Kaletra treatment according to the national guideline for the treatment of COVID-19, during hospitalization.",NA,Yes,NA
im,IRCT20191012045066N1,http://en.irct.ir/trial/42966,"Intervention 1: Intervention group: Oral care with swab and chlorhexidine solution 0.2% every 12 hours and equal care between groups (oral cavity moistening and lipsticking every 4 hours and oral suctioning if needed). Intervention 2: Intervention group: Oral care with toothbrush and chlorhexidine solution  0.2% every 12 hours and equal care between groups. Intervention 3: Intervention group: Oral care every 6 hours, twice with toothbrush and 0.2% chlorhexidine solution every 12 hours, twice with toothbrush and normal saline every 12 hours and equal care between groups.",NA,NA,NA
im,IRCT20191104045328N1,http://en.irct.ir/trial/43435,"Intervention 1: Intervention group: In the first 7 days of treatment, 31 patients will receive colistin (3 million units of TDS injectable colistin) along with oral fosfomycin (3 g per 12-hour dose). The total duration of treatment is 14 days. Intervention 2: Control group: 31 patients will receive colistin for a total of 14 days (3 million units of TDS injectable colistin).",NA,Yes,NA
covid,IRCT20191211045691N1,http://en.irct.ir/trial/49879,Intervention 1: Intervention group: includes 50 patients who receive magnesium sulfate inhaled (5 cc of 20% injectable vial or 2 cc of 50% injectable vial) every 8 hours for 5 days along with standard treatment. Intervention 2: Control group: includes 50 patients who receive standard treatment.,NA,Yes,NA
covid,IRCT20200112046089N1,http://en.irct.ir/trial/48330,"Intervention 1: Intervention group: 1 Tab resveratrol (500mg) from  Sumabe, daily until 14 days in addition to routine drugs. Intervention 2: Control group: this group doesn't receive extra drugs and receive routine drugs.",NA,NA,NA
covid,IRCT20200128046294N2,http://en.irct.ir/trial/46463,"Intervention 1: Control group: Standard of care treatment according to the national guidelines for the treatment of COVID-19. Intervention 2: Intervention group: Sovodak, Company: Rojan, Daily single oral tablet containing 400mg of Sofosbovir and 60mg of Daclatasvir plus Standard of care treatment.",NA,Yes,NA
covid,IRCT20200204046369N1,http://en.irct.ir/trial/46776,"Intervention 1: Intervention group: An initial dose of 1mg/kg will be started for all patients in the case group. The patients will receive the mentioned dose for 5 days, which will then be halved for 5 days and repeated until reached a dose of under 20mg/day, which will then be converted into oral tablet form of prednisolone. Also, patients will receive the national treatment protocol for COVID-19. Intervention 2: Control group: Patients in the control group will receive the standard treatment based on the National protocol.",NA,NA,NA
covid,IRCT20200314046774N1,http://en.irct.ir/trial/46519,"Intervention 1: Intervention Group: ""Consumption of Iranian Oral Vitamin A in the name of Ovigel Company 200,000 units today and repeat it tomorrow and then control the clinical and laboratory symptoms on the first, third, fifth, seventh, fourteenth and fourteenth days. Check the test: INR, LDH, wBC, PLT, LYMPH, CRP, CPK, Cr, Hb n need mechanical ventilation to check vitamin A side effects. Intervention 2: Control group: receives exactly four in appearance similar to the vitamin A capsule (drug Gul) and the next day the same thing is repeated and then the control of clinical symptoms and Laboratory test on the first, third, fifth, seventh, fourteenth, fourteenth day of the test: INR, LDH, wBC, PLT, LYMPH, CRP, CPK, Cr, Hb n.",NA,NA,Yes
covid,IRCT20200317046797N2,http://en.irct.ir/trial/46786,Intervention 1: Intervention group:  Twenty patients with Coronavirus (COVID-19)-induced pneumonia addition to standard regimen of covid-19? will receive Fingolimod for 1 day (50 mg one time). Intervention 2: Control group: standard regimen of covid-19 patients.,NA,NA,NA
covid,IRCT20200318046812N1,http://en.irct.ir/trial/46783,Intervention 1: Intervention group: Group receiving Favipiravir plus Hydroxychloroquine. Stat dose of eight 200 mg Favipiravir tablets (total 1600 mg) and stat dose of two 200mg Hydroxychloroquine tablets (total 400 mg) followed by Favipiravir 600 mg three times a day for 7 days. This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups. Intervention 2: Control group: Group receiving Kaletra plus Hydroxychloroquine regimen. Stat dose of two 200 mg Hydroxychloroquine tablets (total 400 mg) followed by Kaletra(Lopinavir/Ritonavir) 200/50 mg two times a day for 7 days. This regimen could be continued for 10 days if necessary according to clinical response of the patient. Other supportive and routine care will be the same in both groups.,NA,Yes,NA
covid,IRCT20200324046850N1,http://en.irct.ir/trial/46732,"Intervention 1: Intervention group 1: Patients receiving standard country protocol drugs(lopinavir (50 mg) –ritonavir (200 mg) 2 tablets every 12 hours until the patient's clinical symptoms improve + hydroxychloroquine (200 mg) two tablets one dose) with vitamin D3 ampoules of 50,000 units once a week and N-acetylcysteine placebo tablets every 12 hours. Intervention 2: Intervention group 2: Patients receiving standard country protocol drugs (lopinavir (50 mg) –ritonavir (200 mg) 2 tablets every 12 hours until the patient's clinical symptoms improve + hydroxychloroquine (200 mg) two tablets one dose) with 600mg N-acetylcysteine tablet every 12 hours and vitamin D3  placebo once a week. Intervention 3: Intervention group 3: Patients receiving standard country protocol drugs (lopinavir (50 mg) –ritonavir (200 mg) 2 tablets every 12 hours until the patient's clinical symptoms improve + hydroxychloroquine (200 mg) two tablets one dose) with 600mg N-acetylcysteine tablets every 12 hours and 500,000 units of vitamin D3 once a week. Intervention 4: Intervention group 4: Patients receiving standard country protocol drugs (lopinavir (50 mg) –ritonavir (200 mg) 2 tablets every 12 hours until the patient's clinical symptoms improve + hydroxychloroquine (200 mg) two tablets one dose) with placebo vitamin D3 once a week and placebo tablets N-acetylcysteine every 12 hours.",NA,Yes,Yes
covid,IRCT20200324046850N5,http://en.irct.ir/trial/46751,Intervention 1: Control group: Standard Protocol Drugs +  placebo (in terms of appearance and color similar to vitamin C) every 12 hours for 5 days. Intervention 2: Intervention group: Standard Protocol Drugs  + Vitamin C 500mg every 12 hours for 5 days.,NA,NA,Yes
covid,IRCT20200325046860N1,http://en.irct.ir/trial/46759,Intervention 1: Treatment group: Patients with confirmed COVID-19 infection who in addition to their current treatment will be infused with 500 Ml convalescent plasma in 4 hrs. Intervention 2: Control group: Patients hospitalized with COVID-19 disease who are receive routine treatment.,NA,Yes,NA
covid,IRCT20200325046860N2,http://en.irct.ir/trial/46789,"Treatment group: Patients with confirmed COVID-19 infection who in addition to their current treatment will be infused with 70 million mesenchymal stem cell day 0, 3 6 , infusion time 30 min 4..",NA,Yes,NA
covid,IRCT20200328046885N1,http://en.irct.ir/trial/47565,"Intervention 1: Intervention group: out of 300 patients, 150 patients with coronary artery from two medical centers (Rasoul Akram Hospital and Firoozgar Hospital) hydroxychloroquine phosphate treatment regimen 400 mg every 12 hours on the first day and then 200 mg every 12 hours for 5 to 7 Day + Sovodak (sofosbuvir + Daklatasvir) will be taken once a day (60/400 mg) for at least 5 to 7 days. Sovodak drug manufacturer is Faravan Rojan Mohaghegh Daroo (made in Iran) and chloroquine manufacturing company is Iran Daru (made in Iran). Intervention 2: Intervention group: out of 300 patients, 150 patients with coronary artery from two medical centers (Rasoul Akram Hospital and Firoozgar Hospital) Hydroxychloroquine phosphate treatment regimen 400 mg single dose + lupinavir / ritonavir combination 400/100 twice daily They will receive at least 5 days. The manufacturer of the drug is lupinavir / ritonavir (Kaletra), Gilead (made in Iran) and the manufacturer of chloroquine, Iran Daru (made in Iran).",NA,Yes,NA
covid,IRCT20200401046909N1,http://en.irct.ir/trial/46875,"Intervention 1: Intervention group: containing 25OHD soft gelatin capsular 1000 IU , Producer: Dishmen. the case group will receive 1000 IUs of 25(OH)D daily for 8 wks. The subjects will receive a bottle containing 30 capsules in first and second visits that will contain the 25(OH)D. The bottles will be returned to be checked at each visit. Intervention 2: Placebo: containing white to off white color suspension oil. Producer: Dishmen Company. The control group will receive placebo daily for 8 wks..The subjects will receive a bottle containing 30 capsules in first and second visits that will contain the placebo. The bottles will be returned to be checked at each visit.",NA,NA,NA
covid,IRCT20200402046917N1,http://en.irct.ir/trial/46938,"Intervention 1: Intervention group: To 10 patients with COVID-19 who are admitted to kosar hospital. In addition to the usual protocols of the Ministry of Health, patients will be given 5 cc of rose water (Factory Construction Barij Essence) in a glass of water every 8 hours for a week. Intervention 2: Control group: Patients are treated according to national protocol and receive water.",NA,NA,NA
covid,IRCT20200403046926N1,http://en.irct.ir/trial/46926,Intervention 1: Intervention group: COVID-19 Patients receiving hydroxychloroquine + SOVODAK. Intervention 2: Control group: COVID-19 Patients receiving hydroxychloroquine.,NA,Yes,NA
covid,IRCT20200404046937N4,http://en.irct.ir/trial/49935,"Intervention 1: Intervention group: Patients in the main group will receive the drug of this study after treatment with routine drugs of the disease. Ivermectin tablet is 14 mg, so that the patient will receive one Ivermectin tablet every 12 hours for 3 time  and then on the seventh day. Patient symptoms and laboratory data and CT scan will be reviewed. Intervention 2: Control group: Patients in the control group will receive placebo after treatment with routine medication, which is quite similar to ivermectin in that the patient will receive one placebo tablet every 12 hours for 3 time, and then on the seventh day the patient's symptoms and Laboratory data and CT scan will be reviewed.",NA,NA,NA
covid,IRCT20200405046951N1,http://en.irct.ir/trial/47722,Intervention 1: Intervention group: receiving Vitamin 50000 IU through injection. Intervention 2: Control group: Routine care.,NA,NA,Yes
covid,IRCT20200406046965N1,http://en.irct.ir/trial/46958,"Intervention 1: Intervention group:The patients will receive 10 ml of elderberry extract syrup 3 times daily (2.6 g of elderberry extract per day equivalent to 15.76 g of fresh elderberries) beside the standard treatment regimen for COVID-19 according to the Ministry of Health protocol. This treatment will continue for 2 weeks. The syrup is formulated according to the United States Pharmacopoeia description. This syrup is preservative-free and remains stable for up to 1 month. The syrups will be prepared freshly at the School of Pharmacy, Mashhad University of Medical Sciences. Intervention 2: Control group: The patients will receive the placebo syrup beside the standard treatment regimen for COVID-19 according to the Ministry of Health protocol with the same order as the intervention group.The placebo consists of USP syrup formula with food-grade coloring agents with the same shape and size containers as the elderberry syrup. This syrup is preservative-free and will be prepared freshly at the School of Pharmacy, Mashhad University of Medical Sciences.",NA,NA,NA
covid,IRCT20200406046968N2,http://en.irct.ir/trial/47115,"In 30 patients with respiratory failure and ARDS caused by COVID-19 undergoing mechanical ventilation or oxygen therapy, antivirals and supportive care  therapies will be continued, and 200-400 cc of convalescent plasma will transfused for them..",NA,Yes,NA
covid,IRCT20200408046987N1,http://en.irct.ir/trial/47012,"Intervention 1: Control group: Standard regimen based on Iran health ministry. Intervention 2: Intervention group: Standard regimen based on Iran health ministry plus low dose Ivermectin(200 mcg/kg , PO, Once). Intervention 3: Intervention group: Standard regimen based on Iran health ministry plus high dose Ivermectin(200 mcg/kg , PO, interval days:1,2,5). Intervention 4: Control group: Standard regimen based on Iran health ministry plus Placebo,Once in first day. placebo is a simple tablet containing only fillers without any active ingredient and is made by Alborz Darou company. Intervention 5: Intervention group: 400 mcg/kg in day1 followed by 200 mcg/kg in day 2 and day 5.",NA,NA,NA
covid,IRCT20200408046987N2,http://en.irct.ir/trial/51007,"Intervention 1: Control group: Standard regimen based on Iran health ministry. Intervention 2: Control group: Standard regimen based on Iran health ministry plus Placebo,Once in first day. placebo is a simple tablet containing only fillers without any active ingredient and is made by Alborz Darou company. Intervention 3: Intervention group: Standard regimen based on Iran health ministry plus Ivermectin (400 mcg/kg , PO, Once) and Sovodak(400/60, PO, Once). Intervention 4: Intervention group: Standard regimen based on Iran health ministry plus high dose Ivermectin(400 mcg/kg in day1 followed by 200 mcg/kg in day 3 and day 5) and Sovodak(400/60, PO, Once). Intervention 5: Intervention group:  High dose Ivermectin (400 mcg/kg in day1 followed by 200 mcg/kg in day 3 and day 5) and Sovodak(400/60, PO, Once).",NA,NA,NA
covid,IRCT20200413047056N1,http://en.irct.ir/trial/47212,"Intervention 1: Intervention group: In addition to the common national protocol, this group will receive convalescent plasma of recovered individuals twice and 200 cc each time. Intervention 2: Intervention group: In addition to the common national protocol, this group will receive intravenous immunoglobulin (400mg/kg/d). Intervention 3: Control group: This group will receive common national protocol.",NA,Yes,NA
covid,IRCT20200413047063N1,http://en.irct.ir/trial/47156,"Intervention 1: Intervention group:Intervention group: The intervention group 1, Patients will receive three doses of MSCs. Two doses of 100×10e6 (±10%) cells will intravenously infuse as a normally dropped single dose over 10-12 minutes at the infusion speed of 4-5 mL/minute in day 0 and day 2 and day 4. Intervention 2: Control group:Patients will receive conventional therapy.",NA,NA,NA
covid,IRCT20200414047072N1,http://en.irct.ir/trial/47163,"Intervention group:  Convalescent Plasma, Frozen Solution for infusion (FFP) for the prevention and treatment of Covid-19. Human plasma protein. The dosage depends upon the clinical situation and underlying disorder, use within 24 hours, administration based on ABO-blood group compatibility. Avoid shaking.  It should be frozen within 8 hours after collection, stored at -18C or colder and have an expiration date one year from the date of collection. Not to exceed IV infusion rate of 1 mL/kg/min, emergency IND (eIND) approved by FDA. provided by Blood bank of the hospital mentioned in the IRB..",NA,Yes,NA
covid,IRCT20200415047080N1,http://en.irct.ir/trial/47982,"Intervention 1: Intervention group:  15 cases : A-Alteplase (TPA) 25-50 mg ( half of the maximum dose 0.9 / kg /day) over 2 hours intravenous continuing by 25-50 /22 hours up to maximum dose of 0.9 mg/kg/d.  This tPA injection may be repeated for 2 days and the patient's condition (PT level PTT, SPO2 and D- dimer) is observed and checked. After the end of TPA injection, subcutaneous injection of Enoxaparin will be started as 1 mg per kilogram body weight for the patient. Enoxaparin could be continued up to 7 days upon the condition of the patient. The patients will receive regular care and treatment for COVID-19 induced ARDS. Intervention 2: Control group: They will take routine treatment approved by the Ministry of Health for patients with adult respiratory distress from COVID 19,Also  the subcutaneous injection of Enaxaparin one mg per kilogram of body weight for the patient  added to their treatment .",NA,NA,NA
covid,IRCT20200415047080N2,http://en.irct.ir/trial/47186,"Intervention 1: Intervention group: The patients will receive the cocktail contains 100 mg of Thiamine  (Ampoule B complex, Darou Pakhsh Co.), 6 g Ascorbic acid  (ampoule of vitamin C, Darou Pakhsh Co.) and Methylprednisolone 250 mg (Solu-Medrol, Pfizer Co.)  on the first day and then 100 mg of Thiamine and  6 gr of Ascorbic acid and 125 mg of Methylprednisolone on the second and third day of treatment. The cocktail will be prepared in 200 cc dextrose 5 % and  slowly infused over 10 hours. Intervention 2: Control group: Patients of this group will receive all of common treatments (including medications and procedures), except the cocktail composition. During hospitalization outcomes will be assessed and medications and procedures will be recorded.",NA,NA,Yes
covid,IRCT20200416047099N2,http://en.irct.ir/trial/47357,"Intervention group: Plasma exchange (1.5 to 2 liter) with colloidal solution containing 4-5% albumin and fresh frozen plasma (FFP) for two consecutive days, and plasma therapy with convalescent plasma for one day..",NA,Yes,NA
covid,IRCT20200417047113N1,http://en.irct.ir/trial/47264,"Intervention 1: Intervention group 1: treatment group A, 0.1 * 107 NK cells per kilogram of patient weight. The lowest dose of cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after cell injection for safety and efficacy effects. Intervention 2: Intervention group 2: treatment group B, 0.5 * 107 NK cells per kilogram of patient weight. The middle dose of the cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after injection for safety and efficacy effects. Intervention 3: Intervention group 3: treatment group C, 1 * 107 NK cells per kilogram of patient weight. The middle dose of the cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after injection for safety and efficacy effects. Intervention 4: Intervention group 4: treatment group D, 1.5 * 107 NK cells per kilogram of patient weight. The middle dose of the cells will be injected into this treatment cohort. These patients will be examined at intervals 1, 3, 7, 14, 28 after injection for safety and efficacy effects. Intervention 5: Intervention group 5: treatment group E, 2 * 107 NK cells per kilogram of patient weight. The highest dose of cells will be injected into this treatment cohort. These patients will also be examined at intervals of 1, 3, 7, 14, 28 days in terms of safety and effectiveness outcomes. Intervention 6: Intervention group 6: placebo, in this group, only physiological serum will be injected into patients. These patients will also be examined at intervals of 1, 3, 7, 14, 28 days in terms of safety and effectiveness outcomes. Intervention 7: Control group: They do not receive any treatment other than common medications.",NA,NA,NA
covid,IRCT20200420047147N1,http://en.irct.ir/trial/47334,"Intervention 1: Intervention group: Patients in Sitagliptin group receive Sitagliptin (Dr.Abidi Pharmaceuticals, Iran)  at dose of 50 mg BID twice a day for totally 10 days and the other standard and supportive treatment (including Lopinavir and ritonavir at dose of 200/50 mg two tablets BID and Hydroxychloroquine sulfate 400 mg one dose) will be administered. Intervention 2: Standard and supportive treatment (including Lopinavir and ritonavir at dose of 200/50 mg two tablets BID and Hydroxychloroquine sulfate 400 mg one dose) will be administered.",NA,Yes,NA
covid,IRCT20200422047168N1,http://en.irct.ir/trial/47437,"Intervention 1: Intervention group: On the first day, patients will receive chloroquine at a dose of 200 mg, and from the second day for six consecutive days, they will receive Lopinavir / ritonavir (Kaletra) at a dose of 400/100 mg. In addition to the above drugs, Alfamed Tenofovir is given to 25 mg daily for 7 days. Intervention 2: Control group:  On the first day, patients will receive chloroquine at a dose of 200 mg, and from the second day for six consecutive days, they will receive Lopinavir / ritonavir (Kaletra) at a dose of 400/100 mg.",NA,Yes,NA
covid,IRCT20200422047168N2,http://en.irct.ir/trial/48444,"Intervention 1: Intervention group: On the first day, patients will receive chloroquine at a dose of 200 mg, and from the second day for six consecutive days, they will receive Lopinavir / ritonavir (Kaletra) at a dose of 400/100 mg. At the first day,in addition to the above drugs,Ivermectin, 200–150 µg/kg? is given. Intervention 2: Control group: On the first day, patients will receive chloroquine at a dose of 200 mg, and from the second day for six consecutive days, they will receive Lopinavir / ritonavir (Kaletra) at a dose of 400/100 mg.",NA,Yes,NA
covid,IRCT20200426047206N2,http://en.irct.ir/trial/49385,"Intervention 1: Intervention group: This group receiving mesenchymal stem cells. In this group, patients are received 1 million Umbilical core-derived MSCc/BW by intravenous injection  (provided by volunteer donors at Fatemieh Hospital) ( Through the catheter and the Central vein and from the superior vena cava vein ). Also, in addition to cell therapy, Other routine treatments (The last national protocol for COVID-19 treatment) will be given to patients according to the physician's supervision.The umbilical cord will be provided by volunteer donors at Fatemieh Hospital and after that will be cultured and expanded in the cleanroom of Hamadan University of Medical Sciences. Intervention 2: Control group: Receiving routine therapies (The last national protocol for COVID-19 treatment) (without stem cell).",NA,Yes,NA
covid,IRCT20200426047206N4,http://en.irct.ir/trial/51687,"Intervention 1: Intervention group: Melatonin supplement at a dose of 18 mg twice a day for 7 days and orally, with standard treatment. Intervention 2: Control group: They will receive the national standard treatment of Covid-19.",NA,NA,NA
covid,IRCT20200426047212N1,http://en.irct.ir/trial/47572,"Intervention 1: Intervention group: The intervention group in addition to receiving a standard nationwide medication [2 tablets of Hydroxychloroquine sulfate 200 mg as a single dose and 2 tablets of Kaletra(Lopinavir/Ritonavir) 200/200 mg every 12 hours], receives pure thyme oil every 8 hours (8 am, 4 pm, 12 pm) for 30 minutes through a nebulizer for 5 days. So that 4 drops of pure thyme oil with 10 cc of distilled water were prepared for each nebulization. Intervention 2: Control group: The control group in addition to receiving a standard nationwide medication [2 tablets of Hydroxychloroquine sulfate 200 mg as a single dose and 2 tablets of Kaletra(Lopinavir/Ritonavir) 200/200 mg every 12 hours], receives 10 cc of distilled water (placebo) every 8 hours (8 am, 4 pm, 12 pm) for 30 minutes through a nebulizer for 5 days.",NA,Yes,NA
covid,IRCT20200428047232N1,http://en.irct.ir/trial/47637,Intervention 1: Intervention group: Patients in this group are treated with 100 mg oral thalidomide tablets manufactured by Ibn Sina Company on a daily basis for up to fourteen days. These drugs are administered along with hydroxichloroquine tablets 200 mg two times daily for 5 days. Intervention 2: Control group: patients are treated with hydroxichloroquine tablets 200 mg two times daily for 5 days.,NA,Yes,NA
covid,IRCT20200505047318N1,http://en.irct.ir/trial/48007,"Intervention 1: Intervention group :Tab.HCQ 200,Po,Q12h/Amp.Ceftriaxon,1 gr,IV.Q12h/ TTab.finasteride 5mg,PO,Daily,5 days. Intervention 2: Control group:Tab.HCQ 200,Po,Q12h/Amp.Ceftriaxon,1 gr,IV.Q12h/  One placebo daily for 5 days.",NA,NA,NA
covid,IRCT20200506047323N2,http://en.irct.ir/trial/47990,"Intervention 1: Intervention group: The standard treatment regimen for COVID-19 based on the Ministry of Health's protocol, including hydroxychloroquine sulfate (Amin Pharmaceutical company, Isfahan) at a dose of 200 mg twice a day, along with a licorice-based herbal medicine (D-REGLIS 380 mg tablets, registration number: 4750956176234914, Irandarouk Pharmaceutical Company) at a dose of 760 mg three times a day for a period of 14 days. Intervention 2: Control group: Standard treatment for COVID-19 based on the Ministry of Health's protocol, including hydroxychloroquine sulfate (Amin Pharmaceutical company, Isfahan) at a dose of 200 mg twice a day for a period of 14 days.",NA,Yes,Yes
covid,IRCT20200506047323N4,http://en.irct.ir/trial/49881,"Intervention 1: Intervention group: The standard treatment regimen for COVID-19 along with a 10 cc (500 mg) of Deferoxamine solution (Deferoxir, Exirdaru Company, Iran) divided in four times a day through a nebulizer for a period of 7 days. Intervention 2: Control group: The standard treatment for COVID-19 based on the Ministry of Health's protocol including hydroxychloroquine sulfate (Amin Pharmaceutical company, Isfahan) at a dose of 400 mg twice a day for the first day and 200 mg twice a day for 6 following days.",NA,Yes,NA
covid,IRCT20200508047345N1,http://en.irct.ir/trial/47987,"Intervention 1: Control group: Uses common medicines and boiled water. Intervention 2: Intervention group: Due to the fact that the resulting extract is prepared at a temperature of less than 100. C (70) C) and is in fact a kind of drink, the amount of consumption of the rules of consumption of the drink is followed by a slight change in consumption time. Typically, herbal teas are prescribed 3 times a day and 100 cc each time. In this study, people with the disease are prescribed 5 cc of the extract at intervals of 30 minutes. The total amount of extracted in 24 hours for each patient is 240 cc.",NA,NA,Yes
covid,IRCT20200509047373N1,http://en.irct.ir/trial/48001,"Intervention 1: Intervention group:??Dinvl drug,260 mg each time, 4 times a day for 7 days. Made by Health Medicine Chemistry Company. Intervention 2: Control group:  Routine  tablets is given daily for seven days.",NA,NA,NA
covid,IRCT20200510047383N1,http://en.irct.ir/trial/48024,"Intervention 1: Intervention group: Take tocilizumab. This group is given a dose of 8 mg per kilogram of body weight tocilizumab up to a maximum dose of 800 mg. If the symptoms worsen or do not improve, another dose is injected. If side effects occur, the complication is recorded and then the patient is removed from the study. Intervention 2: Control group: Receive standard multi drug protocol.",NA,Yes,NA
covid,IRCT20200511047396N1,http://en.irct.ir/trial/48048,"Intervention 1: Intervention group: Concomitant with the national corona treatment recommendation (based on the Ministry of Health protocol: hydroxychloroquine etc,..), patients will receive 1 puff (equall to 1000 IU of interferon beta 1a)of a nasal spray (CinnaGen Company) at each nostril, every 6 hours for 7 days. Intervention 2: Control group: Concomitant with the national corona treatment recommendation (based on the Ministry of Health protocol: hydroxychloroquine etc,..), patients will receive 1 puff of a nasal spray (CinnaGen Company) at each nostril, every 6 hours for 7 days.",NA,Yes,NA
covid,IRCT20200511047399N1,http://en.irct.ir/trial/48045,Intervention 1: Intervention group: 3 capsules containing 2010 mg EPA and DHA + 2 capsules containing 400 mg Hydroxychloroquine. Intervention 2: Control group: 2 capsules containing 400 mg Hydroxychloroquine.,NA,Yes,NA
covid,IRCT20200513047426N1,http://en.irct.ir/trial/48236,"Intervention 1: Intervention group:  Cases of this group are treated with preventive treatment of hydroxychloroquine as follows.1-hydroxychloroquine 400 mg tablet once on the first night at 22:002- hydroxychloroquine 200 mg tablet once a night for 5 nights at 22:00It should be noted that patients will be monitored directly to prevent the effects of disruptive factors. Intervention 2: Control group:  The cases of this group are treated with preventive treatment of placebo for 6 days, which are used orally once a day at 22:00.The control group also uses vitamin B1 tablets, which, in terms of drug form, color and odor, are similar to hydroxychloroquine.",NA,Yes,Yes
covid,IRCT20200518047497N2,http://en.irct.ir/trial/48644,"Intervention 1: Intervention group: In the intervention group, participants will receive Dinvl    sublingual tablets 399±5 mg containing 43.5 mg of herbal powder made by Zahravi Pharmaceutical Company in Tabriz which will be taken every 6 hours for 7 days (a total of 56 tablets per person) not at the same time with other drugs. Both groups will receive routine treatments. Intervention 2: Control group: The control group will receive a placebo, resembled the Dinvl tablets with the same prescription. Both groups will receive routine treatments.",NA,NA,Yes
covid,IRCT20200522047545N1,http://en.irct.ir/trial/48351,"Intervention group: In addition to the standard treatment (200 mg Hydroxychloroquine tablets or two 250 mg Chloroquine phosphate tablets), herbal tablets containing Anacyclus pyrethrum, Senna, Ferrula asafoetida and Terminalia chebula will be taken in three tablets three times a day for 7 to 14 days..",NA,Yes,Yes
covid,IRCT20200525047562N1,http://en.irct.ir/trial/48493,"Intervention 1: Intervention group: Symptomatic COVID-19 patients who are hospitalized and have Score>4 in terms of WHO Progression Scale. Before 24 hours passed from the hospitalization. A 500 cc unit with blood group compatibility between receiver and donor is injected within 4 hours. In patients with grade 7 and above, a plasma unit can be re-injected after 24 hours. Plasma is obtained by apheresis from patients who have recovered from the covid-19 virus in blood transfusion centers. Intervention 2: Control group: The control group is a patient who is hospitalized with suspicion of Covid-19 but either not in randomization or not satisfied with receiving plasma.",NA,Yes,NA
covid,IRCT20200608047686N1,http://en.irct.ir/trial/48717,Intervention 1: Intervention group: 15 eligible patients with moderate to severe COVID-19 in a 1:1  ratio compared to the control group who receive 250 mg metronidazole tablets orally every 6 hours for 7 days in addition to the standard treatment. Intervention 2: Control group: 15  eligible patients with moderate to severe COVID-19 disease who receive national standard treatment for COVID-19.,NA,NA,NA
covid,IRCT20200705048013N1,http://en.irct.ir/trial/49525,"Intervention 1: Intervention group: Pentoxifylline with a dose of 400 mg, made by Farabi Pharmaceutical Company, Iran, was prescribed to patients weighing less than 70 kg every 12 hours and to patients weighing more than 70 kg every 8 hours. This group receives only Pentoxifylline for two days from the hospitalization day. Intervention 2: Control group: Vitamin D3 (oral capsule) with a dose of 50,000 units, one capsule at hospitalization day, hydroxychloroquine tablets with a dose of 200 mg every 12 hours for two days from the hospitalization day, serum therapy (2.5 to 3.5 liters) and Nasal Prong two to eight liters (depending on the patient's dyspnea condition) were prescribed.",NA,Yes,Yes
covid,IRCT20200723048178N1,http://en.irct.ir/trial/49901,Intervention group: Nimesulide 100 mg twice daily for five days.,NA,NA,NA
covid,IRCT20200727048217N1,http://en.irct.ir/trial/49924,"Intervention 1: Intervention group: patients will receive nasal spray containing 20% ??ethanol (German Merck), 3% dimethyl sulfoxide (German Merck) based on physiological serum. Three times a day (every 8 hours) a puff of spray will be applied to each nostril. The duration of use will be two weeks. Intervention 2: Control group: patients will use a spray containing normal saline (Razi Iran). Three times a day (every 8 hours) a puff spray will be applied to each nostril. The duration of use will be two weeks.",NA,NA,NA
covid,IRCT20200818048444N1,http://en.irct.ir/trial/50780,Intervention 1: Intervention group: The intervention group will receive 8 mg bromhexine tablets every 8 hours for 14 days. Intervention 2: Control group: will receive 3 placebo tablets per day for 14 days.,NA,NA,NA
covid,IRCT20200907048644N1,http://en.irct.ir/trial/50932,Intervention 1: Intervention group: 40 patients receiving routine + celecoxib treatments. This group is divided into two subgroups (20 people in each group):A dose received 200mg / day (in divided doses)B at a dose of 400mg / day (in divided doses). Intervention 2: Control group: 20 subjects with routine therapy.,NA,NA,NA
covid,IRCT20200913048701N1,http://en.irct.ir/trial/50912,"Intervention 1: Intervention group: Patients undergoing intervention with Eucalyptus soft oral capsule from Barij Essential Oil Company containing Eucalyptus essential oil (Eucalyptus globulus) Active ingredients 8 (Cineol (Eucalyptol), Alpha-Pinene, Lemonene) in accordance with the approved drug catalog of the Food and Drug Administration 8 hours for 5 days. Intervention 2: Control group: Patients are not intervened.",NA,NA,NA
covid,IRCT20200921048786N1,http://en.irct.ir/trial/51086,Intervention 1: Individuals in the intervention group approved by the nationally approved hydroxychloroquine regimen as a single dose and then daily administration of Kaletra and in addition to the above treatment with interferon beta-one B (at a dose of 250 micrograms or 8 million subcutaneously every other day). Beta is a subsidiary of Iran Pharmaceutical Company. Intervention 2: Control group: Individuals in the control group receive only the recommended national hydroxychloroquine diet as a single dose and then daily consumption of Coltra.dose and then daily consumption of Kaletra.,NA,Yes,NA
covid,IRCT20201005048936N1,http://en.irct.ir/trial/51499,"Intervention 1: Intervention group:Favipiravir administered orally, produced  by the Dr. Abidi pharmacutical Co, Iran,  3200mg (1600/ bid) on the first day followed by 1200mg (600mg/bid) daily for the next 4 days (days 1-5). Intervention 2: Control group: Hydroxichloroqune (produced by any pharmacutical company in Iran),  administered orally, 400mg (bid) on the first day followed by 200mg/bid/day for the next 4 days (days 1-5) with or without Naproxen and with or without Azythromycin.",NA,Yes,NA
covid,IRCT20201015049030N1,http://en.irct.ir/trial/51736,"Intervention 1: Intervention group: 100 outpatients with Covid 19 with respiratory symptoms who in addition to their standard treatment will receive 8mg Dexamethasone (If patient's condition does not change, the dose will repeat after 48 hours). Intervention 2: Control group: 100 outpatients with Covid 19 with respiratory symptoms who are received standard treatment.",NA,Yes,NA
covid,IRCT20201024049134N1,http://en.irct.ir/trial/51847,"Intervention 1: Control group:  standard approved treatment regimen for COVID-19, including famotidine, cetirizine, N-acetylcysteine, bromhexine, naproxen, and fluticasone inhaler for 7 days. Intervention 2: Intervention group: standard approved treatment regimen for COVID-19, including famotidine, cetirizine, N-acetylcysteine, bromhexine, naproxen, and fluticasone inhaler plus arbidol (manufactured by Pharmstandard, Russia) at the dose of two 40 mg capsules every 8 hours for 7 days.",NA,NA,NA
covid,ISRCTN10207947,http://isrctn.com/ISRCTN10207947,"<br>                The study will be conducted in healthcare settings and other facilities directly involved in COVID-19 case management. We will recruit healthcare workers and other staff working in a facility where there are cases of either proven, or suspected COVID-19, who can be followed reliably for 5 months.<br><br>                The participant will be randomised to receive either chloroquine or placebo (1:1 randomisation), or to hydroxychloroquine or placebo (1:1 randomisation). A loading dose of 10 mg base/kg (between three and five tablets e.g., four 155-mg tablets for a 60-kg subject), followed by 155 mg daily (250 mg chloroquine phosphate salt/200 mg hydroxychloroquine sulphate) will be taken for 3 months.<br><br>                A randomisation list will be prepared by a statistician using block randomisation in a 1:1 ratio for the chloroquine/ hydroxychloroquine arm versus the placebo and stratified by site. The randomisation will be computer-generated and programmed in Stata 15.<br>",NA,Yes,NA
im,ISRCTN10720581,http://isrctn.com/ISRCTN10720581,"This is a step-wedge design so that both index children of group 1 and group 2 (randomly allocated at a 1:1 ratio) receive the standard dose of LAIV but at different times. The group number determines whether the two-year-old (index) child receives LAIV at the first study visit (Group 1) or at the third study visit, 4 weeks later (Group 2).  Serial saliva and nasopharyngeal swabs taken every 2 weeks over an 8-week period will be analysed for Streptococcus pneumoniae using real-time PCR. Standard statistical methods including generalised linear mixed models and individual-based mathematical modelling of transmission dynamics will be used for analysis.",NA,NA,NA
im,ISRCTN11142694,http://isrctn.com/ISRCTN11142694,"<br>                Participants will be randomised using an online randomization generator (http://www.randomization.com) to one of three arms: usual care, blinded n-of-1 experiment, and open-label n-of-1 experiment.<br><br>                Participants in the open-label arm will receive atorvastatin 20mg on and off in 4 week blocks. Participants in the closed label arm will receive encapsulated atorvastatin 20mg and placebo in 4 week blocks (the order of statin/placebo will be randomised for the final 16 weeks of the study). Participants in the control group will receive usual care.<br><br>                Participants will be supported to monitor adverse events and draw sound inferences about their cause using symptom diaries, 4-week on-off periods of medication use, and a review from their GP. We will then test the feasibility of this approach to assess whether GPs deliver the intervention as planned, whether patients engage with this, and whether it improves adherence to statins.<br>",NA,NA,NA
covid,ISRCTN11188345,http://isrctn.com/ISRCTN11188345,"<br>                Eligible patients will be randomised to receive 1:1:1  to one of the following treatment arms (each in addition to standard of care (SoC))<br><br>                Arm 1: Baricitinib oral tablets (4mg OD) in addition to standard of care<br>                Arm 2: Ravulizumab intravenous infusion (single dose, weight-based dosing) in addition to standard of care<br>                Arm 3: Standard of care<br><br>                Randomisation will be carried out using a validated central automated web-based randomisation system.<br><br>                Arm 1 Participants will be given 4mg of Baricitinib PO (2 x 2mg tables, once daily) on days 1-14 PO.<br>                Dose adjustments for age and renal function.<br><br>                Arm 2 Participants will receive Ravulizumab as a single intravenous infusion, Ravulizumab weight-based dosing regimen:<br>                Body weight range (kg)	   Dose (mg)<br>                = 40 to < 60                       2,400<br>                = 60 to < 100                     2,700<br>                = 100                                  3,000<br><br>                Duration of follow up:<br>                There will be two follow up visits at day 28 and day 90 after the first dosing visit.<br><br>                Assessments will include the following:<br>                • Discharge status<br>                • Vaccination status (for ravulizumab arm only)<br>                • Return to normal function status (numeric rating scale 0-10)<br>                • Mortality status<br>                • Adverse event reporting<br>                • ECOG and MRC scores<br>",NA,Yes,NA
covid,ISRCTN11970082,http://isrctn.com/ISRCTN11970082,"<br>                1. Indomethacin 25 mg two times a day (or 75 mg SR once a day at the discretion of the treating physician) and a proton pump inhibitor 20 mg (or 40 mg at the discretion of the treating physician) for 5 days<br>                2. Standard care as per the protocol of the hospital<br>                3. The following drugs are not to be administered: remdesivir, corticosteroids, and paracetamol<br>                4. Total duration of treatment: 5 days<br>                5. Follow-up: 14 days<br>                6. The patients are advised to return to the hospital if they have any problems<br>",NA,Yes,NA
im,ISRCTN12600919,http://isrctn.com/ISRCTN12600919,"<br>                Current interventions as of 28/02/2019:<br>                Participants are randomised to receive standard treatment with the addition of a beta blocker infusion (landiolol) or standard treatment alone.<br><br>                For those in the landiolol group, the rate of drug are adjusted until the heart rate is controlled between 80-94 beats per minute. Landiolol may be used for up to 14 days within the ICU. Follow up continues for up to 90 days following randomisation.<br><br>                One of the aims of this study is to better understand the biological mechanisms that are altered by beta-blockade in septic shock. As part of standard clinical care blood will be taken from a cannula (a thin tube inserted into a vein or body cavity to administer medication). Additional blood samples will be taken at study entry, on days 0, 1, 2, 4 and 6 and at the end of noradrenaline treatment (if not a sampling day). These samples will be sent to University of Birmingham and University Hospitals Birmingham NHS Foundation Trust and will be used in laboratory research to help define the mechanisms involved in treating sepsis with beta blockade. These samples will be destroyed once analysis has been completed.<br><br>                Routinely collected clinical data will be recorded for the trial. However the progress of participants will be followed at day 28 and day 90 after trial entry, at these time points the local research team will call the participant and their GP to find out how they are. The trial will not follow participants beyond 90 days.<br><br><br>                Previous interventions:<br>                Participants are randomised to receive standard treatment with the addition of a beta blocker infusion (landiolol) or standard treatment alone.<br><br>                For those in the la",NA,NA,NA
im,ISRCTN13673233,http://isrctn.com/ISRCTN13673233,"<br>                This is a multicentre, double-blind placebo-controlled feasibility study of Andrographis paniculata leaf extract.  The study aims to recruit 60 participants.<br><br>                Patients will eligible for the trial if they are over 18 years of age and present to their GP with a potential ARTI. Adults 18 years and over presenting with an acute cough (=7 days' duration) or sore throat as their main symptom and, with symptoms localising to the upper respiratory tract (e.g. runny nose, sneezing, fever, muscle ache), for which non-infective diagnoses are judged very unlikely.<br><br>                Participants will be randomised to 1 week of active treatment using Andrographis capsules or placebo. The capsules contain 250 mg of dried Andrographis paniculata. Participants will take 3 capsules 4 times a day with water before food. Treatments will be randomly allocated and double-blinded so that no one, including the doctor and the participant, will know which participant is getting which treatment. Both groups will continue to receive standard care and GPs can prescribe antibiotics if needed to participants in either group, either taken immediately, or issued as a delayed prescription.<br>",NA,Yes,Yes
im,ISRCTN13727958,http://isrctn.com/ISRCTN13727958,"<br>                Enrolled infants were randomized into one of the two study groups using sequential sealed opaque envelopes from a computer-generated randomization list. This allocation sequence was generated centrally by an independent statistician, and sequentially sealed envelopes were sent to each center.<br><br>                Surfactant-iNO group: received treatment with 20 ppm of inhaled Nitric Oxide (INOmax, INO Therapeutics, USA) with up to 2 doses of 100 mg/kg of poractant alfa (Curocerf; Chiesi Farmaceutici, Italy)<br><br>                Control group: received treatment with 20 ppm iNO + placebo (air) and standard intensive care, which in both groups includes high frequency or conventional mechanical ventilation with 100% FiO2., inotropic support and sedation<br><br>                Infants in both groups could receive open-label surfactant if they developed an OI>40 within the first 48 hrs of study. ECMO was considered in patients with a persistent OI>40.<br><br>                Study surfactant combined with iNitric Oxide treatment were used within first 48 hours after study entry, but infants continue receiving standard intensive care later according to local and physician in charge guidelines. Patients were strictly monitored and followed during their whole hospital stay until discharge home.<br>",NA,NA,NA
covid,ISRCTN14212905,http://isrctn.com/ISRCTN14212905,"<br>                Patients will be divided into cohorts, a) community b) hospitalised requiring supplemental oxygen and c) hospitalised requiring assisted ventilation.<br><br>                Two treatments will be compared to standard care. Nafamostat (anti-viral and anti-coagulant) and TD139 (galectin 3 inhibitor).  For Nafamostat, it is intended that the licensed dose (0.2 mg/kg/h) in Japan will be used. Patients randomised to Nafamostat will receive a continuous intravenous infusion at 0.2 mg/kg/h for 7 days. If a participant is discharged from hospital or can no longer receive this treatment, the treatment will be stopped. For TD139, patients will inhale 5 mg x 2 (10 mg) twice daily for the first 48 h and then subsequently 5 mg x 2 (10 mg) once daily for the remaining 12 days. Unless a participant is discharged from hospital or can no longer use an inhaler – in which case treatment will be stopped at such time.<br><br>                Randomisation will be performed using a web-based randomisation system (built in REDCap) hosted at the Edinburgh Clinical Trials Unit (ECTU) at the University of Edinburgh (a fully registered UKCRC CTU (registration #15)). Since these studies are designed to be small, this study will balance underlying risk across the allocations using the method of minimisation.<br><br>                Follow up will be at 30, 60 and 90 days post treatment.<br>",NA,NA,NA
covid,ISRCTN14326006,http://isrctn.com/ISRCTN14326006,"<br>                Intervention: Hydroxychloroquine 400 mg orally once a day as pre-exposure prophylaxis against COVID-19.<br>                Control: Placebo.<br>                Randomization details: Fixed 1:1 allocation ratio produced by a computer-based random number generator. Randomly permuted blocks of varying size will be used to ensure equal allocation to each group, stratified by site.<br>",NA,Yes,NA
main,ISRCTN15245496,http://isrctn.com/ISRCTN15245496,"<br>                The planned intervention is the switch from intravenous to oral antibiotic treatment after 48 hours, provided that clinical criteria according to a predefined checklist are fulfilled (designated as intervention arm). Hence, there will be an intervention arm” and an observation arm.”<br>                Antibiotics used:<br>",NA,Yes,NA
main,ISRCTN17538725,http://isrctn.com/ISRCTN17538725,"<br>                Patient enrollment and allocation:<br>                Eligible patients will be admitted to hospital and included in the study after screening and signing the informed consent, then, they will be 1:1 randomized assigned to receive either epidural hydromorphone infusion (intervention group) or epidural morphine infusion (control group), according to the random table generated by the statistics software.<br>                Treatment procedures:<br>                Before the placement of the epidural catheter, all patients received oral gabapentin 300 mg t.i.d. as basic treatment. A catheter will be placed to the epidural space under the fluoroscopic guidance after percutaneous puncture, the tip of the catheter will be placed at the spinal level corresponding to the peripheral afferent sensory nerves of the personally affected dermatome. Then, the extracutaneous portion of the catheter will be temporarily secured and connected to an external electronic infusion pump, which has a PCA bolus infusion function. A pre-prepared reservoir, containing hydromorphone solution(2mg/100ml NS) or morphine solution (10mg/100ml NS) in the blind state, will be installed in the pump. The initial infusion rate was 1.5 ml/hour and the bolus infusion was 1.5 ml/press/2 hour.<br>                Duration of treatment:<br>                Continuous infusion time is 2~3 days. The overall duration of patient participation from screening to the end of the treatment period study will be approximately 4~5 days. After the infusion, the catheter will be pulled out and the patient will continue to receive treatment according to the Chinese guidelines for neuropathic pain.<br>                Provision of drugs:<br>                All of the aforementioned drugs have been approved in China for the treatment of pain. They will be prescribed by clinicians according to the usual procedures in use and dispensed by the Urban Residents Healthcare Service of Shanghai. The drug reservoir will be prepared before th",NA,NA,NA
im,ISRCTN22467293,http://isrctn.com/ISRCTN22467293,"<br>                A single blind randomised controlled trial design allows an unbiased methods for comparison of four groups comparing S. pneumoniae i) attenuated strain I, ii) attenuated strain, II iii) wild type bacteria (control), and v) saline (control). The laboratory team are blinded for Stage II at the time of assessing carriage as the detection of the wild type S. pneumoniae in nasal washes is the primary outcome. As such there is no need to blind the participant or clinical team.<br><br>                Justification of control: this provides a comparison of symptoms for example that may be influenced by seasonal changes over the period of the study.<br><br>                Clinical visits will take place in the dedicated research facility: Accelerator Research Clinic in the Liverpool School of Tropical Medicine.<br><br>                This is an adaptive trial design with an interim analysis. In the event that one strain does not show either carriage or immune response then the TSC will determine whether to replace this rather than continue with a strain that is unlikely to be effective as a potential vaccine. The strain is attenuated with the intention of making it safer by removing genes associated with illness. Pre-clinical data in mice suggests this strain will stimulate an immune response and this research will evaluate whether this translates to humans.<br><br>                Procedures to reduce bias: the trial will be single blind achieved by blinding the laboratory staff who assess the primary outcome in stage II. Participants are randomised to one of four arms including two control arms.<br><br>                Recruitment: The target is to complete 108 participants, up to 150 may be screened to achieve this as we anticipate 1: 10 will already have pneumococcus in their nose 'natural carriers' (it is commonly found in the nose of healthy adults and more common in children). Also, a higher drop out rate than in previous studies is anticipated due to the 6-month interval between",Yes,NA,NA
covid,ISRCTN33260034,http://isrctn.com/ISRCTN33260034,"<br>                Intervention: Adalimumab<br><br>                Regimen 1. A loading dose of 80 mg Adalimumab given as two injections of 40 mg at separate sites in the thigh or abdomen. Subjects with persistent symptoms and signs may receive a second dose of Adalimumab 40 mg after 14 days.<br><br>                Regimen 2. A loading dose of 160 mg Adalimumab given as four injections of 40 mg at separate sites in the thigh or abdomen. Subjects with persistent symptoms and signs  may receive a second dose of Adalimumab 80 mg after 14 days.<br><br>                This is in addition to standard care as per local Hospital at Home network treatment pathways.<br><br>                Note: The second regimen will start recruitment following a preliminary assessment of safety of the first regimen (25 subjects randomised to regimen 1).<br><br>                Comparator: Standard care as per local treatment pathways for those with confirmed COVID-19 being managed in the community.<br><br>                Participants will be followed up for up to 120 days.<br><br>                Eligible patients will be randomised using the centralised validated computer randomisation program through a secure (encrypted) web-based service, RRAMP (https://rramp.octru.ox.ac.uk), provided by the Oxford Clinical Trials Research Unit (OCTRU), accessed via the study’s RedCap instance, with a minimisation algorithm to ensure balanced allocation across treatment groups, (incorporating a non-deterministic random element) to include age, gender and presence of metabolic or cardiovascular co-morbidities in a 1:1 ratio to either Adalimumab (2 regimens) with standard usual care or standard usual care.  Within the Adalimumab arm, following the review of the initial 25 patients who will receive regimen one, patients within Adalimumab will be randomly a",NA,Yes,NA
covid,ISRCTN33578935,http://isrctn.com/ISRCTN33578935,"<br>                With both subject and the evaluating physician blinded, subjects will be administered the investigational drug injection and placebo (saline) injection at Visit 1 (Day 0), by a non-evaluating (unblinded) study site staff member and will be followed up and re-evaluated by a blinded evaluating physician at Visit 2 (Day 1), Visit 3 (Day 7), Visit 4 (Day 14), Visit 5 (Day 21), Visit 6 (Day 30), Visit 7 (Day 60), Visit 8 (Day 90), visit 9 (day 120), and visit 10 (day 180).<br>                At each visit, participants (and accompanying caregivers) will be informed/reminded about study design, responsibilities, and possible adverse events.<br><br>                Intervention:<br>                Intravenous infusion of purified exosomes, XoGlo®, which are isolated, neonatal, mesenchymal stem cell-derived extracellular vesicles at a dose of 0.2 mg/kg each in a total of 15ml on day 1 and day 3.<br>                Control:<br>                15ml of saline, i.v. on Day 1 and Day 3<br>",NA,Yes,NA
im,ISRCTN51364654,http://isrctn.com/ISRCTN51364654,"<br>                The trial will enroll a total of 1300 children from approximately 30 rural villages in Chikhwawa District, in Southern Malawi, where each village has about 100-150 households . The study will enroll participants at a baseline visit, with two follow-up visits at Days 28 and 56. All study participants will receive IIV vaccine at days 0 and 28; participants’ immunological response to the vaccine will be assessed at Days 28 and 56. Malaria parasitaemia will be assessed in participants at each study visit.<br>                Study subjects will be followed up at Day 3 post-vaccination to assess fever, injection site reactions and other adverse events (AEs). Children with AEs at Day 3 will be followed up through Day 7 to ensure that the AE has resolved. Parents/guardians will be asked to contact study staff in the event of serious clinical events or fever in the study participant at any time throughout the study.<br>",Yes,NA,NA
im,ISRCTN52319075,http://isrctn.com/ISRCTN52319075,"<br>                The eligible subjects who are willing to receive intravenous therapy with human umbilical cord-derived mesenchymal stem cells for ARDS and profound septic shock complicated with multiple organ failure will be enrolled into this study. Blood biochemistry study will be performed at baseline. Sequentially numbered opaque, sealed envelopes (SNOSE) will be used to allocate the study subjects. Three different dosages of human umbilical cord-derived mesenchymal stem cells will be administered intravenously:<br>                1. 1.0 x 106 cells/kg (n=3)<br>                2. 5.0 x 106 cells/kg (n=3)<br>                3. 1.0 x 107 cells/kg (n=4)<br><br><br>                The injected number of stem cells will be gradually titrated up if safety is confirmed after injection of the prior lower dose. The safety is defined as no relevant side effects after human umbilical cord-derived mesenchymal stem cell therapy, e.g., allergy, immunosuppressant effect, or therapy-associated organ damage or death. The duration of cell-based treatment with intravenous infusion of stem cells is less than 2 hours. After discharge, patients will be followed up regularly in the outpatient setting at 1 month and every 3 months. The total follow-up period is one year.<br>",NA,Yes,NA
main,ISRCTN62041885,http://isrctn.com/ISRCTN62041885,"A randomisation code will be generated by the trial statistician using a randomly permuted block size. Participants will be allocated in a 1:1 ratio to receive either (DP) or placebo. Participants in the DP arm will receive two DP doses, one month apart, prior to immunisation followed by monthly DP doses for one year thereafter. Each dose will comprise treatment once a day for three consecutive days. DP will be dosed using weight-based guidelines targeting a total dose of 6.4 mg/kg dihydroartemisinin and 51.2 mg/kg piperaquine. Participants in the placebo arm will receive doses of placebo at the same time points as the DP arm receive DP, i.e. two doses of placebo, one month apart prior to immunisation followed by monthly placebo for one year thereafter. Both DP and placebo will be taken orally. As yet, routine preventive malaria treatment in schools is not Uganda Ministry of Health policy.",NA,Yes,NA
main,ISRCTN65109397,http://isrctn.com/ISRCTN65109397,"<br>                This is a multi-country, factorial design, feasibility trial of nicotine replacement and behavioral support. Once they have agreed to participate, participants will be asked to provide information about themselves, as well as their tobacco use. They will also be asked to provide a saliva sample, so that the level of nicotine by-products in their body can be assessed. They will then be randomly allocated to receive one of four interventions. Participants in intervention arms 2, 3 and 4 will receive either or both of the interventions; those who do not receive an active intervention (arm 1) will receive very brief advice (VBA) along with a self-help leaflet for stopping smokeless tobacco use. The trial will be unblinded, and assignment to intervention arms will be through random allocation using an equal allocation.<br><br>                The interventions include:<br>                Treatment A: Nicotine replacement therapy (NRT) in the form of Nicorette nicotine chewing gum. Participants will receive either a 4-mg or 6-mg dose of nicotine gum, depending on the heaviness of their smokeless tobacco (ST) use (i.e time to first use, number of times ST is used in a day). The nicotine gum will be used from the participant's quit date over a period of 8 weeks. Participants will be instructed to use nicotine replacement on an hourly basis, using no more than 15 gums per day. The first dose will be taken in the morning, within 1 hour of waking up. Participants will be given written instructions on how to use the gum.<br>                Treatment B: Behavioral support Intervention for Smokeless tobacco Cessation in Adults (BISCA): this will be delivered face to face by trained cessation advisors, and will include prequit, quit and post-quit sessions. The first session will",NA,NA,NA
main,ISRCTN73285902,http://isrctn.com/ISRCTN73285902,<br>                Generic drug name: physostigmine and hyoscine (transdermal patch)<br>                Dosage: a single active or placebo 21cm2 patch formulation F-11.<br>                Method and frequency of administration: a single dose of either active or placebo patch formulation F-11 was worn for 72 hours.<br>                Randomisation: a sequential three-digit subject (randomisation) number was assigned once eligibility for the study was confirmed. Subjects were randomised to receive one of the two IMPs in Period 1 and the alternative in Period 2. Treatment was allocated according to the randomisation schedule produced by the CRO.<br>,NA,NA,NA
covid,ISRCTN74727214,http://isrctn.com/ISRCTN74727214,"<br>                Eligible patients providing written informed consent will be administered anakinra (in addition to standard treatment as defined by the hospital protocols) via a subcutaneous route over 10 days as follows: 100 mg twice a day for 3 days, followed by 100 mg once daily for 7 days.<br><br>                In patients on hemodialysis or with a glomerular filtration rate of less than 30 ml/min, the anakinra dosing schedule will be as follows: 100 mg once daily for 3 days, followed by 100 mg once every other day for 7 days via a subcutaneous route<br><br>                A historical cohort retrospectively identified (fulfilling the same inclusion and exclusion criteria as the interventional arm and received the same standard of care) will be used as a comparator group.<br>",NA,NA,NA
main,ISRCTN82984919,http://isrctn.com/ISRCTN82984919,"This is a double blind randomised placebo controlled trial. Participants will be randomised to active treatment, Pravastatin Sodium 40 mg tablets once daily for 7 days, or a matching placebo. Randomisation is a 1:1 ratio, and participants are randomised using a ‘next sequential pack’ methodology. Randomisation block size will use permuted blocks of size 2, 4, and 6, randomly sorted, and spliced with occasional randomly inserted simple runs of random length to aid unpredictability.",NA,NA,NA
covid,ISRCTN83971151,http://isrctn.com/ISRCTN83971151,"<br>                Adults (aged =18 years) recently hospitalized, or already in the hospital, with definite COVID-19 and, in the view of the responsible doctor, no contra-indication to any of the study drugs will be randomly allocated between five groups:<br>                1. Local standard of care alone<br>                OR local standard of care plus one of<br>                2. Remdesivir (daily infusion for 10 days)<br>                3. Chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days)<br>                4. Lopinavir + ritonavir (orally twice daily for 14 days)<br>                5. Lopinavir + ritonavir ((orally twice daily for 14 days) plus interferon-beta (daily injection for 6 days)<br><br>                Follow-up is until death or discharge from hospital.<br>                Randomization is performed at one central global location through an online portal.<br>",NA,Yes,NA
im,ISRCTN89942618,http://isrctn.com/ISRCTN89942618,"<br>                Participants admitted to the ICU under optimised sedation and ventilation for hypoxemic acute respiratory failure a PaO2/FIO2 < 200 and requiring paralysis to improve gas exanges and offset patient-ventilator asynchronies.<br><br>                Neuromuscular blockade is induced respectively by the two cisatracurium forms during two successive periods, separated by a one-hour washout period. Neuromuscular function was monitored by a calibrated train-of-four (TOF) stimulation.<br><br>                A pre-protocol test patient is performed in order to define the minimum delay for paralysis, recovery time, better intervals for monitoring and to train the co-investigator residents (NF, JA & SR) to monitor the different parameters and to get familiar with the form designed to collect these parameters. The same co-investigators monitored all the included patients to ensure the maximal consistency and homogeneity of the collected data.<br><br>                After a one hour of the stabilisation period and referring to the current state-of-the-art targeting respiratory and hemodynamic stability, participants arre randomized to a double-blind inclusion for the order of infusion of the two products under study, based on the random table. The principal investigator (MB) implemented the random allocation sequence, enrolled and assigned participants to interventions. He pre-prepared the assigned drug and concealed the sequence until all interventions were performed. Co-investigators (NF, JA & SR), participants and care providers were blinded after assignment to interventions. Participants are randomised to receiving either one of two paralysis agents, either Nimbex® and Cisatrex®.<br><br>                In all studied patients it was ensured within the study period that the patients displayed no significant patient-ventilator asynchrony.<br><br>                Paralysis depth is monitored by TOF.<br><br>                A short period of stabilization under effective analgo-sedation as assessed b",NA,NA,NA
im,JPRN-JapicCTI-163302,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-163302,"Intervention name : KRP-AM1977Y 150mg KIT FOR INTRAVENOUS DRIP INFUSION<br>INN of the intervention : -<br>Dosage And administration of the intervention : 300mg QD intravenous infusion on Day 1, followed by 150mg QD on Days 2 and after.<br>Control intervention name : -<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -",NA,NA,NA
im,JPRN-JapicCTI-163320,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-163320,Intervention name : Recombinant Human Interferon Beta-1a<br>INN of the intervention : Interferon beta-1a<br>Dosage And administration of the intervention : MR11A8 (10mcg) or placebo is administered intravenously once daily for 6 days<br>Control intervention name : Placebo<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : MR11A8 (10mcg) or placebo is administered intravenously once daily for 6 days,NA,Yes,NA
im,JPRN-JapicCTI-163397,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-163397,Intervention name : CS-8958<br>INN of the intervention : laninamivir (INN)<br>Dosage And administration of the intervention : Single inhalation of nebulized CS-8958 160 mg<br>Control intervention name : null,NA,Yes,NA
im,JPRN-JapicCTI-163398,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-163398,Intervention name : CS-8958<br>INN of the intervention : laninamivir (INN)<br>Dosage And administration of the intervention : Single inhalation of nebulized CS-8958 160 mg<br>Control intervention name : null,NA,Yes,NA
im,JPRN-JapicCTI-163400,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-163400,Intervention name : MEDI3250<br>Dosage And administration of the intervention : Intranasal administration was 0.1 mL per nostril.(total 0.2mL)<br>Control intervention name : placebo<br>Dosage And administration of the control intervention : Intranasal administration was 0.1 mL per nostril.(total 0.2mL),NA,NA,NA
im,JPRN-JapicCTI-163407,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-163407,Intervention name : BK1304<br>Dosage And administration of the intervention : 2 doses of intranasal administration<br>Control intervention name : null,NA,NA,NA
im,JPRN-JapicCTI-163417,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-163417,Intervention name : S-033188<br>Dosage And administration of the intervention : Oral,NA,NA,NA
im,JPRN-JapicCTI-173811,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-173811,Intervention name : S-033188<br>INN of the intervention : baloxavir marboxil<br>Dosage And administration of the intervention : Oral<br>Control intervention name : -<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -,NA,Yes,NA
im,JPRN-JapicCTI-183974,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-183974,"Intervention name : KD-370<br>Dosage And administration of the intervention : 0.5 mL/dose, 4 doses in total, subcutaneous injection<br>Control intervention name : ActHIB(R), Quattrovac(R)<br>Dosage And administration of the control intervention : 0.5 mL/dose, 4 doses in total, subcutaneous injection",NA,NA,NA
im,JPRN-JapicCTI-184135,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-184135,Intervention name : BK1304<br>INN of the intervention : -<br>Dosage And administration of the intervention : 2 doses of intranasal administration<br>Control intervention name : Placebo<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : 2 doses of intranasal administration,NA,NA,NA
im,JPRN-JapicCTI-184176,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-184176,Intervention name : KD-404<br>INN of the intervention : -<br>Dosage And administration of the intervention : [part 1] -Subcutaneously administer 0.1 mL twice with an interval of 3 weeks (+-1 week) between administrations. -Subcutaneously administer 0.25 mL twice with an interval of 3 weeks (+-1 week) between administrations. -Subcutaneously administer 0.5 mL twice with an interval of 3 weeks (+-1 week) between administrations.  [part 2] -Subcutaneously administer 0.1 mL twice with an interval of 3 weeks (+-1 week) between administrations. -Subcutaneously administer 0.25 mL twice with an interval of 3 weeks (+-1 week) between administrations. -Subcutaneously administer 0.5 mL twice with an interval of 3 weeks (+-1 week) between administrations.<br>Control intervention name : FLU(QIV)<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : Subcutaneously administer 0.5 mL twice with an interval of 3 weeks (+-1 week) between administrations,NA,NA,NA
im,JPRN-JapicCTI-184205,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-184205,Intervention name : S-033188/RO7191686<br>INN of the intervention : baloxavir marboxil<br>Dosage And administration of the intervention : Oral,NA,Yes,NA
im,JPRN-JapicCTI-194577,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194577,Intervention name : baloxavir marboxil<br>INN of the intervention : baloxavir marboxil<br>Dosage And administration of the intervention : oral<br>Control intervention name : -<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -,NA,Yes,NA
main,JPRN-JapicCTI-194585,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194585,Intervention name : MLD-55<br>INN of the intervention : escitalopram<br>Dosage And administration of the intervention : oral administration<br>Control intervention name : Placebo<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -,NA,NA,NA
main,JPRN-JapicCTI-194630,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194630,Intervention name : AR-13324<br>INN of the intervention : netarsudil<br>Dosage And administration of the intervention : agents for ophthalmic use<br>Control intervention name : -<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -,NA,NA,NA
main,JPRN-JapicCTI-194633,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194633,Intervention name : T-817MA<br>INN of the intervention : Edonerpic<br>Dosage And administration of the intervention : Oral Multiple Dose<br>Control intervention name : -<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -,NA,NA,NA
main,JPRN-JapicCTI-194678,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194678,"Intervention name : OPA-15406 Ointment (1%)<br>INN of the intervention : Difamilast<br>Dosage And administration of the intervention : Application, Twice daily<br>Control intervention name : Placebo<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : Application, Twice daily",NA,NA,NA
main,JPRN-JapicCTI-194690,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194690,Intervention name : lusutrombopag<br>INN of the intervention : lusutrombopag<br>Dosage And administration of the intervention : Oral<br>Control intervention name : -<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -,NA,NA,NA
main,JPRN-JapicCTI-194796,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194796,Intervention name : TAS-120<br>INN of the intervention : -<br>Dosage And administration of the intervention : -<br>Control intervention name : -<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -,NA,NA,NA
main,JPRN-JapicCTI-194922,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194922,Intervention name : l-menthol<br>INN of the intervention : levo menthol<br>Dosage And administration of the intervention : 20mL /site<br>Control intervention name : -<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -,NA,NA,NA
main,JPRN-JapicCTI-194946,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194946,"Intervention name : Palivizumab (Genetical Recombination)<br>INN of the intervention : Palivizumab<br>Dosage And administration of the intervention : Throughout the RS virus season, total of 4 to 7 doses of the investigational product are intramuscularly administered at 15 mg of palivizumab (genetical recombination) per kg of body weight at an interval of 30 days.  If the injection volume exceeds 1 mL, the liquid for injection shall be given as a divided dose.<br>Control intervention name : -<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -",NA,Yes,NA
main,JPRN-JapicCTI-194964,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194964,"Intervention name : DS-3201b<br>INN of the intervention : valemetostat<br>Dosage And administration of the intervention : Once a day, 200 mg, oral administration <br>Control intervention name : -<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -",NA,NA,NA
main,JPRN-JapicCTI-194971,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194971,"Intervention name : ACT-064992D<br>INN of the intervention : -<br>Dosage And administration of the intervention : Subjects to receive FDC macitentan/tadalafil (macitentan 10 mg and tadalafil 40 mg) plus matching placebos for the two other study treatments.<br>Control intervention name : Macitentan<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : Film-coated tablet with 10 mg macitentan, to be administered orally once daily.<br>Control intervention name : Tadalafil<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : Film-coated tablet with 40 mg tadalafil (2 x 20 mg tablets), to be administered orally once daily.<br>Control intervention name : Placebo<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : FDC therapy + Placebo macitentan + Placebo tadalafil ,  Macitentan mono-therapy + Placebo tadalafil + Placebo FDC,   Tadalafil mono-therapy + Placebo macitentan + Placebo FDC",NA,NA,NA
main,JPRN-JapicCTI-194975,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-194975,Intervention name : Lucerastat<br>INN of the intervention : lucerastat<br>Dosage And administration of the intervention : 1000 mg twice daily<br>Control intervention name : -<br>INN of the control intervention : -<br>Dosage And administration of the control intervention : -,NA,NA,NA
main,JPRN-JapicCTI-195038,https://www.clinicaltrials.jp/user/showCteDetailE.jsp?japicId=JapicCTI-195038,"Intervention name : Benralizumab<br>INN of the intervention : -<br>Dosage And administration of the intervention : Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks<br>Control intervention name : Placebo <br>INN of the control intervention : -<br>Dosage And administration of the control intervention : Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks",NA,Yes,NA
main,JPRN-jRCT1031180196,https://jrct.niph.go.jp/latest-detail/jRCT1031180196,"Conventional therapy group: After initial dose is continued for 2 to 4 weeks, tapering GC every 2 weeks according to the following dose<br>60 mg -50 mg - 45 mg - 40 mg - (tapering every 2 weeks, continued hospitalization)<br>37.5 mg - 35 mg - 32.5 mg - 30 mg - (tapering every 4 weeks)<br>Rapid Tapering Group: After continuing the initial dose for 2 to 4 weeks, tapering GC every week according to the following dose<br>60 mg - 50 mg - 45 mg - 40 mg - 35 mg - 30 mg - (tapering every week, continued hospitalization)<br>After tapering less than 30 mg, GC dose is decided by the attending physician.",NA,NA,NA
main,JPRN-jRCT1041190019,https://jrct.niph.go.jp/latest-detail/jRCT1041190019,Administration of Goreisan or Saireito + complex therapy,NA,NA,NA
main,JPRN-jRCT1051190028,https://jrct.niph.go.jp/latest-detail/jRCT1051190028,"Arm dienogest: oral dienogest 1mg twice a day from menstrual cycle day 2-5 for 24 months.<br>Arm LUNABELL tablets ULD: oral LUNABELL 1 tablet once a day at the same time of each day from menstrual cycle day 2-5 for 24 months. After taking tablets for 21 days, patients stop it for 7 days. These 28 days is one cycle and patients start to take the tablet from cycle day 29.",NA,NA,NA
main,JPRN-jRCT2031190013,https://jrct.niph.go.jp/latest-detail/jRCT2031190013,placebo I.V. and chemotherapy and in maintenance<br>atezolizumab I.V. and chemotherapy and in maintenance<br>(Atezolizumab/placebo 1200mg dose will be delivered every 3 weeks prior to the carboplatin- paclitaxel regimen and in all the maintenance schedule.),NA,Yes,NA
covid,JPRN-jRCT2031200126,https://jrct.niph.go.jp/latest-detail/jRCT2031200126,"The ravulizumab will be administered via IV infusion as below dosage regimen; <br>In cae Patient Body Weight (kg) is 40 to 60, 2400mg at Day1, 600mg at at Day5 and Day10 and 900mg at Day15<br>In cae Patient Body Weight (kg) is 60 to 100, 2700mg at Day1, 900mg at at Day5, Day10 and Day15<br>In cae Patient Body Weight (kg) is over 100, 3000mg at Day1, 900mg at at Day5, Day10 and Day15",NA,Yes,NA
covid,JPRN-jRCT2071200041,https://jrct.niph.go.jp/latest-detail/jRCT2071200041,Intravenous infusion of investigative drug (adrenomedullin or placebo) will be started immediately after the introduction of mechanical ventilation. The administration of the drug are maintained 72 hour and then intermittent administration (8 hours per day) are followed up to 10 days. The drug administration will be stop after withdrawal of mechanical ventilation.,NA,NA,NA
main,JPRN-jRCTc031190101,https://jrct.niph.go.jp/latest-detail/jRCTc031190101,"blood collection for cell culture and tests.<br>combination of of immune cell administrations and immune checkpoint inhibitor infusion, total 4 times",NA,NA,NA
main,JPRN-jRCTs011180015,https://jrct.niph.go.jp/latest-detail/jRCTs011180015,Individuals who shared a room with the influenza patient with a positive immuno-chromatographic test were given oseltamivir for three days as post-exposure prophylaxis.,NA,Yes,NA
im,JPRN-jRCTs011180015,https://jrct.niph.go.jp/latest-detail/jRCTs011180015,Individuals who shared a room with the influenza patient with a positive immuno-chromatographic test were given oseltamivir for three days as post-exposure prophylaxis.,NA,Yes,NA
main,JPRN-jRCTs011180019,https://jrct.niph.go.jp/latest-detail/jRCTs011180019,Switching from DPP4 inhibitor to Luseogliflozin versus continuing of DPP4 inhibitor,NA,NA,NA
main,JPRN-jRCTs011180027,https://jrct.niph.go.jp/latest-detail/jRCTs011180027,Off-label use,NA,NA,NA
main,JPRN-jRCTs011190004,https://jrct.niph.go.jp/latest-detail/jRCTs011190004,"Subcutaneous injection arm: JEBIK V (0.5mL) is injected subcutaneously on the upper arm twice at intervals of 3 weeks, then the neutralizing antibody titer contained in the serum is measured.<br>Microneedle array low dose administration arm (MNA-L arm): Microneedle array low dose (1 patch) is administrated on the upper arm twice at intervals of 3 weeks, then the neutralizing antibody titer contained in the serum is measured.<br>Microneedle array high dose administration arm (MNA-H arm): Microneedle array high dose (1 patch) is administrated on the upper arm twice at intervals of 3 weeks, then the neutralizing antibody titer contained in the serum is measured.",NA,NA,NA
main,JPRN-jRCTs021180016,https://jrct.niph.go.jp/latest-detail/jRCTs021180016,"Ramucirumab 8 mg/kg day 1, 15 <br>Paclitaxel 80 mg/m2 day 1, 8, 15 <br>every 4 weeks",NA,Yes,NA
main,JPRN-jRCTs021180041,https://jrct.niph.go.jp/latest-detail/jRCTs021180041,Group A; Goshajinkigan is given orally 3 times a day from after CIPN episode. It was treated till 1 month after the completion of chemotherapy (TC).<br>Group B; Goshajinkigan is given orally 3 times a day from before 1 week of chemotherapy (TC).It was treated till 1 month after the completion of chemotherapy (TC).,NA,NA,NA
main,JPRN-jRCTs031180201,https://jrct.niph.go.jp/latest-detail/jRCTs031180201,"Arm A: Radiotherapy alone (50.4 Gy/28 fr, 5 days/week)<br>Arm B: Concomitant phase, temozolomide (75 mg/m2, every day from first day to last day of radiation), radiation (50.4 Gy/28 fr, 5 days/week) <br>Maintenance phase, temozolomide (150-200 mg/m2, day1-5, every 4 weeks) 12 cycles",NA,NA,NA
main,JPRN-jRCTs031180213,https://jrct.niph.go.jp/latest-detail/jRCTs031180213,"1.The initial dose of dasatinib will be 40 mg q.d. Subsequently, MRD will be determined every 2 months, and administration will be continued at the same dose if MRD is negative and the dose will be increased according to Criteria for changing treatment in positive cases.<br>2.In the preceding phase I clinical study, administration of dasatinib was started at the time point of 100 days after transplantation. Modification of alloimmune response by dasatinib administration was not observed. Therefore, in the phase II clinical study, administration of dasatinib will be started after eligibility criteria are satisfied.<br>3.Criteria for changing treatment in this study<br>After 4-week oral administration at the initial dose of 40 mg/day, MRD will be determined. If the result is negative for MRD, administration will be continued at 40 mg/day. The dose of dasatinib will be increased when the result turns positive, but administration will be continued at the dose immediately before the increase if MRD becomes negative after that.<br>4.The dose will be adjusted by the following five steps. In case an adverse event (AE) of grade 3 or severer occurs at a certain dose, administration will be temporarily discontinued for 14 days, as a rule. After improvement to grade 1 or milder has been confirmed, administration will be resumed at a dose lower by 1 level than the final dose at the discretion of the investigator. In case the final dose is 40 mg/day, the dose will be reduced to 20 mg/day, and 20 mg/day will be regarded as the minimum dose. When the dose is reduced once and resumed, the dose can be increased again at the discretion of the investigator according to the status of occurrence of AEs of grade 3 or severer at each dose. The dose will be adjusted by the following five levels.",NA,NA,NA
main,JPRN-jRCTs031180252,https://jrct.niph.go.jp/latest-detail/jRCTs031180252,We have randomly assigned high-risk prostate cancer patients who have received 125I-brachytherapy and EBRT plus 6 months of combined androgen blockade into two groups: one receiving no further treatment and another receiving 2 years of a luteinizing hormone-releasing hormone agonist.,NA,NA,NA
main,JPRN-jRCTs031180255,https://jrct.niph.go.jp/latest-detail/jRCTs031180255,Arm A: treatment free<br><br>Arm B: Patients receive S-1 orally twice a day for 4 weeks administration/2-week discontinuation. The initial dose of S-1 is reduced by >1 level versus the standard dose according to Ccr and type of surgery and is administered for 1 year after surgery.,NA,NA,NA
main,JPRN-jRCTs031180257,https://jrct.niph.go.jp/latest-detail/jRCTs031180257,Arm A: Rituximab + Standard CHOP X 6 courses(every 3 weeks)<br>Rituximab 375 mg/m2                                   day1<br>Cyclophosphamide (CPA) 750 mg/m2(div)   day 3<br>Doxorubicin(ADM)50 mg/m2 (div)              day 3<br>Vincristine (VCR)1.4 mg/m2 (iv)                    day 3<br>Prednisolone (PSL) 100 mg (po)day 3-7<br>Arm B: Rituximab + Bi-weekly CHOP X 6 courses (every 2 weeks)<br>Rituximab 375 mg/m2                      day 1<br>Cyclophosphamide (CPA)    750 mg/m2 (div)    day 3<br>Doxorubicin(ADM) 50 mg/m2 (div)        day 3<br>Vincristine (VCR)  1.4 mg/m2 (iv)          day 3<br>Prednisolone (PSL)                               day 3-7<br>G-CSF                                                    day 10-15,NA,Yes,NA
im,JPRN-jRCTs031180322,https://jrct.niph.go.jp/latest-detail/jRCTs031180322,"Patients are randomly allocated to following three regimens.<br>1)Peramivir 300mg single dose: peramivir is intravenously infused at a dose of 300mg once.<br>2)Peramivir 600mg repeated dose for 2 days: peramivir is intravenously infused at a dose of 600mg once for 2 days.<br><br>Infusion time for 300mg: 15min <= , >= 45min<br>Infusion time for 600mg: 30min <= , >= 75min<br><br>A patient allocated to peramivir 600mg will be administered after confirmation of persisting symptom in the morning of second day.<br><br>3)Oseltamivir: 75mg BID is orally administrated for 5 days. Half a day interval (morning /early evening or daytime/night) is required for 1day regimen (75mg x 2).",NA,Yes,NA
main,JPRN-jRCTs031180354,https://jrct.niph.go.jp/latest-detail/jRCTs031180354,Drug injection,NA,NA,NA
main,JPRN-jRCTs031190015,https://jrct.niph.go.jp/latest-detail/jRCTs031190015,Bleeding volume more than normal medical treatment,NA,NA,NA
main,JPRN-jRCTs031190031,https://jrct.niph.go.jp/latest-detail/jRCTs031190031,sitafloxacin (100mg)+amoxicillin (750mg)+Vonoprazan (20mg) given on twice daily for 7days,NA,Yes,NA
main,JPRN-jRCTs031190125,https://jrct.niph.go.jp/latest-detail/jRCTs031190125,Use of Icodextrin dialysate,NA,NA,NA
covid,JPRN-jRCTs031190226,https://jrct.niph.go.jp/latest-detail/jRCTs031190226,oral administration of favipiravir,NA,Yes,NA
covid,JPRN-jRCTs031190269,https://jrct.niph.go.jp/latest-detail/jRCTs031190269,Ciclesonide is inhaled three times a day at a dose of 400 microgram once a day for seven consecutive days.,NA,NA,NA
covid,JPRN-jRCTs031200026,https://jrct.niph.go.jp/latest-detail/jRCTs031200026,COVID-19 patients are randomly assigned to the group which adds Favipiravir and Nafamostat Mesilate to standard treatment or the group which add Favipiravir to standard treatment,NA,Yes,NA
covid,JPRN-jRCTs031200196,https://jrct.niph.go.jp/latest-detail/jRCTs031200196,"10 day treatment with the combination usage of favipiravir, camostat mesilate and inhaled ciclesonide",NA,Yes,NA
main,JPRN-jRCTs041180110,https://jrct.niph.go.jp/latest-detail/jRCTs041180110,"A: Docetaxel (60 mg/m2) given on day 1 every 3 weeks until disease progression. <br>B: Carboplatin (AUC 6) given on day1 plus nab-paclitaxel (100 mg/m2) given on day 1, 8, 15 every 3 weeks until disease progression.",NA,NA,NA
main,JPRN-jRCTs041190009,https://jrct.niph.go.jp/latest-detail/jRCTs041190009,Arm (1) oral administration with rivaroxaban + physical treatment<br>Arm (2) physical treatment,NA,NA,NA
main,JPRN-jRCTs041190022,https://jrct.niph.go.jp/latest-detail/jRCTs041190022,fecal microbiota transplantation,NA,NA,NA
main,JPRN-jRCTs041190070,https://jrct.niph.go.jp/latest-detail/jRCTs041190070,"All participants are divided into two groups, phenylephrine group and conventional group. In phenylephrine group, at the same time of spinal anesthesia, starting preventive infusion of phenylephrine 0.5 microgram/kg/min and gradually discontinuing based on the protocol. Treat hypotension in a same way for both groups.",NA,NA,NA
covid,JPRN-jRCTs041200025,https://jrct.niph.go.jp/latest-detail/jRCTs041200025,Combination therapy with favipiravir and methylprednisolone,NA,Yes,NA
main,JPRN-jRCTs051180055,https://jrct.niph.go.jp/latest-detail/jRCTs051180055,"Active Comparator: Calcium carbonate<br>Start at a dose of 1,500 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 3,000 mg/day.<br>Experimental: Lanthanum carbonate<br>Start at a dose of 750 mg/day, and adjust it to lower serum phosphate concentration <4.5 mg/dL. Maximum dose is 1,500 mg/day. For patients with calcium carbonate at inclusion, calcium carbonate will be replaced with lanthanum carbonate of 750 mg/day.",NA,NA,NA
main,JPRN-jRCTs051180089,https://jrct.niph.go.jp/latest-detail/jRCTs051180089,Octreotide subcutaneous injection,NA,NA,NA
main,JPRN-jRCTs051180111,https://jrct.niph.go.jp/latest-detail/jRCTs051180111,"Oral intake of Sovaldi 400mg once a day with Rebetol twice a day;600mg for those with body weight below 60kg, 800mg for those between 60 and 80kg, or 100mg for those over 80kg.",NA,NA,NA
main,JPRN-jRCTs051190017,https://jrct.niph.go.jp/latest-detail/jRCTs051190017,"Subjects are divided into the following 4 groups below, and capsules containing 25 mg of 5-aminolevulinic acid phosphate + 29 mg of sodium ferrous citrate are orally administered.<br>1.Take 1 capsule once per day, for the first 12 weeks. After 4 weeks washout, take 1 placebo capsule once per day, for the second 12 weeks.<br>2.Take 1 placebo capsule once per day, for the first 12 weeks. After 4 weeks washout, take 1 capsule once per day, for the second 12 weeks.<br>3.Take 6 capsules once per day, for the first 12 weeks. After 4 weeks washout, take 6 placebo capsules once per day, for the second 12 weeks.<br>4.Take 6 placebo capsules once per day, for the first 12 weeks. After 4 weeks washout, take 6 capsules once per day, for the second 12 weeks.",NA,NA,NA
main,JPRN-jRCTs051190071,https://jrct.niph.go.jp/latest-detail/jRCTs051190071,Irinotecan 150 mg/m^2 day 1 div<br>Ramucirumab 8 mg/kg day 1 div<br>Continued for 2-week courses until the subject becomes refractory.,NA,Yes,NA
main,JPRN-jRCTs061180042,https://jrct.niph.go.jp/latest-detail/jRCTs061180042,arm A: Hochuekkito is administrated in apathetic patients with chronic obstructive pulmonary disease who receive pulmonary rehabilitation.<br>arm B: Hochuekkito is not administrated in apathetic patients with chronic obstructive pulmonary disease who receive pulmonary rehabilitation.,NA,NA,NA
main,JPRN-jRCTs061180101,https://jrct.niph.go.jp/latest-detail/jRCTs061180101,"NASVAC (HBsAG 80 microgram, HBcAg 80 microgram) given every 2 weeks for 3 times via nasal route to healthy individuals (HB vaccine naive, HB vaccine responder, HB vaccine non-responder). Additional 1 dose will be administrated, if anti-HBs is under 10 mIU/mL at 28 week.",Yes,NA,NA
main,JPRN-jRCTs071180013,https://jrct.niph.go.jp/latest-detail/jRCTs071180013,Afatinib treatment,NA,NA,NA
main,JPRN-jRCTs071180058,https://jrct.niph.go.jp/latest-detail/jRCTs071180058,"Select vaccine peptides (up to 4) from 31 candidate peptides, to which peptide-specific IgGs are detected before vaccination.<br>Individually emulsify these peptides with adjuvant and subcutaneously inject (3.0mg/peptide).",Yes,NA,NA
im,JPRN-UMIN000020854,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024068,"Treatment with canagliflozin(100mg/day, everyday, 6 months)",NA,NA,NA
im,JPRN-UMIN000021060,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024282,Oseltamivir<br><br>Peramivir,NA,Yes,NA
im,JPRN-UMIN000021109,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024356,Control (n=30): intra- and postoperative management without Sivelestat<br>Trial (n=30): 7days administration of Sivelestat 0.2microgram/kgBW/hr div started from surgical operation,NA,NA,NA
im,JPRN-UMIN000021591,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024894,carboplatin AUC6 D1<br>paclitaxel 200mg/m D1<br>tryweekly 4cycle<br>nintedanib 150mg twice daily,NA,NA,NA
im,JPRN-UMIN000023102,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026319,"Multicenter, single-arm, open-label trial",NA,NA,NA
im,JPRN-UMIN000023732,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026898,"BK1313 High Dose with adjuvant Group (50 persons per group) is intramuscularly vaccinated with the vaccine containing 30microg/dose of hemagglutinin (HA) mixed with aluminum hydroxide (0.15mg). <br>For this study, each groups are vaccinated three times. After 21 days and 81days from first administration, the patients are vaccinated again. <br>BK1313 Super High Dose with adjuvant Group (55 persons per group) is intramuscularly vaccinated with the vaccine containing 45microg/dose of hemagglutinin (HA) mixed with aluminum hydroxide (0.15mg). <br>For this study, each groups are vaccinated three times. After 21 days from first administration, the patients are vaccinated again.After 81days from first administration, the patients receive placebo in this group.",Yes,NA,NA
im,JPRN-UMIN000024362,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028045,Catechin-derivative-treated mask/60 days<br>Non-catechin-derivative-treated mask/60 days,NA,NA,NA
im,JPRN-UMIN000024363,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028046,"Only as for the first time, I gave 200 mg of once after dinner after the second at 400 mg with celecoxib twice a day for the celecoxib group in morning after the next day five hours after an operation.<br>I gave 60 mg of loxoprofen after every meal with 60 mg of once after the second three times a day for the loxoprofen group five hours after an operation only in the first time.",NA,NA,NA
im,JPRN-UMIN000024458,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027881,Individuals who shared a room with the influenza patient with a positive immuno-chromatographic test were given oseltamivir for three days as post-exposure prophylaxis.,NA,Yes,NA
im,JPRN-UMIN000025514,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029296,Oral administration of ramelteon (21 days) -&gt; Polysomnography -&gt; Oral administration of placebo (21 days) -&gt; Polysomnography<br>Oral administration of placebo (21 days) -&gt; Polysomnography -&gt; Oral administration of ramelteon (21 days) -&gt; Polysomnography,NA,NA,NA
im,JPRN-UMIN000026368,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029836,The following each treatment for 14days<br>1.Fexofenadine Hydrochloride(60mg) twice daily<br><br><br>2.Fexofenadine Hydrochloride(60mg)/ Pseudiephedrine Hydrochloride(120mg) Combination Tablets twice daily,NA,NA,NA
im,JPRN-UMIN000026440,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030003,"Josamycine 30 mg/kg BW/days for maximum 14 days.<br>1. Use dry syrup of Josamycin 10%.<br>   (Josamy DS : Josamycin 10% dry syrup)<br>2. 10mg/kg BW x 3 times/day p.o. administration <br>3. Will be able to continue up to 14 days (2 weeks)<br>4. Patient&#39;s family member let the patient take it. If it is difficult to take as it is, dissolve in a small amount of water (less than 5 ml) to give.",NA,Yes,NA
im,JPRN-UMIN000026706,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030659,carboplatin with nab-paclitaxel,NA,NA,NA
im,JPRN-UMIN000028307,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032402,"intervention:removal of tongue coating by using 3% hydrogen peroxide<br>intervention:removal of tongue coating by using 3% hydrogen peroxide, next 5ml of 10% povidone iodine is dropped in oropharynx after irrigation<br>intervention:removal of tongue coating by using 3% hydrogen peroxide, next 5ml of 0.05% chlorhexidine is dropped in oropharynx after irrigation<br>control:general oral care in ICU",NA,NA,NA
im,JPRN-UMIN000029293,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033492,Subcutaneous injections of monovalent inactivated influenza vaccine contained Saitama strain (0.5mL) into subjects arms<br>Subcutaneous injections of monovalent inactivated influenza vaccine contained Honk Kong strain (0.5mL) into subjects,Yes,NA,NA
im,JPRN-UMIN000030830,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035189,"In December 1999, a 15-year-old girl was referred to Habikino hospital for evaluation of respiratory symptoms. BALF, Peripheral blood.process of treatments with ICS.",NA,NA,NA
im,JPRN-UMIN000031513,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035982,SMX/TMP of daily 400 mg/80 mg for 52 weeks.<br>SMX/TMP of daily 200 mg/40 mg for 52 weeks.,NA,NA,NA
im,JPRN-UMIN000031674,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036179,Low dose cohot<br>Initial dose of prednisolone 1mg/kg/day<br>High dose cohot<br>Initial dose of prednisolone 2mg/kg/day,NA,NA,NA
im,JPRN-UMIN000032000,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036525,"Plasma exchange.<br>Plasma exchange therapy should be performed once with 2.0 to 3.0 L and three times as one course. Nafamostat mesilate is used as an anticoagulant and fresh frozen plasma is used as a replenisher. Until the introduction of remission, the number of enforcement courses will be decided appropriately between 1 and 6 courses depending on the condition. For this reason, the total number of plasma exchange therapies ranges from 3 to a maximum of 18, resulting in a fresh frozen plasma transfusion volume of 6.0 L to 54.0 L.",NA,Yes,NA
im,JPRN-UMIN000032175,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036686,"Sulbactam / Ampicillin 1.5g, intravenous drip infusion within 1 hour before bronchoscopy, then Augmentin Combination Tablets (Potassium Clavulanate, Amoxicillin Hydrate) 750 mg, Amoxicillin Hydrate 750mg, tid for 3 days. If eGFR is 10-49 mL/min, dose of Augmentin Combination Tablets and Amoxicillin Hydrate is reduced to 500 mg, bid.",NA,NA,NA
im,JPRN-UMIN000033314,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000037975,Tranexamic acid<br>During surgery and the next day after surgery before breakfast.2 times administration in total.<br>15 mg/kg(0.3 ml/kg)<br>30 mg/kg(0.6 ml/kg) in total.<br>Saline<br>Same as above.<br>0.3 ml/kg<br>0.6 ml/kg in total.,NA,NA,NA
im,JPRN-UMIN000034870,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039755,Baloxavir marboxil<br>Peramivir,NA,Yes,NA
main,JPRN-UMIN000034922,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000039687,administration of ketamine ( 0.5mg/kg ) for 40 min every 7 days for 2 week,NA,NA,NA
main,JPRN-UMIN000035457,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040395,Oral administration test drug (Goreisan) 7.5g (2.5g/pack*3 packs) before meals and test drug (BIO-THREE) 3g (1g/tab*3 tabs) after meals.<br>Oral administration test drug (BIO-THREE) 3g (1g/tab*3 tabs) after meals.,NA,NA,NA
main,JPRN-UMIN000035638,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000040531,TFTD: fixed dose<br>Bevacizumab: fixed dose,NA,Yes,NA
main,JPRN-UMIN000036157,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041172,"The treatment consisted in the administration of 85 mg/m2 oxaliplatin and 200 mg/m2 LV by a 2-h intravenous infusion, followed by the administration of 400 mg/m2 bolus 5-FU and 2400 mg/m2 5-FU by a 46-h continuous infusion. The treatment was repeated every 2 weeks.",NA,NA,NA
main,JPRN-UMIN000036183,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041225,"Canagliflozin 100mg daily, 12 weeks",NA,NA,NA
main,JPRN-UMIN000036236,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041000,Platelet rich plasma transplantation,NA,Yes,NA
main,JPRN-UMIN000037111,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042285,Switch from Eplerenone 50mg/day to Esaxerenone2.5mg/day<br>Switch from Esaxerenone2.5mg/day to Eplerenone 50mg/day,NA,NA,NA
main,JPRN-UMIN000037239,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042464,romosozumab group<br>denosumab group<br>bisphosphonate group,NA,Yes,NA
im,JPRN-UMIN000037464,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042262,"Ceftriaxone 2g IV, every 24 hrs, for 4-14 days. <br>Clarithromycin 200mg PO, bid, for 4-14 days. <br>May be adjusted when renal failure. <br>Ampicillin/sulbactam 3g IV, every 12 hrs, for 4-14 days. <br>Clarithromycin 200mg PO, bid, for 4-14 days. <br>May be adjusted when renal failure.",NA,Yes,NA
main,JPRN-UMIN000037946,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041477,Switching multiple daily dosing regimen of antipsychotics to single dosing regimen<br>Continuing multiple daily dosing regimen of antipsychotics,NA,NA,NA
main,JPRN-UMIN000038214,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043328,"intravenous administration of remifentanil<br>effect-site concentration: 1.0-3.0 nanogram/ml, 5 minutes<br>intravenous administration of propofol<br>effect-site concentration: 0.5-1.0 microgram/ml, 5 minutes<br>inhalation of sevoflurane<br>0.2-0.5 age-related minimum alveolar concentration, 5 minutes",NA,NA,NA
main,JPRN-UMIN000038738,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044169,modified nab-Paclitaxel+Gemcitabine as first line chemotherapy,NA,NA,NA
main,JPRN-UMIN000038747,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044174,"Treatment group:  Patients received immunotherapy for UC<br><br>Control group: Standard chemotherapy: Patients received either gemcitabine 800 mg/m2 on days 1, 8, and 15 plus cisplatin 70 mg/m2 (GCis) on day 2 every 3 wk, or gemcitabine 800 mg/m2 on days 1, 8, and 15 plus carboplatin (GCb) at an area under the curve of 4 according to the Calvert formula on day 2 every 3 wk, for two to four cycles. GCarbo is selected based on renal function (eGFR &lt;60 mL/min/1.73m2) or presence of frailty.",NA,NA,NA
covid,JPRN-UMIN000040407,https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046108,Duration: 1 hour<br>Dose: JHQG Granule 5 g<br>Number of doses: 1,NA,NA,NA
main,KCT0003479,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=12940,Others(toothpaste) : tetrasodium pyrophosphate-added anti-calculus toothpaste<br>Wrap an appropriate amount on a toothbrush and brush three times a day for three months.<br>-       Experimental group: Toothpaste containing anti-calculus agent (40 patients)<br>-       Control group: Toothpaste  without anti-calculus agent (40 patients),NA,NA,NA
main,KCT0003670,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=13131,Drug : Hytrin (Terazosin) alone or Hytrin (Terazosin) and Hinechol (Bethanechol) are administrated on patients suffering from dysuria due to benign prostatic hyperplasia.,NA,NA,NA
main,KCT0003735,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=13675,Dietary Supplement : The experimentaty group was received CL capsules (CL extract 500 mg/capsule) and placebo group was received control capsules (CL extract 0 mg/capsule). The subjects take 2 capsules with water once a day for 6 weeks.,NA,NA,NA
main,KCT0003790,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=16825,Drug : Patients are assigned to two groups according to drug differences. Group 1 was treated with celecoxib 200 mg once daily for two weeks from the day following surgery and group 2 received naproxen 500 mg plus esomeprazole magnesium 20 mg twice daily for two weeks from the day following surgery. VAS pain score and knee clinical score are evaluated at 2 weeks and 6 months after surgery.,NA,Yes,NA
main,KCT0003841,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=16432,"Drug : The subjects will be administered bortezomib with a dose of 1.3mg/m2/day on the day 1, 8 and 15 among 1 cycle (which was consists of 28 days). Bortezomib can be used subcutenously or intravenouslty. Intervention with bortezomib will be terminated as follows; if the subject carries out the treatment of bortezomib maintenence until 24 months after initiation of treatment; if the subject experiences progressive disease of multiple myeloma; or if the subject presents unacceptable adverse events.",NA,NA,NA
main,KCT0003885,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=16273,"Drug : 1. Study group (Prophylaxis group)<br>Patients recieve acyclovir from the start date of conditioning to the date of neutrophil engraftment.<br>Acyclovir 400 mg bid (oral acyclovir can be changed into acyclovir I.V. 250 mg/m2 bid if patient cannot tolerate oral medication)<br><br>2. Control group (On demand early treatment group)<br>Patients do not receive prophylactic acyclovir and continue autologous hematopoietic stem cell transplantation. If patients have any symptom or sign suggestive of oral mucositis or other infection due to HSV reactivation or other infections caused by viruses such as CMV, appropriate antiviral agents can be use as therapeutic intent under physician&#39;s discretion.",NA,Yes,NA
main,KCT0003991,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=17500,"Drug : This is a single-center center, open-label, randomized comparison trial. All patients will be treated according to current guideline recommendation including statins, antihypertensive medications, etc after admission. Randomization will be performed immediately after successful CABG with the use of one or more SVGs. Allocation of study medication will proceed through an Interactive Web Response System (IWRS). After completion of the treatment period and, the investigator may initiate treatment with any medications, according to the standard of care.<br>Enrolled patients will be randomized at a ratio 1:1 to two treatment arms by a computer-generated randomisation sequence with a permutated block size 6. <br>a) dual-therapy group: aspirin 100mg once daily plus clopidogrel 75mg once daily for 12 months, followed by aspirin alone. <br>b) aspirin-alone group: aspirin 100mg once daily for 12 months, followed by aspirin alone.",NA,NA,NA
main,KCT0004010,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=11755,"Drug : This study is a two-phase clinical trial to validate the efficacy of cytarabine, bortezomib, dexamethasone (AVD) in patients with mantle cell lymphoma (MCL) that has not been treated by previous chemotherapy or relapsed/refractory after complete response at chemotherapy, outpatients or inpatients who meet the criteria for selecting a study should be provided with sufficient judgment time after explaining the purpose, methods, procedures, benefits and risks of the study, and then it is performed on patients who have expressed voluntary consent to participate in this study. Potential subjects of study are to perform hearing medical history, blood test, chest x-ray, electrocradiogram, serum or urine hCG tests for childbearing age woman within 2 weeks and full body 18F-FDG PET/CT within 4 weeks of the study. Additional bone marrow, CT, MRI, gastroscopy or colonoscopy may be performed if the investigator judge that it is necessary to establish the correct disease stage. If the above test results meet the criteria for selecting the study subjects, the final decision is to be made.<br>This study defines four weeks as a cycle. Following the protocol, the subjects are either hospitalized or visit clinic every cycle for given cytarabine, bortezomib and dexamethasone with an individualized dose considering their own age. If there’s no other reason to continue hospitalization after the medication is given by the Day3, the subject will be discharged from the hospital and the subject given the remaining medication until Day11. In case of the cytarabine is injected during the cycle, a 6mg of pegteograstim will be administered by subcutaneous route for the purpose of preventing neutropenia.",NA,Yes,NA
main,KCT0004020,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=14240,"Drug : This study is only for the patients with acute isovelemic anemia whose hemoglobin (Hb) level is low at the blood test postoperatively. For the patients with hemoglobin level of less than 10g/dL or hemoglobin concentration fall of more than 3g/dL versus the preoperative value, patients would be administered 1000mg Ferric Carboxymaltose intravenously. All of the above injections shall be made immediately after surgery. In case a patient’s hemoglobin level falls below 8g/dL or patient shows symptoms of acute anemia (dizziness, chest pain, tachycardia and hypotension), allogeneic blood transfusion shall be performed. For patients weighing less than 35 kg, total iron dosage shall not exceed 500 mg. After iron supplementation is administered, periodic evaluation shall be made to ensure that patient’s iron level is normalized and maintained. <br>Patients shall be closely monitored for any sign or symptoms of hypersensitivity reaction during and after each administration of this medicine. This medicine shall be injected when professionals (physician and / or nurse) who are trained to promptly recognize and provide treatment on anaphylactic reactions, are readily available and where CPR is possible (eg, where CPR-related medical devices are located and /or where emergency medication is available for an urgent event). Patients shall be also monitored for any adverse symptoms for at least 30 minutes after injection. This medicine shall be administered only by intravenous injections. It shall not be injected by either hypodermic or intramuscular injections. It can be administered either by direct intravenous injection or intravenous drip injection, and can be directly injected without dilution into vein-side branch of a hemodialysis machine. <br>1. Intravenous Injection: This drug can be administered up to 1,000mg (20mL) in non-diluted iron solution by intravenous injections. There is no administration time limit up to 200 mg. A dosage of between 200mg and 500mg shall be admin",NA,Yes,NA
main,KCT0004066,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=12372,"Drug : This study is a single-arm,phase II study of gefitinib in patient with epidermal growth factor receptor amplification Refractory solid tumors.Gefitinib 250 mg will be administered orally daily.<br>To investigate the efficacy and safety of gefitinib in patient with epidermal growth factor receptor amplification Refractory solid tumors.",NA,NA,NA
main,KCT0004084,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=12043,"Drug : To find out the Motilitone in patients who have undergone distal subtotal gastrectomy has an effect on <br>representative gastroenterostomy Billroth I, Billroth II or Roux-en_Y, perform a gastric emptying study on two times. The first test does not take test medication, and the second test takes 30mg of Motilitone tablet three times a day, 30 minutes before meal for 2weeks.",NA,NA,NA
main,KCT0004134,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=16631,"Procedure/Surgery : In the test group, mixed injection of 1ml of corticosteroid hormone, 1ml of hyaluronic acid, 1ml of lidocaine, 1ml of bupivacaine, and 1ml of normal saline were used. 1ml of dexamethasone 5mg/1ml( Dexamethasone disodium phosphate 5ml, Cheil Pharmaceutical Co., Ltd) is used as the corticosteroid hormone.",NA,Yes,NA
main,KCT0004189,http://cris.nih.go.kr/cris/en/search/search_result_st01.jsp?seq=14399,"Drug : Nivolumab 240 mg fixed dose every 2 weeks, for maximum of 3 cycles",NA,Yes,NA
covid,LBCTR2020043495,https://lbctr.moph.gov.lb/Trials/Details/4658,"Local standard of care alone, <br>OR local standard of care plus one of:<br>Remdesivir <br>Chloroquine or hydroxychloroquine (suspended) <br>Lopinavir with Ritonavir (suspended)<br>Lopinavir with Ritonavir plus interferon (suspended) <br>Interferon arm alone is added (and then suspended)<br>;as per the hospital standards; Daily infusion for 10 days;standard care;Remdesivir",NA,Yes,NA
im,NCT02655133,https://clinicaltrials.gov/show/NCT02655133,Drug: Pentaglobin®;Drug: Physiologic solution;Drug: Pentaglobin®;Drug: Physiologic solution;Drug: Pentaglobin®;Drug: Physiologic solution,NA,NA,NA
im,NCT02655874,https://clinicaltrials.gov/show/NCT02655874,Biological: Influenza vaccine;Biological: Influenza vaccine;Biological: Tetanus-diphtheria-pertussis vaccine;Biological: Influenza vaccine;Biological: Influenza vaccine;Biological: Tetanus-diphtheria-pertussis vaccine;Biological: Influenza vaccine;Biological: Influenza vaccine;Biological: Tetanus-diphtheria-pertussis vaccine;Biological: Influenza vaccine;Biological: Influenza vaccine;Biological: Tetanus-diphtheria-pertussis vaccine,Yes,NA,NA
im,NCT02656160,https://clinicaltrials.gov/show/NCT02656160,Drug: Placebo;Drug: Dalfampridine;Drug: Placebo;Drug: Dalfampridine;Drug: Placebo;Drug: Dalfampridine;Drug: Placebo;Drug: Dalfampridine,NA,NA,NA
im,NCT02665351,https://clinicaltrials.gov/show/NCT02665351,Drug: Peramivir,NA,Yes,NA
im,NCT02665871,https://clinicaltrials.gov/show/NCT02665871,Biological: one dose of Influenza Vaccine;Biological: one dose of Influenza Vaccine;Biological: placebo;Biological: placebo,Yes,NA,NA
im,NCT02677493,https://clinicaltrials.gov/show/NCT02677493,Biological: IL-YANG Quadrivalent Influenza Vaccine;Biological: IL-YANG Flu Vaccine Prefilled Syringe;Biological: IL-YANG Trivalent Influenza Vaccine;Biological: IL-YANG Quadrivalent Influenza Vaccine;Biological: IL-YANG Flu Vaccine Prefilled Syringe;Biological: IL-YANG Trivalent Influenza Vaccine;Biological: IL-YANG Quadrivalent Influenza Vaccine;Biological: IL-YANG Flu Vaccine Prefilled Syringe;Biological: IL-YANG Trivalent Influenza Vaccine;Biological: IL-YANG Quadrivalent Influenza Vaccine;Biological: IL-YANG Flu Vaccine Prefilled Syringe;Biological: IL-YANG Trivalent Influenza Vaccine,Yes,NA,NA
im,NCT02677584,https://clinicaltrials.gov/show/NCT02677584,Drug: Prophylactic caffeine citrate;Drug: Therapeutic caffeine citrate,NA,Yes,NA
im,NCT02678195,https://clinicaltrials.gov/show/NCT02678195,Drug: Amoxicillin;Drug: Placebo,NA,NA,NA
im,NCT02679573,https://clinicaltrials.gov/show/NCT02679573,Drug: Delafloxacin;Drug: Moxifloxacin;Drug: Linezolid,NA,Yes,NA
im,NCT02680002,https://clinicaltrials.gov/show/NCT02680002,Biological: 7.5 mcg H5N1 (stored as monobulk);Biological: 15 mcg H5N1 (stored as monobulk);Biological: 90 mcg H5N1 (stored as monobulk);Biological: 90 mcg H5N1 (stored in vials);Other: MF59;Other: MF59 (stored as monobulk);Biological: 7.5 mcg H5N1 (stored as monobulk);Biological: 15 mcg H5N1 (stored as monobulk);Biological: 90 mcg H5N1 (stored as monobulk);Biological: 90 mcg H5N1 (stored in vials);Other: MF59;Other: MF59 (stored as monobulk);Biological: 7.5 mcg H5N1 (stored as monobulk);Biological: 15 mcg H5N1 (stored as monobulk);Biological: 90 mcg H5N1 (stored as monobulk);Biological: 90 mcg H5N1 (stored in vials);Other: MF59;Other: MF59 (stored as monobulk);Biological: 7.5 mcg H5N1 (stored as monobulk);Biological: 15 mcg H5N1 (stored as monobulk);Biological: 90 mcg H5N1 (stored as monobulk);Biological: 90 mcg H5N1 (stored in vials);Other: MF59;Other: MF59 (stored as monobulk),NA,NA,NA
im,NCT02683603,https://clinicaltrials.gov/show/NCT02683603,Drug: AS colistin and imipenem;Drug: IV colistin  and imipenem .;Drug: AS colimycin (colistin);Drug: IV colimycin (colistin);Drug: AS colistin and imipenem;Drug: IV colistin and imipenem,NA,Yes,NA
im,NCT02684487,https://clinicaltrials.gov/show/NCT02684487,Drug: vitamin D3;Drug: Placebo;Drug: vitamin D3;Drug: Placebo;Drug: vitamin D3;Drug: Placebo;Drug: vitamin D3;Drug: Placebo,NA,NA,Yes
im,NCT02685618,https://clinicaltrials.gov/show/NCT02685618,"Drug: Iloprost;Drug: Saline;Device: Phillips M1006B, offset by -10mmHg;Device: Philips M1006B, No offset;Drug: Iloprost;Drug: Saline;Device: Phillips M1006B, offset by -10mmHg;Device: Philips M1006B, No offset;Drug: Iloprost;Drug: Saline;Device: Phillips M1006B, offset by -10mmHg;Device: Philips M1006B, No offset;Drug: Iloprost;Drug: Saline;Device: Phillips M1006B, offset by -10mmHg;Device: Philips M1006B, No offset",NA,NA,NA
im,NCT02686398,https://clinicaltrials.gov/show/NCT02686398,Biological: Fluad;Biological: Agrippal,NA,NA,NA
im,NCT02699125,https://clinicaltrials.gov/show/NCT02699125,Drug: Guanfacine;Drug: Hydrochlorothiazide,NA,NA,NA
im,NCT02704923,https://clinicaltrials.gov/show/NCT02704923,Drug: Atropine;Drug: Placebo,NA,NA,NA
im,NCT02710409,https://clinicaltrials.gov/show/NCT02710409,Biological: Quadrivalent influenza vaccine;Biological: Trivalent influenza vaccine A;Biological: Trivalent influenza vaccine B,Yes,NA,NA
im,NCT02717780,https://clinicaltrials.gov/show/NCT02717780,Drug: Fentanyl and sevoflurane;Drug: Remifentanil and desflurane,NA,NA,NA
im,NCT02723812,https://clinicaltrials.gov/show/NCT02723812,"Biological: GCFLU® Influenza vaccine (Split virion, Inactivated)",Yes,NA,NA
im,NCT02730624,https://clinicaltrials.gov/show/NCT02730624,Drug: Piperacillin-tazobactam;Drug: Piperacillin-tazobactam;Drug: Piperacillin-tazobactam;Drug: Piperacillin-tazobactam,NA,NA,NA
im,NCT02743117,https://clinicaltrials.gov/show/NCT02743117,Biological: Monovalent Influenza Vaccine;Other: Placebo;Biological: Monovalent Influenza Vaccine;Other: Placebo;Biological: Monovalent Influenza Vaccine;Other: Placebo;Biological: Monovalent Influenza Vaccine;Other: Placebo,Yes,NA,NA
im,NCT02746211,https://clinicaltrials.gov/show/NCT02746211,Biological: High Titre Influenza virus;Biological: Medium - High Influenza virus;Biological: Medium Low Titre Influenza virus;Biological: Low titre,NA,NA,NA
im,NCT02758145,https://clinicaltrials.gov/show/NCT02758145,Other: Flu vaccination information in 3 phases,NA,NA,NA
im,NCT02760420,https://clinicaltrials.gov/show/NCT02760420,Drug: Amoxicillin;Drug: Placebo,NA,NA,NA
im,NCT02762851,https://clinicaltrials.gov/show/NCT02762851,Other: Sterile saline;Drug: inactivated trivalent influenza vaccine,Yes,NA,NA
im,NCT02768740,https://clinicaltrials.gov/show/NCT02768740,Drug: Hydrocortisone hemisuccinate,NA,NA,NA
im,NCT02783859,https://clinicaltrials.gov/show/NCT02783859,Drug: Amoxicillin-clavulanic Acid;Drug: Placebo (for Amoxicillin-clavulanic Acid),NA,NA,NA
im,NCT02790164,https://clinicaltrials.gov/show/NCT02790164,Drug: Esmeron;Drug: Saline,NA,NA,NA
im,NCT02790788,https://clinicaltrials.gov/show/NCT02790788,Drug: Methylprednisolone; hydrocortisone;Drug: Saline Placebo,NA,NA,NA
im,NCT02802722,https://clinicaltrials.gov/show/NCT02802722,Dietary Supplement: Vitamin D3 supplementation;Biological: Peripheral blood and induced sputum sampling;Radiation: Chest computerised tomography (CT) scans;Other: Symptom questionnaire;Other: Placebo;Dietary Supplement: Vitamin D3 supplementation;Biological: Peripheral blood and induced sputum sampling;Radiation: Chest computerised tomography (CT) scans;Other: Symptom questionnaire;Other: Placebo;Dietary Supplement: Vitamin D3 supplementation;Biological: Peripheral blood and induced sputum sampling;Radiation: Chest computerised tomography (CT) scans;Other: Symptom questionnaire;Other: Placebo;Dietary Supplement: Vitamin D3 supplementation;Biological: Peripheral blood and induced sputum sampling;Radiation: Chest computerised tomography (CT) scans;Other: Symptom questionnaire;Other: Placebo,NA,NA,Yes
im,NCT02804945,https://clinicaltrials.gov/show/NCT02804945,Biological: Mesenchymal Stem Cells (MSCs),NA,Yes,NA
im,NCT02806141,https://clinicaltrials.gov/show/NCT02806141,Drug: Aerosolized plus intravenous colistin;Drug: Intravenous colistin,NA,NA,NA
im,NCT02806895,https://clinicaltrials.gov/show/NCT02806895,Drug: JZP-110;Drug: Placebo,NA,NA,NA
im,NCT02813694,https://clinicaltrials.gov/show/NCT02813694,Drug: lefamulin;Drug: Moxifloxacin,NA,Yes,NA
im,NCT02815098,https://clinicaltrials.gov/show/NCT02815098,Biological: IVAC-H5N1-15ug;Biological: IVAC-H5N1-30ug;Biological: IVAC-placebo,NA,NA,NA
im,NCT02819141,https://clinicaltrials.gov/show/NCT02819141,Drug: Dexmedetomidine,NA,NA,NA
im,NCT02820987,https://clinicaltrials.gov/show/NCT02820987,Drug: MEROPENEM;Drug: PIPERACILLIN-TAZOBACTAM;Drug: CEFEPIME,NA,NA,NA
im,NCT02821195,https://clinicaltrials.gov/show/NCT02821195,Biological: DTaP-IPV-Hep B-PRP-T combined vaccine;Biological: DTaP-IPV-Hep B-PRP-T combined vaccine,Yes,NA,NA
im,NCT02822001,https://clinicaltrials.gov/show/NCT02822001,Drug: Sugammadex;Drug: Placebo;Device: Train-of-Four Monitoring;Device: ExSpiron Respiratory Volume Monitoring,NA,Yes,NA
im,NCT02822105,https://clinicaltrials.gov/show/NCT02822105,Biological: the H3N2 M2SR monovalent influenza vaccine;Other: Placebo,Yes,NA,NA
im,NCT02834624,https://clinicaltrials.gov/show/NCT02834624,Drug: Poractant alfa;Drug: calfactant;Drug: Poractant alfa;Drug: calfactant;Drug: Poractant alfa;Drug: calfactant;Drug: Poractant alfa;Drug: calfactant,NA,NA,NA
im,NCT02837835,https://clinicaltrials.gov/show/NCT02837835,Drug: ceftazidime;Drug: ceftazidime,NA,NA,NA
im,NCT02839330,https://clinicaltrials.gov/show/NCT02839330,Biological: aH5N1c;Biological: Placebo,NA,NA,NA
im,NCT02860039,https://clinicaltrials.gov/show/NCT02860039,Biological: Trivalent Influenza Vaccine;Biological: Quadrivalent Influenza Vaccine;Other: Laboratory Biomarker Analysis,Yes,NA,NA
im,NCT02867358,https://clinicaltrials.gov/show/NCT02867358,Drug: KT07 Capsule;Other: Placebo,NA,NA,NA
im,NCT02874313,https://clinicaltrials.gov/show/NCT02874313,Device: Continuous positive airway pressure;Drug: Pharmacological treatment;Other: Conventional anti-diabetic diet recommendations,NA,NA,NA
im,NCT02875236,https://clinicaltrials.gov/show/NCT02875236,Drug: OctaplasLG®;Drug: Ringer-acetat,NA,NA,NA
im,NCT02876159,https://clinicaltrials.gov/show/NCT02876159,Biological: 2016-2017 Influenza Vaccine,Yes,NA,NA
im,NCT02877160,https://clinicaltrials.gov/show/NCT02877160,Drug: AL-794 suspension;Drug: AL-794 tablet;Drug: AL-794 suspension;Drug: AL-794 tablet;Drug: AL-794 suspension;Drug: AL-794 tablet;Drug: AL-794 suspension;Drug: AL-794 tablet,NA,NA,NA
im,NCT02878031,https://clinicaltrials.gov/show/NCT02878031,Drug: Oral amoxicillin for CI pneumonia,NA,NA,NA
im,NCT02882100,https://clinicaltrials.gov/show/NCT02882100,Biological: adjuvanted trivalent influenza vaccine;Biological: trivalent influenza vaccine,Yes,NA,NA
im,NCT02883426,https://clinicaltrials.gov/show/NCT02883426,Biological: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV);Biological: H3N2v inactivated subvirion influenza vaccine;Biological: Placebo;Biological: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV);Biological: H3N2v inactivated subvirion influenza vaccine;Biological: Placebo;Biological: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV);Biological: H3N2v inactivated subvirion influenza vaccine;Biological: Placebo,Yes,NA,NA
im,NCT02883803,https://clinicaltrials.gov/show/NCT02883803,Biological: Injection of mesenchymal stem cells;Biological: Injection of albumin alone,NA,Yes,NA
im,NCT02885168,https://clinicaltrials.gov/show/NCT02885168,Drug: Recombinant Activated Protein C;Device: Near-infrared spectroscopy (NIRS);Drug: Phenylephrine;Biological: Blood sample,NA,NA,NA
im,NCT02888327,https://clinicaltrials.gov/show/NCT02888327,Drug: AL-794;Drug: Oseltamivir;Drug: Digoxin;Drug: Midazolam;Drug: Pitavastatin;Drug: JNJ-63623872,NA,Yes,NA
im,NCT02896621,https://clinicaltrials.gov/show/NCT02896621,Drug: Chlorthalidone plus amiloride;Drug: Amlodipine,NA,NA,NA
im,NCT02897011,https://clinicaltrials.gov/show/NCT02897011,Drug: Methotrexate,NA,NA,NA
im,NCT02898792,https://clinicaltrials.gov/show/NCT02898792,Drug: Targeted infusion of remifentanil;Drug: Targeted infusion of remifentanil,NA,NA,NA
im,NCT02902055,https://clinicaltrials.gov/show/NCT02902055,Drug: Neuromuscular Blocking Agents;Drug: Isotonic saline,NA,NA,NA
im,NCT02908269,https://clinicaltrials.gov/show/NCT02908269,"Biological: Fluzone Quadrivalent vaccine, 2016 2017 formulation, No Preservative;Biological: Fluzone Quadrivalent vaccine, 2016 2017 formulation, No Preservative;Biological: Fluzone High Dose, vaccine, 2016 2017 formulation;Biological: Fluzone Quadrivalent vaccine, 2016 2017 formulation, No Preservative;Biological: Fluzone Quadrivalent vaccine, 2016 2017 formulation, No Preservative;Biological: Fluzone High Dose, vaccine, 2016 2017 formulation;Biological: Fluzone Quadrivalent vaccine, 2016 2017 formulation, No Preservative;Biological: Fluzone Quadrivalent vaccine, 2016 2017 formulation, No Preservative;Biological: Fluzone High Dose, vaccine, 2016 2017 formulation;Biological: Fluzone Quadrivalent vaccine, 2016 2017 formulation, No Preservative;Biological: Fluzone Quadrivalent vaccine, 2016 2017 formulation, No Preservative;Biological: Fluzone High Dose, vaccine, 2016 2017 formulation",Yes,NA,NA
im,NCT02908529,https://clinicaltrials.gov/show/NCT02908529,"Drug: Combination product of Atomoxetine and Oxybutynin;Drug: Placebo, 2 tablets",NA,NA,NA
im,NCT02913118,https://clinicaltrials.gov/show/NCT02913118,"Drug: Andrographolid Sulfonate Injection (AS Injection);Drug: Cephalosporin;Drug: Azithromycin, Minocycline or Doxycycline;Drug: Amoxicillin-clavulantic acid;Drug: Fluoroquinolones;Drug: Placebo;Drug: Andrographolid Sulfonate Injection (AS Injection);Drug: Cephalosporin;Drug: Azithromycin, Minocycline or Doxycycline;Drug: Amoxicillin-clavulantic acid;Drug: Fluoroquinolones;Drug: Placebo;Drug: Andrographolid Sulfonate Injection (AS Injection);Drug: Cephalosporin;Drug: Azithromycin, Minocycline or Doxycycline;Drug: Amoxicillin-clavulantic acid;Drug: Fluoroquinolones;Drug: Placebo",NA,Yes,NA
im,NCT02914275,https://clinicaltrials.gov/show/NCT02914275,Biological: Seqirus Quadrivalent Inactivated Influenza Vaccine;Biological: Comparator Quadrivalent Inactivated Influenza Vaccine,Yes,NA,NA
im,NCT02915302,https://clinicaltrials.gov/show/NCT02915302,"Biological: Fluzone Quadrivalent vaccine, No Preservative;Biological: Fluzone Quadrivalent vaccine, No Preservative;Biological: Fluzone Quadrivalent vaccine, No Preservative;Biological: Fluzone Quadrivalent vaccine, No Preservative;Biological: Fluzone Quadrivalent vaccine, No Preservative;Biological: Fluzone Quadrivalent vaccine, No Preservative",Yes,NA,NA
im,NCT02915809,https://clinicaltrials.gov/show/NCT02915809,Biological: GC3110B vaccine;Biological: GCFLU Quadrivalent Inj. vaccine;Biological: GC3110B vaccine;Biological: GCFLU Quadrivalent Inj. vaccine,Yes,NA,NA
im,NCT02916160,https://clinicaltrials.gov/show/NCT02916160,"Drug: SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)",NA,NA,NA
im,NCT02917304,https://clinicaltrials.gov/show/NCT02917304,Biological: GC3110A vaccine;Biological: GC3110A vaccine;Biological: GC3110A vaccine;Biological: GC3110A vaccine,Yes,NA,NA
im,NCT02918006,https://clinicaltrials.gov/show/NCT02918006,Biological: VXA-A1.1;Biological: Fluzone®;Other: Placebo Tablets;Other: Saline Solution for Placebo IM Injection,Yes,NA,NA
im,NCT02921997,https://clinicaltrials.gov/show/NCT02921997,"Drug: AS03;Biological: Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203;Biological: Monovalent influenza A/H7N9 virus vaccine",Yes,NA,NA
im,NCT02922894,https://clinicaltrials.gov/show/NCT02922894,Procedure: Acute episodic hypoxia;Procedure: Supplemental oxygen;Drug: Trazodone;Drug: Placebo;Procedure: Sham,NA,NA,NA
im,NCT02934555,https://clinicaltrials.gov/show/NCT02934555,Drug: Ubiquinol;Dietary Supplement: Ensure,NA,NA,NA
im,NCT02935192,https://clinicaltrials.gov/show/NCT02935192,Biological: Seasonal Influenza Vaccine;Other: Phosphate Buffered Saline;Biological: Seasonal Influenza Vaccine;Other: Phosphate Buffered Saline;Biological: Seasonal Influenza Vaccine;Other: Phosphate Buffered Saline;Biological: Seasonal Influenza Vaccine;Other: Phosphate Buffered Saline,Yes,NA,NA
im,NCT02936895,https://clinicaltrials.gov/show/NCT02936895,Drug: Vitamin D3;Drug: Placebo;Drug: Vitamin D3;Drug: Placebo,NA,NA,Yes
im,NCT02939742,https://clinicaltrials.gov/show/NCT02939742,Drug: Betamethasone;Drug: Placebo,NA,Yes,NA
im,NCT02945644,https://clinicaltrials.gov/show/NCT02945644,Drug: Trazodone;Drug: Placebo,NA,NA,NA
im,NCT02949011,https://clinicaltrials.gov/show/NCT02949011,Drug: Baloxavir Marboxil;Drug: Placebo to Baloxavir Marboxil;Drug: Oseltamivir;Drug: Placebo to Oseltamivir,NA,Yes,NA
im,NCT02951130,https://clinicaltrials.gov/show/NCT02951130,Drug: Milrinone;Drug: Placebo (5% Dextrose),NA,NA,NA
im,NCT02954354,https://clinicaltrials.gov/show/NCT02954354,Drug: Baloxavir Marboxil;Drug: Placebo to Baloxavir Marboxil;Drug: Oseltamivir;Drug: Placebo to Oseltamivir,NA,Yes,NA
im,NCT02957890,https://clinicaltrials.gov/show/NCT02957890,Biological: Inactivated influenza vaccine (NH formulation);Biological: Inactivated influenza vaccine (SH formulation);Biological: Placebo;Biological: Inactivated influenza vaccine (NH formulation);Biological: Inactivated influenza vaccine (SH formulation);Biological: Placebo;Biological: Inactivated influenza vaccine (NH formulation);Biological: Inactivated influenza vaccine (SH formulation);Biological: Placebo;Biological: Inactivated influenza vaccine (NH formulation);Biological: Inactivated influenza vaccine (SH formulation);Biological: Placebo,Yes,NA,NA
im,NCT02960815,https://clinicaltrials.gov/show/NCT02960815,Biological: Intanza;Biological: Mutagrip;Drug: Aldara;Biological: Intanza;Biological: Mutagrip;Drug: Aldara;Biological: Intanza;Biological: Mutagrip;Drug: Aldara;Biological: Intanza;Biological: Mutagrip;Drug: Aldara,NA,NA,NA
im,NCT02961231,https://clinicaltrials.gov/show/NCT02961231,Biological: PCV 2p+1;Biological: PCV 3p+0;Biological: PCV 1p+1;Biological: PCV 0p+1,NA,NA,NA
im,NCT02962908,https://clinicaltrials.gov/show/NCT02962908,Biological: FLU-v;Biological: adjuvanted FLU-v;Biological: Saline;Biological: Adjuvanted placebo,NA,NA,NA
im,NCT02964065,https://clinicaltrials.gov/show/NCT02964065,Biological: Live-Attenuated influenza Vaccine(LAIV);Biological: Placebo;Biological: Live-Attenuated influenza Vaccine(LAIV);Biological: Placebo;Biological: Live-Attenuated influenza Vaccine(LAIV);Biological: Placebo;Biological: Live-Attenuated influenza Vaccine(LAIV);Biological: Placebo,Yes,NA,NA
im,NCT02972957,https://clinicaltrials.gov/show/NCT02972957,Biological: Nasovac-S;Drug: Azithromycin,NA,Yes,NA
im,NCT02974257,https://clinicaltrials.gov/show/NCT02974257,Drug: Thiamine;Other: placebo,NA,NA,NA
im,NCT02987088,https://clinicaltrials.gov/show/NCT02987088,Drug: Sodium Nitrite;Drug: Sodium Nitrite;Drug: Sodium Nitrite,NA,NA,NA
im,NCT02987985,https://clinicaltrials.gov/show/NCT02987985,"Drug: Acetaminophen, gabapentin;Drug: Acetaminophen;Drug: Ketamine , Lidocaine , Dexmedetomidine;Drug: Fentanyl, Dexmedetomidine;Drug: Dexamethasone , Ondansetron;Drug: Sevoflurane;Drug: Sevoflurane, Fentanyl",NA,Yes,NA
im,NCT02988739,https://clinicaltrials.gov/show/NCT02988739,Biological: seasonal influenza vaccine;Device: fractional Er:Yag laser;Biological: seasonal influenza vaccine;Device: fractional Er:Yag laser;Biological: seasonal influenza vaccine;Device: fractional Er:Yag laser,Yes,NA,NA
im,NCT02990546,https://clinicaltrials.gov/show/NCT02990546,Drug: midodrine;Other: Standard of Care;Drug: midodrine;Other: Standard of Care;Drug: midodrine;Other: Standard of Care,NA,NA,NA
im,NCT02998996,https://clinicaltrials.gov/show/NCT02998996,"Biological: 15 µg HA/strain and 1% Endocine™;Biological: 15 µg HA/strain and 2% Endocine™;Biological: 15 µg HA/strain;Biological: intramuscular comparator;Biological: intranasal comparator;Biological: Placebo, Saline;Biological: 15 µg HA/strain and 1% Endocine™;Biological: 15 µg HA/strain and 2% Endocine™;Biological: 15 µg HA/strain;Biological: intramuscular comparator;Biological: intranasal comparator;Biological: Placebo, Saline;Biological: 15 µg HA/strain and 1% Endocine™;Biological: 15 µg HA/strain and 2% Endocine™;Biological: 15 µg HA/strain;Biological: intramuscular comparator;Biological: intranasal comparator;Biological: Placebo, Saline;Biological: 15 µg HA/strain and 1% Endocine™;Biological: 15 µg HA/strain and 2% Endocine™;Biological: 15 µg HA/strain;Biological: intramuscular comparator;Biological: intranasal comparator;Biological: Placebo, Saline",NA,NA,NA
im,NCT03014310,https://clinicaltrials.gov/show/NCT03014310,Drug: AS03;Drug: MF59 adjuvant;Biological: Monovalent Influenza A/H5N8 vaccine,Yes,NA,NA
im,NCT03016143,https://clinicaltrials.gov/show/NCT03016143,Biological: Allantoic Split Inactivated Seasonal flu Vaccine;Biological: VAXIGRIP,Yes,NA,NA
im,NCT03018834,https://clinicaltrials.gov/show/NCT03018834,Drug: ANAKINRA 100 mg/daily subcutaneously;Drug: Placebo,NA,NA,NA
im,NCT03020628,https://clinicaltrials.gov/show/NCT03020628,Biological: NBP607-QIV;Biological: NBP607-TIV;Biological: NBP607-QIV;Biological: NBP607-TIV;Biological: NBP607-QIV;Biological: NBP607-TIV;Biological: NBP607-QIV;Biological: NBP607-TIV,NA,NA,NA
im,NCT03022396,https://clinicaltrials.gov/show/NCT03022396,Biological: High Dose Fluzone® (intramuscular);Biological: Fluzone® (intramuscular);Biological: High Dose Fluzone® (intramuscular);Biological: Fluzone® (intramuscular);Biological: High Dose Fluzone® (intramuscular);Biological: Fluzone® (intramuscular);Biological: High Dose Fluzone® (intramuscular);Biological: Fluzone® (intramuscular),Yes,NA,NA
im,NCT03022435,https://clinicaltrials.gov/show/NCT03022435,Biological: TIV;Biological: High-Dose TIV;Biological: LAIV;Biological: TIV;Biological: High-Dose TIV;Biological: LAIV;Biological: TIV;Biological: High-Dose TIV;Biological: LAIV;Biological: TIV;Biological: High-Dose TIV;Biological: LAIV,NA,NA,NA
im,NCT03023176,https://clinicaltrials.gov/show/NCT03023176,Biological: Fluzone® standard IIV3;Biological: Fluzone® standard IIV3 Pediatric Dose;Biological: Fluzone® standard IIV3;Biological: Fluzone® standard IIV3 Pediatric Dose;Biological: Fluzone® standard IIV3;Biological: Fluzone® standard IIV3 Pediatric Dose;Biological: Fluzone® standard IIV3;Biological: Fluzone® standard IIV3 Pediatric Dose,Yes,NA,NA
im,NCT03023553,https://clinicaltrials.gov/show/NCT03023553,Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®,Yes,NA,NA
im,NCT03023683,https://clinicaltrials.gov/show/NCT03023683,Biological: FluMist®;Biological: FluMist®;Biological: FluMist®;Biological: FluMist®,NA,NA,NA
im,NCT03023709,https://clinicaltrials.gov/show/NCT03023709,Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®,Yes,NA,NA
im,NCT03025841,https://clinicaltrials.gov/show/NCT03025841,Drug: Ceftaroline,NA,NA,NA
im,NCT03028116,https://clinicaltrials.gov/show/NCT03028116,Biological: influenza vaccine;Biological: Placebo;Biological: influenza vaccine;Biological: Placebo;Biological: influenza vaccine;Biological: Placebo;Biological: influenza vaccine;Biological: Placebo,Yes,NA,NA
im,NCT03028974,https://clinicaltrials.gov/show/NCT03028974,Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®,Yes,NA,NA
im,NCT03028987,https://clinicaltrials.gov/show/NCT03028987,Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®;Biological: Fluzone®;Biological: FluMist®,Yes,NA,NA
im,NCT03029169,https://clinicaltrials.gov/show/NCT03029169,Drug: Propafenone i.v.;Drug: Amiodarone i.v.,NA,NA,NA
im,NCT03031210,https://clinicaltrials.gov/show/NCT03031210,Drug: Amoxicillin,NA,NA,NA
im,NCT03032380,https://clinicaltrials.gov/show/NCT03032380,Drug: S-649266;Drug: Meropenem;Drug: Linezolid,NA,NA,NA
im,NCT03038503,https://clinicaltrials.gov/show/NCT03038503,Drug: Methylene Blue;Drug: Terlipressin;Drug: Methylene Blue;Drug: Terlipressin,NA,NA,NA
im,NCT03038776,https://clinicaltrials.gov/show/NCT03038776,Biological: Recombinant influenza hemagglutinin,NA,NA,NA
im,NCT03042143,https://clinicaltrials.gov/show/NCT03042143,Biological: Human umbilical cord derived CD362 enriched MSCs;Biological: Placebo (Plasma-Lyte 148),NA,Yes,NA
im,NCT03049306,https://clinicaltrials.gov/show/NCT03049306,Drug: Propranolol Oral Tablet;Drug: Placebo Oral Tablet;Device: CPAP,NA,NA,NA
im,NCT03058692,https://clinicaltrials.gov/show/NCT03058692,Biological: Influenza Multimeric-001 Vaccine;Other: Placebo;Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine,Yes,NA,NA
im,NCT03065751,https://clinicaltrials.gov/show/NCT03065751,Device: Plasmaexchange,NA,Yes,NA
im,NCT03068949,https://clinicaltrials.gov/show/NCT03068949,Biological: FluBlok;Biological: Fluzone;Biological: FluCelVax,Yes,NA,NA
im,NCT03072173,https://clinicaltrials.gov/show/NCT03072173,Drug: Xylometazoline;Drug: placebo (saline);Drug: Xylometazoline;Drug: placebo (saline);Drug: Xylometazoline;Drug: placebo (saline);Drug: Xylometazoline;Drug: placebo (saline),NA,NA,NA
im,NCT03076385,https://clinicaltrials.gov/show/NCT03076385,Other: Placebo;Biological: VAL-506440,NA,NA,NA
im,NCT03081728,https://clinicaltrials.gov/show/NCT03081728,Device: Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml;Drug: IV diclofenac and IV paracetamol;Device: Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml;Drug: IV diclofenac and IV paracetamol;Device: Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml;Drug: IV diclofenac and IV paracetamol;Device: Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml;Drug: IV diclofenac and IV paracetamol,NA,Yes,NA
im,NCT03085758,https://clinicaltrials.gov/show/NCT03085758,Biological: Adrecizumab;Biological: Placebo,NA,Yes,NA
im,NCT03086473,https://clinicaltrials.gov/show/NCT03086473,Drug: Caffeine Citrate;Drug: Placebo (Normal Saline),NA,Yes,NA
im,NCT03087890,https://clinicaltrials.gov/show/NCT03087890,Drug: Cotrimoxazole;Drug: Placebo,NA,NA,NA
im,NCT03088904,https://clinicaltrials.gov/show/NCT03088904,Biological: FluMist® Quadrivalent;Biological: Fluzone® Quadrivalent vaccine,Yes,NA,NA
im,NCT03089957,https://clinicaltrials.gov/show/NCT03089957,Drug: Ulinastatin;Other: Usual care,NA,NA,NA
im,NCT03091894,https://clinicaltrials.gov/show/NCT03091894,Drug: Propofol;Drug: Dexmedetomidine;Drug: Propofol;Drug: Dexmedetomidine;Drug: Propofol;Drug: Dexmedetomidine,NA,NA,NA
im,NCT03092245,https://clinicaltrials.gov/show/NCT03092245,Drug: OctaplasLG;Drug: Ringer-Acetate,NA,NA,NA
im,NCT03095599,https://clinicaltrials.gov/show/NCT03095599,Biological: IVACFLU-S;Other: Placebo;Biological: IVACFLU-S;Other: Placebo;Biological: IVACFLU-S;Other: Placebo;Biological: IVACFLU-S;Other: Placebo,NA,NA,NA
im,NCT03096314,https://clinicaltrials.gov/show/NCT03096314,Drug: Vitamin D3;Drug: Placebo,NA,NA,Yes
im,NCT03101462,https://clinicaltrials.gov/show/NCT03101462,Biological: Licensed Trivalent FluMist;Biological: Inactivated Trivalent Influenza Vaccine (TIV);Biological: Licensed Trivalent FluMist;Biological: Inactivated Trivalent Influenza Vaccine (TIV);Biological: Licensed Trivalent FluMist;Biological: Inactivated Trivalent Influenza Vaccine (TIV);Biological: Licensed Trivalent FluMist;Biological: Inactivated Trivalent Influenza Vaccine (TIV),Yes,NA,NA
im,NCT03103490,https://clinicaltrials.gov/show/NCT03103490,Drug: 18F-FSPG,NA,NA,NA
im,NCT03104075,https://clinicaltrials.gov/show/NCT03104075,Biological: Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein;Biological: Pneumococcal Vaccine Polyvalent,Yes,NA,NA
im,NCT03104140,https://clinicaltrials.gov/show/NCT03104140,Drug: Ketamine;Drug: Thiopental,NA,NA,NA
im,NCT03104790,https://clinicaltrials.gov/show/NCT03104790,"Biological: Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)",NA,NA,NA
im,NCT03109418,https://clinicaltrials.gov/show/NCT03109418,Drug: Ketamine;Procedure: Control,NA,NA,NA
im,NCT03111212,https://clinicaltrials.gov/show/NCT03111212,Drug: Iloprost;Drug: control,NA,NA,NA
im,NCT03111485,https://clinicaltrials.gov/show/NCT03111485,Drug: Sinemet CR;Drug: Placebo oral capsule,NA,NA,NA
im,NCT03119701,https://clinicaltrials.gov/show/NCT03119701,Drug: Interferon Beta-1A;Drug: Placebo,NA,Yes,NA
im,NCT03120637,https://clinicaltrials.gov/show/NCT03120637,Drug: Methylene Blue,NA,NA,NA
im,NCT03121690,https://clinicaltrials.gov/show/NCT03121690,Drug: Prednisone;Drug: placebo,NA,NA,NA
im,NCT03133936,https://clinicaltrials.gov/show/NCT03133936,Biological: Fluarix,Yes,NA,NA
im,NCT03139565,https://clinicaltrials.gov/show/NCT03139565,Biological: Fluzone High-dose Influenza Vaccine;Biological: Standard 2016-2017 Flu vaccine,Yes,NA,NA
im,NCT03142191,https://clinicaltrials.gov/show/NCT03142191,Drug: CC-90001;Other: Placebo,NA,NA,NA
im,NCT03149640,https://clinicaltrials.gov/show/NCT03149640,Drug: Inhaled amikacin;Drug: Inhaled placebo,NA,Yes,NA
im,NCT03158038,https://clinicaltrials.gov/show/NCT03158038,Biological: Monovalent Influenza Vaccine;Other: Placebo,Yes,NA,NA
im,NCT03163342,https://clinicaltrials.gov/show/NCT03163342,Biological: Licensed seasonal influenza vaccine;Biological: Licensed seasonal influenza vaccine;Biological: Licensed seasonal influenza vaccine,Yes,NA,NA
im,NCT03163615,https://clinicaltrials.gov/show/NCT03163615,Drug: Tibet Rhodiola Capsule;Drug: Placebo oral capsule;Drug: Tibet Rhodiola Capsule;Drug: Placebo oral capsule;Drug: Tibet Rhodiola Capsule;Drug: Placebo oral capsule;Drug: Tibet Rhodiola Capsule;Drug: Placebo oral capsule,NA,NA,NA
im,NCT03165617,https://clinicaltrials.gov/show/NCT03165617,Biological: QIVc;Biological: Non-influenza Comparator Vaccine,Yes,NA,NA
im,NCT03172988,https://clinicaltrials.gov/show/NCT03172988,Drug: Dexamethasone;Drug: Normal saline;Drug: Flurbiprofen axetil;Drug: Lipid microsphere,NA,Yes,NA
im,NCT03177720,https://clinicaltrials.gov/show/NCT03177720,Drug: Ciprofloxacin;Drug: Imipenem,NA,Yes,NA
im,NCT03180801,https://clinicaltrials.gov/show/NCT03180801,Biological: adjuvanted FLU-v;Biological: adjuvanted placebo;Other: Influenza challenge,NA,NA,NA
im,NCT03186781,https://clinicaltrials.gov/show/NCT03186781,Biological: VRC-FLUNPF081-00-VP (HA-F A/Sing);Biological: VRC-FLUDNA082-00-VP (DNA A/Sing),NA,NA,NA
im,NCT03191240,https://clinicaltrials.gov/show/NCT03191240,Drug: Vasopressins;Drug: Normal saline;Drug: Vasopressins;Drug: Normal saline;Drug: Vasopressins;Drug: Normal saline;Drug: Vasopressins;Drug: Normal saline,NA,NA,NA
im,NCT03197376,https://clinicaltrials.gov/show/NCT03197376,Biological: Pneumosil;Biological: Synflorix,NA,NA,NA
im,NCT03200600,https://clinicaltrials.gov/show/NCT03200600,Drug: Dexamethasone;Drug: Normal saline;Drug: Flurbiprofen axetil;Drug: Lipid microsphere,NA,Yes,NA
im,NCT03206346,https://clinicaltrials.gov/show/NCT03206346,Drug: Ingavirin;Drug: Placebo oral capsule;Drug: Ingavirin;Drug: Placebo oral capsule;Drug: Ingavirin;Drug: Placebo oral capsule;Drug: Ingavirin;Drug: Placebo oral capsule,NA,NA,NA
im,NCT03207152,https://clinicaltrials.gov/show/NCT03207152,Biological: Influenza A/California/04/09,NA,NA,NA
im,NCT03207165,https://clinicaltrials.gov/show/NCT03207165,Drug: Milrinone;Drug: Dobutamine,NA,NA,NA
im,NCT03208257,https://clinicaltrials.gov/show/NCT03208257,Drug: Esmolol,NA,NA,NA
im,NCT03212716,https://clinicaltrials.gov/show/NCT03212716,Drug: Oseltamivir;Drug: Diltiazem;Drug: Placebos,NA,Yes,NA
im,NCT03220048,https://clinicaltrials.gov/show/NCT03220048,Drug: PrEP-001;Other: Placebo Comparator;Drug: PrEP-001;Other: Placebo Comparator;Drug: PrEP-001;Other: Placebo Comparator;Drug: PrEP-001;Other: Placebo Comparator,NA,NA,NA
im,NCT03233217,https://clinicaltrials.gov/show/NCT03233217,Biological: QIV-HD by IM;Biological: QIV-SD by SC;Biological: QIV-HD by SC,NA,NA,NA
im,NCT03238612,https://clinicaltrials.gov/show/NCT03238612,"Drug: FFA, clarithromycin, oseltamivir;Drug: Oseltamivir alone",NA,Yes,NA
im,NCT03266237,https://clinicaltrials.gov/show/NCT03266237,Drug: Vaxigrip®;Drug: Vaxigrip®;Drug: Vaxigrip®;Drug: Vaxigrip®,NA,NA,NA
im,NCT03273075,https://clinicaltrials.gov/show/NCT03273075,Drug: Cangrelor;Drug: Placebo;Drug: Prasugrel;Drug: Ticagrelor;Drug: Cangrelor;Drug: Placebo;Drug: Prasugrel;Drug: Ticagrelor;Drug: Cangrelor;Drug: Placebo;Drug: Prasugrel;Drug: Ticagrelor;Drug: Cangrelor;Drug: Placebo;Drug: Prasugrel;Drug: Ticagrelor,NA,NA,NA
im,NCT03275389,https://clinicaltrials.gov/show/NCT03275389,Biological: D-SUIV Formulation 9;Biological: Placebo;Biological: FLU-D-QIV;Biological: D-SUIV Formulation 1;Biological: D-SUIV Formulation 2;Biological: D-SUIV Formulation 3;Biological: D-SUIV Formulation 4;Biological: D-SUIV Formulation 5;Biological: D-SUIV Formulation 6;Biological: D-SUIV Formulation 7;Biological: D-SUIV Formulation 8,NA,NA,NA
im,NCT03283319,https://clinicaltrials.gov/show/NCT03283319,Biological: 3.75 ug Panblok H7;Biological: 7.5 ug Panblok H7;Biological: 15 ug Panblok H7;Biological: MF59;Biological: AS03,NA,NA,NA
im,NCT03293498,https://clinicaltrials.gov/show/NCT03293498,Biological: NanoFlu;Biological: Fluzone HD - Day 0;Biological: Fluzone HD - Day 21;Other: Saline - Day 21,Yes,NA,NA
im,NCT03296059,https://clinicaltrials.gov/show/NCT03296059,Other: conventional treatment with RBC transfusion;Other: conventional treatment,NA,NA,NA
im,NCT03298347,https://clinicaltrials.gov/show/NCT03298347,Drug: 80mg/kg of caffeine;Drug: 20mg/kg of caffeine;Drug: 80mg/kg of caffeine;Drug: 20mg/kg of caffeine;Drug: 80mg/kg of caffeine;Drug: 20mg/kg of caffeine;Drug: 80mg/kg of caffeine;Drug: 20mg/kg of caffeine,NA,Yes,NA
im,NCT03300050,https://clinicaltrials.gov/show/NCT03300050,Biological: cH8/1N1 LAIV;Biological: cH5/1N1 IIV + adjuvant;Biological: cH5/1N1 IIV;Biological: cH8/1N1 IIV + adjuvant;Biological: Normal saline;Biological: Phosphate buffered saline,NA,NA,NA
im,NCT03300362,https://clinicaltrials.gov/show/NCT03300362,Drug: Seasonal influenza vaccine;Drug: MVA-NP+M1;Drug: Sodium chloride,Yes,NA,NA
im,NCT03302650,https://clinicaltrials.gov/show/NCT03302650,Drug: Angiotensin II;Drug: Normal saline;Drug: Norepinephrine,NA,NA,NA
im,NCT03303976,https://clinicaltrials.gov/show/NCT03303976,Biological: Bioconjugate pneumococcal vaccine;Biological: Multivalent plain polysaccharide vaccine,Yes,NA,NA
im,NCT03308578,https://clinicaltrials.gov/show/NCT03308578,Drug: Atorvastatin;Drug: Placebo oral capsule,NA,NA,NA
im,NCT03308825,https://clinicaltrials.gov/show/NCT03308825,Biological: Fluzone Quadrivalent vaccine;Biological: Fluzone Quadrivalent vaccine;Biological: Fluzone High-Dose vaccine;Biological: Fluzone Quadrivalent vaccine;Biological: Fluzone Quadrivalent vaccine;Biological: Fluzone High-Dose vaccine;Biological: Fluzone Quadrivalent vaccine;Biological: Fluzone Quadrivalent vaccine;Biological: Fluzone High-Dose vaccine;Biological: Fluzone Quadrivalent vaccine;Biological: Fluzone Quadrivalent vaccine;Biological: Fluzone High-Dose vaccine,Yes,NA,NA
im,NCT03312231,https://clinicaltrials.gov/show/NCT03312231,Drug: AS03;Biological: Inactivated influenza H7N9 vaccine;Other: Phosphate Buffered Saline (PBS) diluent,Yes,NA,NA
im,NCT03314662,https://clinicaltrials.gov/show/NCT03314662,Biological: MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV);Biological: Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1);Biological: MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2),Yes,NA,NA
im,NCT03315104,https://clinicaltrials.gov/show/NCT03315104,Biological: FLU-IGIV;Other: Placebo for FLU-IGIV,NA,NA,NA
im,NCT03317197,https://clinicaltrials.gov/show/NCT03317197,Drug: Control Group;Drug: Experimental Group 1;Drug: Experimental Group 2;Drug: Experimental Group 3;Drug: Control Group;Drug: Experimental Group 1;Drug: Experimental Group 2;Drug: Experimental Group 3;Drug: Control Group;Drug: Experimental Group 1;Drug: Experimental Group 2;Drug: Experimental Group 3;Drug: Control Group;Drug: Experimental Group 1;Drug: Experimental Group 2;Drug: Experimental Group 3,NA,NA,NA
im,NCT03318315,https://clinicaltrials.gov/show/NCT03318315,Drug: AS03;Biological: Inactivated influenza H7N9 vaccine;Biological: Influenza Virus Quadrivalent Inactivated Vaccine;Other: Phosphate Buffered Saline (PBS) diluent,Yes,NA,NA
im,NCT03325452,https://clinicaltrials.gov/show/NCT03325452,Biological: venous lactate;Biological: venous lactate;Biological: venous lactate;Biological: venous lactate,NA,NA,NA
im,NCT03328325,https://clinicaltrials.gov/show/NCT03328325,Biological: Influenza Virus Quadrivalent Inactivated Vaccine;Biological: Influenza Virus Quadrivalent Inactivated Vaccine,Yes,NA,NA
im,NCT03335904,https://clinicaltrials.gov/show/NCT03335904,Other: Hyperoxic Hypercapnic Ventilatory Response Test;Other: Hypoxic Hypercapnic Ventilatory Response Test;Other: Repeated Hypoxic Apneas;Other: Hypoxic Sleep Study;Drug: Losartan;Drug: Placebo,NA,NA,NA
im,NCT03336814,https://clinicaltrials.gov/show/NCT03336814,Drug: Terlipressin;Other: Placebo,NA,NA,NA
im,NCT03338569,https://clinicaltrials.gov/show/NCT03338569,Drug: Vitamin C;Drug: Placebo,NA,NA,Yes
im,NCT03340727,https://clinicaltrials.gov/show/NCT03340727,Drug: Caffeine Citrate;Drug: Placebo,NA,Yes,NA
im,NCT03340779,https://clinicaltrials.gov/show/NCT03340779,Drug: Norepinephrine;Drug: Norepinephrine;Drug: Norepinephrine;Drug: Norepinephrine,NA,NA,NA
im,NCT03344029,https://clinicaltrials.gov/show/NCT03344029,Biological: SP Shz TIV;Biological: Hualan TIV,NA,NA,NA
im,NCT03344627,https://clinicaltrials.gov/show/NCT03344627,Drug: Meropenem standard dose;Drug: Meropenem high dose,NA,NA,NA
im,NCT03346681,https://clinicaltrials.gov/show/NCT03346681,Drug: N-acetyl cysteine;Drug: N-acetyl cysteine;Drug: N-acetyl cysteine,NA,NA,NA
im,NCT03357263,https://clinicaltrials.gov/show/NCT03357263,Biological: GC3114;Biological: GCFLU Quadrivalent,NA,NA,NA
im,NCT03365336,https://clinicaltrials.gov/show/NCT03365336,Drug: polyherbal formulation;Drug: Oseltamivir 75mg;Drug: polyherbal formulation;Drug: Oseltamivir 75mg;Drug: polyherbal formulation;Drug: Oseltamivir 75mg,NA,Yes,Yes
im,NCT03366220,https://clinicaltrials.gov/show/NCT03366220,Drug: Plasma;Drug: Balanced crystalloids,NA,Yes,NA
im,NCT03369275,https://clinicaltrials.gov/show/NCT03369275,Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells;Other: Placebo;Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells;Other: Placebo;Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells;Other: Placebo;Biological: Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells;Other: Placebo,NA,Yes,NA
im,NCT03370289,https://clinicaltrials.gov/show/NCT03370289,Biological: BLB-750 Vaccine (Qinghai RG strain);Biological: BLB-750 Vaccine (Qinghai RG strain);Biological: BLB-750 Vaccine (Qinghai RG strain),Yes,NA,NA
im,NCT03371498,https://clinicaltrials.gov/show/NCT03371498,Drug: Methylprednisolone;Drug: Methylprednisolone placebo,NA,NA,NA
im,NCT03371680,https://clinicaltrials.gov/show/NCT03371680,Drug: Injection of 1-13 Carbon Leucine and deuterated water;Drug: Injection of 1-13 Carbon Leucine and deuterated water;Drug: Injection of 1-13 Carbon Leucine and deuterated water;Drug: Injection of 1-13 Carbon Leucine and deuterated water,NA,NA,NA
im,NCT03376321,https://clinicaltrials.gov/show/NCT03376321,Drug: Pimodivir 600 mg;Drug: Placebo;Other: SOC Treatment,NA,Yes,NA
im,NCT03384589,https://clinicaltrials.gov/show/NCT03384589,Biological: PCV13,NA,NA,NA
im,NCT03387605,https://clinicaltrials.gov/show/NCT03387605,Drug: Ivabradine;Drug: Placebo,NA,NA,NA
im,NCT03389555,https://clinicaltrials.gov/show/NCT03389555,"Drug: vitamin C, vitamin B1, hydrocortisone;Drug: Normal saline",NA,NA,Yes
im,NCT03390166,https://clinicaltrials.gov/show/NCT03390166,Biological: GPO Tri Fluvac vaccine;Biological: Licensed influenza vaccine,Yes,NA,NA
im,NCT03391193,https://clinicaltrials.gov/show/NCT03391193,Biological: Multi-dose Quadrivalent Influenza Vaccine;Biological: Single-dose Quadrivalent Influenza Vaccine,Yes,NA,NA
im,NCT03392389,https://clinicaltrials.gov/show/NCT03392389,Biological: mRNA-1653;Other: Placebo,NA,NA,NA
im,NCT03394209,https://clinicaltrials.gov/show/NCT03394209,Drug: Favipiravir;Drug: Oseltamivir 75Mg Capsule,NA,Yes,NA
im,NCT03398044,https://clinicaltrials.gov/show/NCT03398044,Drug: Dexamethasone;Drug: Placebo,NA,Yes,NA
im,NCT03400735,https://clinicaltrials.gov/show/NCT03400735,Combination Product: Cefdinir/clavulanic acide 300/125 mg film-coated tablets;Drug: Cefdinir 300Mg Capsule,NA,NA,NA
im,NCT03401398,https://clinicaltrials.gov/show/NCT03401398,"Drug: Hydrocortisone, sodium succinate;Drug: Normal saline",NA,NA,NA
im,NCT03406936,https://clinicaltrials.gov/show/NCT03406936,Drug: Daily interruption of midazolam,NA,NA,NA
im,NCT03422159,https://clinicaltrials.gov/show/NCT03422159,Drug: Ascorbic Acid;Drug: Thiamine;Drug: Hydrocortisone;Drug: Sodium Chloride 0.9%,NA,NA,NA
im,NCT03430089,https://clinicaltrials.gov/show/NCT03430089,"Biological: Shz QIV 0.25 mL, 2 doses;Biological: Shz QIV 0.5 mL, 2 doses;Biological: Shz QIV 0.5 mL, single dose",NA,NA,NA
im,NCT03434028,https://clinicaltrials.gov/show/NCT03434028,Drug: Early Vasopressors;Drug: Early Fluids,NA,NA,NA
im,NCT03434691,https://clinicaltrials.gov/show/NCT03434691,Device: Microdialysis Probe (Muscle microdialysis);Drug: remifentanyl,NA,NA,NA
im,NCT03437304,https://clinicaltrials.gov/show/NCT03437304,"Biological: Immunose™ FLU 1%;Biological: Immunose™ FLU 2%, 200 µl;Biological: Immunose™ FLU 2%, 300 µl;Biological: Influenza antigen;Drug: Placebo;Biological: i.m comparator;Biological: Immunose™ FLU 1%;Biological: Immunose™ FLU 2%, 200 µl;Biological: Immunose™ FLU 2%, 300 µl;Biological: Influenza antigen;Drug: Placebo;Biological: i.m comparator;Biological: Immunose™ FLU 1%;Biological: Immunose™ FLU 2%, 200 µl;Biological: Immunose™ FLU 2%, 300 µl;Biological: Influenza antigen;Drug: Placebo;Biological: i.m comparator",NA,NA,NA
im,NCT03437369,https://clinicaltrials.gov/show/NCT03437369,Drug: Ivabradine Oral Tablet;Other: Standard of Care treatment,NA,NA,NA
im,NCT03439124,https://clinicaltrials.gov/show/NCT03439124,Drug: Ceftobiprole medocaril;Drug: Ceftazidime;Drug: Ceftriaxone,NA,NA,NA
im,NCT03445468,https://clinicaltrials.gov/show/NCT03445468,Biological: IL-YANG Quadrivalent Influenza Vaccine;Biological: IL-YANG Flu Vaccine Pre-filled Syringe,Yes,NA,NA
im,NCT03446534,https://clinicaltrials.gov/show/NCT03446534,Drug: Amoxicillin;Drug: Placebos;Drug: Amoxicillin;Drug: Placebos;Drug: Amoxicillin;Drug: Placebos,NA,NA,NA
im,NCT03446937,https://clinicaltrials.gov/show/NCT03446937,Drug: Dexamethasone Sodium Phosphate Injection;Drug: Betamethasone Sodium Phosphate Injection (Medication);Drug: Water for injection,NA,Yes,NA
im,NCT03448705,https://clinicaltrials.gov/show/NCT03448705,"Biological: 4Fluart ID suspension for injection study drug 1 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted);Biological: 4Fluart ID suspension for injection study drug 2 µg/0.1 ml, influenza vaccine (whole virion, inactivated, adjuvanted);Biological: 3Fluart suspension for injection, influenza vaccine (whole virion, inactivated, adjuvanted)",Yes,NA,NA
im,NCT03450707,https://clinicaltrials.gov/show/NCT03450707,Drug: Thiamine 500 mg IV;Other: Placebo,NA,NA,NA
im,NCT03452917,https://clinicaltrials.gov/show/NCT03452917,Drug: Placebo;Drug: sodium nitrite 45 mg;Drug: sodium nitrite 60 mg,NA,NA,NA
im,NCT03455491,https://clinicaltrials.gov/show/NCT03455491,Drug: XC221 100 mg;Drug: XC221 200 mg;Drug: Placebo,NA,NA,NA
im,NCT03460743,https://clinicaltrials.gov/show/NCT03460743,Biological: Study group - quadrivalent recombinant hemagglutinin influenza vaccine;Biological: Control group - quadrivalent inactivated influenza vaccine,Yes,NA,NA
im,NCT03467750,https://clinicaltrials.gov/show/NCT03467750,Drug: Ketorolac;Drug: Standard of Care,NA,NA,NA
im,NCT03472976,https://clinicaltrials.gov/show/NCT03472976,"Other: Aqueous Cream B.P.;Drug: Imiquimod;Biological: Influenza Virus Vaccine, Monovalent A/H5N1 A/Vietnam/1203/04",Yes,NA,NA
im,NCT03474991,https://clinicaltrials.gov/show/NCT03474991,Drug: Celestamine®,NA,NA,NA
im,NCT03492736,https://clinicaltrials.gov/show/NCT03492736,Dietary Supplement: Melatonin;Other: Placebo,NA,NA,NA
im,NCT03494959,https://clinicaltrials.gov/show/NCT03494959,Drug: Pentaglobin,NA,NA,NA
im,NCT03497845,https://clinicaltrials.gov/show/NCT03497845,Biological: VN;Biological: IN;Biological: dk/BANG;Biological: gf/WA;Biological: bhg/QL;Biological: AS03 adjuvant;Biological: MF59 adjuvant,NA,NA,NA
im,NCT03502291,https://clinicaltrials.gov/show/NCT03502291,Biological: Study one: LAIV + Inoculation;Biological: Study one: Placebo + Inoculation;Biological: Study two: Inoculation + LAIV;Biological: Study two: Inoculation + placebo;Biological: Study one: LAIV + Inoculation;Biological: Study one: Placebo + Inoculation;Biological: Study two: Inoculation + LAIV;Biological: Study two: Inoculation + placebo;Biological: Study one: LAIV + Inoculation;Biological: Study one: Placebo + Inoculation;Biological: Study two: Inoculation + LAIV;Biological: Study two: Inoculation + placebo,NA,NA,NA
im,NCT03509662,https://clinicaltrials.gov/show/NCT03509662,Drug: Vitamin C;Drug: Thiamine;Drug: Placebos,NA,NA,Yes
im,NCT03521063,https://clinicaltrials.gov/show/NCT03521063,Drug: Budesonide;Drug: Poractant Alfa;Drug: Saline,NA,NA,NA
im,NCT03528213,https://clinicaltrials.gov/show/NCT03528213,Drug: Sodium Lactate light dose;Drug: Sodium Lactate high dose;Drug: Normal saline,NA,NA,NA
im,NCT03545373,https://clinicaltrials.gov/show/NCT03545373,Drug: Azithromycin;Drug: Amoxicillin,NA,Yes,NA
im,NCT03545997,https://clinicaltrials.gov/show/NCT03545997,Drug: Montelukast 10mg;Drug: Placebo,NA,NA,NA
im,NCT03546192,https://clinicaltrials.gov/show/NCT03546192,Biological: Fluzone Quadrivalent Influenza Vaccine,Yes,NA,NA
im,NCT03551964,https://clinicaltrials.gov/show/NCT03551964,Drug: Cangrelor;Drug: Ticagrelor,NA,NA,NA
im,NCT03552848,https://clinicaltrials.gov/show/NCT03552848,Biological: MSC,NA,NA,NA
im,NCT03553940,https://clinicaltrials.gov/show/NCT03553940,Biological: Influenza Virus Monovalent A/H3N2/Bris 10 M2SR Live Vaccine;Other: Placebo;Biological: Quadrivalent MDCK Inactivated Influenza Vaccine,Yes,NA,NA
im,NCT03557229,https://clinicaltrials.gov/show/NCT03557229,Drug: Melatonin 5 mg;Drug: Vitamin C 1 GM Oral Tablet;Drug: Vitamin E 400 UNT;Drug: N-acetylcysteine,NA,NA,Yes
im,NCT03564444,https://clinicaltrials.gov/show/NCT03564444,Biological: Bivalent influenza vaccine;Other: Placebo,Yes,NA,NA
im,NCT03572491,https://clinicaltrials.gov/show/NCT03572491,Biological: influenza vaccine,Yes,NA,NA
im,NCT03581370,https://clinicaltrials.gov/show/NCT03581370,Drug: 1 hour infusion;Drug: 4 hours infusion,NA,NA,NA
im,NCT03582007,https://clinicaltrials.gov/show/NCT03582007,Drug: Murepavadin;Drug: One anti-pseudomonal antibiotic,NA,Yes,NA
im,NCT03583333,https://clinicaltrials.gov/show/NCT03583333,Drug: IMI/REL FDC;Drug: PIP/TAZ FDC;Drug: Linezolid,NA,NA,NA
im,NCT03589807,https://clinicaltrials.gov/show/NCT03589807,"Biological: A/H7N9;Drug: AS03;Biological: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013;Other: Phosphate Buffered Saline (PBS) diluent",Yes,NA,NA
im,NCT03590808,https://clinicaltrials.gov/show/NCT03590808,Biological: Influenza vaccination,NA,NA,NA
im,NCT03598439,https://clinicaltrials.gov/show/NCT03598439,Biological: Standard IIV4;Biological: Recombinant;Biological: Cell-culture,NA,NA,NA
im,NCT03600428,https://clinicaltrials.gov/show/NCT03600428,Biological: Live Attenuated Influenza Vaccine (LAIV);Biological: Inactivated Influenza Vaccine (IIV),Yes,NA,NA
im,NCT03603509,https://clinicaltrials.gov/show/NCT03603509,Drug: Fluad Vaccine;Drug: Fluzone High-Dose,Yes,NA,NA
im,NCT03603678,https://clinicaltrials.gov/show/NCT03603678,Drug: BAY2253651;Drug: Placebo,NA,NA,NA
im,NCT03608592,https://clinicaltrials.gov/show/NCT03608592,Biological: umbilical cord derived mesenchymal stem cells (UCMSCs) suspension;Biological: normal saline,NA,Yes,NA
im,NCT03609099,https://clinicaltrials.gov/show/NCT03609099,Drug: Moxifloxacin;Drug: Placebo,NA,Yes,NA
im,NCT03619876,https://clinicaltrials.gov/show/NCT03619876,Drug: Abatacept;Drug: Adalimumab,NA,Yes,NA
im,NCT03622450,https://clinicaltrials.gov/show/NCT03622450,Drug: Colistin;Drug: Carbapenem + Aminoglycoside/ Quinolone,NA,NA,NA
im,NCT03623529,https://clinicaltrials.gov/show/NCT03623529,Drug: LJPC-501 (angiotensin II);Drug: Placebo,NA,NA,NA
im,NCT03625687,https://clinicaltrials.gov/show/NCT03625687,Drug: Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 12 weeks,NA,NA,NA
im,NCT03629184,https://clinicaltrials.gov/show/NCT03629184,Drug: Baloxavir Marboxil;Drug: Oseltamivir,NA,Yes,NA
im,NCT03634293,https://clinicaltrials.gov/show/NCT03634293,Drug: Alirocumab Injectable Product;Drug: Saline Solution,NA,Yes,NA
im,NCT03640468,https://clinicaltrials.gov/show/NCT03640468,Drug: Ketamine full dose;Drug: Ketamine half dose;Drug: Lidocaine;Drug: Midazolam;Drug: Normal saline,NA,Yes,NA
im,NCT03646266,https://clinicaltrials.gov/show/NCT03646266,Drug: Rocuronium Bromide,NA,NA,NA
im,NCT03646552,https://clinicaltrials.gov/show/NCT03646552,Drug: THX-110,NA,NA,NA
im,NCT03649633,https://clinicaltrials.gov/show/NCT03649633,Drug: Stress-dose Hydrocortisone plus Vitamin C;Drug: isotonic sodium chloride solution placebo plus isotonic sodium chloride solution placebo,NA,NA,Yes
im,NCT03651544,https://clinicaltrials.gov/show/NCT03651544,Biological: GamFluVac,NA,NA,NA
im,NCT03653364,https://clinicaltrials.gov/show/NCT03653364,Drug: Baloxavir Marboxil,NA,Yes,NA
im,NCT03654937,https://clinicaltrials.gov/show/NCT03654937,Biological: Influenza Vaccination;Biological: Influenza Vaccination,NA,NA,NA
im,NCT03656198,https://clinicaltrials.gov/show/NCT03656198,Biological: Rabivax-S;Drug: Sterile Water Injection,NA,NA,NA
im,NCT03658629,https://clinicaltrials.gov/show/NCT03658629,Biological: NanoFlu (Quad-NIV);Other: Matrix-M Adjuvant;Other: Placebo;Biological: Fluzone HD;Biological: Flublok Quadrivalent,Yes,NA,NA
im,NCT03669627,https://clinicaltrials.gov/show/NCT03669627,Biological: aTIV Primer;Biological: QIV Primer;Biological: aTIV Booster;Biological: QIV Booster,NA,NA,NA
im,NCT03673345,https://clinicaltrials.gov/show/NCT03673345,Biological: Influenza Virus Quadrivalent Inactivated Vaccine,Yes,NA,NA
im,NCT03679143,https://clinicaltrials.gov/show/NCT03679143,Drug: ZSP1273 100 mg;Drug: Placebo 100 mg;Drug: ZSP1273 200 mg;Drug: Placebo 200 mg;Drug: ZSP1273 400 mg;Drug: Placebo 400 mg;Drug: ZSP1273 600 mg;Drug: Placebo 600 mg;Drug: ZSP1273 900 mg;Drug: Placebo 900 mg;Drug: ZSP1273 1200 mg;Drug: Placebo 1200 mg;Drug: ZSP1273;Drug: Placebo;Drug: ZSP1273 Low Dose;Drug: Placebo;Drug: ZSP1273 Median Dose;Drug: Placebo;Drug: ZSP1273 High Dose;Drug: Placebo,NA,NA,NA
im,NCT03684044,https://clinicaltrials.gov/show/NCT03684044,Drug: Baloxavir Marboxil;Other: Placebo,NA,Yes,NA
im,NCT03685214,https://clinicaltrials.gov/show/NCT03685214,Drug: 0.9% saline;Drug: lactated Ringer's solution,NA,NA,NA
im,NCT03695432,https://clinicaltrials.gov/show/NCT03695432,Biological: Flubio;Dietary Supplement: Lacidofil;Other: Placebo Vaccine;Other: Placebo probiotic;Biological: Flubio;Dietary Supplement: Lacidofil;Other: Placebo Vaccine;Other: Placebo probiotic,Yes,NA,NA
im,NCT03698279,https://clinicaltrials.gov/show/NCT03698279,"Biological: QIV-HD, 30 µg HA/strain/dose;Biological: QIV-HD, 45 µg µg HA/strain/dose;Biological: QIV-HD 60 µg HA/strain/dose;Biological: Unadjuvanted QIV-SD, 15 µg HA/strain/dose;Biological: Adjuvanted TIV, 7.5 µg HA/strain/dose",NA,NA,NA
im,NCT03699839,https://clinicaltrials.gov/show/NCT03699839,Biological: High-dose influenza vaccine;Biological: MF59-adjuvanted influenza vaccine;Biological: Standard intramuscular influenza vaccine,Yes,NA,NA
im,NCT03701061,https://clinicaltrials.gov/show/NCT03701061,Biological: Seasonal Influenza Vaccine;Biological: Seasonal Influenza Vaccine,Yes,NA,NA
im,NCT03704740,https://clinicaltrials.gov/show/NCT03704740,Biological: NBP607-QIV;Biological: Agrippal,NA,NA,NA
im,NCT03710187,https://clinicaltrials.gov/show/NCT03710187,Drug: Combination (Hydrocortisone and Fludrocortisone);Drug: Hydrocortisone,NA,NA,NA
im,NCT03715556,https://clinicaltrials.gov/show/NCT03715556,Drug: Amiodarone;Drug: 0.9% physiological solution,NA,NA,NA
im,NCT03718468,https://clinicaltrials.gov/show/NCT03718468,Biological: GC FLU Quadrivalent;Biological: Fluarix Tetra,Yes,NA,NA
im,NCT03718507,https://clinicaltrials.gov/show/NCT03718507,Drug: Fentanyl;Drug: Sucrose 24% Oral Solution,NA,NA,NA
im,NCT03734237,https://clinicaltrials.gov/show/NCT03734237,Biological: Egg based influenza vaccines;Biological: Recombinant influenza vaccines;Biological: Cell-culture based influenza vaccines,Yes,NA,NA
im,NCT03735147,https://clinicaltrials.gov/show/NCT03735147,Biological: Live attenuated influenza vaccine (LAIV),Yes,NA,NA
im,NCT03738241,https://clinicaltrials.gov/show/NCT03738241,Biological: A/H7N9;Drug: AS03;Other: Phosphate Buffered Saline (PBS) diluent,NA,NA,NA
im,NCT03745274,https://clinicaltrials.gov/show/NCT03745274,Biological: GHB04L1;Other: Placebo,NA,NA,NA
im,NCT03745664,https://clinicaltrials.gov/show/NCT03745664,Drug: Methylprednisolone Sodium Succinate;Drug: Saline Solution for Injection,NA,NA,NA
im,NCT03748537,https://clinicaltrials.gov/show/NCT03748537,Drug: Hydrocortisone,NA,NA,NA
im,NCT03749525,https://clinicaltrials.gov/show/NCT03749525,Drug: shenfu injection,NA,NA,NA
im,NCT03753347,https://clinicaltrials.gov/show/NCT03753347,Biological: 2018-19 quadrivalent inactivated influenza vaccine,Yes,NA,NA
im,NCT03755427,https://clinicaltrials.gov/show/NCT03755427,Biological: 15µg H7N9 Vaccine;Biological: Aluminum Hydroxide Adjuvant,Yes,NA,NA
im,NCT03756220,https://clinicaltrials.gov/show/NCT03756220,Drug: Combination therapy of vitamin C and thiamine;Drug: Normal saline solution,NA,NA,Yes
im,NCT03765294,https://clinicaltrials.gov/show/NCT03765294,Drug: ACT-541468;Drug: Placebo,NA,NA,NA
im,NCT03765437,https://clinicaltrials.gov/show/NCT03765437,Biological: Quadrivalent Influenza Vaccine,Yes,NA,NA
im,NCT03770208,https://clinicaltrials.gov/show/NCT03770208,Drug: Intervention: Lidocaine;Drug: Control: Standard Care + Placebo,NA,Yes,NA
im,NCT03777163,https://clinicaltrials.gov/show/NCT03777163,Biological: Butantan Institute Trivalent Seasonal Influenza Vaccine;Biological: Sanofi Trivalent Seasonal Influenza Vaccine,Yes,NA,NA
im,NCT03778203,https://clinicaltrials.gov/show/NCT03778203,Biological: Fluzone 0.25 mL dose;Biological: Fluzone 0.5 mL dose;Other: natural influenza infection,Yes,NA,NA
im,NCT03790176,https://clinicaltrials.gov/show/NCT03790176,Drug: Intravenous Infusion,NA,NA,NA
main,NCT03794037,https://clinicaltrials.gov/show/NCT03794037,Drug: dydrgesterone 10 mg( tab)/12hs/14 days;Combination Product: montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 days,NA,NA,NA
main,NCT03794960,https://clinicaltrials.gov/show/NCT03794960,Biological: TOL-3021;Other: TOL-3021 Placebo,NA,NA,NA
im,NCT03796026,https://clinicaltrials.gov/show/NCT03796026,Drug: Seltorexant 40 mg;Drug: Placebo,NA,NA,NA
main,NCT03796390,https://clinicaltrials.gov/show/NCT03796390,Biological: CD123 CAR-T cells,NA,NA,NA
main,NCT03796572,https://clinicaltrials.gov/show/NCT03796572,Drug: Ropivacaine;Other: Puncture Wound and Dressing,NA,Yes,NA
main,NCT03797456,https://clinicaltrials.gov/show/NCT03797456,Drug: ICP-022,NA,NA,NA
main,NCT03798197,https://clinicaltrials.gov/show/NCT03798197,Drug: 30 mg estetrol (E4),NA,NA,NA
main,NCT03798366,https://clinicaltrials.gov/show/NCT03798366,Drug: GLPG1690;Drug: Placebo,NA,NA,NA
main,NCT03799601,https://clinicaltrials.gov/show/NCT03799601,Drug: Anlotinib;Drug: Docetaxel;Drug: Carboplatin,NA,NA,NA
main,NCT03801915,https://clinicaltrials.gov/show/NCT03801915,Drug: MVT-5873;Procedure: pancreatectomy or hepatectomy,NA,NA,NA
main,NCT03802292,https://clinicaltrials.gov/show/NCT03802292,Biological: YQ23;Biological: Matching Placebo,NA,NA,NA
main,NCT03804580,https://clinicaltrials.gov/show/NCT03804580,Drug: osimertinib,NA,NA,NA
main,NCT03806933,https://clinicaltrials.gov/show/NCT03806933,Drug: NT 201,NA,NA,NA
im,NCT03807804,https://clinicaltrials.gov/show/NCT03807804,Biological: HLCM051,NA,NA,NA
main,NCT03807843,https://clinicaltrials.gov/show/NCT03807843,Biological: MV-CHIK;Other: Placebo,NA,NA,NA
main,NCT03808298,https://clinicaltrials.gov/show/NCT03808298,Drug: Balovaptan therapeutic dose Treatment A;Drug: Balovaptan supra-therapeutic dose Treatment B;Drug: Active control [moxifloxacin] on Day 2 Treatment C;Drug: Active control [moxifloxacin] on Day 15 Treatment D;Drug: Placebo for Balovaptan Treatment C;Drug: Placebo for Balovaptan Treatment D;Drug: Placebo for Moxifloxacin Treatment A;Drug: Placebo for moxifloxacin Treatment B;Drug: Moxifloxacin Treatment C;Drug: Placebo for moxifloxacin Treatment C;Drug: Placebo for moxifloxacin Treatment D;Drug: Moxifloxacin Treatment D,NA,Yes,NA
main,NCT03810235,https://clinicaltrials.gov/show/NCT03810235,Drug: Transdermal Lidocaine Patch;Drug: Transdermal Hydrocolloid Placebo Patch,NA,Yes,NA
main,NCT03810313,https://clinicaltrials.gov/show/NCT03810313,Drug: Brolucizumab 6 mg;Drug: Aflibercept 2 mg;Other: Sham injection,NA,Yes,NA
main,NCT03811548,https://clinicaltrials.gov/show/NCT03811548,Drug: Janagliflozin 25mg;Drug: Janagliflozin 50mg;Drug: Placebo/Janagliflozin,NA,NA,NA
main,NCT03813394,https://clinicaltrials.gov/show/NCT03813394,Drug: pembrolizumab;Drug: bevacizumab,NA,Yes,NA
main,NCT03814720,https://clinicaltrials.gov/show/NCT03814720,Biological: VRC-FLUNPF099-00-VP (H1ssF_3928),NA,NA,NA
im,NCT03814720,https://clinicaltrials.gov/show/NCT03814720,Biological: VRC-FLUNPF099-00-VP (H1ssF_3928),NA,NA,NA
main,NCT03818945,https://clinicaltrials.gov/show/NCT03818945,Drug: shofu PRG barrier coat;Drug: Sodium fluoride varnish,NA,NA,NA
main,NCT03820037,https://clinicaltrials.gov/show/NCT03820037,Drug: Ongentys;Drug: BIA 9-1067 (test),NA,NA,NA
main,NCT03822052,https://clinicaltrials.gov/show/NCT03822052,Other: Lactated ringers;Other: 5% dextrose lactated ringers,NA,NA,NA
main,NCT03822117,https://clinicaltrials.gov/show/NCT03822117,Drug: Pemigatinib,NA,NA,NA
main,NCT03824340,https://clinicaltrials.gov/show/NCT03824340,Drug: Doxycycline before ICSI,NA,NA,NA
im,NCT03824457,https://clinicaltrials.gov/show/NCT03824457,Drug: Rheosorbilact®;Drug: Ringer lactate,NA,NA,NA
im,NCT03824847,https://clinicaltrials.gov/show/NCT03824847,Drug: Clarithromycin 250 MG;Drug: Placebos,NA,Yes,NA
main,NCT03825367,https://clinicaltrials.gov/show/NCT03825367,Drug: Nivolumab;Drug: 5-azacytidine,NA,Yes,NA
im,NCT03826524,https://clinicaltrials.gov/show/NCT03826524,Drug: Epinephrine,NA,NA,NA
main,NCT03826628,https://clinicaltrials.gov/show/NCT03826628,Drug: rapamycin;Drug: placebo,NA,Yes,NA
im,NCT03826719,https://clinicaltrials.gov/show/NCT03826719,Biological: NBP607QIV;Biological: Agrippal,NA,NA,NA
main,NCT03826992,https://clinicaltrials.gov/show/NCT03826992,Drug: Vyxeos;Drug: Venetoclax,NA,NA,NA
main,NCT03827798,https://clinicaltrials.gov/show/NCT03827798,Drug: CFZ533;Drug: Placebo to CFZ533;Drug: LYS006;Drug: Placebo to LYS006,NA,NA,NA
im,NCT03828929,https://clinicaltrials.gov/show/NCT03828929,Drug: Vitamin C;Drug: Normal saline,NA,NA,Yes
main,NCT03829345,https://clinicaltrials.gov/show/NCT03829345,Drug: Olaparib,NA,NA,NA
im,NCT03829618,https://clinicaltrials.gov/show/NCT03829618,Drug: Nebuliser solution;Drug: Nebuliser Suspension;Drug: Topical lidocaine,NA,Yes,NA
main,NCT03830385,https://clinicaltrials.gov/show/NCT03830385,"Drug: PaclitaxelPaclitaxel (Albumin Bound),Bleomycin combined with Cisplatin or Carboplatin",NA,Yes,NA
main,NCT03835676,https://clinicaltrials.gov/show/NCT03835676,Drug: Treprostinil,NA,NA,NA
im,NCT03837171,https://clinicaltrials.gov/show/NCT03837171,Biological: Liberal Red blood cell transfusion;Biological: Restrictive Red blood cell transfusion,NA,NA,NA
main,NCT03837353,https://clinicaltrials.gov/show/NCT03837353,Drug: DKN-01 300 mg;Drug: DKN-01 600 mg;Drug: Docetaxel 75 mg/m2;Drug: DKN-01 150 mg,NA,NA,NA
main,NCT03837925,https://clinicaltrials.gov/show/NCT03837925,Drug: Atorvastatin 40mg Tablet;Drug: Placebo comparator,NA,NA,NA
main,NCT03837938,https://clinicaltrials.gov/show/NCT03837938,Drug: Levopront® syrup 30 mg/5 ml;Drug: Libexin®,NA,NA,NA
im,NCT03838497,https://clinicaltrials.gov/show/NCT03838497,Biological: Prevenar13,NA,NA,NA
main,NCT03839134,https://clinicaltrials.gov/show/NCT03839134,Device: DentalVibe® Comfort Injection System;Drug: Lidocaine Epinephrine,NA,Yes,NA
main,NCT03840902,https://clinicaltrials.gov/show/NCT03840902,Drug: M7824;Drug: Placebo;Drug: Durvalumab;Drug: Etoposide;Drug: Pemetrexed;Drug: Carboplatin;Drug: Paclitaxel;Drug: Cisplatin;Radiation: Intensity Modulated Radiation Therapy (IMRT),NA,Yes,NA
main,NCT03840967,https://clinicaltrials.gov/show/NCT03840967,Drug: Niraparib,NA,NA,NA
main,NCT03842267,https://clinicaltrials.gov/show/NCT03842267,Drug: Gemigliptin 50mg;Drug: Gemigliptin Placebo,NA,NA,NA
main,NCT03844217,https://clinicaltrials.gov/show/NCT03844217,Drug: Macimorelin 0.5mg/kg body weight;Drug: Macimorelin 0.75mg/kg body weight,NA,NA,NA
im,NCT03844984,https://clinicaltrials.gov/show/NCT03844984,Drug: ketamine full dose;Drug: Midazolam;Drug: Normal saline;Drug: ketamine half dose;Drug: Lidocaine,NA,Yes,NA
im,NCT03845023,https://clinicaltrials.gov/show/NCT03845023,Drug: AD036 Dose 1;Drug: AD036 Dose 2;Drug: AD036 Dose 3;Drug: Placebo,NA,NA,NA
main,NCT03845348,https://clinicaltrials.gov/show/NCT03845348,Other: TD03;Other: TD07;Drug: Ketoconazole 2% Shampoo,NA,NA,NA
main,NCT03845894,https://clinicaltrials.gov/show/NCT03845894,Drug: Liposomal bupivacaine;Drug: Bupivacaine with adjuvants,NA,Yes,NA
main,NCT03846258,https://clinicaltrials.gov/show/NCT03846258,Drug: Low bicarbonate solution (22 mmol/L);Drug: High Bicarbonate solution (32 mmol/L),NA,NA,NA
main,NCT03846765,https://clinicaltrials.gov/show/NCT03846765,Drug: Phenylephrine;Drug: Dobutamine,NA,NA,NA
main,NCT03847246,https://clinicaltrials.gov/show/NCT03847246,"Drug: Baraclude® tablets,1.0 mg;Drug: Entecavir tablets,1.0 mg",NA,Yes,NA
im,NCT03849560,https://clinicaltrials.gov/show/NCT03849560,"Biological: Grippol® Quadri;Biological: Grippol® Plus, trivalent (Yamagata lineage);Biological: Grippol® Plus, trivalent (Victoria lineage)",NA,NA,NA
main,NCT03850886,https://clinicaltrials.gov/show/NCT03850886,Dietary Supplement: Niacinamide Oral Tablet;Drug: Antidiabetic,NA,NA,NA
main,NCT03851250,https://clinicaltrials.gov/show/NCT03851250,Drug: MRx-4DP0004;Drug: Placebo,NA,NA,NA
main,NCT03851627,https://clinicaltrials.gov/show/NCT03851627,Drug: Testosterone Undecanoate;Drug: Placebo,NA,NA,NA
im,NCT03852537,https://clinicaltrials.gov/show/NCT03852537,Drug: Methylprednisolone;Other: Usual Care,NA,NA,NA
im,NCT03853993,https://clinicaltrials.gov/show/NCT03853993,Biological: Quadrivalent influenza vaccine;Biological: Trivalent influenza vaccine (contains B/Victoria strain);Biological: Trivalent influenza vaccine (contains B/Yamagata strain),Yes,NA,NA
main,NCT03854344,https://clinicaltrials.gov/show/NCT03854344,Drug: Lidocaine Hydrochloride;Drug: Liposomal bupivacaine,NA,Yes,NA
main,NCT03854552,https://clinicaltrials.gov/show/NCT03854552,Drug: BI 764198;Drug: Placebo,NA,NA,NA
im,NCT03858751,https://clinicaltrials.gov/show/NCT03858751,Drug: Placebo oral capsule;Drug: LTM1201AZ;Drug: LTM1201AT;Drug: LTM1201AG;Drug: LTM1201AD,NA,NA,NA
im,NCT03859141,https://clinicaltrials.gov/show/NCT03859141,Biological: Quadrivalent influenza vaccine;Biological: Quadrivalent influenza vaccine;Biological: Trivalent influenza vaccine (contains B/Victoria strain);Biological: Trivalent influenza vaccine (contains B/Yamagata strain),Yes,NA,NA
im,NCT03860233,https://clinicaltrials.gov/show/NCT03860233,Drug: Oxytocin;Drug: Placebo,NA,Yes,NA
main,NCT03861143,https://clinicaltrials.gov/show/NCT03861143,Drug: BT-11 (500 mg);Drug: BT-11 (1000 mg);Drug: Placebo,NA,NA,NA
im,NCT03862040,https://clinicaltrials.gov/show/NCT03862040,Drug: Cefiderocol;Drug: Standard of Care Antibiotic,NA,Yes,NA
main,NCT03862456,https://clinicaltrials.gov/show/NCT03862456,Other: Azithromycin;Other: Metronidazole,NA,Yes,NA
main,NCT03864185,https://clinicaltrials.gov/show/NCT03864185,Biological: Rituximab (genetical recombination);Other: Placebo,NA,Yes,NA
main,NCT03866798,https://clinicaltrials.gov/show/NCT03866798,Biological: Panzyga,NA,NA,NA
im,NCT03869385,https://clinicaltrials.gov/show/NCT03869385,Drug: Albutein® 200 g/L or Plasbumin® 20,NA,NA,NA
im,NCT03872011,https://clinicaltrials.gov/show/NCT03872011,"Drug: Vitamin C,thiamine,hydrocortisone;Drug: Placebo",NA,NA,Yes
main,NCT03876717,https://clinicaltrials.gov/show/NCT03876717,Drug: Colesevelam Hydrochloride;Drug: Placebo oral capsule,NA,NA,NA
main,NCT03878589,https://clinicaltrials.gov/show/NCT03878589,Drug: Oxytocin (OT);Drug: Placebo (P),NA,Yes,NA
main,NCT03878771,https://clinicaltrials.gov/show/NCT03878771,Biological: Platelet rich fibrin gel in Orabase;Drug: Dermovate cream in Orabase,NA,NA,NA
main,NCT03880045,https://clinicaltrials.gov/show/NCT03880045,Drug: Topical TA;Drug: vasopressin;Other: placebo to TA,NA,NA,NA
main,NCT03880357,https://clinicaltrials.gov/show/NCT03880357,Drug: Betamethasone Scalp Suspension 0.064%;0.0005%;Drug: Taclonex®;Drug: Placebo topical suspension,NA,Yes,NA
im,NCT03880474,https://clinicaltrials.gov/show/NCT03880474,Biological: MVA-NP+M1;Drug: Saline,NA,NA,NA
im,NCT03882801,https://clinicaltrials.gov/show/NCT03882801,Drug: Gefapixant;Drug: Placebo,NA,NA,NA
im,NCT03883113,https://clinicaltrials.gov/show/NCT03883113,Biological: MVA-NP+M1;Biological: Saline;Biological: H3N2 (A/Belgium/2417/2015),NA,NA,NA
main,NCT03883893,https://clinicaltrials.gov/show/NCT03883893,Drug: Intravenous acetaminophen;Other: Normal saline,NA,NA,NA
im,NCT03884296,https://clinicaltrials.gov/show/NCT03884296,Biological: FluMist,NA,NA,NA
main,NCT03887000,https://clinicaltrials.gov/show/NCT03887000,Other: magnesium;Other: placebo,NA,Yes,NA
main,NCT03887377,https://clinicaltrials.gov/show/NCT03887377,Drug: Botulinum Toxins;Drug: Normal saline,NA,NA,NA
main,NCT03888612,https://clinicaltrials.gov/show/NCT03888612,Drug: ARV-110,NA,NA,NA
im,NCT03888989,https://clinicaltrials.gov/show/NCT03888989,Biological: Quadrivalent inactivated influenza vaccine (IIV),Yes,NA,NA
main,NCT03890068,https://clinicaltrials.gov/show/NCT03890068,Drug: Anlotinib Hydrochloride,NA,NA,NA
main,NCT03890289,https://clinicaltrials.gov/show/NCT03890289,Drug: Idelalisib;Drug: Obinutuzumab,NA,Yes,NA
im,NCT03891433,https://clinicaltrials.gov/show/NCT03891433,"Drug: Meropenem;Drug: Ertapenem 1000 MG;Drug: Piperacillin, Tazobactam 4-0.5G Solution for Injection",NA,NA,NA
main,NCT03891550,https://clinicaltrials.gov/show/NCT03891550,Drug: Epclusa,NA,NA,NA
im,NCT03892122,https://clinicaltrials.gov/show/NCT03892122,Drug: Propofol Fresenius;Drug: Dexmedetomidine,NA,NA,NA
main,NCT03892616,https://clinicaltrials.gov/show/NCT03892616,Drug: BI 1358894 (B);Drug: BI 1358894 (C);Drug: BI 1358894 (D);Drug: BI 1358894 (E);Drug: BI 1358894 (A),NA,NA,NA
im,NCT03892772,https://clinicaltrials.gov/show/NCT03892772,Drug: SAS0421a;Drug: SAS0421b;Drug: SAS0421c;Drug: placebo,NA,NA,NA
main,NCT03895671,https://clinicaltrials.gov/show/NCT03895671,Drug: Ponatinib;Drug: Azacitidine,NA,NA,NA
main,NCT03895879,https://clinicaltrials.gov/show/NCT03895879,Drug: Tocilizumab;Drug: Tocilizumab,NA,Yes,NA
main,NCT03895944,https://clinicaltrials.gov/show/NCT03895944,Biological: ET190L1-ARTEMIS™ T cells -iv low dose;Biological: ET190L1-ARTEMIS™ T cells -iv middle dose;Biological: ET190L1-ARTEMIS™ T cells - iv high dose,NA,NA,NA
main,NCT03896269,https://clinicaltrials.gov/show/NCT03896269,Drug: Liposome-encapsulated Daunorubicin-Cytarabine,NA,Yes,NA
im,NCT03896477,https://clinicaltrials.gov/show/NCT03896477,Biological: Pneumosil;Biological: Prevenar 13;Biological: Synflorix,NA,NA,NA
main,NCT03897257,https://clinicaltrials.gov/show/NCT03897257,Drug: UHE-103A1 cream;Drug: UHE-103A2 cream;Drug: UHE-103B cream;Drug: UHE-103A1B cream;Drug: UHE-103A2B cream,NA,NA,NA
main,NCT03897673,https://clinicaltrials.gov/show/NCT03897673,Dietary Supplement: Early Iron;Dietary Supplement: Delayed Iron,NA,Yes,NA
main,NCT03898102,https://clinicaltrials.gov/show/NCT03898102,Drug: Regorafenib;Dietary Supplement: Zinc gluconate supplement,NA,NA,NA
im,NCT03898986,https://clinicaltrials.gov/show/NCT03898986,Biological: Live attenuated influenza vaccine (LAIV4);Biological: Inactivated Influenza Vaccine (IIV4),Yes,NA,NA
main,NCT03899415,https://clinicaltrials.gov/show/NCT03899415,Biological: TCR redirected T cells,NA,NA,NA
im,NCT03899571,https://clinicaltrials.gov/show/NCT03899571,Drug: Oseltamivir Oral Capsule for 5 days post-exposure;Drug: Oseltamivir Oral Capsule for 10 days post-exposure,NA,Yes,NA
main,NCT03899805,https://clinicaltrials.gov/show/NCT03899805,Drug: Eribulin;Drug: Pembrolizumab,NA,Yes,NA
main,NCT03901638,https://clinicaltrials.gov/show/NCT03901638,Drug: Tllsh2910;Drug: Placebo,NA,NA,NA
main,NCT03902665,https://clinicaltrials.gov/show/NCT03902665,Drug: Up-front allogeneic hematopoietic stem cell transplantation (HSCT),NA,Yes,NA
main,NCT03903016,https://clinicaltrials.gov/show/NCT03903016,Drug: Insulin Lispro SAR342434;Drug: Insulin Lispro SAR342434,NA,NA,NA
main,NCT03903549,https://clinicaltrials.gov/show/NCT03903549,Drug: [18F]P17-059,NA,NA,NA
main,NCT03904108,https://clinicaltrials.gov/show/NCT03904108,Drug: Ramucirumab,NA,Yes,NA
main,NCT03905512,https://clinicaltrials.gov/show/NCT03905512,Drug: SEL-212;Drug: SEL-037;Drug: SEL-110;Drug: KRYSTEXXA®,NA,NA,NA
main,NCT03905837,https://clinicaltrials.gov/show/NCT03905837,Drug: Lidocaine;Drug: Remifentanil,NA,Yes,NA
main,NCT03908814,https://clinicaltrials.gov/show/NCT03908814,Drug: Whole Human Anti-PD-L1 Antibody Injection (LDP),NA,NA,NA
main,NCT03909594,https://clinicaltrials.gov/show/NCT03909594,Drug: Bupivacaine;Drug: Ketamine,NA,Yes,NA
main,NCT03911466,https://clinicaltrials.gov/show/NCT03911466,Drug: Buprenorphine Injection;Drug: Buprenorphine Sublingual Product,NA,NA,NA
main,NCT03912532,https://clinicaltrials.gov/show/NCT03912532,Biological: NGM282;Other: Placebo,NA,NA,NA
main,NCT03918135,https://clinicaltrials.gov/show/NCT03918135,Drug: Paracetamol;Drug: Ibuprofen,NA,NA,NA
im,NCT03919955,https://clinicaltrials.gov/show/NCT03919955,Drug: Atomoxetine;Drug: Oxybutynin;Drug: Placebo,NA,NA,NA
main,NCT03922321,https://clinicaltrials.gov/show/NCT03922321,Drug: RVT-1401 (Administered via subcutaneous injection),NA,NA,NA
main,NCT03922815,https://clinicaltrials.gov/show/NCT03922815,Drug: rescue fentanyl;Drug: rescue propofol,NA,NA,NA
main,NCT03923270,https://clinicaltrials.gov/show/NCT03923270,Drug: Durvalumab;Drug: Tremelimumab;Drug: Olaparib Pill;Radiation: Thoracic Radiotherapy,NA,Yes,NA
main,NCT03924635,https://clinicaltrials.gov/show/NCT03924635,Combination Product: Symbicort® and salbutamol,NA,NA,NA
main,NCT03924869,https://clinicaltrials.gov/show/NCT03924869,Radiation: Stereotactic Body Radiotherapy (SBRT);Biological: Pembrolizumab;Drug: Placebo,NA,Yes,NA
main,NCT03925051,https://clinicaltrials.gov/show/NCT03925051,Drug: Prolia®;Drug: CMAB807,NA,NA,NA
main,NCT03925480,https://clinicaltrials.gov/show/NCT03925480,Drug: Azithromycin 500 mg Oral Tablet x 4;Drug: Matching Placebo,NA,Yes,NA
main,NCT03925818,https://clinicaltrials.gov/show/NCT03925818,Drug: Bismuth Subcitrate Potassium;Dietary Supplement: Gastrus,NA,NA,NA
main,NCT03926143,https://clinicaltrials.gov/show/NCT03926143,Drug: BAY94-9343 (Anetumab ravtansine),NA,Yes,NA
im,NCT03926416,https://clinicaltrials.gov/show/NCT03926416,Biological: CodaVax-H1N1;Biological: Fluzone quadrivalent,Yes,NA,NA
im,NCT03927131,https://clinicaltrials.gov/show/NCT03927131,Biological: QIV-IB;Biological: TIVV-IB;Biological: TIVY-IB;Biological: QIV-IB Lot A;Biological: QIV-IB Lot B;Biological: QIV-IB Lot C,NA,NA,NA
main,NCT03930446,https://clinicaltrials.gov/show/NCT03930446,Drug: Ethanol;Other: Placebo,NA,NA,NA
main,NCT03930732,https://clinicaltrials.gov/show/NCT03930732,Drug: Dupilumab SAR231893;Drug: Inhaled Corticosteroid;Drug: Inhaled Long-Acting Beta Agonist;Drug: Inhaled Long-Acting Muscarinic Antagonist;Drug: Placebo,NA,Yes,NA
main,NCT03932253,https://clinicaltrials.gov/show/NCT03932253,Drug: FCN-159,NA,NA,NA
main,NCT03932435,https://clinicaltrials.gov/show/NCT03932435,Drug: Fisrt period TWLO_C;Drug: Fisrt period TWLO;Other: Washout period;Drug: Second period TWLO_C;Drug: Second period TWLO,NA,NA,NA
main,NCT03932669,https://clinicaltrials.gov/show/NCT03932669,Drug: Nilotinib,NA,NA,NA
main,NCT03936907,https://clinicaltrials.gov/show/NCT03936907,Drug: OWCP Orally Disintegrating Tablet;Drug: Sativex,NA,NA,NA
main,NCT03938272,https://clinicaltrials.gov/show/NCT03938272,Biological: Oxabact OC5 - Oxalobacter formigenes Strain HC-1,NA,NA,NA
main,NCT03939975,https://clinicaltrials.gov/show/NCT03939975,Drug: pembrolizumab or nivolumab or JS001,NA,Yes,NA
main,NCT03940807,https://clinicaltrials.gov/show/NCT03940807,Drug: 11.25mg GnRH agonist;Drug: 0.1 mg GnRH agonist;Drug: 25 µg transdermal oestradiol,NA,NA,NA
main,NCT03941132,https://clinicaltrials.gov/show/NCT03941132,Drug: Ustekinumab;Drug: Placebo,NA,Yes,NA
main,NCT03941561,https://clinicaltrials.gov/show/NCT03941561,Drug: S-1 for 9 months;Drug: S-1 for 1 year,NA,NA,NA
main,NCT03941574,https://clinicaltrials.gov/show/NCT03941574,Drug: HLX10,NA,NA,NA
main,NCT03943290,https://clinicaltrials.gov/show/NCT03943290,Drug: ACE-083,NA,NA,NA
main,NCT03943446,https://clinicaltrials.gov/show/NCT03943446,Drug: TAK-018;Drug: TAK-018 Placebo,NA,NA,NA
main,NCT03943576,https://clinicaltrials.gov/show/NCT03943576,Drug: GXCPC1;Device: HA,NA,NA,NA
main,NCT03944577,https://clinicaltrials.gov/show/NCT03944577,Drug: Evolocumab (Repatha),NA,Yes,NA
main,NCT03944759,https://clinicaltrials.gov/show/NCT03944759,Procedure: serratus anterior plan block,NA,NA,NA
main,NCT03944980,https://clinicaltrials.gov/show/NCT03944980,Drug: Docetaxel;Biological: PD1-T cells,NA,NA,NA
main,NCT03945526,https://clinicaltrials.gov/show/NCT03945526,Drug: Astaxanthine;Drug: Placebo Oral Tablet,NA,NA,NA
im,NCT03945825,https://clinicaltrials.gov/show/NCT03945825,Drug: AF03;Biological: Delta Inulin-CpG55.2;Biological: Influenza Virus Quadrivalent Inactivated Vaccine;Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine,Yes,NA,NA
main,NCT03946722,https://clinicaltrials.gov/show/NCT03946722,Drug: GnRH analogue downregulation;Procedure: Uterine flushing;Other: Patient questionnaire,NA,NA,NA
im,NCT03947411,https://clinicaltrials.gov/show/NCT03947411,Drug: Oseltamivir Phosphate;Drug: Xiyanping injection+Oseltamivir Phosphate,NA,Yes,NA
main,NCT03949426,https://clinicaltrials.gov/show/NCT03949426,Drug: KPG-818,NA,NA,NA
main,NCT03953599,https://clinicaltrials.gov/show/NCT03953599,Biological: CD19-STAR-T cells,NA,NA,NA
im,NCT03953677,https://clinicaltrials.gov/show/NCT03953677,Drug: Dexmedetomidine 100 Mcg/mL Intravenous Solution;Drug: 5% glucose Infusion solution,NA,NA,NA
main,NCT03955445,https://clinicaltrials.gov/show/NCT03955445,Drug: LNP023,NA,NA,NA
main,NCT03957499,https://clinicaltrials.gov/show/NCT03957499,Drug: Bupivacaine;Drug: Dexamethasone/bupivacaine;Drug: Magnesium Sulfate/bupivacaine,NA,Yes,NA
main,NCT03958890,https://clinicaltrials.gov/show/NCT03958890,Drug: HLX10 100 mg in 10 ml Injection;Drug: Placebos,NA,NA,NA
im,NCT03962725,https://clinicaltrials.gov/show/NCT03962725,Drug: Neuromuscular Blocking Agents;Drug: Anesthetic Adjuncts,NA,NA,NA
main,NCT03963336,https://clinicaltrials.gov/show/NCT03963336,Drug: LMWH;Drug: acetazolamide,NA,NA,NA
main,NCT03964207,https://clinicaltrials.gov/show/NCT03964207,Drug: Tiotropium Respimat® (T1);Drug: Tiotropium Handihaler® (T2),NA,NA,NA
im,NCT03965195,https://clinicaltrials.gov/show/NCT03965195,Biological: Recombinant Influenza Vaccine;Biological: Standard Dose Quadrivalent Influenza Vaccine,Yes,NA,NA
im,NCT03969212,https://clinicaltrials.gov/show/NCT03969212,Drug: Baloxavir Marboxil;Drug: Placebo,NA,Yes,NA
main,NCT03969849,https://clinicaltrials.gov/show/NCT03969849,Drug: REGN5713-5714-5715;Drug: Matching placebo,NA,NA,NA
main,NCT03971825,https://clinicaltrials.gov/show/NCT03971825,Drug: CC-92252;Other: Placebo,NA,NA,NA
main,NCT03973112,https://clinicaltrials.gov/show/NCT03973112,Drug: HLX10+HLX04,NA,NA,NA
main,NCT03973632,https://clinicaltrials.gov/show/NCT03973632,Drug: SH-1028 Tablets,NA,NA,NA
main,NCT03974854,https://clinicaltrials.gov/show/NCT03974854,Drug: XELOXIRI-3;Drug: Gemcitabine,NA,NA,NA
main,NCT03975010,https://clinicaltrials.gov/show/NCT03975010,Drug: Buprenorphine Transdermal Patch,NA,NA,NA
main,NCT03977272,https://clinicaltrials.gov/show/NCT03977272,Drug: Combination drug;Drug: Chemotherapy,NA,NA,NA
im,NCT03978559,https://clinicaltrials.gov/show/NCT03978559,Drug: caspofungin;Drug: TMP/SMZ(trimethoprim/sulfisoxazole);Drug: Methylprednisolone,NA,NA,NA
im,NCT03978845,https://clinicaltrials.gov/show/NCT03978845,Drug: Lidocaine,NA,Yes,NA
main,NCT03979365,https://clinicaltrials.gov/show/NCT03979365,Drug: Envarsus XR;Drug: Tacrolimus twice daily,NA,NA,NA
main,NCT03980691,https://clinicaltrials.gov/show/NCT03980691,Biological: Chidamide with CAR-T or TCR-T cell therapy,NA,NA,NA
main,NCT03981081,https://clinicaltrials.gov/show/NCT03981081,Drug: Prednisone,NA,NA,NA
im,NCT03981341,https://clinicaltrials.gov/show/NCT03981341,Drug: Duavive (0.45 estrogens mg and 20 mg bazedoxifene),NA,NA,NA
main,NCT03981627,https://clinicaltrials.gov/show/NCT03981627,Drug: ADO09 formulation;Drug: NovoRapid®,NA,NA,NA
main,NCT03981822,https://clinicaltrials.gov/show/NCT03981822,Combination Product: VP-102 and applicator,NA,NA,NA
main,NCT03982069,https://clinicaltrials.gov/show/NCT03982069,Biological: FluMist live attenuated influenza vaccine;Biological: Flucelvax inactivated influenza vaccine,Yes,NA,NA
im,NCT03982069,https://clinicaltrials.gov/show/NCT03982069,Biological: FluMist live attenuated influenza vaccine;Biological: Flucelvax inactivated influenza vaccine,Yes,NA,NA
main,NCT03983395,https://clinicaltrials.gov/show/NCT03983395,"Biological: ISB 1302 250 ng/kg;Biological: ISB 1302 325 ng/kg;Biological: ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22;Biological: ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22;Biological: ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22;Biological: ISB 1302 325ng/kg D1;550 ng/kg D8;900 ng/kg D15,22;Biological: ISB 1302 escalating doses,1200 ng/kg D15,22;Biological: ISB 1302 at the MTD and/or RP2D dose",NA,NA,NA
main,NCT03983759,https://clinicaltrials.gov/show/NCT03983759,Drug: sintilimab maintenance,NA,Yes,NA
main,NCT03985007,https://clinicaltrials.gov/show/NCT03985007,Drug: CDIAG regimen,NA,NA,NA
main,NCT03986385,https://clinicaltrials.gov/show/NCT03986385,Drug: Apatinib Capecitabine Oxaliplatin;Drug: Capecitabine Oxaliplatin,NA,NA,NA
main,NCT03987763,https://clinicaltrials.gov/show/NCT03987763,Drug: IDP-122 Lotion,NA,NA,NA
main,NCT03989037,https://clinicaltrials.gov/show/NCT03989037,Drug: SIBP-01;Drug: Herceptin;Drug: Docetaxel;Drug: Carboplatin,NA,NA,NA
main,NCT03989440,https://clinicaltrials.gov/show/NCT03989440,Drug: AXER-204;Drug: Placebo,NA,NA,NA
im,NCT03989531,https://clinicaltrials.gov/show/NCT03989531,Biological: Adrecizumab;Drug: Placebo,NA,Yes,NA
im,NCT03989609,https://clinicaltrials.gov/show/NCT03989609,Drug: Dexmedetomidine Injection [Precedex];Drug: Midazolam,NA,NA,NA
im,NCT03990467,https://clinicaltrials.gov/show/NCT03990467,"Biological: Plasma dosage of amikacin, piperacillin and tazobactam",NA,Yes,NA
main,NCT03990649,https://clinicaltrials.gov/show/NCT03990649,Drug: TAK-935;Drug: TAK-935 Placebo,NA,NA,NA
main,NCT03992872,https://clinicaltrials.gov/show/NCT03992872,Biological: Chikungunya,NA,NA,NA
main,NCT03993262,https://clinicaltrials.gov/show/NCT03993262,Drug: Bortezomib;Drug: Placebo,NA,NA,NA
main,NCT03994913,https://clinicaltrials.gov/show/NCT03994913,Biological: CAR-CD19 T Cells,NA,NA,NA
main,NCT03994965,https://clinicaltrials.gov/show/NCT03994965,Drug: Pimavanserin 34 milligrams (MG) [Nuplazid],NA,NA,NA
im,NCT03995628,https://clinicaltrials.gov/show/NCT03995628,Drug: Dexamethasone,NA,Yes,NA
main,NCT03995732,https://clinicaltrials.gov/show/NCT03995732,Drug: PC-SOD;Drug: placebo,NA,NA,NA
main,NCT03997032,https://clinicaltrials.gov/show/NCT03997032,Dietary Supplement: Ocufolin,NA,NA,NA
main,NCT03997123,https://clinicaltrials.gov/show/NCT03997123,Drug: Capivasertib;Drug: Paclitaxel;Drug: Placebo,NA,NA,NA
main,NCT03999216,https://clinicaltrials.gov/show/NCT03999216,Drug: Loop Diuretics vs. loop + thiazide diuretics,NA,NA,NA
im,NCT03999554,https://clinicaltrials.gov/show/NCT03999554,Biological: LD Sing2016 M2SR H3N2 influenza vaccine;Biological: MD Sing2016 M2SR H3N2 influenza vaccine;Biological: HD Sing2016 M2SR H3N2 influenza vaccine;Biological: LD Bris10 M2SR H3N2 influenza vaccine;Other: Placebo,Yes,NA,NA
main,NCT04000919,https://clinicaltrials.gov/show/NCT04000919,Drug: 5HTP;Drug: L-DOPA;Drug: Placebo oral tablet;Drug: Carbidopa,NA,NA,NA
main,NCT04003350,https://clinicaltrials.gov/show/NCT04003350,Drug: Oxycodone;Drug: Tramadol;Drug: Tylenol;Drug: Meloxicam;Drug: Gabapentin;Drug: Metaxalone;Drug: Esomeprazole 20mg,NA,NA,NA
main,NCT04008706,https://clinicaltrials.gov/show/NCT04008706,Drug: Acalabrutinib,NA,NA,NA
im,NCT04009759,https://clinicaltrials.gov/show/NCT04009759,Drug: Morphine;Drug: Ketamine Injectable Solution;Drug: Saline 0.9%,NA,NA,NA
main,NCT04012424,https://clinicaltrials.gov/show/NCT04012424,"Drug: curcumin group:Curcumin is an ancient coloring spice . Interestingly, it has various pharmacological activities including analgesic, anti-inf;Dietary Supplement: 400mg starch",NA,NA,Yes
main,NCT04012775,https://clinicaltrials.gov/show/NCT04012775,Biological: Insulin Humulin® NPH;Biological: Insulin Rinsulin® NPH,NA,NA,NA
main,NCT04014244,https://clinicaltrials.gov/show/NCT04014244,Drug: Corticosteroid vs. Dextrose;Procedure: Corticosteroid or Dextrose vs. Surgery,NA,NA,NA
im,NCT04014413,https://clinicaltrials.gov/show/NCT04014413,Procedure: Fecal Microbiota Transplantation,NA,NA,NA
main,NCT04016142,https://clinicaltrials.gov/show/NCT04016142,Drug: Carboplatin-Paclitaxel adjuvant chemotherapy,NA,NA,NA
main,NCT04018157,https://clinicaltrials.gov/show/NCT04018157,Drug: Ketamine and dexmedetomidine and propofol and 0.9%saline,NA,NA,NA
im,NCT04019106,https://clinicaltrials.gov/show/NCT04019106,Drug: Budesonide in bovine lipid extract surfactant (BLES),NA,NA,NA
main,NCT04019717,https://clinicaltrials.gov/show/NCT04019717,Drug: AT-527;Drug: Daclatasvir;Drug: AT-527;Drug: Daclatasvir,NA,Yes,NA
main,NCT04019834,https://clinicaltrials.gov/show/NCT04019834,Drug: regional nerve block with local anesthesia of bupivacaine with steroid;Other: Placebo regional nerveblock with normal saline,NA,Yes,NA
main,NCT04022928,https://clinicaltrials.gov/show/NCT04022928,Other: PRP,NA,NA,NA
main,NCT04022941,https://clinicaltrials.gov/show/NCT04022941,Drug: Sodium Benzoate;Other: Powdered table sugar as palcebo,NA,NA,NA
main,NCT04022967,https://clinicaltrials.gov/show/NCT04022967,Drug: dolutegravir;Drug: atazanavir boosted with ritonavir;Drug: tenofovir + lamivudine +efavirenz;Drug: Lamivudine,NA,Yes,NA
main,NCT04023149,https://clinicaltrials.gov/show/NCT04023149,Drug: recombinant human interleukin-2 (rhIL-2);Drug: placebo,NA,NA,NA
main,NCT04023864,https://clinicaltrials.gov/show/NCT04023864,Dietary Supplement: Platycodon Grandiflorus Extract(GCWB107);Dietary Supplement: Placebo,NA,NA,NA
im,NCT04024137,https://clinicaltrials.gov/show/NCT04024137,Drug: ZSP1273 200 mg;Drug: Placebo;Drug: ZSP1273-400 mg;Drug: Placebo;Drug: ZSP1273-600 mg;Drug: Placebo;Drug: Placebo,NA,NA,NA
im,NCT04024228,https://clinicaltrials.gov/show/NCT04024228,"Biological: Standard-Dose influenza virus surface antigens (haemagglutinin and neuraminidase), Inactivated, Influenza Vaccine Quadrivalent, 2019-2020 Northern Hemisphere Strains QIV-SD;Biological: High-Dose Influenza Vaccine (split virion, inactivated), Quadrivalent (QIV-HD) 2019-2020 Northern Hemisphere formulation QIV-HD",Yes,NA,NA
main,NCT04024800,https://clinicaltrials.gov/show/NCT04024800,Biological: AE37 Peptide vaccine;Biological: Pembrolizumab,Yes,Yes,NA
main,NCT04027751,https://clinicaltrials.gov/show/NCT04027751,Drug: Tropisetron;Drug: Placebos,NA,NA,NA
main,NCT04029545,https://clinicaltrials.gov/show/NCT04029545,Device: PN40082,NA,NA,NA
im,NCT04031573,https://clinicaltrials.gov/show/NCT04031573,Drug: Ivabradine;Drug: Ivabradine;Drug: Placebo,NA,NA,NA
main,NCT04032093,https://clinicaltrials.gov/show/NCT04032093,Biological: RSV vaccine;Biological: Placebo,Yes,NA,NA
main,NCT04032626,https://clinicaltrials.gov/show/NCT04032626,Drug: Lenalidomide 10 mg;Drug: Placebos,NA,NA,NA
main,NCT04033250,https://clinicaltrials.gov/show/NCT04033250,Drug: Sodium Picosulfate / Magnesium Oxide / Citric Acid in two split doses + one dose of polyethylene glycol + two Bisacodyl tablets day before the procedure,NA,Yes,NA
main,NCT04034836,https://clinicaltrials.gov/show/NCT04034836,Drug: Scalp blocks with ropivacaine plus parecoxib;Drug: Scalp blocks with ropivacaine and intravenous parecoxib;Drug: Scalp blocks with ropivacaine and intravenous saline,NA,Yes,NA
main,NCT04036110,https://clinicaltrials.gov/show/NCT04036110,Dietary Supplement: Vitamin C 500 mg;Dietary Supplement: Vitamin C 1000 mg;Other: Placebo,NA,NA,Yes
main,NCT04036721,https://clinicaltrials.gov/show/NCT04036721,Drug: Prolonged glucocorticosteroid (prednisone) regimen;Drug: Short glucocorticosteroid (prednisone) regimen,NA,NA,NA
main,NCT04037072,https://clinicaltrials.gov/show/NCT04037072,Drug: Mitomycin C;Other: Control,NA,Yes,NA
main,NCT04038970,https://clinicaltrials.gov/show/NCT04038970,"Biological: KN019, 5mg/kg;Biological: KN019, 10 mg/kg;Biological: Placebo;Combination Product: Methotrexate",NA,NA,NA
im,NCT04040621,https://clinicaltrials.gov/show/NCT04040621,Drug: Ceftazidime-avibactam,NA,NA,NA
im,NCT04043923,https://clinicaltrials.gov/show/NCT04043923,Drug: Norketotifen;Drug: Placebo,NA,NA,NA
main,NCT04044001,https://clinicaltrials.gov/show/NCT04044001,Drug: BTZ-043;Drug: Rifafour e-275®;Drug: Probe Drug Cocktail;Drug: Dolutegravir 50mg Tab,NA,Yes,NA
im,NCT04044352,https://clinicaltrials.gov/show/NCT04044352,Biological: Influenza A/Bethesda/MM2/H1N1 Challenge,NA,NA,NA
main,NCT04044859,https://clinicaltrials.gov/show/NCT04044859,Genetic: Autologous genetically modified ADP-A2M4CD8 cells,NA,NA,NA
main,NCT04046978,https://clinicaltrials.gov/show/NCT04046978,"Other: ConM SOSIP 50 ug and ConS UFO 50 ug;Other: Mos3.1 100 ug;Other: Mos3.2 100 ug;Other: Mos3.3 100 ug;Other: Mos3.1 33 ug, Mos3.2 33 ug and Mos3.3 33 ug",NA,NA,NA
main,NCT04049253,https://clinicaltrials.gov/show/NCT04049253,Drug: Phosphate Buffer Solution,NA,NA,NA
main,NCT04050410,https://clinicaltrials.gov/show/NCT04050410,Drug: Moxonidine;Drug: Placebo,NA,NA,NA
im,NCT04057872,https://clinicaltrials.gov/show/NCT04057872,Procedure: Therapeutic plasma exchange,NA,Yes,NA
main,NCT04059900,https://clinicaltrials.gov/show/NCT04059900,"Drug: STW5 (Iberogast®, BAY98-7411);Drug: Placebo",NA,NA,NA
main,NCT04060511,https://clinicaltrials.gov/show/NCT04060511,Drug: HS-10342,NA,NA,NA
main,NCT04061057,https://clinicaltrials.gov/show/NCT04061057,Drug: Lidocaine;Drug: Normal saline,NA,Yes,NA
main,NCT04061161,https://clinicaltrials.gov/show/NCT04061161,Drug: Tiotropium Bromide,NA,NA,NA
main,NCT04063358,https://clinicaltrials.gov/show/NCT04063358,Drug: Lucentis,NA,NA,NA
main,NCT04064190,https://clinicaltrials.gov/show/NCT04064190,Drug: Vactosertib(TEW-7197)/ Durvalumab,NA,Yes,NA
main,NCT04064411,https://clinicaltrials.gov/show/NCT04064411,Combination Product: abaloparatide solid microstructured transdermal system;Combination Product: abaloparatide-SC,NA,NA,NA
im,NCT04064684,https://clinicaltrials.gov/show/NCT04064684,Drug: Budesonide;Drug: Placebo,NA,NA,NA
main,NCT04064879,https://clinicaltrials.gov/show/NCT04064879,Other: AD-SVF,NA,NA,NA
main,NCT04066244,https://clinicaltrials.gov/show/NCT04066244,Drug: BLZ945,NA,NA,NA
main,NCT04067011,https://clinicaltrials.gov/show/NCT04067011,Drug: Ciprofloxacin 500Mg Tablet;Drug: Doxycycline 100Mg Tablet;Biological: AV7909,NA,Yes,NA
main,NCT04068948,https://clinicaltrials.gov/show/NCT04068948,Drug: Meperidine;Drug: Hydroxyzine;Drug: Midazolam,NA,NA,NA
main,NCT04069286,https://clinicaltrials.gov/show/NCT04069286,Drug: Oral Aroeira/ Amoxicillin/ Claritromycin;Drug: Omeprazole/ Amoxicillin/ Claritromycin,NA,Yes,NA
main,NCT04070313,https://clinicaltrials.gov/show/NCT04070313,Drug: S-1,NA,NA,NA
main,NCT04071626,https://clinicaltrials.gov/show/NCT04071626,Drug: Ertugliflozin 5 mg;Drug: Placebo oral tablet,NA,NA,NA
im,NCT04074928,https://clinicaltrials.gov/show/NCT04074928,Biological: QIVc;Biological: Comparator QIV,NA,NA,NA
main,NCT04075266,https://clinicaltrials.gov/show/NCT04075266,Drug: Ocrelizumab,NA,Yes,NA
main,NCT04077424,https://clinicaltrials.gov/show/NCT04077424,Biological: Fluzone-High Dose Quadrivalent;Biological: Fluad;Biological: Flublock,Yes,NA,NA
im,NCT04080245,https://clinicaltrials.gov/show/NCT04080245,Biological: Treatment Group Live Attenuated Flu Vaccine (LAIV),Yes,NA,NA
main,NCT04081610,https://clinicaltrials.gov/show/NCT04081610,Drug: lagricel ofteno multidose;Drug: lagricel ofteno single dose,NA,NA,NA
main,NCT04083014,https://clinicaltrials.gov/show/NCT04083014,Drug: combination of a single dose anti-CD20 antibody and bortezomib,NA,NA,NA
main,NCT04087252,https://clinicaltrials.gov/show/NCT04087252,Biological: tumor neoantigen,NA,NA,NA
im,NCT04087460,https://clinicaltrials.gov/show/NCT04087460,Biological: Protein based pneumococcal vaccine(Low dose);Biological: Protein based pneumococcal vaccine placebo(Low dose);Biological: Protein based pneumococcal vaccine(Middle dose);Biological: Protein based pneumococcal vaccine placebo(Middle dose);Biological: Protein based pneumococcal vaccine(High dose);Biological: Protein based pneumococcal vaccine placebo(High dose),Yes,NA,NA
main,NCT04088058,https://clinicaltrials.gov/show/NCT04088058,Drug: GXHPC1,NA,NA,NA
main,NCT04088396,https://clinicaltrials.gov/show/NCT04088396,Drug: Baricitinib;Drug: Placebo,NA,NA,NA
im,NCT04089072,https://clinicaltrials.gov/show/NCT04089072,Drug: Methylene Blue;Drug: Phenylephrine,NA,NA,NA
main,NCT04090190,https://clinicaltrials.gov/show/NCT04090190,"Drug: Oxybutynin, Solifenacin, Tolterodine, Sanctura or Toviaz",NA,Yes,NA
main,NCT04090736,https://clinicaltrials.gov/show/NCT04090736,Drug: Pevonedistat;Drug: Azacitidine,NA,NA,NA
im,NCT04091425,https://clinicaltrials.gov/show/NCT04091425,Drug: TAK-925;Drug: Placebo,NA,NA,NA
main,NCT04092686,https://clinicaltrials.gov/show/NCT04092686,Drug: SEP-363856 75mg;Drug: SEP-363856 100mg;Drug: Placebo,NA,NA,NA
main,NCT04093167,https://clinicaltrials.gov/show/NCT04093167,Drug: Pembrolizumab,NA,Yes,NA
main,NCT04096417,https://clinicaltrials.gov/show/NCT04096417,Drug: Pemigatinib;Other: Quality-of-Life Assessment,NA,NA,NA
main,NCT04097379,https://clinicaltrials.gov/show/NCT04097379,Drug: LRX712;Drug: Placebo,NA,NA,NA
main,NCT04100473,https://clinicaltrials.gov/show/NCT04100473,Drug: Inhaled Human Insulin;Drug: Insulin Lispro (Humalog U-100),NA,NA,NA
im,NCT04101435,https://clinicaltrials.gov/show/NCT04101435,Biological: AdimFlu-S (QIS),NA,NA,NA
main,NCT04101643,https://clinicaltrials.gov/show/NCT04101643,Drug: evolocumab,NA,Yes,NA
main,NCT04101721,https://clinicaltrials.gov/show/NCT04101721,Drug: aflibercept;Procedure: laser photocoagulation,NA,NA,NA
main,NCT04102150,https://clinicaltrials.gov/show/NCT04102150,Drug: Valemetostat Tosylate,NA,NA,NA
main,NCT04104672,https://clinicaltrials.gov/show/NCT04104672,Drug: AB680;Drug: Zimberelimab;Drug: Nab-paclitaxel;Drug: Gemcitabine,NA,Yes,NA
main,NCT04105972,https://clinicaltrials.gov/show/NCT04105972,Drug: ELX/TEZ/IVA;Drug: TEZ/IVA;Drug: IVA,NA,NA,NA
main,NCT04106362,https://clinicaltrials.gov/show/NCT04106362,Biological: Cetuximab;Drug: Cisplatin;Other: Quality-of-Life Assessment;Other: Questionnaire Administration;Radiation: Radiation Therapy,NA,Yes,NA
im,NCT04106817,https://clinicaltrials.gov/show/NCT04106817,"Biological: Live, wild-type A/California/H1N1 2009 influenza virus",NA,NA,NA
main,NCT04108325,https://clinicaltrials.gov/show/NCT04108325,Drug: YY-20394,NA,NA,NA
im,NCT04108845,https://clinicaltrials.gov/show/NCT04108845,Biological: 15-Valent Pneumococcal Conjugate Vaccine,Yes,NA,NA
im,NCT04109222,https://clinicaltrials.gov/show/NCT04109222,"Biological: Fluzone Quadrivalent vaccine, 2019-2020 formulation;Biological: Fluzone High-Dose vaccine, 2019-2020 formulation",Yes,NA,NA
main,NCT04109859,https://clinicaltrials.gov/show/NCT04109859,Drug: Saline;Drug: Methylene Blue,NA,NA,NA
main,NCT04111419,https://clinicaltrials.gov/show/NCT04111419,Drug: Amlodipine/Atorvastatin 5 Mg-20 Mg ORAL TABLET;Drug: Amlodipine/Atorvastatin 5 Mg-10 Mg ORAL TABLET;Drug: Allisartan Isoproxil,NA,NA,NA
main,NCT04112147,https://clinicaltrials.gov/show/NCT04112147,Drug: Antroquinonol capsule 100mg;Drug: Antroquinonol capsule 200mg;Drug: Placebo oral capsule,NA,NA,NA
im,NCT04115514,https://clinicaltrials.gov/show/NCT04115514,Drug: Liothyronine Sodium (T3) (modified formulation),NA,NA,NA
im,NCT04115878,https://clinicaltrials.gov/show/NCT04115878,Drug: Atomoxetine and oxybutynin (ato-oxy),NA,NA,NA
main,NCT04116775,https://clinicaltrials.gov/show/NCT04116775,Biological: Fecal microbiota transplant;Drug: Pembrolizumab;Drug: Enzalutamide,NA,Yes,NA
main,NCT04118556,https://clinicaltrials.gov/show/NCT04118556,Biological: Decidua Stroma Cells (DSC);Drug: Best available Treatment (BAT),NA,NA,NA
im,NCT04120194,https://clinicaltrials.gov/show/NCT04120194,Biological: NanoFlu;Biological: Fluzone Quadrivalent,Yes,NA,NA
im,NCT04123444,https://clinicaltrials.gov/show/NCT04123444,Drug: Iloprost;Drug: Isotonic saline,NA,NA,NA
main,NCT04124211,https://clinicaltrials.gov/show/NCT04124211,Biological: Fecal Microbiota Transplantation (FMT),NA,NA,NA
main,NCT04124497,https://clinicaltrials.gov/show/NCT04124497,Drug: Daratumumab;Drug: Pomalidomide;Drug: Dexamethasone,NA,Yes,NA
main,NCT04124666,https://clinicaltrials.gov/show/NCT04124666,Biological: Granulocytes,NA,NA,NA
main,NCT04124926,https://clinicaltrials.gov/show/NCT04124926,Drug: Vonoprazan;Drug: Lansoprazole,NA,NA,NA
main,NCT04125511,https://clinicaltrials.gov/show/NCT04125511,Drug: 68Ga-FAPI,NA,NA,NA
main,NCT04126317,https://clinicaltrials.gov/show/NCT04126317,Drug: aflibercept;Drug: High-dose aflibercept,NA,NA,NA
main,NCT04128423,https://clinicaltrials.gov/show/NCT04128423,Biological: AMV564,NA,NA,NA
main,NCT04128540,https://clinicaltrials.gov/show/NCT04128540,Drug: Fentanyl;Procedure: Erector spinae plane block,NA,NA,NA
main,NCT04128787,https://clinicaltrials.gov/show/NCT04128787,Drug: AG881 Formulation 1;Drug: AG881 Formulation 2;Drug: Omeprazole,NA,NA,NA
main,NCT04128800,https://clinicaltrials.gov/show/NCT04128800,Drug: Apatinib S-1,NA,NA,NA
main,NCT04133311,https://clinicaltrials.gov/show/NCT04133311,Drug: DE-130A;Drug: Xalatan®,NA,NA,NA
im,NCT04133584,https://clinicaltrials.gov/show/NCT04133584,Biological: EV71 +SIV;Biological: EV71;Biological: SIV,NA,NA,NA
im,NCT04134403,https://clinicaltrials.gov/show/NCT04134403,Drug: STASIS,NA,NA,NA
main,NCT04134650,https://clinicaltrials.gov/show/NCT04134650,Combination Product: Linagliptin + metformin;Drug: Metformin,NA,NA,NA
im,NCT04136080,https://clinicaltrials.gov/show/NCT04136080,Other: vasopressors,NA,NA,NA
main,NCT04138056,https://clinicaltrials.gov/show/NCT04138056,Biological: RSVPreF3 formulation 3;Biological: RSVPreF3 formulation 2;Biological: Boostrix-ex-US;Procedure: Boostrix-US;Drug: Placebo,NA,NA,NA
main,NCT04138719,https://clinicaltrials.gov/show/NCT04138719,Drug: Nab-paclitaxel + Carboplatin;Drug: Nab-paclitaxel + Epirubicin,NA,Yes,NA
main,NCT04139070,https://clinicaltrials.gov/show/NCT04139070,Drug: Bleomycin,NA,Yes,NA
main,NCT04139122,https://clinicaltrials.gov/show/NCT04139122,Drug: SJP-0132;Drug: Placebo,NA,NA,NA
main,NCT04139655,https://clinicaltrials.gov/show/NCT04139655,Drug: Colchicine 0.6 mg;Drug: Placebo oral tablet,NA,NA,NA
main,NCT04139681,https://clinicaltrials.gov/show/NCT04139681,Drug: A. Vogels Sore Throat lozenges,NA,NA,NA
main,NCT04140396,https://clinicaltrials.gov/show/NCT04140396,Drug: Saline infusion;Drug: Lidocaine infusion,NA,Yes,NA
main,NCT04143191,https://clinicaltrials.gov/show/NCT04143191,Drug: Sorafenib;Procedure: Transarterial chemoembolization,NA,NA,NA
main,NCT04145037,https://clinicaltrials.gov/show/NCT04145037,Drug: AVR-RD-02,NA,NA,NA
main,NCT04145115,https://clinicaltrials.gov/show/NCT04145115,Biological: Ipilimumab;Biological: Nivolumab,NA,Yes,NA
main,NCT04147572,https://clinicaltrials.gov/show/NCT04147572,Drug: Placebo Tiotropium inhalation powder type A;Drug: Placebo Spiriva capsule;Drug: Placebo Tiotropium inhalation powder type B;Device: Substudy Placebo Tiotropium Easyhaler;Device: Substudy Placebo Spiriva® via HandiHaler,NA,NA,NA
main,NCT04148118,https://clinicaltrials.gov/show/NCT04148118,Biological: BW-1010: 50 µg - sprayer - IN;Biological: BW-1010: 50 µg - pipette - IN;Biological: BW-1010: 100 µg - sprayer - IN;Biological: BW-1010: 100 µg - pipette - IN;Biological: Saline (Placebo) - sprayer - IN;Biological: Saline (Placebo) - pipette - IN;Biological: BioThrax (positive control) - SC,NA,NA,NA
main,NCT04149080,https://clinicaltrials.gov/show/NCT04149080,Procedure: SIM + polypropylene membrane;Procedure: Placebo,NA,NA,NA
main,NCT04149678,https://clinicaltrials.gov/show/NCT04149678,Drug: Ozanimod;Drug: Cyclosporine,NA,NA,NA
main,NCT04150640,https://clinicaltrials.gov/show/NCT04150640,Drug: Nal-IRI;Drug: Oxaliplatin;Drug: 5-FU;Drug: Trastuzumab,NA,Yes,NA
main,NCT04152915,https://clinicaltrials.gov/show/NCT04152915,Drug: Semaglutide,NA,NA,NA
main,NCT04154293,https://clinicaltrials.gov/show/NCT04154293,Drug: Isotretinoin;Other: Vehicle,NA,NA,NA
main,NCT04154943,https://clinicaltrials.gov/show/NCT04154943,Drug: Cemiplimab,NA,Yes,NA
main,NCT04154956,https://clinicaltrials.gov/show/NCT04154956,Drug: SAR408701;Drug: Docetaxel,NA,NA,NA
main,NCT04157686,https://clinicaltrials.gov/show/NCT04157686,Drug: MT10109L,NA,NA,NA
main,NCT04157998,https://clinicaltrials.gov/show/NCT04157998,Drug: normal saline;Drug: Metoclopramide 10mg,NA,NA,NA
im,NCT04157998,https://clinicaltrials.gov/show/NCT04157998,Drug: normal saline;Drug: Metoclopramide 10mg,NA,NA,NA
main,NCT04158713,https://clinicaltrials.gov/show/NCT04158713,Drug: Intermittent Preventive Therapy with Dihydroartemisinin-Piperaquine,NA,Yes,NA
main,NCT04161339,https://clinicaltrials.gov/show/NCT04161339,Drug: Hydroxychloroquine;Drug: Placebo oral tablet,NA,Yes,NA
im,NCT04161339,https://clinicaltrials.gov/show/NCT04161339,Drug: Hydroxychloroquine;Drug: Placebo oral tablet,NA,Yes,NA
main,NCT04162340,https://clinicaltrials.gov/show/NCT04162340,Biological: CD4 CAR T cells,NA,NA,NA
im,NCT04162743,https://clinicaltrials.gov/show/NCT04162743,Drug: Trazodone;Drug: Placebo oral tablet,NA,NA,NA
main,NCT04163458,https://clinicaltrials.gov/show/NCT04163458,"Drug: MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL;Drug: MENOPUR powder and solvent for solution for injection, 75 IU;Other: Placebo (for MENOPUR solution for injection in pre-filled pen);Other: Placebo (for MENOPUR powder and solvent for solution for injection)",NA,NA,NA
main,NCT04163835,https://clinicaltrials.gov/show/NCT04163835,Drug: Normal-dose Wenxin Granules;Drug: 1/2 Normal-dose Wenxin Granules;Drug: Twice Normal-dose Wenxin Granules;Drug: Placebo,NA,NA,NA
main,NCT04165356,https://clinicaltrials.gov/show/NCT04165356,Procedure: Mouth-rinse with 0.12% clorhexidine;Procedure: Mouth-rinse with isotonic solution with 1.5% sodium bicarbonate,NA,NA,NA
main,NCT04165590,https://clinicaltrials.gov/show/NCT04165590,Other: Plasmodium immunotherapy,NA,NA,NA
main,NCT04167033,https://clinicaltrials.gov/show/NCT04167033,Drug: Hormone replacement therapy:effect on ventricular repolarization;Diagnostic Test: ECG,NA,NA,NA
main,NCT04167761,https://clinicaltrials.gov/show/NCT04167761,Drug: Ertugliflozin;Drug: Glipizide,NA,NA,NA
im,NCT04168190,https://clinicaltrials.gov/show/NCT04168190,Drug: pPCV;Biological: Pneumovax™23,NA,NA,NA
main,NCT04168346,https://clinicaltrials.gov/show/NCT04168346,Drug: Ferric carboxymaltose;Drug: Placebos,NA,NA,NA
main,NCT04169711,https://clinicaltrials.gov/show/NCT04169711,Drug: ARO-HIF2,NA,NA,NA
main,NCT04171219,https://clinicaltrials.gov/show/NCT04171219,Biological: Pembrolizumab;Drug: Talabostat Mesylate,NA,Yes,NA
im,NCT04171674,https://clinicaltrials.gov/show/NCT04171674,Drug: Treatment with high-dose ceftobiprole (500mg loading dose followed by 2.5g under continuos infusion).,NA,NA,NA
main,NCT04172220,https://clinicaltrials.gov/show/NCT04172220,Drug: Midazolam;Procedure: PECS;Procedure: Opioid-free general anesthesia;Procedure: General anesthesia;Procedure: Postoperative analgesia,NA,NA,NA
main,NCT04172311,https://clinicaltrials.gov/show/NCT04172311,Other: Modified Atkins Diet;Drug: Levetiracetam,NA,NA,NA
main,NCT04172987,https://clinicaltrials.gov/show/NCT04172987,Drug: Tirzepatide;Drug: EE/NGM,NA,NA,NA
main,NCT04173312,https://clinicaltrials.gov/show/NCT04173312,Combination Product: Bupivacaine infusion;Combination Product: Saline,NA,Yes,NA
main,NCT04173338,https://clinicaltrials.gov/show/NCT04173338,Drug: Cabozantinib;Drug: Pemetrexed,NA,NA,NA
main,NCT04173780,https://clinicaltrials.gov/show/NCT04173780,Drug: Atropine 0.01%;Drug: Placebo,NA,NA,NA
main,NCT04179461,https://clinicaltrials.gov/show/NCT04179461,Drug: Cholecalciferol;Drug: antihistamine;Drug: Azithromycin;Drug: emollient cream;Drug: Fluticasone Propionate;Drug: Asthma Controller Medication,NA,Yes,NA
main,NCT04181385,https://clinicaltrials.gov/show/NCT04181385,Drug: Olanzapine 10 milligram;Drug: Bromocriptine 5 milligram;Drug: Placebo oral tablet,NA,NA,NA
main,NCT04181788,https://clinicaltrials.gov/show/NCT04181788,Drug: PF-06801591,NA,NA,NA
main,NCT04181827,https://clinicaltrials.gov/show/NCT04181827,Drug: JNJ-68284528;Drug: Pomalidomide;Drug: Bortezomib;Drug: Dexamethasone;Drug: Daratumumab,NA,Yes,NA
main,NCT04182191,https://clinicaltrials.gov/show/NCT04182191,Drug: Tenoxicam,NA,NA,NA
main,NCT04182568,https://clinicaltrials.gov/show/NCT04182568,Drug: nab-paclitaxel followed by anthracycline and cyclophosphamide;Drug: Docetaxel followed by anthracycline and cyclophosphamide,NA,NA,NA
main,NCT04183335,https://clinicaltrials.gov/show/NCT04183335,Drug: Dupilumab SAR231893;Drug: Placebo;Drug: Moisturizers;Drug: Low to medium potent topical corticosteroids;Drug: Topical calcineurin inhibitors,NA,Yes,NA
im,NCT04183725,https://clinicaltrials.gov/show/NCT04183725,Drug: Reduning injection;Drug: Oseltamivir phosphate granules,NA,Yes,NA
main,NCT04184232,https://clinicaltrials.gov/show/NCT04184232,Biological: Dendritic cells;Other: Standard treatment according to the Clinical protocols,NA,NA,NA
main,NCT04185025,https://clinicaltrials.gov/show/NCT04185025,Drug: Ceramides,NA,NA,NA
main,NCT04185090,https://clinicaltrials.gov/show/NCT04185090,Combination Product: ID1803;Combination Product: ID1801;Combination Product: ID1803+ID1801,NA,NA,NA
im,NCT04186494,https://clinicaltrials.gov/show/NCT04186494,Drug: Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml;Device: Continuous positive airway pressure treatment;Combination Product: Liraglutide and CPAP,NA,NA,NA
main,NCT04187404,https://clinicaltrials.gov/show/NCT04187404,Biological: EO2401,NA,NA,NA
main,NCT04188691,https://clinicaltrials.gov/show/NCT04188691,Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine(low);Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine(middle);Biological: Norovirus Bivalent (GI.1 / GII.4) Vaccine(high);Biological: Normal saline;Biological: Aluminum adjuvant,Yes,NA,NA
main,NCT04189952,https://clinicaltrials.gov/show/NCT04189952,Drug: Acalabrutinib;Drug: Rituximab;Drug: Ifosfamide;Drug: Carboplatin;Drug: Etoposide,NA,Yes,NA
main,NCT04191148,https://clinicaltrials.gov/show/NCT04191148,Drug: LBP-EC01;Drug: Lactated Ringers Solution for Injection,NA,NA,NA
main,NCT04191577,https://clinicaltrials.gov/show/NCT04191577,Drug: CVN424 Low Dose;Drug: CVN424 High Dose;Drug: Placebo,NA,NA,NA
main,NCT04192019,https://clinicaltrials.gov/show/NCT04192019,Drug: Micro-glucagon;Drug: Mini-glucagon,NA,NA,NA
main,NCT04192136,https://clinicaltrials.gov/show/NCT04192136,Dietary Supplement: Nicotinamide Riboside;Dietary Supplement: Placebo;Other: Exercise Intervention,NA,NA,NA
main,NCT04192370,https://clinicaltrials.gov/show/NCT04192370,Drug: Cannabidiol 600mg,NA,Yes,NA
im,NCT04193878,https://clinicaltrials.gov/show/NCT04193878,Drug: Inhaled budesonide and formoterol;Drug: Inhaled placebo,NA,NA,NA
main,NCT04195256,https://clinicaltrials.gov/show/NCT04195256,Drug: IN Ketodex (D4K2);Drug: IN Ketodex (D3K3);Drug: IN Ketodex (D2K4);Drug: IV Ketamine,NA,NA,NA
main,NCT04197687,https://clinicaltrials.gov/show/NCT04197687,Biological: Pertuzumab;Other: Placebo Administration;Biological: Sargramostim;Biological: Trastuzumab;Biological: Trastuzumab Emtansine;Biological: Vaccine Therapy,Yes,Yes,NA
im,NCT04199364,https://clinicaltrials.gov/show/NCT04199364,Drug: Poractant Alfa 80 mg/mL Intratracheal Suspension,NA,NA,NA
im,NCT04204967,https://clinicaltrials.gov/show/NCT04204967,Drug: Fentanyl Transdermal System;Drug: Remifentanil,NA,NA,NA
im,NCT04205136,https://clinicaltrials.gov/show/NCT04205136,Drug: Spironolactone;Drug: Placebo,NA,Yes,NA
main,NCT04208620,https://clinicaltrials.gov/show/NCT04208620,Drug: Placebo;Drug: Cotadutide,NA,NA,NA
im,NCT04208945,https://clinicaltrials.gov/show/NCT04208945,Drug: Colistin,NA,NA,NA
im,NCT04210349,https://clinicaltrials.gov/show/NCT04210349,Biological: Quadrivalent Influenza Vaccine;Biological: Trivalent Influenza Vaccine 1 SP Shz TIV1;Biological: Trivalent Influenza Vaccine 2 SP Shz TIV2,Yes,NA,NA
im,NCT04227093,https://clinicaltrials.gov/show/NCT04227093,Drug: Acetazolamide;Drug: Placebo,NA,NA,NA
im,NCT04230681,https://clinicaltrials.gov/show/NCT04230681,Drug: Hydromorphone;Drug: Fentanyl,NA,NA,NA
im,NCT04234217,https://clinicaltrials.gov/show/NCT04234217,Device: Continuous positive airway pressure;Other: Niacin,NA,Yes,NA
main,NCT04243434,https://clinicaltrials.gov/show/NCT04243434,Drug: Vincristine Sulfate Liposome;Combination Product: CHOP;Combination Product: R-CHOP,NA,NA,NA
covid,NCT04246242,https://clinicaltrials.gov/show/NCT04246242,"Drug: Conventional treatment group;Drug: arbidol,200mg,tid;Drug: arbidol,400mg,tid",NA,NA,NA
covid,NCT04252274,https://clinicaltrials.gov/show/NCT04252274,Drug: Darunavir and Cobicistat,NA,Yes,NA
covid,NCT04252664,https://clinicaltrials.gov/show/NCT04252664,Drug: Remdesivir;Drug: Remdesivir placebo,NA,Yes,NA
covid,NCT04252885,https://clinicaltrials.gov/show/NCT04252885,Drug: Lopinavir and Ritonavir Tablets;Drug: Arbidol,NA,Yes,NA
covid,NCT04257656,https://clinicaltrials.gov/show/NCT04257656,Drug: Remdesivir;Drug: Remdesivir placebo,NA,Yes,NA
covid,NCT04261270,https://clinicaltrials.gov/show/NCT04261270,Drug: ASC09F+Oseltamivir;Drug: Ritonavir+Oseltamivir;Drug: Oseltamivir,NA,Yes,NA
covid,NCT04264858,https://clinicaltrials.gov/show/NCT04264858,Drug: Immunoglobulin of cured patients;Drug: ?-Globulin,NA,NA,NA
covid,NCT04273321,https://clinicaltrials.gov/show/NCT04273321,Drug: Methylprednisolone,NA,NA,NA
covid,NCT04276896,https://clinicaltrials.gov/show/NCT04276896,Biological: Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs,Yes,NA,NA
covid,NCT04276987,https://clinicaltrials.gov/show/NCT04276987,Biological: MSCs-derived exosomes,NA,NA,NA
covid,NCT04287686,https://clinicaltrials.gov/show/NCT04287686,Drug: Recombinant human angiotensin-converting enzyme 2 (rhACE2),NA,NA,NA
main,NCT04297839,https://clinicaltrials.gov/show/NCT04297839,Drug: Citrate Anticoagulation Solution;Drug: Control Group (heparin or continuous saline),NA,Yes,NA
covid,NCT04298060,https://clinicaltrials.gov/show/NCT04298060,Drug: DAS181;Drug: Placebo,NA,NA,NA
covid,NCT04302519,https://clinicaltrials.gov/show/NCT04302519,Biological: Dental pulp mesenchymal stem cells,NA,Yes,NA
covid,NCT04303299,https://clinicaltrials.gov/show/NCT04303299,Drug: Oral,NA,NA,NA
covid,NCT04303507,https://clinicaltrials.gov/show/NCT04303507,Drug: Chloroquine or Hydroxychloroquine;Drug: Placebo,NA,Yes,NA
covid,NCT04304053,https://clinicaltrials.gov/show/NCT04304053,Drug: Treatment and prophylaxis;Other: Standard Public Health measures,NA,NA,NA
covid,NCT04304313,https://clinicaltrials.gov/show/NCT04304313,Drug: Sildenafil citrate tablets,NA,NA,NA
covid,NCT04305106,https://clinicaltrials.gov/show/NCT04305106,Drug: Bevacizumab,NA,Yes,NA
covid,NCT04307693,https://clinicaltrials.gov/show/NCT04307693,Drug: Lopinavir/ritonavir;Drug: Hydroxychloroquine sulfate,NA,Yes,NA
covid,NCT04308317,https://clinicaltrials.gov/show/NCT04308317,Drug: Tetrandrine,NA,NA,NA
covid,NCT04310228,https://clinicaltrials.gov/show/NCT04310228,Drug: Favipiravir Combined With Tocilizumab;Drug: Favipiravir;Drug: Tocilizumab,NA,Yes,NA
covid,NCT04319731,https://clinicaltrials.gov/show/NCT04319731,Biological: Human Amniotic Fluid,NA,NA,NA
covid,NCT04319900,https://clinicaltrials.gov/show/NCT04319900,Drug: favipiravir tablets+chloroquine phosphatetablets tablets;Drug: Favipiravir tablets;Drug: Placebo,NA,Yes,NA
covid,NCT04321278,https://clinicaltrials.gov/show/NCT04321278,Drug: Hydroxychloroquine + azithromycin;Drug: Hydroxychloroquine,NA,Yes,NA
covid,NCT04321421,https://clinicaltrials.gov/show/NCT04321421,Other: hyperimmune plasma,NA,Yes,NA
covid,NCT04321616,https://clinicaltrials.gov/show/NCT04321616,Drug: Hydroxychloroquine;Drug: Remdesivir;Other: (Standard of Care) SoC,NA,Yes,NA
covid,NCT04321993,https://clinicaltrials.gov/show/NCT04321993,Drug: Baricitinib (janus kinase inhibitor),NA,NA,NA
covid,NCT04324606,https://clinicaltrials.gov/show/NCT04324606,Biological: ChAdOx1 nCoV-19;Biological: MenACWY;Biological: ChAdOx1 nCoV-19 full boost;Biological: ChAdOx1 nCoV-19 half boost;Biological: MenACWY boost;Drug: Paracetamol;Biological: ChAdOx1 nCoV-19 0.5mL boost,Yes,NA,NA
covid,NCT04326426,https://clinicaltrials.gov/show/NCT04326426,Drug: Tradipitant;Drug: Placebo,NA,NA,NA
covid,NCT04326790,https://clinicaltrials.gov/show/NCT04326790,Drug: Colchicine;Drug: Standard treatment,NA,NA,NA
covid,NCT04327349,https://clinicaltrials.gov/show/NCT04327349,Biological: Convalescent Plasma,NA,Yes,NA
covid,NCT04328467,https://clinicaltrials.gov/show/NCT04328467,Drug: Hydroxychloroquine;Other: Placebo,NA,Yes,NA
covid,NCT04328480,https://clinicaltrials.gov/show/NCT04328480,Drug: Colchicine;Other: Local standard of care,NA,NA,NA
covid,NCT04330300,https://clinicaltrials.gov/show/NCT04330300,Drug: Thiazide or Thiazide-like diuretics;Drug: Calcium Channel Blockers;Drug: ACE inhibitor;Drug: Angiotensin receptor blocker,NA,NA,NA
covid,NCT04331470,https://clinicaltrials.gov/show/NCT04331470,Drug: Levamisole Pill + Budesonide+Formoterol inhaler;Drug: Lopinavir/Ritonavir + hydoxychloroquine,NA,Yes,NA
covid,NCT04331665,https://clinicaltrials.gov/show/NCT04331665,Drug: Ruxolitinib,NA,NA,NA
covid,NCT04331795,https://clinicaltrials.gov/show/NCT04331795,Drug: Tocilizumab;Drug: Tocilizumab,NA,Yes,NA
covid,NCT04331834,https://clinicaltrials.gov/show/NCT04331834,Drug: Hydroxychloroquine;Drug: Placebos,NA,Yes,NA
covid,NCT04331899,https://clinicaltrials.gov/show/NCT04331899,Drug: Peginterferon Lambda-1a;Other: Placebo,NA,Yes,NA
covid,NCT04333589,https://clinicaltrials.gov/show/NCT04333589,Drug: Favipiravir,NA,Yes,NA
covid,NCT04334265,https://clinicaltrials.gov/show/NCT04334265,Drug: Anluohuaxian,NA,NA,NA
covid,NCT04336332,https://clinicaltrials.gov/show/NCT04336332,Combination Product: Hydroxychloroquine Sulfate + Azithromycin;Drug: Hydroxychloroquine Sulfate,NA,Yes,NA
covid,NCT04336410,https://clinicaltrials.gov/show/NCT04336410,Drug: INO-4800;Device: CELLECTRA® 2000,NA,NA,NA
covid,NCT04337216,https://clinicaltrials.gov/show/NCT04337216,Drug: Mavrilimumab,NA,Yes,NA
covid,NCT04338802,https://clinicaltrials.gov/show/NCT04338802,Drug: Nintedanib 150 MG;Other: Placebo,NA,NA,NA
covid,NCT04338958,https://clinicaltrials.gov/show/NCT04338958,Drug: Ruxolitinib,NA,NA,NA
covid,NCT04339426,https://clinicaltrials.gov/show/NCT04339426,Drug: Atovaquone/Azithromycin,NA,Yes,NA
covid,NCT04339712,https://clinicaltrials.gov/show/NCT04339712,Drug: Anakinra;Drug: Tocilizumab,NA,Yes,NA
covid,NCT04341207,https://clinicaltrials.gov/show/NCT04341207,Drug: Hydroxychloroquine;Drug: Azithromycin,NA,Yes,NA
covid,NCT04341389,https://clinicaltrials.gov/show/NCT04341389,Biological: Recombinant novel coronavirus vaccine (Adenovirus type 5 vector);Other: Placebo,Yes,NA,NA
covid,NCT04341870,https://clinicaltrials.gov/show/NCT04341870,Drug: Sarilumab;Drug: Azithromycin;Drug: Hydroxychloroquine,NA,Yes,NA
covid,NCT04342650,https://clinicaltrials.gov/show/NCT04342650,Drug: Chloroquine Diphosphate;Drug: Placebo oral tablet,NA,Yes,NA
covid,NCT04342663,https://clinicaltrials.gov/show/NCT04342663,Drug: Fluvoxamine;Drug: Placebo,NA,NA,NA
covid,NCT04343677,https://clinicaltrials.gov/show/NCT04343677,Drug: Hydroxychloroquine;Dietary Supplement: Placebo,NA,Yes,NA
covid,NCT04343976,https://clinicaltrials.gov/show/NCT04343976,Drug: Pegylated interferon lambda,NA,Yes,NA
covid,NCT04344041,https://clinicaltrials.gov/show/NCT04344041,"Drug: cholecalciferol 200,000 IU;Drug: cholecalciferol 50,000 IU",NA,NA,NA
covid,NCT04344457,https://clinicaltrials.gov/show/NCT04344457,Drug: Hydroxychloroquine;Drug: Indomethacin;Drug: Zithromax Oral Product,NA,Yes,NA
covid,NCT04344535,https://clinicaltrials.gov/show/NCT04344535,Biological: Convalescent Plasma;Biological: Standard Donor Plasma,NA,Yes,NA
covid,NCT04344600,https://clinicaltrials.gov/show/NCT04344600,Drug: Peginterferon lambda alfa-1a subcutaneous injection;Other: Saline,NA,Yes,NA
covid,NCT04345601,https://clinicaltrials.gov/show/NCT04345601,Biological: Mesenchymal Stromal Cells;Other: Supportive Care,NA,NA,NA
covid,NCT04345653,https://clinicaltrials.gov/show/NCT04345653,Drug: Hydroxychloroquine Sulfate (HCQ),NA,Yes,NA
covid,NCT04345679,https://clinicaltrials.gov/show/NCT04345679,Biological: anti-SARS-CoV-2 convalescent plasma,NA,Yes,NA
covid,NCT04345991,https://clinicaltrials.gov/show/NCT04345991,Drug: Transfusion of COVID-19 convalescent plasma,NA,Yes,NA
covid,NCT04346368,https://clinicaltrials.gov/show/NCT04346368,Biological: BM-MSCs;Biological: Placebo,NA,NA,NA
covid,NCT04346446,https://clinicaltrials.gov/show/NCT04346446,Drug: Convalescent Plasma Transfusion;Other: Supportive Care;Drug: Random Donor Plasma,NA,Yes,NA
covid,NCT04348383,https://clinicaltrials.gov/show/NCT04348383,Drug: Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days;Drug: Placebo 250 cc 24 hours continuous infusion for 15 days,NA,NA,NA
covid,NCT04348435,https://clinicaltrials.gov/show/NCT04348435,Drug: HB-adMSCs;Drug: Placebos,NA,NA,NA
covid,NCT04348461,https://clinicaltrials.gov/show/NCT04348461,Drug: Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells,NA,NA,NA
covid,NCT04348513,https://clinicaltrials.gov/show/NCT04348513,Drug: T3 solution for injection;Drug: Placebo,NA,NA,NA
covid,NCT04348656,https://clinicaltrials.gov/show/NCT04348656,Biological: Convalescent plasma,NA,Yes,NA
covid,NCT04349371,https://clinicaltrials.gov/show/NCT04349371,Drug: Chloroquine;Drug: Placebo oral tablet,NA,Yes,NA
covid,NCT04349592,https://clinicaltrials.gov/show/NCT04349592,Drug: Hydroxychloroquine;Drug: Azithromycin;Other: Placebo Tablet;Other: Placebo capsules,NA,Yes,NA
covid,NCT04349631,https://clinicaltrials.gov/show/NCT04349631,Drug: HB-adMSCs,NA,NA,NA
covid,NCT04350320,https://clinicaltrials.gov/show/NCT04350320,Drug: Colchicine Tablets;Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.;Drug: Colchicine Tablets;Drug: Standard therapy for COVID-19 according to the stablished hospital protocols.,NA,NA,NA
covid,NCT04350450,https://clinicaltrials.gov/show/NCT04350450,Drug: Hydroxychloroquine,NA,Yes,NA
covid,NCT04350671,https://clinicaltrials.gov/show/NCT04350671,Drug: Interferon Beta-1A;Drug: Lopinavir / Ritonavir;Drug: Single Dose of Hydroxychloroquine,NA,Yes,NA
covid,NCT04351347,https://clinicaltrials.gov/show/NCT04351347,Drug: Ivermectin;Drug: Nitazoxanide with ivermectin;Drug: Ivermectin wth chloroquine,NA,Yes,NA
covid,NCT04351919,https://clinicaltrials.gov/show/NCT04351919,Drug: Hydroxychloroquine;Drug: Azithromycin,NA,Yes,NA
covid,NCT04352608,https://clinicaltrials.gov/show/NCT04352608,Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule;Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule;Biological: Two doses of placebo at the emergency vaccination schedule;Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule;Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule;Biological: Two doses of placebo at the routine vaccination schedule,Yes,NA,NA
covid,NCT04352751,https://clinicaltrials.gov/show/NCT04352751,Other: convalescent plasma,NA,Yes,NA
covid,NCT04352803,https://clinicaltrials.gov/show/NCT04352803,Biological: Autologous Adipose MSC's,NA,NA,NA
covid,NCT04352946,https://clinicaltrials.gov/show/NCT04352946,Drug: Hydroxychloroquine Pre-Exposure Prophylaxis;Drug: Placebo oral tablet,NA,Yes,NA
covid,NCT04353128,https://clinicaltrials.gov/show/NCT04353128,Drug: Melatonin 2mg;Drug: Placebo oral tablet,NA,NA,NA
main,NCT04353986,https://clinicaltrials.gov/show/NCT04353986,Drug: Sofosbuvir and Ledipasvir,NA,Yes,NA
covid,NCT04354389,https://clinicaltrials.gov/show/NCT04354389,Drug: DAS181;Drug: Placebo;Drug: DAS181,NA,NA,NA
covid,NCT04354805,https://clinicaltrials.gov/show/NCT04354805,Drug: Chlorpromazine,NA,NA,NA
covid,NCT04354831,https://clinicaltrials.gov/show/NCT04354831,Biological: anti-SARS-CoV-2 convalescent plasma,NA,Yes,NA
covid,NCT04354870,https://clinicaltrials.gov/show/NCT04354870,Drug: Hydroxychloroquine (HCQ),NA,Yes,NA
covid,NCT04355026,https://clinicaltrials.gov/show/NCT04355026,Drug: Bromhexine Oral Tablet and/or hydroxychloroquine tablet,NA,Yes,NA
covid,NCT04355143,https://clinicaltrials.gov/show/NCT04355143,Drug: Colchicine Tablets;Other: Current care per UCLA treating physicians,NA,NA,NA
covid,NCT04355962,https://clinicaltrials.gov/show/NCT04355962,Drug: Sevoflurane;Drug: Intravenous drug,NA,NA,NA
covid,NCT04356482,https://clinicaltrials.gov/show/NCT04356482,Biological: convalescent plasma,NA,Yes,NA
covid,NCT04356833,https://clinicaltrials.gov/show/NCT04356833,Drug: nebulised recombinant tissue-Plasminogen Activator (rt-PA),NA,NA,NA
covid,NCT04358068,https://clinicaltrials.gov/show/NCT04358068,Drug: Hydroxychloroquine (HCQ);Drug: Azithromycin (Azithro);Drug: Placebo for Hydroxychloroquine;Drug: Placebo for Azithromycin,NA,Yes,NA
covid,NCT04358081,https://clinicaltrials.gov/show/NCT04358081,Drug: HCQ;Drug: HCQ+AZT;Drug: Placebo,NA,NA,NA
covid,NCT04358549,https://clinicaltrials.gov/show/NCT04358549,Drug: Favipiravir + Standard of Care;Drug: Standard of Care,NA,Yes,NA
covid,NCT04359537,https://clinicaltrials.gov/show/NCT04359537,Drug: Hydroxychloroquine Sulfate 200 MG;Other: Placebo,NA,Yes,NA
covid,NCT04359615,https://clinicaltrials.gov/show/NCT04359615,Drug: Favipiravir;Drug: Hydroxychloroquine,NA,Yes,NA
covid,NCT04359680,https://clinicaltrials.gov/show/NCT04359680,Drug: Nitazoxanide;Drug: Placebo;Dietary Supplement: Vitamin Super B-Complex,NA,NA,Yes
covid,NCT04359810,https://clinicaltrials.gov/show/NCT04359810,Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma);Biological: Non-convalescent Plasma (control plasma),NA,Yes,NA
covid,NCT04359862,https://clinicaltrials.gov/show/NCT04359862,Drug: Sevoflurane;Drug: Propofol,NA,NA,NA
covid,NCT04360759,https://clinicaltrials.gov/show/NCT04360759,Drug: Chloroquine or hydroxychloroquine,NA,Yes,NA
covid,NCT04360824,https://clinicaltrials.gov/show/NCT04360824,Drug: Intermediate dose thromboprophylaxis;Drug: Standard of Care thromboprophylaxis,NA,NA,NA
covid,NCT04361032,https://clinicaltrials.gov/show/NCT04361032,Drug: Tocilizumab Injection;Drug: Deferoxamine,NA,Yes,NA
covid,NCT04361461,https://clinicaltrials.gov/show/NCT04361461,Drug: Hydroxychloroquine Sulfate;Drug: Hydroxychloroquine Sulfate + Azythromycin,NA,Yes,NA
covid,NCT04361643,https://clinicaltrials.gov/show/NCT04361643,"Drug: Lenalidomide as a 5 mg capsule PO daily, days 1, 3, and 5.;Drug: Placebo",NA,NA,NA
covid,NCT04361942,https://clinicaltrials.gov/show/NCT04361942,Biological: Mesenchymal Stromal Cells;Other: Placebo,NA,NA,NA
covid,NCT04362085,https://clinicaltrials.gov/show/NCT04362085,Drug: Therapeutic Anticoagulation,NA,NA,NA
covid,NCT04363346,https://clinicaltrials.gov/show/NCT04363346,Drug: FT516,NA,NA,NA
covid,NCT04363450,https://clinicaltrials.gov/show/NCT04363450,Drug: Hydroxychloroquine;Drug: Placebo,NA,Yes,NA
covid,NCT04363814,https://clinicaltrials.gov/show/NCT04363814,Biological: Bactek-R,NA,NA,NA
covid,NCT04364802,https://clinicaltrials.gov/show/NCT04364802,Drug: Povidone-Iodine Nasal Spray and Gargle;Drug: Povidone-Iodine Nasal Spray and Gargle;Drug: Povidone-Iodine Nasal Spray and Gargle,NA,NA,NA
covid,NCT04365101,https://clinicaltrials.gov/show/NCT04365101,Biological: CYNK-001,NA,NA,NA
covid,NCT04365127,https://clinicaltrials.gov/show/NCT04365127,Drug: Progesterone 100 MG,NA,NA,NA
covid,NCT04365439,https://clinicaltrials.gov/show/NCT04365439,Biological: Blood plasma,NA,Yes,NA
covid,NCT04365699,https://clinicaltrials.gov/show/NCT04365699,Drug: AT-001,NA,NA,NA
covid,NCT04366245,https://clinicaltrials.gov/show/NCT04366245,Biological: Hyperimmune plasma;Drug: Standard of care for SARS-CoV-2 infection,NA,Yes,NA
covid,NCT04366271,https://clinicaltrials.gov/show/NCT04366271,Biological: Mesenchymal cells;Drug: Standard of care,NA,NA,NA
covid,NCT04366960,https://clinicaltrials.gov/show/NCT04366960,Drug: Enoxaparin,NA,NA,NA
covid,NCT04368728,https://clinicaltrials.gov/show/NCT04368728,Biological: BNT162b1;Biological: BNT162b2;Other: Placebo,Yes,NA,NA
covid,NCT04369365,https://clinicaltrials.gov/show/NCT04369365,Drug: Azithromycin 500 milligram (mg) oral Tablet;Drug: Placebo,NA,Yes,NA
covid,NCT04369742,https://clinicaltrials.gov/show/NCT04369742,Drug: Hydroxychloroquine (HCQ);Other: Pacebo: Calcium citrate,NA,Yes,NA
covid,NCT04370015,https://clinicaltrials.gov/show/NCT04370015,Drug: Hydroxychloroquine;Drug: Placebo oral tablet,NA,Yes,NA
covid,NCT04370262,https://clinicaltrials.gov/show/NCT04370262,Drug: SOC + Intravenous Famotidine;Drug: SOC + Placebo,NA,NA,NA
covid,NCT04370782,https://clinicaltrials.gov/show/NCT04370782,Drug: Hydroxychloroquine;Drug: Azithromycin;Drug: Zinc Sulfate;Drug: Doxycycline,NA,Yes,NA
covid,NCT04371926,https://clinicaltrials.gov/show/NCT04371926,Drug: Hydroxychloroquine Sulfate,NA,Yes,NA
covid,NCT04374149,https://clinicaltrials.gov/show/NCT04374149,Procedure: Therapeutic Plasma Exchange;Drug: Ruxolitinib,NA,Yes,NA
covid,NCT04374526,https://clinicaltrials.gov/show/NCT04374526,Biological: COVID-19 Convalescent Plasma,NA,Yes,NA
covid,NCT04374552,https://clinicaltrials.gov/show/NCT04374552,Drug: Hydroxychloroquine sulfate &Azithromycin;Drug: Placebo,NA,Yes,NA
covid,NCT04374903,https://clinicaltrials.gov/show/NCT04374903,Drug: HCQ & AZ vs HCQ+SIR;Drug: HCQ & AZ vs HCQ+SIR,NA,NA,NA
covid,NCT04374942,https://clinicaltrials.gov/show/NCT04374942,Drug: Hydroxychloroquine;Drug: Placebo oral tablet,NA,Yes,NA
covid,NCT04375397,https://clinicaltrials.gov/show/NCT04375397,Drug: Ibrutinib;Drug: Placebo,NA,NA,NA
covid,NCT04376788,https://clinicaltrials.gov/show/NCT04376788,Biological: exchange blood transfusion from normal donor;Biological: plasma from convalescent patients with COVID-19;Drug: Methylene Blue 5 MG/ML,NA,Yes,NA
covid,NCT04377503,https://clinicaltrials.gov/show/NCT04377503,Drug: Tocilizumab 180 MG/ML;Drug: Methylprednisolone Sodium Succinate,NA,Yes,NA
covid,NCT04377646,https://clinicaltrials.gov/show/NCT04377646,Drug: Hydroxychloroquine;Drug: Hydroxychloroquine (placebo);Drug: Zinc;Drug: Zinc (Placebo),NA,Yes,NA
covid,NCT04377750,https://clinicaltrials.gov/show/NCT04377750,Drug: Tocilizumab,NA,Yes,NA
covid,NCT04379076,https://clinicaltrials.gov/show/NCT04379076,Drug: Interleukin-7;Drug: Placebos,NA,NA,NA
covid,NCT04379336,https://clinicaltrials.gov/show/NCT04379336,Biological: Bacille Calmette-Guérin (BCG);Other: Placebo Comparator,NA,NA,NA
covid,NCT04380935,https://clinicaltrials.gov/show/NCT04380935,Biological: Convalescent plasma;Drug: Standard of care,NA,Yes,NA
covid,NCT04380961,https://clinicaltrials.gov/show/NCT04380961,Drug: Sirukumab;Drug: Placebo;Other: Standard of Care (SOC),NA,Yes,NA
covid,NCT04381052,https://clinicaltrials.gov/show/NCT04381052,Drug: Clazakizumab;Other: Placebo,NA,Yes,NA
covid,NCT04382625,https://clinicaltrials.gov/show/NCT04382625,Drug: Hydroxychloroquine,NA,Yes,NA
covid,NCT04382651,https://clinicaltrials.gov/show/NCT04382651,Drug: MAS825;Drug: Matching placebo,NA,NA,NA
covid,NCT04382768,https://clinicaltrials.gov/show/NCT04382768,Drug: Inhaled Hypertonic ibuprofen,NA,NA,NA
covid,NCT04383535,https://clinicaltrials.gov/show/NCT04383535,Other: Convalescent SARS COVID-19 plasma;Other: Placebo,NA,Yes,NA
covid,NCT04383548,https://clinicaltrials.gov/show/NCT04383548,Other: hyper immunoglobulins containing anti-Corona VS2 immunoglobulin,NA,NA,NA
covid,NCT04384380,https://clinicaltrials.gov/show/NCT04384380,Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil],NA,Yes,NA
covid,NCT04384445,https://clinicaltrials.gov/show/NCT04384445,Biological: Zofin;Other: Placebo,NA,NA,NA
covid,NCT04384497,https://clinicaltrials.gov/show/NCT04384497,Biological: SARS-CoV-2 convalescent plasma,NA,Yes,NA
covid,NCT04384731,https://clinicaltrials.gov/show/NCT04384731,Drug: poractant alfa,NA,NA,NA
covid,NCT04385043,https://clinicaltrials.gov/show/NCT04385043,Other: plasma hyperimmune;Drug: standard therapy,NA,Yes,NA
covid,NCT04385199,https://clinicaltrials.gov/show/NCT04385199,Biological: Convalescent plasma,NA,Yes,NA
covid,NCT04386070,https://clinicaltrials.gov/show/NCT04386070,Drug: Lopinavir-Ritonavir;Drug: Hydroxychloroquine,NA,Yes,NA
covid,NCT04386239,https://clinicaltrials.gov/show/NCT04386239,Drug: Sarilumab Prefilled Syringe,NA,Yes,NA
covid,NCT04387760,https://clinicaltrials.gov/show/NCT04387760,Drug: Hydroxychloroquine;Drug: Favipiravir;Other: Routine care for COVID-19 patients,NA,Yes,NA
covid,NCT04388410,https://clinicaltrials.gov/show/NCT04388410,Biological: convalescent plasma,NA,Yes,NA
covid,NCT04388527,https://clinicaltrials.gov/show/NCT04388527,Biological: COVID-19 Convalescent Plasma,NA,Yes,NA
covid,NCT04388709,https://clinicaltrials.gov/show/NCT04388709,Drug: Peginterferon Lambda-1A,NA,Yes,NA
covid,NCT04389710,https://clinicaltrials.gov/show/NCT04389710,Drug: Convalescent Plasma,NA,Yes,NA
covid,NCT04389801,https://clinicaltrials.gov/show/NCT04389801,Drug: Desferal 500 MG Injection,NA,NA,NA
covid,NCT04389944,https://clinicaltrials.gov/show/NCT04389944,Other: convalescent plasma application to SARS-CoV-2 infected patients,NA,Yes,NA
covid,NCT04390503,https://clinicaltrials.gov/show/NCT04390503,Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma);Biological: Control (albumin 5%),NA,Yes,NA
covid,NCT04391101,https://clinicaltrials.gov/show/NCT04391101,Drug: Convalescent plasma,NA,Yes,NA
covid,NCT04391127,https://clinicaltrials.gov/show/NCT04391127,Drug: Hydroxychloroquine;Drug: Ivermectin;Drug: Placebo,NA,Yes,NA
main,NCT04391621,https://clinicaltrials.gov/show/NCT04391621,"Procedure: Autologous Adipose Derived stem cell transplantation;Drug: Triamcinolone Acetonide 40Mg/Ml Inj,Susp_#1",NA,Yes,NA
covid,NCT04392232,https://clinicaltrials.gov/show/NCT04392232,Drug: Convalescent Plasma,NA,Yes,NA
covid,NCT04393038,https://clinicaltrials.gov/show/NCT04393038,Drug: ABX464;Drug: Placebo,NA,NA,NA
covid,NCT04393311,https://clinicaltrials.gov/show/NCT04393311,Drug: Ulinastatin;Drug: Placebo,NA,NA,NA
covid,NCT04396106,https://clinicaltrials.gov/show/NCT04396106,Drug: AT-527;Other: Placebo,NA,NA,NA
covid,NCT04397497,https://clinicaltrials.gov/show/NCT04397497,Drug: Mavrilimumab;Drug: Placebo,NA,Yes,NA
covid,NCT04397523,https://clinicaltrials.gov/show/NCT04397523,Biological: anti-SARS-CoV-2 convalescent plasma,NA,Yes,NA
covid,NCT04397757,https://clinicaltrials.gov/show/NCT04397757,Biological: COVID-19 Convalescent Plasma,NA,Yes,NA
covid,NCT04399980,https://clinicaltrials.gov/show/NCT04399980,Drug: Mavrilimumab;Drug: Placebos,NA,Yes,NA
covid,NCT04400799,https://clinicaltrials.gov/show/NCT04400799,Drug: Enoxaparin 40Mg/0.4Ml Inj Syringe 0.4Ml,NA,NA,NA
covid,NCT04401202,https://clinicaltrials.gov/show/NCT04401202,Dietary Supplement: Nigella sativa,NA,NA,NA
covid,NCT04401527,https://clinicaltrials.gov/show/NCT04401527,Drug: Sodium Nitrite;Drug: Normal Saline,NA,NA,NA
covid,NCT04402203,https://clinicaltrials.gov/show/NCT04402203,Drug: Favipiravir;Drug: Only Standard Treatment,NA,Yes,NA
covid,NCT04402892,https://clinicaltrials.gov/show/NCT04402892,"Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (hospitalized Patients );Other: 35 ml blood, 5 tubes LITHIUM HEPARINATE at each time (cured Patients)",NA,Yes,NA
covid,NCT04402957,https://clinicaltrials.gov/show/NCT04402957,Drug: LSALT peptide;Drug: Placebo,NA,NA,NA
covid,NCT04403100,https://clinicaltrials.gov/show/NCT04403100,Drug: Hydroxychloroquine Sulfate Tablets;Drug: Lopinavir/ Ritonavir Oral Tablet;Drug: Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets;Drug: Placebo,NA,Yes,NA
covid,NCT04403555,https://clinicaltrials.gov/show/NCT04403555,Drug: Ivermectin;Drug: Doxycycline;Drug: Chloroquine,NA,Yes,NA
covid,NCT04403685,https://clinicaltrials.gov/show/NCT04403685,Drug: Tocilizumab,NA,Yes,NA
covid,NCT04404361,https://clinicaltrials.gov/show/NCT04404361,Drug: Pacritinib;Drug: Placebo,NA,NA,NA
main,NCT04404517,https://clinicaltrials.gov/show/NCT04404517,Drug: Adalimumab,NA,Yes,NA
covid,NCT04405271,https://clinicaltrials.gov/show/NCT04405271,Drug: Emtricitabine/Tenofovir Alafenamide 200 MG-25 MG Oral Tablet;Drug: Placebo,NA,Yes,NA
covid,NCT04405570,https://clinicaltrials.gov/show/NCT04405570,Drug: EIDD-2801;Drug: Placebo (PBO),NA,NA,NA
covid,NCT04406246,https://clinicaltrials.gov/show/NCT04406246,Drug: Nitazoxanide 500Mg Oral Tablet,NA,NA,NA
covid,NCT04407390,https://clinicaltrials.gov/show/NCT04407390,Dietary Supplement: Nicotinamide riboside;Dietary Supplement: Placebo,NA,NA,NA
covid,NCT04408235,https://clinicaltrials.gov/show/NCT04408235,Drug: Enoxaparin,NA,NA,NA
covid,NCT04409873,https://clinicaltrials.gov/show/NCT04409873,Drug: Oral-B Mouth Sore mouthwash;Drug: Crest Pro-Health Multi-Protection mouthwash;Drug: CloSYS mouthwash;Drug: Distilled water;Drug: Listerine Mouthwash Product,NA,NA,NA
covid,NCT04409925,https://clinicaltrials.gov/show/NCT04409925,Drug: rhDNase I,NA,NA,NA
covid,NCT04411602,https://clinicaltrials.gov/show/NCT04411602,Drug: SARS-CoV-2 plasma,NA,Yes,NA
covid,NCT04411680,https://clinicaltrials.gov/show/NCT04411680,Drug: Sargramostim;Drug: Standard of care,NA,NA,NA
covid,NCT04412486,https://clinicaltrials.gov/show/NCT04412486,Biological: COVID Convalescent Plasma,NA,Yes,NA
covid,NCT04412785,https://clinicaltrials.gov/show/NCT04412785,Drug: Cyclosporine,NA,NA,NA
covid,NCT04414618,https://clinicaltrials.gov/show/NCT04414618,Drug: Opaganib;Drug: Placebo,NA,NA,NA
covid,NCT04415060,https://clinicaltrials.gov/show/NCT04415060,Drug: Isoflurane Inhalant Product;Drug: Sevoflurane inhalant product,NA,NA,NA
covid,NCT04418518,https://clinicaltrials.gov/show/NCT04418518,Biological: Convalescent plasma,NA,Yes,NA
covid,NCT04419610,https://clinicaltrials.gov/show/NCT04419610,Biological: TRV027;Other: sodium chloride 0.9%,NA,NA,NA
covid,NCT04420364,https://clinicaltrials.gov/show/NCT04420364,Other: Maintenance or reduction of immunosuppression,NA,NA,NA
covid,NCT04421664,https://clinicaltrials.gov/show/NCT04421664,Drug: Hydroxychloroquine;Drug: Placebo oral tablet,NA,Yes,NA
covid,NCT04422561,https://clinicaltrials.gov/show/NCT04422561,Drug: Ivermectin Tablets,NA,NA,NA
covid,NCT04422678,https://clinicaltrials.gov/show/NCT04422678,Drug: Imatinib Mesylate;Drug: Standard of Care,NA,NA,NA
covid,NCT04425733,https://clinicaltrials.gov/show/NCT04425733,Drug: MK-5475;Drug: Placebo,NA,NA,NA
covid,NCT04427501,https://clinicaltrials.gov/show/NCT04427501,Drug: LY3819253;Drug: LY3832479;Drug: Placebo,NA,NA,NA
covid,NCT04428021,https://clinicaltrials.gov/show/NCT04428021,Drug: Standard Therapy Protocol (STP);Other: STP + Standard Plasma (SP);Other: STP + COVID-19 Convalescent Plasma (CP),NA,Yes,NA
covid,NCT04428073,https://clinicaltrials.gov/show/NCT04428073,Biological: Covax-19™,NA,NA,NA
covid,NCT04428801,https://clinicaltrials.gov/show/NCT04428801,Biological: autologous adipose-derived stem cells,NA,Yes,NA
covid,NCT04429711,https://clinicaltrials.gov/show/NCT04429711,Drug: Ivermectin Oral Product,NA,NA,NA
covid,NCT04431453,https://clinicaltrials.gov/show/NCT04431453,Drug: Remdesivir,NA,Yes,NA
covid,NCT04432103,https://clinicaltrials.gov/show/NCT04432103,Biological: Anti SARS-CoV 2 Convalescent Plasma in severe COVID-19 patients;Biological: Anti SARS-CoV 2 Convalescent Plasma in critical COVID-19 patients,NA,Yes,NA
covid,NCT04432766,https://clinicaltrials.gov/show/NCT04432766,Drug: BAT2020,NA,NA,NA
covid,NCT04433546,https://clinicaltrials.gov/show/NCT04433546,Drug: Pemziviptadil (PB1046);Drug: Low Dose (10 mg) Control,NA,NA,NA
covid,NCT04435015,https://clinicaltrials.gov/show/NCT04435015,"Drug: Camostat Mesylate;Drug: Microcrystalline Cellulose, NF",NA,NA,NA
covid,NCT04435314,https://clinicaltrials.gov/show/NCT04435314,Drug: Nitazoxanide;Drug: Placebo,NA,NA,NA
covid,NCT04435808,https://clinicaltrials.gov/show/NCT04435808,Drug: Hydroxychloroquine,NA,Yes,NA
covid,NCT04436471,https://clinicaltrials.gov/show/NCT04436471,Biological: Gam-COVID-Vac,NA,NA,NA
covid,NCT04437693,https://clinicaltrials.gov/show/NCT04437693,Drug: Hydroxychloroquine,NA,Yes,NA
covid,NCT04437875,https://clinicaltrials.gov/show/NCT04437875,Biological: Gam-COVID-Vac Lyo,NA,NA,NA
covid,NCT04438057,https://clinicaltrials.gov/show/NCT04438057,Biological: CCP,NA,NA,NA
covid,NCT04438694,https://clinicaltrials.gov/show/NCT04438694,Biological: Convalescent Plasma;Drug: Standard of Care,NA,Yes,NA
covid,NCT04438850,https://clinicaltrials.gov/show/NCT04438850,Drug: Ivermectin;Other: Placebo,NA,NA,NA
covid,NCT04439006,https://clinicaltrials.gov/show/NCT04439006,Other: Best Practice;Drug: Ibrutinib,NA,NA,NA
covid,NCT04441918,https://clinicaltrials.gov/show/NCT04441918,Combination Product: JS016 (anti-SARS-CoV-2 monoclonal antibody),NA,NA,NA
covid,NCT04441996,https://clinicaltrials.gov/show/NCT04441996,Biological: Therapeutic plasma exchange (TPE);Other: Standard of care,NA,Yes,NA
covid,NCT04445454,https://clinicaltrials.gov/show/NCT04445454,Biological: Mesenchymal stromal cells,NA,NA,NA
covid,NCT04445467,https://clinicaltrials.gov/show/NCT04445467,Drug: Favipiravir,NA,Yes,NA
covid,NCT04446104,https://clinicaltrials.gov/show/NCT04446104,Drug: Hydroxychloroquine Sulfate Tablets;Drug: Ivermectin 3mg Tab;Drug: Zinc;Drug: Povidone-Iodine;Dietary Supplement: Vitamin C,NA,Yes,Yes
main,NCT04447846,https://clinicaltrials.gov/show/NCT04447846,Drug: Cannabidiol,NA,Yes,NA
covid,NCT04452097,https://clinicaltrials.gov/show/NCT04452097,Biological: Human umbilical cord mesenchymal stem cells + best supportive care;Other: Placebo control + best supportive care,NA,Yes,NA
covid,NCT04452799,https://clinicaltrials.gov/show/NCT04452799,Drug: Hesperidin and Diosmin mixture,NA,NA,NA
covid,NCT04455243,https://clinicaltrials.gov/show/NCT04455243,Drug: N-Acetyl cysteine;Drug: Placebo,NA,NA,NA
covid,NCT04457349,https://clinicaltrials.gov/show/NCT04457349,Procedure: Therapeutic Plasma Exchange (TPE),NA,Yes,NA
covid,NCT04457609,https://clinicaltrials.gov/show/NCT04457609,Drug: Oseltamivir;Drug: Azithromycin;Biological: Umbilical Cord Mesenchymal Stem Cells,NA,Yes,NA
covid,NCT04457726,https://clinicaltrials.gov/show/NCT04457726,Biological: SARS-CoV-2 Specific T Cells,NA,NA,NA
covid,NCT04459247,https://clinicaltrials.gov/show/NCT04459247,Drug: Vit D,NA,NA,NA
covid,NCT04460105,https://clinicaltrials.gov/show/NCT04460105,Drug: Lanadelumab;Other: Placebo,NA,Yes,NA
covid,NCT04461340,https://clinicaltrials.gov/show/NCT04461340,Drug: Sirolimus,NA,NA,NA
covid,NCT04463420,https://clinicaltrials.gov/show/NCT04463420,Drug: PHR160 Spray;Drug: Placebo;Drug: Standard treatment,NA,NA,NA
covid,NCT04463602,https://clinicaltrials.gov/show/NCT04463602,Drug: Desidustat;Other: Standard of Care,NA,NA,NA
covid,NCT04464408,https://clinicaltrials.gov/show/NCT04464408,Drug: Favipiravir;Drug: Placebo,NA,Yes,NA
covid,NCT04467918,https://clinicaltrials.gov/show/NCT04467918,Drug: Cannabidiol;Other: PLACEBO,NA,Yes,NA
covid,NCT04469179,https://clinicaltrials.gov/show/NCT04469179,Biological: SAB-185;Other: Normal Saline,NA,NA,NA
covid,NCT04469491,https://clinicaltrials.gov/show/NCT04469491,Drug: inhaled type I interferon;Drug: WFI water nebulization,NA,Yes,NA
covid,NCT04471662,https://clinicaltrials.gov/show/NCT04471662,Combination Product: Nelfinavir/Favipiravir;Other: Active comparator,NA,Yes,NA
covid,NCT04472585,https://clinicaltrials.gov/show/NCT04472585,Drug: Nigella Sativa / Black Cumin;Drug: Ivermectin Injectable Solution;Other: Placebo;Drug: Zinc,NA,NA,NA
covid,NCT04473170,https://clinicaltrials.gov/show/NCT04473170,Biological: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC);Drug: COVID-19 standard care,NA,Yes,NA
covid,NCT04475107,https://clinicaltrials.gov/show/NCT04475107,Drug: Pyronaridine-Artesunate;Drug: Placebo,NA,NA,NA
covid,NCT04476979,https://clinicaltrials.gov/show/NCT04476979,Drug: Tocilizumab;Drug: Dexamethasone,NA,Yes,NA
covid,NCT04477083,https://clinicaltrials.gov/show/NCT04477083,Drug: inhalable hydroxychloroquine (HCQ);Drug: supportive and symptomatic treatment,NA,Yes,NA
covid,NCT04477642,https://clinicaltrials.gov/show/NCT04477642,Drug: Abatacept,NA,NA,NA
covid,NCT04477993,https://clinicaltrials.gov/show/NCT04477993,Drug: Janus Kinase Inhibitor (ruxolitinib);Other: Placebo,NA,NA,NA
covid,NCT04479631,https://clinicaltrials.gov/show/NCT04479631,Drug: BRII-196;Drug: Placebo,NA,NA,NA
covid,NCT04480138,https://clinicaltrials.gov/show/NCT04480138,Drug: Pegylated Interferon-a2b;Other: Standard of Care,NA,Yes,NA
covid,NCT04481685,https://clinicaltrials.gov/show/NCT04481685,Drug: ATI-450;Drug: Placebo,NA,NA,NA
covid,NCT04482699,https://clinicaltrials.gov/show/NCT04482699,Biological: RAPA-501-Allo off-the-shelf Therapy of COVID-19;Other: Placebo,NA,NA,NA
covid,NCT04482712,https://clinicaltrials.gov/show/NCT04482712,Drug: Rapamycin;Drug: Placebo,NA,Yes,NA
covid,NCT04483375,https://clinicaltrials.gov/show/NCT04483375,Biological: SCTA01;Other: Placebo,NA,NA,NA
covid,NCT04483635,https://clinicaltrials.gov/show/NCT04483635,Dietary Supplement: Placebo;Dietary Supplement: Vitamin D,NA,NA,Yes
covid,NCT04484025,https://clinicaltrials.gov/show/NCT04484025,Drug: Ebselen;Drug: Placebo,NA,NA,NA
covid,NCT04484493,https://clinicaltrials.gov/show/NCT04484493,Drug: mometasone furoate nasal spray,NA,NA,NA
covid,NCT04485169,https://clinicaltrials.gov/show/NCT04485169,Procedure: Therapeutic Plasma Exchange,NA,Yes,NA
covid,NCT04486482,https://clinicaltrials.gov/show/NCT04486482,Other: KB109 + Self Supportive Care (SSC);Other: Self Supportive Care (SSC) Alone,NA,NA,NA
covid,NCT04488081,https://clinicaltrials.gov/show/NCT04488081,Drug: Remdesivir;Drug: Cenicriviroc;Drug: Icatibant;Drug: Razuprotafib;Drug: Apremilast,NA,Yes,NA
covid,NCT04489446,https://clinicaltrials.gov/show/NCT04489446,Drug: Sildenafil;Drug: Placebo,NA,NA,NA
covid,NCT04491240,https://clinicaltrials.gov/show/NCT04491240,Drug: EXO 1 inhalation;Drug: EXO 2 inhalation;Drug: Placebo inhalation,NA,NA,NA
covid,NCT04492358,https://clinicaltrials.gov/show/NCT04492358,Drug: Colchicine;Drug: Prednisone tablet;Drug: standard of care,NA,NA,NA
covid,NCT04493242,https://clinicaltrials.gov/show/NCT04493242,Biological: DB-001,NA,NA,NA
covid,NCT04494204,https://clinicaltrials.gov/show/NCT04494204,Combination Product: Immunofree tablets and Reginmune capsule,NA,NA,NA
covid,NCT04494646,https://clinicaltrials.gov/show/NCT04494646,Drug: Bardoxolone methyl;Drug: Placebo,NA,NA,NA
covid,NCT04495101,https://clinicaltrials.gov/show/NCT04495101,Biological: Prolastin;Drug: Standard Medical Treatment,NA,NA,NA
covid,NCT04496245,https://clinicaltrials.gov/show/NCT04496245,Drug: Broncho-Vaxom®,NA,NA,NA
covid,NCT04497324,https://clinicaltrials.gov/show/NCT04497324,Biological: Convalescent plasma,NA,Yes,NA
covid,NCT04497519,https://clinicaltrials.gov/show/NCT04497519,Drug: inhaled hydroxychloroquine,NA,Yes,NA
covid,NCT04497948,https://clinicaltrials.gov/show/NCT04497948,Drug: Acalabrutinib,NA,NA,NA
covid,NCT04497987,https://clinicaltrials.gov/show/NCT04497987,Drug: LY3819253;Drug: Placebo,NA,NA,NA
covid,NCT04498273,https://clinicaltrials.gov/show/NCT04498273,Drug: Apixaban 2.5 MG;Drug: Apixaban 5MG;Drug: Aspirin;Drug: Placebo,NA,NA,NA
covid,NCT04500067,https://clinicaltrials.gov/show/NCT04500067,Drug: IVIG,NA,NA,NA
covid,NCT04500132,https://clinicaltrials.gov/show/NCT04500132,Drug: EC-18;Drug: Placebo EC-18,NA,NA,NA
covid,NCT04500418,https://clinicaltrials.gov/show/NCT04500418,Drug: Cenicriviroc (CVC);Drug: Placebo,NA,NA,NA
covid,NCT04501796,https://clinicaltrials.gov/show/NCT04501796,Drug: Double-Blind NT-I7;Drug: Double-Blind Placebo,NA,NA,NA
covid,NCT04502472,https://clinicaltrials.gov/show/NCT04502472,Biological: Convalescent plasma transfusion,NA,Yes,NA
covid,NCT04504032,https://clinicaltrials.gov/show/NCT04504032,Drug: Rivaroxaban;Drug: Placebo,NA,NA,NA
covid,NCT04504240,https://clinicaltrials.gov/show/NCT04504240,Drug: Famotidine 20 MG,NA,NA,NA
covid,NCT04504877,https://clinicaltrials.gov/show/NCT04504877,Drug: Cannabidiol,NA,Yes,NA
covid,NCT04505098,https://clinicaltrials.gov/show/NCT04505098,Drug: Icosapent ethyl,NA,NA,NA
covid,NCT04505722,https://clinicaltrials.gov/show/NCT04505722,Biological: Ad26.COV2.S;Other: Placebo,NA,NA,NA
covid,NCT04505774,https://clinicaltrials.gov/show/NCT04505774,Drug: theraputic heparin;Drug: prophylactic heparin,NA,Yes,NA
covid,NCT04510233,https://clinicaltrials.gov/show/NCT04510233,Drug: Ivermectin nasal;Drug: Ivermectin oral;Other: standard care,NA,NA,NA
covid,NCT04510402,https://clinicaltrials.gov/show/NCT04510402,Drug: Povidine iodine nasal swabs,NA,NA,NA
covid,NCT04511650,https://clinicaltrials.gov/show/NCT04511650,Drug: Razuprotafib Subcutaneous Solution;Drug: Placebo Subcutaneous Solution,NA,NA,NA
covid,NCT04511923,https://clinicaltrials.gov/show/NCT04511923,Drug: Nebulised heparin,NA,Yes,NA
covid,NCT04512079,https://clinicaltrials.gov/show/NCT04512079,Drug: Enoxaparin;Drug: Apixaban,NA,NA,NA
main,NCT04512950,https://clinicaltrials.gov/show/NCT04512950,Drug: Ringer's lactate;Drug: 0.9% saline,NA,NA,NA
covid,NCT04515147,https://clinicaltrials.gov/show/NCT04515147,Biological: CVnCoV 6 µg;Biological: CVnCoV 12 µg;Biological: Hepatitis A vaccine;Biological: Pneumococcal vaccine;Biological: CVnCoV 12µg,Yes,NA,NA
covid,NCT04516759,https://clinicaltrials.gov/show/NCT04516759,Drug: AZD1656;Other: Placebo,NA,NA,NA
covid,NCT04516941,https://clinicaltrials.gov/show/NCT04516941,Drug: Edoxaban Tablets;Drug: Colchicine Tablets,NA,NA,NA
covid,NCT04517162,https://clinicaltrials.gov/show/NCT04517162,Drug: Collagen-Polyvinylpyrrolidone,NA,NA,NA
covid,NCT04517188,https://clinicaltrials.gov/show/NCT04517188,Drug: Povidone-Iodine Solution 1.25% w/w [0.125% available iodine] USP,NA,NA,NA
covid,NCT04519424,https://clinicaltrials.gov/show/NCT04519424,Biological: CSL324;Drug: Placebo,NA,NA,NA
covid,NCT04520620,https://clinicaltrials.gov/show/NCT04520620,Drug: Lovenox 40 MG in 0.4 mL Prefilled Syringe;Device: Ultrasound of the lower limbs,NA,NA,NA
covid,NCT04521309,https://clinicaltrials.gov/show/NCT04521309,Biological: SARS-CoV-2 antibody based IVIG therapy,NA,NA,NA
covid,NCT04521400,https://clinicaltrials.gov/show/NCT04521400,Drug: High dose Interferon-beta 1a;Drug: Lopinavir/Ritonavir;Drug: Low dose Interferon-beta 1a,NA,Yes,NA
covid,NCT04522817,https://clinicaltrials.gov/show/NCT04522817,Biological: CLBS119,NA,NA,NA
covid,NCT04524962,https://clinicaltrials.gov/show/NCT04524962,Biological: Descartes 30,NA,NA,NA
covid,NCT04525820,https://clinicaltrials.gov/show/NCT04525820,Drug: Single high dose vitamin D;Drug: Placebo;Drug: Treatment as usual vitamin D,NA,NA,Yes
covid,NCT04527133,https://clinicaltrials.gov/show/NCT04527133,Drug: Aprotinin,NA,NA,NA
covid,NCT04527211,https://clinicaltrials.gov/show/NCT04527211,Drug: Ivermectin,NA,NA,NA
covid,NCT04527562,https://clinicaltrials.gov/show/NCT04527562,Drug: Colchicine;Drug: Placebo,NA,NA,NA
covid,NCT04528368,https://clinicaltrials.gov/show/NCT04528368,Biological: Convalescent plasma,NA,Yes,NA
covid,NCT04528771,https://clinicaltrials.gov/show/NCT04528771,Drug: SNO;Drug: Nitrogen gas,NA,NA,NA
covid,NCT04528888,https://clinicaltrials.gov/show/NCT04528888,Drug: Enoxaparin;Drug: Methylprednisolone;Drug: unfractionated heparin,NA,Yes,NA
covid,NCT04529525,https://clinicaltrials.gov/show/NCT04529525,Drug: Ivermectin;Drug: Placebo,NA,NA,NA
covid,NCT04530136,https://clinicaltrials.gov/show/NCT04530136,Drug: Ruconest,NA,NA,NA
covid,NCT04530474,https://clinicaltrials.gov/show/NCT04530474,Drug: Ivermectin Pill;Drug: Placebo,NA,NA,NA
covid,NCT04530656,https://clinicaltrials.gov/show/NCT04530656,"Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28;Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28;Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28;Biological: Two doses of placebo at the schedule of day 0, 28(middle-dose group);Biological: Two doses of placebo at the schedule of day 0, 28(high-dose group);Biological: Three doses of placebo at the schedule of day 0, 14, 28(high-dose group)",Yes,NA,NA
covid,NCT04533048,https://clinicaltrials.gov/show/NCT04533048,Combination Product: MW33 injection;Combination Product: MW33 injection placebo,NA,NA,NA
covid,NCT04534673,https://clinicaltrials.gov/show/NCT04534673,Drug: Lambda 180 mcg S.C,NA,NA,NA
covid,NCT04534725,https://clinicaltrials.gov/show/NCT04534725,Drug: Interferon alfa;Drug: Selinexor;Drug: Lenzilumab,NA,Yes,NA
covid,NCT04535063,https://clinicaltrials.gov/show/NCT04535063,Biological: COVID19 convalescent plasma infusion,NA,Yes,NA
covid,NCT04535791,https://clinicaltrials.gov/show/NCT04535791,Drug: Cholecalciferol,NA,NA,NA
covid,NCT04535869,https://clinicaltrials.gov/show/NCT04535869,Drug: Sofosbuvir 400 MG plus Daclatasvir 200mg,NA,Yes,NA
covid,NCT04536350,https://clinicaltrials.gov/show/NCT04536350,Drug: Aviptadil 67µg;Drug: Placebo 0.9% NaCl solution,NA,NA,NA
covid,NCT04536363,https://clinicaltrials.gov/show/NCT04536363,"Drug: Analogs, Prostaglandin E1;Drug: Standard therapeutic protocol",NA,NA,NA
covid,NCT04540406,https://clinicaltrials.gov/show/NCT04540406,Drug: NBT-NM108;Other: Usual Care Only,NA,NA,NA
covid,NCT04542213,https://clinicaltrials.gov/show/NCT04542213,Drug: Linagliptin tablet;Drug: Insulin,NA,NA,NA
covid,NCT04545749,https://clinicaltrials.gov/show/NCT04545749,Biological: UB-612,NA,NA,NA
covid,NCT04547127,https://clinicaltrials.gov/show/NCT04547127,Biological: Convalescent anti-SARS-CoV-2 MBT Plasma;Drug: Standard Medical Treatment,NA,Yes,NA
covid,NCT04548557,https://clinicaltrials.gov/show/NCT04548557,Biological: intravenous immunoglobulin therapy,NA,NA,NA
covid,NCT04552951,https://clinicaltrials.gov/show/NCT04552951,Drug: Cholecalciferol,NA,NA,NA
covid,NCT04554433,https://clinicaltrials.gov/show/NCT04554433,Drug: Ethanol with Asprin,NA,NA,NA
covid,NCT04558021,https://clinicaltrials.gov/show/NCT04558021,Drug: Niclosamide suspension;Other: Placebo,NA,NA,NA
covid,NCT04561219,https://clinicaltrials.gov/show/NCT04561219,Drug: Nitazoxanide;Drug: Placebo,NA,NA,NA
covid,NCT04565392,https://clinicaltrials.gov/show/NCT04565392,Drug: Famotidine 20 MG,NA,NA,NA
covid,NCT04567810,https://clinicaltrials.gov/show/NCT04567810,Drug: anti-SARS-CoV-2 IgY;Drug: Placebo,NA,NA,NA
covid,NCT04568031,https://clinicaltrials.gov/show/NCT04568031,Drug: AZD1222;Drug: AZD1222,Yes,NA,NA
covid,NCT04568096,https://clinicaltrials.gov/show/NCT04568096,Combination Product: Aerosolized All-Trans Retinoic acid plus oral Tamoxifen;Other: Standard treatment,NA,NA,NA
covid,NCT04568863,https://clinicaltrials.gov/show/NCT04568863,Drug: Melatonin intravenous;Drug: Placebo intravenous,NA,NA,NA
covid,NCT04570449,https://clinicaltrials.gov/show/NCT04570449,Drug: Fluoxetine;Drug: Placebo,NA,NA,NA
covid,NCT04570501,https://clinicaltrials.gov/show/NCT04570501,Drug: Angiotensin-(1-7);Drug: Placebo,NA,NA,NA
covid,NCT04573153,https://clinicaltrials.gov/show/NCT04573153,Drug: Hydroxychloroquine + Metabolic cofactor supplementation;Drug: Hydroxychloroquine + Sorbitol,NA,Yes,NA
covid,NCT04574869,https://clinicaltrials.gov/show/NCT04574869,Drug: RLS-0071;Drug: RLS-0071;Drug: Placebo;Drug: RLS-0071;Drug: RLS-0071;Drug: Placebo,NA,NA,NA
covid,NCT04577378,https://clinicaltrials.gov/show/NCT04577378,Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid) plus Aerosolized Itraconazole;Drug: Drug: Isotretinoin(Aerosolized 13 cis retinoic acid),NA,NA,NA
covid,NCT04578236,https://clinicaltrials.gov/show/NCT04578236,Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg;Drug: Drug: Standard treatment Standard treatment,NA,NA,NA
covid,NCT04579640,https://clinicaltrials.gov/show/NCT04579640,Dietary Supplement: Vitamin D,NA,NA,Yes
covid,NCT04581915,https://clinicaltrials.gov/show/NCT04581915,Drug: Triazavirin (Riamilovir);Other: Placebo,NA,Yes,NA
covid,NCT04583410,https://clinicaltrials.gov/show/NCT04583410,Drug: Nicotine patch;Drug: Placebo patch,NA,NA,NA
covid,NCT04583592,https://clinicaltrials.gov/show/NCT04583592,Drug: Camostat Mesilate;Drug: Placebo,NA,NA,NA
covid,NCT04584697,https://clinicaltrials.gov/show/NCT04584697,Biological: COVI-AMG;Drug: Placebo,NA,NA,NA
covid,NCT04584710,https://clinicaltrials.gov/show/NCT04584710,Drug: RTB101;Drug: Placebo,NA,NA,NA
covid,NCT04592705,https://clinicaltrials.gov/show/NCT04592705,Device: Therapeutic plasma exchange,NA,Yes,NA
covid,NCT04592835,https://clinicaltrials.gov/show/NCT04592835,Drug: DWRX2003,NA,NA,NA
covid,NCT04593641,https://clinicaltrials.gov/show/NCT04593641,Biological: CT-P59,NA,NA,NA
covid,NCT04594668,https://clinicaltrials.gov/show/NCT04594668,Drug: Senicapoc,NA,NA,NA
covid,NCT04600895,https://clinicaltrials.gov/show/NCT04600895,Drug: Favipiravir;Drug: Placebo,NA,Yes,NA
covid,NCT04600999,https://clinicaltrials.gov/show/NCT04600999,Drug: Favipiravir,NA,Yes,NA
covid,NCT04602000,https://clinicaltrials.gov/show/NCT04602000,Biological: CT-P59/Placebo,NA,NA,NA
covid,NCT04602507,https://clinicaltrials.gov/show/NCT04602507,Drug: Ivermectin;Other: Placebo,NA,NA,NA
covid,NCT04604223,https://clinicaltrials.gov/show/NCT04604223,Drug: Pioglitazone 45 mg,NA,NA,NA
covid,NCT04604678,https://clinicaltrials.gov/show/NCT04604678,Drug: Metformin;Drug: Naltrexone,NA,NA,NA
covid,NCT04608266,https://clinicaltrials.gov/show/NCT04608266,Drug: Camostat Mesylate;Drug: Placebo,NA,NA,NA
covid,NCT04609865,https://clinicaltrials.gov/show/NCT04609865,Drug: Lidocaine 2%;Drug: Control,NA,Yes,NA
covid,NCT04610567,https://clinicaltrials.gov/show/NCT04610567,Drug: Methotrexate-LDE phase 1;Drug: Methotrexate-LDE phase 2;Drug: Placebo-LDE phase 2,NA,NA,NA
covid,NCT04610801,https://clinicaltrials.gov/show/NCT04610801,Drug: Nasal Spray,NA,NA,NA
covid,NCT04612972,https://clinicaltrials.gov/show/NCT04612972,Biological: Inactivated SARS CoV 2 vaccine (Vero cell). Wuhan,Yes,NA,NA
covid,NCT04613271,https://clinicaltrials.gov/show/NCT04613271,Drug: Favipiravir;Drug: Azithromycin,NA,Yes,NA
covid,NCT04613986,https://clinicaltrials.gov/show/NCT04613986,Device: therapeutic plasmaexchnage,NA,Yes,NA
covid,NCT04619706,https://clinicaltrials.gov/show/NCT04619706,Drug: FSD201;Drug: Placebo,NA,NA,NA
covid,NCT04622826,https://clinicaltrials.gov/show/NCT04622826,Biological: immune plasma,NA,Yes,NA
covid,NCT04623021,https://clinicaltrials.gov/show/NCT04623021,Drug: Nafamostat Mesilate,NA,NA,NA
covid,NCT04623385,https://clinicaltrials.gov/show/NCT04623385,Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone;Drug: The standard therapy,NA,NA,NA
covid,NCT04626089,https://clinicaltrials.gov/show/NCT04626089,Drug: metformin glycinate;Drug: Placebo oral tablet,NA,NA,NA
covid,NCT04627233,https://clinicaltrials.gov/show/NCT04627233,Drug: Human Ezrin Peptide 1 (HEP1);Drug: Placebo,NA,NA,NA
covid,NCT04629703,https://clinicaltrials.gov/show/NCT04629703,Drug: Fostamatinib;Drug: Placebo,NA,NA,NA
covid,NCT04632537,https://clinicaltrials.gov/show/NCT04632537,Drug: Tice® BCG (for intravesical use) BCG LIVE strain of the BCG (Merck) vaccine;Drug: Preservative-free saline,Yes,NA,NA
covid,NCT04634370,https://clinicaltrials.gov/show/NCT04634370,Biological: Natural Killer Cells infusion,NA,NA,NA
covid,NCT04634409,https://clinicaltrials.gov/show/NCT04634409,Drug: LY3819253;Drug: LY3832479;Drug: Placebo,NA,NA,NA
covid,NCT04636034,https://clinicaltrials.gov/show/NCT04636034,"Procedure: Sphenopalatine Ganglion Block with Local Anesthetic;Procedure: Sphenopalatine Ganglion Block with Placebo (Isotone NaCl);Procedure: ""Sham""-block with Placebo (Isotone NaCl)",NA,NA,NA
covid,NCT04636333,https://clinicaltrials.gov/show/NCT04636333,"Biological: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14;Biological: Three doses of middle-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28;Biological: Two doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14;Biological: Three doses of high-dose recombinant SARS-CoV-2 vaccine (CHO Cell) at the schedule of day 0, 14, 28;Biological: Two doses of placebo at the schedule of day 0, 14 #middle-dose group#;Biological: Three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#;Biological: Two doses of placebo at the schedule of day 0, 14 #High-dose group#;Biological: Three doses of placebo at the schedule of day 0, 14, 28 #High-dose group#",Yes,NA,NA
covid,NCT04636671,https://clinicaltrials.gov/show/NCT04636671,Drug: Methylprednisolone;Drug: Dexamethasone,NA,Yes,NA
covid,NCT04638634,https://clinicaltrials.gov/show/NCT04638634,Biological: CSL760,NA,NA,NA
covid,NCT04639375,https://clinicaltrials.gov/show/NCT04639375,Biological: Vaccinated with polio vaccine (IPV),Yes,NA,NA
covid,NCT04640168,https://clinicaltrials.gov/show/NCT04640168,Drug: Baricitinib;Drug: Dexamethasone;Other: Placebo;Drug: Remdesivir,NA,Yes,NA
covid,NCT04640402,https://clinicaltrials.gov/show/NCT04640402,Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen;Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen;Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Two dose regimen;Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (18-59 years) & Three dose regimen;Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen;Biological: Low-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen;Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Two dose regimen;Biological: High-dose Recombinant COVID-19 vaccine (Sf9 cells) (60-85 years) & Three dose regimen;Biological: Low-dose placebo (18-59 years) & Two dose regimen;Biological: Low-dose placebo (18-59 years) & Three dose regimen;Biological: High-dose placebo (18-59 years) & Two dose regimen;Biological: High-dose placebo (18-59 years) & Three dose regimen;Biological: Low-dose placebo (60-85 years) & Two dose regimen;Biological: Low-dose placebo (60-85 years) & Three dose regimen;Biological: High-dose placebo (60-85 years) & Two dose regimen;Biological: High-dose placebo (60-85 years) & Three dose regimen,Yes,NA,NA
covid,NCT04641481,https://clinicaltrials.gov/show/NCT04641481,Biological: BBV152;Biological: Placebo,NA,NA,NA
covid,NCT04642014,https://clinicaltrials.gov/show/NCT04642014,Biological: COVID-19 convalescent plasma treatment,NA,Yes,NA
covid,NCT04642638,https://clinicaltrials.gov/show/NCT04642638,Drug: INO-4800;Device: CELLECTRA® 2000;Drug: Placebo;Device: CELLECTRA® 2000,NA,NA,NA
covid,NCT04644120,https://clinicaltrials.gov/show/NCT04644120,Drug: ABBV-47D11;Drug: Placebo for ABBV-47D11,NA,NA,NA
main,NL7733,https://trialregister.nl/trial/7733,Atorvastatin 40 mg once daily,NA,NA,NA
covid,NL8523,https://trialregister.nl/trial/8523,"The administration of inhaled isoflurane for sedation, compared to intravenous sedation. In this pilot study, patients will intermittent receive inhaled or intravenous sedation, according to the randomisation scheme.",NA,NA,NA
covid,NL8578,https://trialregister.nl/trial/8578,"All COVID-19 patients with an indication for admittance to the ICU department will be included and will (after informed consent) be rondomised to receive a bolus of alkaline phosphatase of 1000iU, followed by 9000 iU the same day. For the 3 consecutive days 10.000iU/day on top of regular care.",NA,NA,NA
covid,NL8609,https://trialregister.nl/trial/8609,1.	Placebo treatment<br>2.	BCG vaccination<br>3.	BCG vaccination + oral bisphosphonate supplementation (alendronic acid)<br>4.	BCG vaccination + MMR vaccine<br>5.	MMR vaccine alone<br>,Yes,NA,NA
covid,NL8633,https://trialregister.nl/trial/8633,Enrolled patients will either receive convalescent thawed fresh frozen plasma 1 unit (250-325 ml) (=treatment group) or standard thawed fresh frozen plasma 1 unit (250-325 ml) (=control group),NA,Yes,NA
im,NTR5934,https://trialregister.nl/trial/5578,Part A: none<br>Part B: altered dosage flucloxacillin,NA,NA,NA
im,NTR7354,https://trialregister.nl/trial/7155,Intravenous treatment with acylated ghrelin 600micrg twice daily for 1 week vs. placebo.,NA,NA,NA
im,PACTR201706002232945,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=2232,;propofol;dexmedetomidine;ketofol,NA,NA,NA
main,PACTR201902478249291,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=5900,;treatment arm ;placebo arm,NA,NA,NA
im,PACTR201904797961340,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=6059,;Standard of Care;TBT plus Standard of Care;Valganciclovir plus Standard of Care;TBT plus Valganciclovir plus SoC,NA,Yes,NA
main,PACTR201905466349317,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=8119,;Amoxicillin;Placebo,NA,NA,NA
main,PACTR201907659337128,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=8241,;Opioid free anaesthesia group;Opioid based anaesthesia group,NA,NA,NA
main,PACTR201909547623017,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=8285,;Amlodipine;Bisoprolol,NA,NA,NA
covid,PACTR202006922165132,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12166,;ChAdOx1 nCoV19;Normal saline 0.9;ChAdOx1 nCov19;Normal saline 0.9;ChAdOx1 nCoV19;Normal saline 0.9;ChAdOx1 nCoV19;Normal saline 0.9,Yes,NA,NA
covid,PACTR202007720062393,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=12183,;Lopinavir ritonavir;Lopinavir ritonavir and telmisartan ;Lopinavir ritonavir and atorvastatin,NA,Yes,NA
covid,PACTR202009786901147,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=11019,;Placebo;hydroxychloroquine,NA,Yes,NA
covid,PACTR202010718451278,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=13432,;Paracetamol;Hydroxychloroquine;Lopinavir Ritonavir,NA,Yes,NA
covid,PACTR202011523101903,https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=13475,;Placebo ;Vaccine,Yes,NA,NA
im,PER-011-19,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=011-19,"Group name:Part A - Group 1 Type of group;1 N° of participants:109 Intervention(s) description:1.0 g ETX2514/1.0 g sulbactam IV infused over 3 hours q6h plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h<br>Group name:Part B (Open label, supportive portion for patients resistent to Colistin) Type of group;1 N° of participants:80 Intervention(s) description:1.0 g ETX2514/1.0 g sulbactam IV infused over 3 hours q6h plus 1.0 g imipenem/1.0 g cilastatin IV infused over 1 hour q6h<br>",NA,NA,NA
im,PER-021-18,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=021-18,"Group name:V114 Type of group;1 N° of participants:150 Intervention(s) description:Single dose of V114 (day 1) followed by single dose of Pneumovax™ 23, 8 weeks later<br>Group name:Prevenar 13 Type of group;2 N° of participants:150 Intervention(s) description:Single dose of Prevenar 13™ (day 1) followed by single dose of Pneumovax™ 23, 8 weeks later<br>",NA,NA,NA
main,PER-025-19,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=025-19,"Group name:Induction Period Type of group;1 N° of participants:790 Intervention(s) description:All patients fulfilling eligibility criteria will enter the Induction Period, where they will receive 3 cycles of<br>standard first-line platinum doublet chemotherapy per investigator choice (carboplatin/paclitaxel,<br>cisplatin/gemcitabine or carboplatin/gemcitabine) until the end of the Induction Period or documented disease progression.<br>Group name:Treatment Period Type of group;1 N° of participants:790 Intervention(s) description:•Category 1: Patients with a CR, PR or SD after 3 cycles of platinum induction chemotherapy. Patients with a CR, PR or SD during the Induction Period will be randomized<br>in a 3:1 ratio to receive either molecularly-guided therapy or to continuation of the same chemotherapy regimen used during induction, respectively.<br>•Category 2: Patients with a documented PD during 3 cycles of platinum induction chemotherapy. Category 2 patients, i.e., PD after or during 3 cycles of platinum induction<br>chemotherapy, will be assigned molecularly-guided therapy by the investigator in consultation with the MTB, as described for Category 1 patients.<br>",NA,NA,NA
im,PER-051-18,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=051-18,"Group name:V114 Type of group;1 N° of participants:167 Intervention(s) description:IM injection of 0.5ml of V114, Sterile<br>Suspension 64 ug/ml, at 2, 4, 6 and 12 months of age. <br><br>Group name:Prevenar 13 Type of group;2 N° of participants:33 Intervention(s) description:IM injection of 0.5ml of Prevnar 13™, Sterile<br>Suspension 64 ug/ml, at 2, 4, 6 and 12 months of age. <br><br>",NA,NA,NA
im,PER-054-18,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=054-18,"Group name:Experimental Arm Type of group;1 N° of participants:125 Intervention(s) description:Murepavadin + Ertapenem<br><br>a) Murepavadin<br>- Dosage Form: 30 mL of a sterile concentrate for solution for infusion at 8 mg/mL in 30R glass vials.<br>- Dose and Frequency: 230 mg TID in subjects with an eGFR-MDRD-6 &#8805; 60 mL/min/1.73 m2 or 170 mg TID in subjects with 30 mL/min/1.73 m2 &#8804; eGFR-MDRD-6 < 60 mL/min/1.73 m2<br>(*) Throughout the course of the study, murepavadin dosing regimen will be adjusted (either increased or decreased) based on the eGFR-MDRD-6.<br>- Duration of treatment: Infused over 2 hours.<br>- Route of administration: Administered by IV route only.<br><br>b) Ertapenem<br>- Dosage Form: vial contains 1.046 gram Ertapenem sodium<br>- Dose and Frequency: 1 g BID in subjects with an eGFR-MDRD-6 &#8805; 30 mL/min/1.73 m2 or 500 mg BID in subjects with eGFR-MDRD-6 < 30 mL/min/1.73 m2<br>- Duration of treatment: Infused over 30 minutes.<br>- Route of administration: Administered by IV route only.<br>Group name:Comparator Arm Type of group;2 N° of participants:125 Intervention(s) description:Meropenem OR Piperacillin-tazobactam<br><br>a) Meropenem<br>- Dosage Form: 1.0 g powder for solution for infusion containing meropenem trihydrate equivalent to 1 gram anhydrous meropenem.<br>- Dose and Frequency: 1 g TID or 1 g BID in subjects with 26 mL/min/1.73 m2 &#8804; eGFR-MDRD-6 &#8804; 50 mL/min/1.73 m2.<br>- Duration of treatment: Infused over 30 minutes.<br>- Route of administration: Administered by i.v. route only.<br><br>b) Piperacillin-tazobactam<br>- Dosage Form: Piperacillin-Tazobactam for injection is commercialized as a lyophilized powder for reconstitution.<br>- Dose and Frequency: 4.5 g QID or 3.375 g QID in subjects with 20 mL/min/1.73 m2 &#8",NA,NA,NA
covid,PER-054-20,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=054-20,"Group name:Arm 1 Type of group;1 N° of participants:90 Intervention(s) description:•	Group 1 (6 mcg dose of CVnCoV vaccine (COVID-19 vaccine)). This group of people, from 18 to 60 years of age, will receive a 6-mcg dose of the vaccine on Day 1 and on Day 29 of the study.<br>Subject Follow up Time:	180 days (booster dose)<br><br>Group name:Arm 6 Type of group;2 N° of participants:12 Intervention(s) description:•Group 6 (control group with the pneumococcal vaccine). This group of people, 61 years of age and older, will receive an injection with the pneumococcal control vaccine on Day 1 and Day 29 of the study.<br>",Yes,NA,NA
covid,PER-060-20,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=060-20,Group name:Experimental Type of group;1 N° of participants:100 Intervention(s) description:A 200 ml unit of COVID 19 convalescent donor s plasma will be transfused considering ABO and Rh compatibility through an intravenous line up to 2 times spaced 24 hours apart.<br><br>,NA,Yes,NA
im,PER-075-15,https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec=075-15,"•Lefamulin IV of 150 mg in 15 mL mL concentrate solution for infusion.of 0.9% saline, to be further diluted in 10mM citrate buffered 0.9% saline<br>•Lefamulin 600 mg of lefamulin as a yellow oval film coated immediate-release tablet<br>•Moxifloxacin IV of 400 mg/250 mL of moxifloxacin in a ready-to-use latex-free flexibagsolution for infusion.<br>•Moxifloxacin 400 mg of moxifloxacin as an over-encapsulated film-coated tablet<br>•Linezolid IV of 600 mg/300mL  of linezolid in a ready-to-use flexible plastic (latex-free)solution for infusion. bag<br>•Lenizolid 600 mg of linezolid as an over-encapsulated film-coated tablet<br>Subjects will be randomized in a 1:1 ratio to either IV lefamulin or IV moxifloxacin. Subjects randomized to IV lefamulin will receive 150 mg of lefamulin q12h.  Subjects randomized to IV moxifloxacin will receive 400 mg of moxifloxacin q24h.  In order to maintain the blind, subjects randomized to IV moxifloxacin will receive alternating doses of IV placebo administered q24h so that IV study drug is administered q12h.",NA,Yes,NA
covid,RBR-35734p,http://www.ensaiosclinicos.gov.br/rg/RBR-35734p/,"initially, 30 patients with severe Covid-19 grade will be treated with intravenous administration of angiotensin- (1-7) for up to 7 days to assess the safety of this treatment (Phase I).<br>If this step provides positive data, the second phase (Phase 2) will start. Patients with severe Covid -19 form will be divided into two groups. The experimental group (N = 50) had received intravenous angiotensin- (1-7) for up to 7 days. The second group will be treated with placebo, for the same period.<br>Patients will be followed for up to 28 days.;Biological/vaccine;Other;Angiotensins",Yes,NA,NA
covid,RBR-3fz9yr,http://www.ensaiosclinicos.gov.br/rg/RBR-3fz9yr/,"Ten patients with COVID-19 will receive an intravenous infusion of three doses of 500.000 cells/kg of umbilical cord mesechymal cells and five patients will receive a placebo (saline, albumin and ACD infusion). Conventional treatment will be performed together with the infusion of cells, during the study period. It will be performed clinical, laboratory, and medical diagnosis imaging evaluation. Patient follow-up will be for four months after the first infusion of cells;Biological/vaccine;Transplantation",Yes,NA,NA
covid,RBR-3k4wxb,http://www.ensaiosclinicos.gov.br/rg/RBR-3k4wxb/,"1. Control group - 15 participants<br>The Control group will receive proper COVID19 treatment but will not receive hydroxychloroquine, chloroquine, azithromycin, or another macrolide.<br>PT-BR<br>EN<br>2. G1 - 15 participants<br>This group will receive proper COVID19 treatment and hydroxychloroquine 400mg + azithromycin 500mg bid D0, orally, or enterally, and the following days, hydroxychloroquine 400mg + azithromycin 500mg once each, orally, or enterally, for 10 days or negative PCR, what comes first. <br>3. G2 - 15 participants<br>This group will receive proper COVID19 treatment and hydroxychloroquine 200mg + azithromycin 500mg bid D0, orally, or enterally, and the following days, hydroxychloroquine 200mg + azithromycin 500mg once each, orally, or enterally, for 10 days or negative PCR, what comes first.;Drug;Hydroxychloroquine;Azithromycin",NA,Yes,NA
im,RBR-3p4npx,http://www.ensaiosclinicos.gov.br/rg/RBR-3p4npx/,"Experimental group: 155 adults with flu/cold symptoms treated with one tablet of 400mg of paracetamol + 4 mg chlorpheniramine maleate 4mg + phenylephrine hydrochloride four times a day, for 3 days.<br>Control group: 155 adults with flu/cold symptoms treated with 1 capsule of 400mg paracetamol + 4 mg chlorpheniramine maleate 4mg + phenylephrine hydrochloride every four hours, up to 5 capsules daily maximum, for 3 days.;Drug;Acetaminophen;Chlorpheniramine;Phenylephrine",NA,NA,NA
im,RBR-4bfx9c,http://www.ensaiosclinicos.gov.br/rg/RBR-4bfx9c/,Adult group:  60 subjects between 18 and 60 years old  will receive one dose of vaccine against influenza administered intramuscularly<br><br>Elderly group:  60 subjects above 60 years old  will receive one dose of vaccine against influenza administered intramuscularly<br>;Biological/vaccine;Influenza Vaccines,Yes,NA,NA
main,RBR-4dx8n4,http://www.ensaiosclinicos.gov.br/rg/RBR-4dx8n4/,"0.375% ropivacaine injection in the doses of 2.5 ml in each ventricle of the anterior and middle scolenes muscles, guided by ultrasonography,compared to the skin touch with the same syringe-needle set at the same access points from where the injection would be. <br><br>Participants Number: 19 in 2 groups;Drug;Anesthetics",NA,Yes,NA
covid,RBR-4nr86m,http://www.ensaiosclinicos.gov.br/rg/RBR-4nr86m/,Patients diagnosed with COVID-19 will be randomly divided into 2 groups: experimental and control groups.<br>Experimental group: 196 patients diagnosed with COVID-19 confirmed by RT-PCR will receive nitazoxanide 500mg 8/8 hs for 5 days. Control group: 196 patients diagnosed with COVID-19 confirmed by RT-PCR will receiveplacebo 8/8 hs for 5 days.;Drug;/drug effects;Off-Label Use,NA,NA,NA
covid,RBR-4vm3yy,http://www.ensaiosclinicos.gov.br/rg/RBR-4vm3yy/,"Hyperimmune plasma anti-SARS-CoV-2<br>20 patients will be included and will be compared with historical controls, that were admitted before the start of the current study;Biological/vaccine;Immunization, Passive",Yes,Yes,NA
covid,RBR-58ftdj,http://www.ensaiosclinicos.gov.br/rg/RBR-58ftdj/,"a) Experimental / Antiseptic group and active toothpaste: 20 patients will perform mouthwash / gargle for 1 minute (30s mouthwash / 30s gargle) with 5 ml of the solution. Time timed through an hourglass used by researchers. These should perform 5 gargling / mouthwash a day, which are: upon waking up, after breakfast, lunch and dinner and before sleeping. Tooth brushing should be performed with toothpaste provided by the researchers for the patients participating in the study.<br><br>b) Control / Antiseptic group without active and Active toothpaste: 20 patients will perform mouthwash / gargle for 1 minute (30sbocheho / 30s gargle) with 5 ml of the solution. Time timed through an hourglass used by researchers. They must perform 5 gargling / mouthwash a day, namely: upon waking up, after breakfast, lunch and dinner and before going to sleep. Tooth brushing should be performed with toothpaste provided by the researchers for the patients participating in the study.<br><br>Patients will be followed for 3 days (D0, D2 and D5) to collect their saliva, produced in the posterior oropharynx.;Drug;Mouthwashes",NA,NA,NA
main,RBR-7wv259,http://www.ensaiosclinicos.gov.br/rg/RBR-7wv259/,"Open-label, randomized controlled trial on demand acetaminophen prescription. Patients in need of clinical crown augmentation were included in the study. After surgery, the patient was allocated to the test group or control group. The test group (34 participants) was prescribed paracetamol (500mg) in a fixed regimen every 4 hours for 48 hours to control postoperative pain. In case the pain did not pass within 1 hour after acetaminophen consumption, the patient was instructed to consume ibuprofen (600mg), with minimum intervals of 6 hours between doses. The control group  (34 participants) received paracetamol (500mg) in case of pain, with minimum intervals of 4 hours for 48 hours to control postoperative pain. In case the pain did not pass within 1 hour after acetaminophen consumption, the patient was instructed to consume ibuprofen (600mg), with minimum intervals of 6 hours between doses.;Drug;Procedure/surgery;Randomized Controlled Trial",NA,NA,NA
covid,RBR-949z6v,http://www.ensaiosclinicos.gov.br/rg/RBR-949z6v/,"Patients will be randomized in a 1: 1 ratio between two groups through a digital application.<br>Group 1) Full heparinization with enoxaparin: Full heparinization will be performed with enoxaparin adjusted for creatinine clerance according to the scheme below): 10 patients<br>Creatinine clearance <75 years> 75 years<br>> 50 ml / min 1 mg / Kg SC BID 0.75 mg / Kg SC BID<br>30-50 ml / min 0.75 mg / Kg BID 1 mg / Kg SC 1x<br>10-30 ml / min 1 mg / kg SC1x 0.75 mg / kg 1x<br><10 ml / h Will not be included Will not be included<br><br>As renal function can change during the study, we consider daily creatinine dosage necessary and the adjustment of the dose of enoxaparin should be performed daily according to the evolution of renal function. Duration of heparinization: 96 hours. Enoxaparin may be extended up to 7-10 days at the discretion of the medical team for those patients who show significant clinical improvement. Enoxaparin may be suspended at any time if any major or minor bleeding is observed according to the safety criteria included in this study or platelet count below 30,000 mm3. If, during the course, renal function worsens with creatine clearance below 10 ml / min, he should receive unfractionated heparin adjusted by APTT aiming at a ratio between 1.5 and 2.0.<br><br>Group 2) Prophylactic heparinization: 10 patients<br><br>The control group will receive prophylactic heparin with unfractionated heparin SC at a dose of 5000 IU 8/8 h or enoxaparin 40 mg SC 1 x day. In obese patients (weight> 120 kg), the dose in UFH SC may be increased to 7500 IU SC 8/8 hs and the dose of enoxaparin may be increased to 40 mg SC 12/12 h<br><br><br>Note: The full UFH arm was abandoned due to difficulties in adjusting the heparin dose in these patients requiring multiple test collection;Drug;Anticoagulants",NA,Yes,NA
main,RBR-9fkttf,http://www.ensaiosclinicos.gov.br/rg/RBR-9fkttf/,"After informed consent, patients will be randomized 1: 1 to Influenza Vaccine or corresponding placebo under confidential allocation. The non-blinded study nurse in each center who is not protected or participating in the study will prepare a study medication (Tetravalent influenza vaccine (fragmented, inactivated) / placebo). A vaccine will be delivered to each participating center and the placebo will be obtained from each center's common clinical supply (normal saline).<br>According to  randomization, FluQuadri® will be administered in a pre-filled syringe or the same volume of placebo (0.5 ml saline - 0.9% saline). Influenza vaccination, or placebo, will be given up to 7 days after the ACS index event. During Flu Season , and for those who´s the treatment with be a primary angioplasty, a vaccine will be given within 72 hours to allow  a joint analysis with IAMI study data.<br><br>Control Group: 1000 patients with Acute Coronary Syndrome will receive Placebo-Saline - 0.9%<br>Experimental Group: 1000 patients with Acute Coronary Syndrome will receive Tetravalent Influenza Vaccine (fragmented, inactivate);Biological/vaccine;Influenza Vaccines;Placebos",Yes,NA,NA
im,RBR-9m6bny,http://www.ensaiosclinicos.gov.br/rg/RBR-9m6bny/,"This will be a prospective, controlled, double-blind, randomized trial. The sample size number obtained was 116 patients. <br>Patients will be randomized by the project coordinator (professor) and allocated to two groups: thiamine (T) supplementation and placebo (C). Patients will received 200 mg thiamine intravenously twice daily for 5 days or until ICU discharge. <br>Placebo will be administered in equivalent volume by the same via and period described for thiamine. Thiamine or placebo will be provided by the project coordinator as numbered ampules and healthcare personnel and the research team remained blinded throughout the study period.<br>;Drug;Thiamine",NA,NA,NA
im,RBR-9w3k77,http://www.ensaiosclinicos.gov.br/rg/RBR-9w3k77/,"Experimental group (GE), contained 20 patients, who underwent laparoscopic bypass surgery for weight reduction. In this group the Esmolol initial dose of 0.5mg / kg was used followed by continuous infusion of esmolol 15mcg / kg / min during the whole surgery aiming the reduction of postoperative pain. The other group, placebo group (GP) also contained 20 patients who also underwent laparoscopic bypass surgery for weight reduction. However, saline (placebo) was used in this group without clinical effects. Both groups received all medications from conventional anesthesia without detriment to the participants' health.;Drug;Bariatric Surgery;/drug effects",NA,NA,NA
im,RBR-9ztf3b,http://www.ensaiosclinicos.gov.br/rg/RBR-9ztf3b/,"This study consists of two arms: placebo and intervention. Patients in the intervention group receiving ketamine drug dose 4 mg / kg once, and those in the placebo group received saline at a dose 4 mg / kg once. The sample 20 subjects in each group.<br>The attending physician who is treating the child should indicate the use of the sedative before the procedure, citing the study for the escort and requesting the presence of the nurse for further explanation. The accounting Legal consenting to child participation, will be prescribed in the patient's medical record using the solution, route of administration and dose, and participation in research.<br>The child will be brought to the bed or stretcher procedures in the dorsal position with high ment will be given half the dose in each nostril. The professional waiting 15 minutes after administration and performs the procedure, puncturing venous access and completing the study protocol (is attached with the project). Prior to administration of the solution, 1 hour after administration and until 24 hours after the procedure must be recorded vital signs and the patient should be monitored in the first hour with saturômetro.<br>After administering the IN solution the nurse will wait 15 minutes and perform the procedure. A second person with the aid of a timer will make the time count. Importantly, the punch time will be timed from the time of placing the tourniquet to the installation of saline showing the success of the puncture.<br>The nurse who performed the procedure will answer the questions of the study protocol on the ease in performing the procedure and the patient's escort will be questioned about the reactions of the patient.<br>The child will remain with saturômetro until 1 hour after the procedure, or even when y;Drug;Conscious Sedation;Placebos",NA,NA,NA
covid,RPCEC00000307,https://rpcec.sld.cu/en/trials/RPCEC00000307-En,"Group A: HeberFERON (Recombinant Interferon Alpha Gamma, 3.5 MUI), subcutaneously, twice a week for three consecutive weeks. Group B (Control): Heberon Alfa R (Recombinant Interferon alfa 2b, 3.0 MUI), subcutaneously, three times per week for three consecutive weeks. All the patients included in the study (as part of the protocol of action foreseen in the country for cases of SARS-CoV-2 in nasopharyngeal exudates) receive basic treatment (in addition to interferon according to study group) with caletra, chloroquine, azithromycin or rocefin, depending on the magnitude of respiratory symptoms.;Interferon alpha-2;HeberFERON Kaletra Rocephin",NA,Yes,NA
covid,RPCEC00000313,https://rpcec.sld.cu/en/trials/RPCEC00000313-En,"Group CIGB-258 peptide: 1 mg intravenously every 12 hours until extubation, followed by the same dose every 24 hours for three days (in patients with mechanical ventilation, where the dose can be increased to 2 mg if at 72 hours, there is no clinical, blood gas, and radiological improvement) or 1 mg intravenously every 24 hours in patients without mechanical ventilation, until their condition reverts.;Peptides;P?ptido CIGB-258,      Jusvinza",NA,NA,NA
covid,RPCEC00000322,https://rpcec.sld.cu/en/trials/RPCEC00000322-En,"Experimental Group: Mobilization of stem cells with the intramuscular administration of IOR(R) LEUKOCIM in 4 doses of 10 ug / kg of weight every 12 hours for 2 days as a strategy to stimulate the hematopoietic system of the patient. With a view to obtaining 400 ml of blood, cell separation and intravenous infusion of 200 x 106 mononuclear cells or more containing at least 1% CD34 + progenitor cells in a single dose. Control Group: Prednisone at a dose of 0.75-1 mg / kg / day, not exceeding a total single dose of 60mg / day during a period of 2 weeks, oral administration;Hematopoietic Stem Cell Mobilization;IOR(R) LEUKOCIM",NA,Yes,NA
covid,RPCEC00000335,https://rpcec.sld.cu/en/trials/RPCEC00000335-En,"Biomodulina T, 1 bulb (3mg / 3mL), once a week, intramuscularly (IM) for 6 weeks.;Immunologic Factors;Biomodulin T",NA,NA,NA
covid,RPCEC00000338,https://rpcec.sld.cu/en/trials/RPCEC00000338-En,"Group 1- FINLAY-FR-1 (Experimental): High dose of RBD+adjuvant; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. Group 2- FINLAY-FR-1A (Experimental): High dose of RBD+adjuvant A; 0.5 mL by intramuscular route. Treatment scheme: 0-28 days. Presentation: Vial with single dose. Group 3- FINLAY-FR-1A (Experimental): Low dose of RBD+adjuvant A; 0.5 mL by intramuscular route. Treatment scheme: 0-28-56 days. Presentation: Vial with single dose;Immunogenicity, Vaccine",Yes,NA,NA
im,TCTR20161101004,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=2072,"Calcitriol 2 micrograms (2 ml) IV injection  , Normal saline solution 2 ml IV injection",NA,NA,NA
im,TCTR20161226001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=2272,"Thiamine is a vitamin B1. We give 100 mg of thiamine intravenously every 8 hours for 7 days to patients. , Normal saline is an intravenous fluid.",NA,NA,Yes
im,TCTR20170222001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=2394,"ATB which desired by primary doctors , given sitafloxacin for combination",NA,Yes,NA
im,TCTR20170802004,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=2731,"Influenza vaccination for patients with currently recorgnized Influenza vaccination. <br>We use VAXIGRIP Susp inj/0,5ml (R)(Sanofi). <br>Each patient receive one dose 0.5ml subcutaneous or intramuscular<br>Vaccin constitutiuon is adapted each year. In 2016-2017, vaccin constituion is: A/California/7/2009 (H1N1)pdm09 - souche analogue (A/California/7/2009, NYMC X-179A) 15 Âµg HA** A/Hong Kong/4801/2014 (H3N2) - souche analogue (A/Hong Kong/4801/2014, NYMC X-263B) 15 Âµg HA** B/Brisbane/60/2008 - souche analogue (B/Brisbane/60/2008, type sauvage) 15 Âµg HA",NA,Yes,NA
im,TCTR20180302002,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=3296,"treatment group : vitamin C 1.5 gm + NSS 100 ml IV infusion 30 min q 6 hr combination with  Hydrocortisone 200 mg+ NSS 250 ml IV infusion in 24 hr combination with Thiamine 200 mg + NSS 100 ml  IV infusion 30 min q 12 hr in 4 days, NSS 100 ml IV infusion",NA,NA,Yes
im,TCTR20180310001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=3330,"Thiamine 200 mg + 5%DW 50 mL iv drip in 30 min for 7 days, 5%DW 50ml iv drip in 30 min for 7 day",NA,NA,NA
im,TCTR20180614004,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=3597,"Fluticasone furoate,Nasal spray 27.5 mcg/1dose, 120 doses/bottle, 1C 13/51 (N) [drug's ID], Placebo nasal spray, contains glucose anhydrous, polysorbate 80, benzalkonium chloride, disodium edetate, purified water",NA,NA,NA
im,TCTR20180925004,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=3905,"Vitamin C 1.5 gm add in 0.9% NaCl 100 ml iv drip in 30 min q6h x 4 days or until vasopressor was stopped for 24 hr with standard treatment, NSS 100 ml iv drip in 30 min q6h x 4 days or until vasopressor was stopped for 24 hr with standard treatment",NA,NA,Yes
im,TCTR20181007001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4033,Influenza vaccination on level of phenytoin in Thai epileptic patients treated with phenytoin,NA,NA,NA
im,TCTR20190220001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4486,"The intervention group will receive 15 mg zinc orally twice a day for 7 days or until discharge from hospital., The control group will receive placebo which is prepared by the same company in the identical package, colour and taste as same as the treatment group.",NA,NA,NA
main,TCTR20190222004,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4472,"Sodium nitrite solution administered by inhaled nebulization to asthma patients , Normal treatment and placebo",NA,NA,NA
main,TCTR20190430003,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4709,"A single dose of Rivaroxaban 10-mg Tablets, Test Product, A single dose of Rivaroxaban 10-mg Tablets, Reference Product",NA,NA,NA
im,TCTR20190530003,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4830,"Moraceae plus 0.12% chlorexidine mouthwash three times a day for 7 days , 0.12% chlorexidine mouthwash three times a day for 7 days",NA,NA,NA
im,TCTR20190623002,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4928,"Give colistin combined with sulbactam 9-g/d , Give colistin combined with sulbactam 12-g/d",NA,NA,NA
main,TCTR20190703003,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4962,"1. Study A <br>- Subjects will fast overnight at least 10 h prior to drug administration.  <br>- A 35 mg modified release tablet of trimetazidine dihydrochloride will be taken with 240 ml drinking water at room temperature.<br><br>2. Study B<br>- Subjects will fast overnight at least 10 h prior to drug administration.<br>- High fat, high-calorie breakfast will be served at 30 minutes before drug administration. Subjects should take the meal completely within 30 minutes after serving.<br>- After meal serving for 30 minutes, subjects will take a 35 mg modified release tablet of trimetazidine dihydrochloride with 240 ml drinking water at room temperature.<br><br>3. Study C<br>3.1 Steady state build-up (During day 1 to 4 and day 8 to 11)<br>- During steady-state build-up, one tablet of trimetazidine dihydrochloride 35 mg modified release with 240 ml of drinking water will be administrated to subjects in the morning and evening for 4 days, a total of 8 doses. <br>- The standard meal will be served 30 minutes before each drug administration. Subjects should take the meal completely within 30 minutes after serving.<br><br>3.2 Profiling day (Day 5 and 12)<br>- Subjects will fast overnight at least 10 h prior to the administration on profiling day <br>- The standard meal will be served 30 minutes before drug administration. Subjects should take the meal completely within 30 minutes after serving.<br>- After meal serving for 30 minutes, subjects will take a 35 mg modified release tablet of trimetazidine dihydrochloride with 240 ml drinking water at room temperature., 1. Study A <br>- Subjects will fast overnight at least 10 h prior to drug administration.  <br>- A 35 mg modified release tablet of trimetazidine dihydrochloride will be taken with 240 ml drinking water at room temperature.<br><br>2. Study B<br>- Subjects will fast overnight at lea",NA,NA,NA
main,TCTR20190705002,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4969,"will start with 10 mg subcutaneous injection/week and the dose of methotrexate will increase to 15, 20, and then 25 mg/week every 4-week visit if PASI 75 does not achieve, will start with 10 mg subcutaneous injection/week and the dose of methotrexate will increase to 15, 20, and then 25 mg/week every 4-week visit if PASI 75 does not achieve",NA,NA,NA
main,TCTR20190717001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4987,"Voriconazole is given in normal dose.<br>Other supportive cares are given according to on primary physicians., Amphotericin B deoxycholate is given in normal dose.<br>Other supportive cares are given according to on primary physicians.",NA,Yes,NA
main,TCTR20190805002,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4983,"patients in Group LFA received a fresh gas flow of 2 LPM and vaporizer of sevoflurane was open until 1 MAC then a fresh gas flow will be decrease to 1 LPM. , Group MFA received the same initial fresh gas flow of 2 LPM and vaporizer of sevoflurane was open with a fresh gas flow of 2 LPM.",NA,NA,NA
main,TCTR20190823001,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=4935,"The selected burn wound will be dressing with Polyester Dressing Containing Herbal Extracts and Silver Sulfadiazine Cream., The selected burn wound will be dressing with only Silver Sulfadiazine Cream in the old fashion.",NA,NA,Yes
main,TCTR20191006002,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=5254,"Antihypertensive drug, Antihypertensive drug",NA,NA,NA
main,TCTR20191010002,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=5362,"Patients in dexamethasone group (group D) will be received intravenous 8 mg (1.6 mL) of dexamethasone , Patients in control group (group C) will be received intravenous 1.6 mL of isotonic saline",NA,Yes,NA
main,TCTR20200114006,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=5313,"High-fat meal (50% fat of total calories), a HF meal plus 1 g of Clitoria ternatea flower extact, a HF meal plus 2 g of Clitoria ternatea flower extact",NA,NA,NA
covid,TCTR20200404004,http://www.clinicaltrials.in.th/index.php?tp=regtrials&menu=trialsearch&smenu=fulltext&task=search&task2=view1&id=5995,"Chloroquine 10 mg base/kg once a day on Day 1 and Day 8, Vitamin C 1000 mg once a day from Day 1 to Day 14",NA,Yes,Yes
